{"PMC7444954": [["IntroductionThe recent decade has witnessed an expansion of 3D printing (3DP) technologies into each and every field of science involving electrochemistry.", [["3D printing (3DP) technologies", "TREATMENT", 60, 90]]], ["[1, 2] Approaches of 3DP create objects by positioning target material on previously formed layers.", [["3DP", "SIMPLE_CHEMICAL", 21, 24], ["layers", "TISSUE", 92, 98], ["Approaches of 3DP create objects", "TREATMENT", 7, 39], ["positioning", "OBSERVATION_MODIFIER", 43, 54], ["target", "OBSERVATION_MODIFIER", 55, 61], ["layers", "OBSERVATION_MODIFIER", 92, 98]]], ["The combination of 3DP with computer assisted design (CAD) allows rapid, inexpensive, safe and environmentally friendly manufacture of customized \u2018reactionware\u2019 (cells and electrodes) directly in an electrochemical laboratory.IntroductionElectrochemical cells manufactured by 3D printing offer several advantages over their glass counterparts: (I) cells may be printed directly in a chemical laboratory without specially trained personal, (II) CAD allows rapid prototyping and redesign of cells, (III) cells with complicated inner structure may be created, (IV) 3D printed cells are significantly less breakable than glass cells, (V) 3D printing offers considerable reduction of material and energy consumption.", [["cells", "ANATOMY", 162, 167], ["cells", "ANATOMY", 254, 259], ["cells", "ANATOMY", 348, 353], ["cells", "ANATOMY", 489, 494], ["cells", "ANATOMY", 502, 507], ["inner structure", "ANATOMY", 525, 540], ["cells", "ANATOMY", 573, 578], ["glass cells", "ANATOMY", 617, 628], ["CAD", "DISEASE", 444, 447], ["3DP", "SIMPLE_CHEMICAL", 19, 22], ["cells", "CELL", 162, 167], ["cells", "CELL", 254, 259], ["cells", "CELL", 348, 353], ["cells", "CELL", 489, 494], ["cells", "CELL", 502, 507], ["cells", "CELL", 573, 578], ["glass cells", "CELL", 617, 628], ["(I) cells", "CELL_TYPE", 344, 353], ["(III) cells", "CELL_TYPE", 496, 507], ["3D printed cells", "CELL_LINE", 562, 578], ["glass cells", "CELL_TYPE", 617, 628], ["computer assisted design (CAD)", "PROBLEM", 28, 58], ["customized \u2018reactionware\u2019 (cells and electrodes", "TREATMENT", 135, 182], ["IntroductionElectrochemical cells", "TREATMENT", 226, 259], ["CAD", "PROBLEM", 444, 447], ["rapid prototyping and redesign of cells", "PROBLEM", 455, 494], ["complicated inner structure", "PROBLEM", 513, 540], ["considerable reduction of material", "PROBLEM", 653, 687]]], ["The first 3DP electrochemical cell was constructed by Symes et al [3] in 2012 by extruding acetoxysilicone polymer through a syringe and casting it onto a glass substrate.", [["3DP electrochemical cell", "ANATOMY", 10, 34], ["acetoxysilicone polymer", "CHEMICAL", 91, 114], ["acetoxysilicone", "CHEMICAL", 91, 106], ["cell", "CELL", 30, 34], ["acetoxysilicone polymer", "SIMPLE_CHEMICAL", 91, 114], ["3DP electrochemical cell", "CELL_LINE", 10, 34], ["a syringe", "TREATMENT", 123, 132], ["a glass substrate", "TREATMENT", 153, 170]]], ["Presently, the most widely used 3DP technologies are selective laser melting (SLM), stereolithography (SLA) and fused deposition modelling (FDM).", [["3DP technologies", "TREATMENT", 32, 48], ["selective laser melting (SLM), stereolithography (SLA)", "TREATMENT", 53, 107], ["fused deposition modelling (FDM", "TREATMENT", 112, 143]]], ["[4] The SLM technique creates objects by fusing atomized metallic powders melted locally by a laser beam and was applied to manufacture metallic electrodes for supercapacitors [5] and water electrolysers.", [["water electrolysers", "SIMPLE_CHEMICAL", 184, 203], ["The SLM technique", "TREATMENT", 4, 21], ["fusing atomized metallic powders", "TREATMENT", 41, 73], ["a laser beam", "TREATMENT", 92, 104], ["metallic electrodes for supercapacitors", "TREATMENT", 136, 175], ["water electrolysers", "TREATMENT", 184, 203]]], ["[6], [7], [8] Recently, multi-material mode of SLM technique employing stainless steel, titanium and graphite was utilized to manufacture integrated proton exchange membrane electrolyzer cells.", [["membrane electrolyzer cells", "ANATOMY", 165, 192], ["titanium", "CHEMICAL", 88, 96], ["graphite", "CHEMICAL", 101, 109], ["stainless steel", "CHEMICAL", 71, 86], ["titanium", "CHEMICAL", 88, 96], ["graphite", "CHEMICAL", 101, 109], ["cells", "CELL", 187, 192], ["proton exchange membrane electrolyzer cells", "CELL_LINE", 149, 192], ["SLM technique employing stainless steel, titanium and graphite", "TREATMENT", 47, 109], ["integrated proton exchange membrane electrolyzer cells", "TREATMENT", 138, 192]]], ["[9] The SLA technique forms objects from layers of resins polymerized locally by a laser-induced photochemical process.", [["The SLA technique", "TREATMENT", 4, 21], ["a laser-induced photochemical process", "TREATMENT", 81, 118], ["photochemical process", "OBSERVATION", 97, 118]]], ["This technique was employed to develop cells for water electrolysis, [10] spectroelectrochemical measurements [11] and electroanalytical applications.", [["cells", "ANATOMY", 39, 44], ["cells", "CELL", 39, 44], ["water", "SIMPLE_CHEMICAL", 49, 54], ["This technique", "TREATMENT", 0, 14], ["water electrolysis", "TREATMENT", 49, 67], ["electroanalytical applications", "TREATMENT", 119, 149]]], ["[12] Though the first conductive resins have been recently synthesized, [13] values of their electric conductivity are insufficient to manufacture electrodes.", [["the first conductive resins", "TREATMENT", 12, 39], ["their electric conductivity", "TEST", 87, 114], ["electric conductivity", "OBSERVATION_MODIFIER", 93, 114], ["manufacture electrodes", "OBSERVATION", 135, 157]]], ["The FDM as the most common and versatile 3DP technique relies on extruding filament through a heated nozzle.", [["filament", "ANATOMY", 75, 83], ["versatile 3DP technique", "TREATMENT", 31, 54], ["a heated nozzle", "TREATMENT", 92, 107]]], ["Low expenses and wide availability of printers render the FDM particularly suitable for the manufacture of cells.", [["cells", "ANATOMY", 107, 112], ["cells", "CELL", 107, 112], ["Low expenses", "PROBLEM", 0, 12], ["the FDM", "PROBLEM", 54, 61], ["wide", "OBSERVATION_MODIFIER", 17, 21]]], ["Most frequently used filaments are polylactic acid (PLA), [8, 7, [14], [15], [16], [17], [18], [19]] acrylonitrile butadiene styrene (ABS), [20], [21], [22], [23], [24], [25], [26], [27], [28], [29] polypropylene, [30], [31], [32] and polyesters.", [["filaments", "ANATOMY", 21, 30], ["polylactic acid", "CHEMICAL", 35, 50], ["PLA", "CHEMICAL", 52, 55], ["[8, 7, [14], [15], [16], [17], [18], [19]] acrylonitrile butadiene styrene", "CHEMICAL", 58, 132], ["ABS", "CHEMICAL", 134, 137], ["[20], [21], [22], [23], [24], [25], [26], [27], [28], [29] polypropylene, [30], [31], [32]", "CHEMICAL", 140, 230], ["polylactic acid", "CHEMICAL", 35, 50], ["PLA", "CHEMICAL", 52, 55], ["[8, 7, [14], [15], [16], [17], [18], [19]] acrylonitrile butadiene styrene", "CHEMICAL", 58, 132], ["ABS", "CHEMICAL", 134, 137], ["[29] polypropylene", "CHEMICAL", 194, 212], ["polylactic acid", "SIMPLE_CHEMICAL", 35, 50], ["PLA", "SIMPLE_CHEMICAL", 52, 55], ["[8, 7, [14], [15], [16], [17], [18], [19]] acrylonitrile butadiene styrene", "SIMPLE_CHEMICAL", 58, 132], ["ABS)", "SIMPLE_CHEMICAL", 134, 138], ["[20], [21], [22], [23], [24], [25], [26], [27], [28]", "SIMPLE_CHEMICAL", 140, 192], ["[29] polypropylene", "SIMPLE_CHEMICAL", 194, 212], ["[30], [31], [32]", "SIMPLE_CHEMICAL", 214, 230], ["polylactic acid (PLA)", "TEST", 35, 56], ["acrylonitrile butadiene styrene (ABS)", "TEST", 101, 138], ["polypropylene", "TEST", 199, 212], ["polyesters", "TEST", 235, 245]]], ["[33] Cells manufactured by FDM 3D printing involve multitude of functionalities and have found use in a broad range of electrochemical processes and applications, which are summarized in Table 1.", [["Cells", "ANATOMY", 5, 10], ["Cells", "CELL", 5, 10]]], ["However, none of these cells allows a fundamental analysis of electron transfer processes and related phenomena which requires strictly oxygen-free environment, separated compartments for working, counter and reference electrode and an interface to introduce reaction components.", [["cells", "ANATOMY", 23, 28], ["oxygen", "CHEMICAL", 136, 142], ["oxygen", "CHEMICAL", 136, 142], ["cells", "CELL", 23, 28], ["electron", "SIMPLE_CHEMICAL", 62, 70], ["oxygen", "SIMPLE_CHEMICAL", 136, 142], ["these cells", "PROBLEM", 17, 28], ["a fundamental analysis", "TEST", 36, 58], ["electron transfer processes", "PROBLEM", 62, 89], ["related phenomena", "PROBLEM", 94, 111], ["strictly oxygen", "TREATMENT", 127, 142], ["working, counter and reference electrode", "TREATMENT", 188, 228], ["reaction components", "PROBLEM", 259, 278]]], ["The goal of this work is the development, manufacture and inspection of such cell design.IntroductionRecent advancements in the preparation of printable conductive composite materials enabled the use of FDM to manufacture electrodes.", [["cell", "ANATOMY", 77, 81], ["cell", "CELL", 77, 81], ["such cell design", "PROBLEM", 72, 88], ["IntroductionRecent advancements", "TREATMENT", 89, 120], ["printable conductive composite materials", "TREATMENT", 143, 183], ["FDM to manufacture electrodes", "TREATMENT", 203, 232], ["such cell", "OBSERVATION", 72, 81]]], ["In the pioneering work of Rymansaib et al. [35] polystyrene was blended with graphite and carbon nanofibers to extrude a conductive composite filament further employed to print electrodes for the electroanalytical determination of Pb2+ ions.", [["graphite", "CHEMICAL", 77, 85], ["Pb2", "CHEMICAL", 231, 234], ["polystyrene", "CHEMICAL", 48, 59], ["graphite", "CHEMICAL", 77, 85], ["carbon", "CHEMICAL", 90, 96], ["Pb2+", "CHEMICAL", 231, 235], ["[35] polystyrene", "SIMPLE_CHEMICAL", 43, 59], ["graphite", "SIMPLE_CHEMICAL", 77, 85], ["carbon nanofibers", "SIMPLE_CHEMICAL", 90, 107], ["Pb2+ ions", "SIMPLE_CHEMICAL", 231, 240], ["Pb2", "PROTEIN", 231, 234], ["polystyrene", "TREATMENT", 48, 59], ["graphite and carbon nanofibers", "TREATMENT", 77, 107], ["a conductive composite filament", "TREATMENT", 119, 150], ["the electroanalytical determination", "TEST", 192, 227], ["ions", "PROBLEM", 236, 240], ["ions", "OBSERVATION", 236, 240]]], ["Following works employed commercial composites of PLA with graphene, [14, 21, 24, 28, 36, 37] carbon black, [17, 18, 28, [38], [39], [40]] carbon nanotubes [41] and copper [42] as conductive fillers.", [["PLA", "CHEMICAL", 50, 53], ["graphene", "CHEMICAL", 59, 67], ["carbon nanotubes", "CHEMICAL", 139, 155], ["copper", "CHEMICAL", 165, 171], ["PLA", "CHEMICAL", 50, 53], ["graphene", "CHEMICAL", 59, 67], ["[14, 21, 24, 28, 36, 37] carbon black", "CHEMICAL", 69, 106], ["[17, 18, 28, [38], [39], [40]] carbon", "CHEMICAL", 108, 145], ["copper", "CHEMICAL", 165, 171], ["PLA", "SIMPLE_CHEMICAL", 50, 53], ["graphene", "SIMPLE_CHEMICAL", 59, 67], ["[14, 21, 24, 28, 36, 37] carbon black", "SIMPLE_CHEMICAL", 69, 106], ["[17, 18, 28, [38], [39], [40]] carbon nanotubes [41]", "SIMPLE_CHEMICAL", 108, 160], ["copper [42]", "SIMPLE_CHEMICAL", 165, 176], ["carbon black", "TEST", 94, 106], ["carbon nanotubes", "TREATMENT", 139, 155], ["fillers", "OBSERVATION", 191, 198]]], ["Electrodes manufactured from in-lab synthesized PLA-based composites containing MoSe2, carbon/platinum [43] and graphite [44] used as conductive additives were reported recently.", [["PLA", "CHEMICAL", 48, 51], ["MoSe2", "CHEMICAL", 80, 85], ["carbon/platinum [43] and graphite", "CHEMICAL", 87, 120], ["PLA", "CHEMICAL", 48, 51], ["MoSe2", "CHEMICAL", 80, 85], ["carbon", "CHEMICAL", 87, 93], ["platinum", "CHEMICAL", 94, 102], ["graphite", "CHEMICAL", 112, 120], ["PLA", "SIMPLE_CHEMICAL", 48, 51], ["MoSe2", "SIMPLE_CHEMICAL", 80, 85], ["carbon", "SIMPLE_CHEMICAL", 87, 93], ["platinum [43]", "SIMPLE_CHEMICAL", 94, 107], ["graphite [44]", "SIMPLE_CHEMICAL", 112, 125], ["Electrodes", "TREATMENT", 0, 10], ["based composites containing MoSe2, carbon/platinum", "TREATMENT", 52, 102], ["conductive additives", "TREATMENT", 134, 154]]], ["Furthermore, commercial carbon-loaded ABS filaments were employed.", [["carbon", "CHEMICAL", 24, 30], ["carbon", "CHEMICAL", 24, 30], ["carbon", "SIMPLE_CHEMICAL", 24, 30], ["commercial carbon-loaded ABS filaments", "TREATMENT", 13, 51]]], ["[17, 45] Bi-material FDM 3D printing combining conductive composites for electrodes and insulating filaments for cells enabled the manufacture of integrated platforms dedicated to electroanalysis [14, 17, 18, 21, 27, 35, 45] and Raman spectroelectrochemistry.", [["cells", "ANATOMY", 113, 118], ["[17, 45] Bi-material", "SIMPLE_CHEMICAL", 0, 20], ["cells", "CELL", 113, 118], ["3D printing combining conductive composites for electrodes and insulating filaments", "TREATMENT", 25, 108], ["electroanalysis", "TEST", 180, 195], ["Raman spectroelectrochemistry", "TEST", 229, 258]]]], "PMC7523478": [["Development of a Cough Simulator ::: METHODSA physiologically accurate cough simulator was built to test the barrier devices.", [["the barrier devices", "TREATMENT", 105, 124], ["Cough", "OBSERVATION", 17, 22]]], ["Standard parameters for a human cough used to create this simulator included a duration of approximately 0.5\u20131 second, an average cough flow rate of 0.48\u20130.90 L/s, a peak expiratory flow rate of 4.75\u20136.42 L/s, fine particles (\u201caerosols\u201d) of <5 \u00b5m, and coarse particles (\u201cdroplets\u201d) >50 \u00b5m.19\u201322Development of a Cough Simulator ::: METHODSOur cough simulator was created using a jet ventilator (BE 183-SU, Instrumentation Industries, Inc, Bethel Park, PA), T-piece connector, and standard respiratory tubing (Figure 1A, B), mounted inside an intubation mannequin placed in sniffing position.23Validation of the Cough Simulator ::: METHODSUsing a flow analyzer (BC Biomedical PFC-3000, St Charles, MO), we confirmed that the simulator achieved a flow similar to a physiologic cough, 2.6 L/s.", [["cough", "DISEASE", 32, 37], ["BE", "CHEMICAL", 394, 396], ["cough", "DISEASE", 774, 779], ["human", "ORGANISM", 26, 31], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["a human cough", "PROBLEM", 24, 37], ["an average cough flow rate", "TEST", 119, 145], ["a peak expiratory flow rate", "TEST", 164, 191], ["L/s", "TEST", 205, 208], ["fine particles", "TEST", 210, 224], ["coarse particles", "TEST", 252, 268], ["METHODSOur cough simulator", "TREATMENT", 331, 357], ["a jet ventilator", "TREATMENT", 376, 392], ["Instrumentation Industries", "TREATMENT", 405, 431], ["T-piece connector", "TREATMENT", 456, 473], ["standard respiratory tubing", "TREATMENT", 479, 506], ["an intubation mannequin", "TREATMENT", 538, 561], ["a flow analyzer", "TEST", 643, 658], ["a physiologic cough", "PROBLEM", 760, 779], ["respiratory tubing", "OBSERVATION", 488, 506], ["intubation mannequin", "OBSERVATION", 541, 561], ["cough", "OBSERVATION", 774, 779]]], ["Although this is lower than peak expiratory flow rates reported in the literature, it is significantly higher than average cough flow rates.", [["peak expiratory flow rates", "TEST", 28, 54], ["cough flow rates", "TEST", 123, 139], ["lower", "OBSERVATION_MODIFIER", 17, 22], ["expiratory flow", "OBSERVATION", 33, 48], ["significantly", "OBSERVATION_MODIFIER", 89, 102], ["higher", "OBSERVATION_MODIFIER", 103, 109]]], ["A cough duration of 0.7\u20130.9 seconds was selected to best approximate a physiologic cough volume of 1.8\u20132.3 L. In addition, coughs produced by our simulator were similar in geometry and distance to those observed in Schlieren imaging of coughs in human volunteers, and our simulator produced horizontal coughs similar to those observed in other studies.20Particle Generation Models ::: METHODSFor our aerosol model (Figure 1A), a reservoir bag was placed between the T-piece connector and a commerciallyavailable fog machine (Chavuet DJ Hurricane 1200, Sunrise, FL), creating a spread of particle sizes between 10nm and 10 \u00b5m, with 2 dominant particle size distributions at 60 nm and 4 \u00b5m.24 Fog was drawn into the tubing from the reservoir via the Venturi effect produced by the jet ventilator.", [["cough", "DISEASE", 2, 7], ["cough", "DISEASE", 83, 88], ["human", "ORGANISM", 246, 251], ["volunteers", "ORGANISM", 252, 262], ["human", "SPECIES", 246, 251], ["human", "SPECIES", 246, 251], ["A cough duration", "PROBLEM", 0, 16], ["a physiologic cough volume", "TEST", 69, 95], ["coughs", "PROBLEM", 123, 129], ["Schlieren imaging", "TEST", 215, 232], ["coughs in human volunteers", "PROBLEM", 236, 262], ["horizontal coughs", "PROBLEM", 291, 308], ["other studies", "TEST", 338, 351], ["a reservoir bag", "TREATMENT", 427, 442], ["the T-piece connector", "TREATMENT", 462, 483], ["a commerciallyavailable fog machine", "TREATMENT", 488, 523], ["Chavuet DJ Hurricane", "TREATMENT", 525, 545], ["the Venturi effect", "TREATMENT", 744, 762], ["the jet ventilator", "TREATMENT", 775, 793], ["coughs", "OBSERVATION", 236, 242], ["particle", "OBSERVATION_MODIFIER", 642, 650], ["size", "OBSERVATION_MODIFIER", 651, 655], ["distributions", "OBSERVATION_MODIFIER", 656, 669], ["60 nm", "OBSERVATION_MODIFIER", 673, 678], ["reservoir", "ANATOMY_MODIFIER", 730, 739], ["Venturi effect", "OBSERVATION", 748, 762], ["jet ventilator", "OBSERVATION", 779, 793]]], ["The fog starts as an aqueous mixture, which is then heated to its boiling point and expelled from the machine.", [["The fog", "PROBLEM", 0, 7], ["an aqueous mixture", "TREATMENT", 18, 36], ["fog", "OBSERVATION", 4, 7]]], ["It then rapidly expands, dissipates, and cools to room temperature over the course of 20\u201330 seconds.", [["rapidly", "OBSERVATION_MODIFIER", 8, 15], ["expands", "OBSERVATION_MODIFIER", 16, 23]]], ["Its high temperature causes it to rise slowly, similar to cigarette smoke.", [["cigarette", "ORGANISM", 58, 67], ["Its high temperature", "PROBLEM", 0, 20], ["high temperature", "OBSERVATION_MODIFIER", 4, 20]]], ["Compared to a human cough, the fog is hotter, causing it to rise further and faster.", [["cough", "DISEASE", 20, 25], ["human", "ORGANISM", 14, 19], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["a human cough", "PROBLEM", 12, 25]]], ["However, to mitigate this, all images presented were taken no later than 12 seconds after cough initiation.", [["cough", "DISEASE", 90, 95], ["all images", "TEST", 27, 37], ["cough initiation", "PROBLEM", 90, 106]]], ["Furthermore, while fog machines have not previously been used in this specific manner, they have been extensively used to study aerodynamics, such as in wind tunnels, and provide an accurate visualization of airflow for the purposes of PPE analysis.Particle Generation Models ::: METHODSFor our droplet model (Figure 1B), a laryngotracheal mucosal atomization device (MAD; MADgic Laryngo-Tracheal Mucosal Atomization Device, Teleflex, Morrisville, NC), creating droplets with sizes 30\u2013100 \u00b5m, was used in place of the reservoir bag in the aerosol model.25Barrier Devices ::: METHODSA plastic intubation box, or \u201caerosolbox,\u201d was constructed according to publicly available specifications using \u215b\u201d thick, clear acrylic plastic and rubber cement.14 A 1 \u00d71 m intubation sheet was constructed from a standard machine cover made of clear plastic.15,16Testing Scenarios ::: METHODSTo mimic airway management situations with high potential for infection transmission, we assessed the following scenarios using aerosol and droplet models:Testing Scenarios ::: METHODSEach scenario was tested at least 3 times to ensure reproducibility; all trials were inspected, and the authors agreed that the aerosol and droplet spread were consistent within trials for each scenario.", [["mucosal", "ANATOMY", 340, 347], ["airway", "ANATOMY", 884, 890], ["infection", "DISEASE", 937, 946], ["airway", "MULTI-TISSUE_STRUCTURE", 884, 890], ["fog machines", "TREATMENT", 19, 31], ["an accurate visualization of airflow", "TEST", 179, 215], ["PPE analysis", "TEST", 236, 248], ["a laryngotracheal mucosal atomization device (MAD", "TREATMENT", 322, 371], ["MADgic Laryngo", "TREATMENT", 373, 387], ["Tracheal Mucosal Atomization Device", "TREATMENT", 388, 423], ["Teleflex, Morrisville, NC", "TREATMENT", 425, 450], ["creating droplets with sizes", "TREATMENT", 453, 481], ["the reservoir bag", "TREATMENT", 514, 531], ["the aerosol model", "TREATMENT", 535, 552], ["METHODSA plastic intubation box", "TREATMENT", 575, 606], ["\u215b\u201d thick", "TREATMENT", 694, 702], ["clear acrylic plastic and rubber cement", "TREATMENT", 704, 743], ["A 1 \u00d71 m intubation sheet", "TREATMENT", 747, 772], ["a standard machine", "TREATMENT", 794, 812], ["METHODSTo mimic airway management", "TREATMENT", 868, 901], ["infection transmission", "PROBLEM", 937, 959], ["the aerosol and droplet spread", "PROBLEM", 1183, 1213], ["laryngotracheal mucosal", "ANATOMY", 324, 347], ["Tracheal Mucosal", "ANATOMY", 388, 404], ["sizes", "OBSERVATION_MODIFIER", 476, 481], ["reservoir bag", "OBSERVATION", 518, 531], ["aerosol model", "OBSERVATION", 539, 552], ["acrylic plastic", "OBSERVATION", 710, 725], ["rubber cement", "OBSERVATION", 730, 743], ["clear plastic", "OBSERVATION", 827, 840]]], ["Simulator elements were fixed in place, except in scenarios 4 and 6, and the primary variability between trials was cough duration, as coughs were manually triggered.", [["Simulator elements", "DNA", 0, 18], ["Simulator elements", "TREATMENT", 0, 18], ["cough duration", "PROBLEM", 116, 130], ["coughs", "PROBLEM", 135, 141]]], ["Trials were video recorded for assessment of cough duration, and only those within the target cough durations were used in data analysis.", [["cough", "DISEASE", 45, 50], ["video", "TEST", 12, 17], ["assessment", "TEST", 31, 41], ["cough duration", "PROBLEM", 45, 59], ["data analysis", "TEST", 123, 136]]], ["Before testing, all air vents in the testing room were blocked off and doors were closed during experiments to limit confounding airflow.Data Capture and Analysis ::: METHODSFor the aerosol model, high-speed flash photography was used to provide easily understandable, detailed information on cough propagation through time and space (Figure 1C).", [["cough", "DISEASE", 293, 298], ["testing", "TEST", 7, 14], ["all air vents", "TREATMENT", 16, 29], ["the aerosol model", "TREATMENT", 178, 195], ["high-speed flash photography", "TREATMENT", 197, 225], ["cough propagation", "TEST", 293, 310], ["air vents", "OBSERVATION", 20, 29]]], ["For the droplet model, the simulator was placed on a fluid-resistant drape and a grid was drawn to standardize droplet deposition; exposure to health care workers (HCWs) near the patient was thus inferred (Figure 1D).", [["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 179, 186], ["the droplet model", "TEST", 4, 21], ["a fluid-resistant drape", "TREATMENT", 51, 74], ["a grid", "TEST", 79, 85], ["droplet deposition", "OBSERVATION", 111, 129]]], ["The cough simulator was placed at the center of the drape and the mannequin head was again placed in sniffing position.", [["head", "ANATOMY", 76, 80], ["cough", "DISEASE", 4, 9], ["head", "ORGANISM_SUBDIVISION", 76, 80], ["The cough simulator", "PROBLEM", 0, 19], ["the drape", "TREATMENT", 48, 57], ["the mannequin head", "TREATMENT", 62, 80], ["cough", "OBSERVATION", 4, 9]]], ["Two millilitersof fluorescein dye (1 mg/mL) was rapidly injected through the cough simulator\u2019s MAD.26,27 A camera and blue light were mounted on a tripod, then used for imaging individual grid locations separately after visual identification of at least 1 droplet in a particular square (Figure 1D).", [["fluorescein dye", "CHEMICAL", 18, 33], ["fluorescein", "CHEMICAL", 18, 29], ["fluorescein dye", "SIMPLE_CHEMICAL", 18, 33], ["Two millilitersof fluorescein dye", "TREATMENT", 0, 33], ["imaging", "TEST", 169, 176], ["visual identification", "TEST", 220, 241]]], ["Grid locations were imaged separately to ensure light falloff near the edges of each frame did not negatively impact visual analysis.", [["visual analysis", "TEST", 117, 132]]], ["Scenarios 1, 3, and 5 were repeated in this manner with droplets.Data Capture and Analysis ::: METHODSImages were processed in Adobe Photoshop and organized in Adobe Photoshop Lightroom (Adobe Inc, San Jose, CA).", [["Scenarios", "TEST", 0, 9]]], ["Cameras and flashes were triggered remotely while stationary on tripods, with consistent exposure, white balance, and flash intensity.", [["flashes", "PROBLEM", 12, 19], ["tripods", "TREATMENT", 64, 71], ["flash intensity", "PROBLEM", 118, 133], ["flashes", "OBSERVATION", 12, 19], ["flash intensity", "OBSERVATION", 118, 133]]], ["The image processing strategy was similar to that used in digital subtraction angiography, in which the background noise was subtracted using an image of the scene without fog present28 (Figure 2).", [["digital subtraction angiography", "TEST", 58, 89]]], ["In all images involving fog, the mannequin and cough simulator in the foreground were not altered.", [["cough", "DISEASE", 47, 52], ["the mannequin", "TREATMENT", 29, 42], ["cough simulator", "TEST", 47, 62]]], ["Analysis of fluorescein deposition was conducted by separating the green droplets from the blue background by isolating the green channel from the full-color image; photos of different grid locations were then manually aligned and assembled in Photoshop (Figure 4).RESULTSResults from scenarios 1 and 2 are seen in Figure 2.", [["fluorescein", "CHEMICAL", 12, 23], ["fluorescein", "CHEMICAL", 12, 23], ["fluorescein", "SIMPLE_CHEMICAL", 12, 23], ["green channel", "PROTEIN", 124, 137], ["fluorescein deposition", "PROBLEM", 12, 34], ["scenarios", "TEST", 285, 294], ["fluorescein deposition", "OBSERVATION", 12, 34], ["green droplets", "OBSERVATION", 67, 81], ["green channel", "OBSERVATION", 124, 137]]], ["The fog was visualized near the intubator\u2019s head while the simulator was in standard sniffing position (Figure 2A).", [["intubator\u2019s head", "ANATOMY", 32, 48], ["head", "ORGAN", 44, 48], ["The fog", "PROBLEM", 0, 7], ["fog", "OBSERVATION", 4, 7], ["head", "ANATOMY", 44, 48]]], ["When the simulator was placed in 15\u00b0 of reverse Trendelenburg, fog was directed away from the intubator\u2019s head (Figure 2B).RESULTSScenarios including barrier devices are seen in Figure 3.", [["intubator\u2019s head", "ANATOMY", 94, 110], ["head", "ORGANISM_SUBDIVISION", 106, 110], ["reverse Trendelenburg", "TREATMENT", 40, 61], ["barrier devices", "TREATMENT", 150, 165], ["head", "ANATOMY", 106, 110], ["barrier devices", "OBSERVATION", 150, 165]]], ["Using the intubation box, fog was seen exiting the box after a simulated cough, with the majority escaping toward the feet.", [["feet", "ANATOMY", 118, 122], ["cough", "DISEASE", 73, 78], ["feet", "ORGANISM_SUBDIVISION", 118, 122], ["the intubation box", "TREATMENT", 6, 24], ["a simulated cough", "PROBLEM", 61, 78], ["cough", "OBSERVATION", 73, 78], ["feet", "ANATOMY", 118, 122]]], ["Figure 3C was captured 2 seconds after Figure 3A was captured.", [["Figure 3C", "TREATMENT", 0, 9]]], ["In scenarios 4 and 6, a small amount of fog was visible underneath each barrier during its removal.", [["a small amount of fog", "PROBLEM", 22, 43], ["its removal", "TREATMENT", 87, 98], ["small", "OBSERVATION_MODIFIER", 24, 29], ["amount", "OBSERVATION_MODIFIER", 30, 36], ["fog", "OBSERVATION", 40, 43]]], ["In some instances, the fog was propelled toward the intubator, depending on the manner in which the barrier was removed (Figure 3D\u2013F).", [["intubator", "ANATOMY", 52, 61], ["barrier", "TISSUE", 100, 107], ["the fog", "PROBLEM", 19, 26], ["the intubator", "TREATMENT", 48, 61], ["the barrier", "TREATMENT", 96, 107], ["some", "OBSERVATION_MODIFIER", 3, 7], ["instances", "OBSERVATION", 8, 17]]], ["When using a 1 \u00d71 m clear plastic intubation sheet, a small amount of fog was seen escaping toward the intubator (Figure 3G, H).", [["a 1 \u00d71 m clear plastic intubation sheet", "TREATMENT", 11, 50], ["a small amount of fog", "PROBLEM", 52, 73], ["small", "OBSERVATION_MODIFIER", 54, 59], ["amount", "OBSERVATION_MODIFIER", 60, 66]]], ["To better visualize this phenomenon and avoid dilution of the fog with the simulated cough, the fog machine was run continuously for 3 seconds under both the intubation box and sheet to track air flow (Figure 3I, J).RESULTSDroplet deposition from an uncovered cough, at the level of the patient, is presented in Figure 4A, which shows 3 trials overlaid.", [["cough", "DISEASE", 85, 90], ["cough", "DISEASE", 260, 265], ["patient", "ORGANISM", 287, 294], ["patient", "SPECIES", 287, 294], ["this phenomenon", "PROBLEM", 20, 35], ["the fog", "PROBLEM", 58, 65], ["the simulated cough", "PROBLEM", 71, 90], ["the fog machine", "TREATMENT", 92, 107], ["the intubation box", "TREATMENT", 154, 172], ["RESULTSDroplet deposition", "PROBLEM", 216, 241], ["an uncovered cough", "PROBLEM", 247, 265], ["cough", "OBSERVATION", 85, 90], ["deposition", "OBSERVATION_MODIFIER", 231, 241], ["uncovered", "OBSERVATION_MODIFIER", 250, 259], ["cough", "OBSERVATION", 260, 265]]], ["Trials involving the intubation box (not pictured) showed droplet deposition within the box, with a minimal amount on the face; no droplets were seen outside the chamber.", [["face", "ANATOMY", 122, 126], ["droplets", "ANATOMY", 131, 139], ["the intubation box", "TREATMENT", 17, 35], ["droplet deposition within the box", "PROBLEM", 58, 91], ["a minimal amount on the face", "PROBLEM", 98, 126], ["droplets", "PROBLEM", 131, 139], ["droplet deposition", "OBSERVATION", 58, 76], ["box", "ANATOMY_MODIFIER", 88, 91], ["minimal", "OBSERVATION_MODIFIER", 100, 107], ["amount", "OBSERVATION_MODIFIER", 108, 114], ["face", "ANATOMY", 122, 126], ["no", "UNCERTAINTY", 128, 130], ["droplets", "OBSERVATION", 131, 139], ["chamber", "ANATOMY_MODIFIER", 162, 169]]], ["The intubation sheet also appeared to effectively capture droplets (Figure 4B); however, after its removal, gross contamination was noted on both the sheet and the patient\u2019s face (Figure 4C).DISCUSSIONBarrier devices have been recommended to limit HCWs\u2019 exposure during aerosolizing procedures such as intubation and extubation.", [["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["The intubation sheet", "TREATMENT", 0, 20], ["its removal", "TREATMENT", 95, 106], ["gross contamination", "PROBLEM", 108, 127], ["DISCUSSIONBarrier devices", "TREATMENT", 191, 216], ["aerosolizing procedures", "TREATMENT", 270, 293], ["intubation", "TREATMENT", 302, 312], ["extubation", "TREATMENT", 317, 327], ["gross", "OBSERVATION_MODIFIER", 108, 113], ["contamination", "OBSERVATION", 114, 127]]], ["This study is the first to qualitatively assess these barrier devices with both aerosol and droplet models, using a physiologically accurate cough simulator.DISCUSSIONBoth intubation boxes and sheets were seemingly capable of capturing droplets in our model, many of which could otherwise have reached the face, neck, and shoes of the HCW.", [["face", "ANATOMY", 306, 310], ["neck", "ANATOMY", 312, 316], ["face", "ORGANISM_SUBDIVISION", 306, 310], ["neck", "ORGANISM_SUBDIVISION", 312, 316], ["This study", "TEST", 0, 10], ["these barrier devices", "TREATMENT", 48, 69], ["both aerosol and droplet models", "TREATMENT", 75, 106], ["intubation boxes", "TREATMENT", 172, 188], ["neck", "ANATOMY", 312, 316]]], ["Aerosols were seen escaping both barrier devices during simulated coughs, sometimes directed toward the HCW.", [["Aerosols", "TREATMENT", 0, 8], ["both", "OBSERVATION_MODIFIER", 28, 32], ["barrier devices", "OBSERVATION", 33, 48]]], ["Depending on how the intubation sheet is draped, it is possible that reaching under the drapes may provide a pathway for warm, rising aerosol to travel toward the HCW.", [["the intubation sheet", "TREATMENT", 17, 37], ["the drapes", "TREATMENT", 84, 94], ["warm", "PROBLEM", 121, 125]]], ["Our model does not allow for visualization of fog beyond 30 seconds after a simulated cough, due to its evaporation; however, our observations suggest that the act of removing these barriers may propel entrained aerosol in an unintended manner, potentially toward the HCW.", [["cough", "DISEASE", 86, 91], ["a simulated cough", "PROBLEM", 74, 91], ["these barriers", "TREATMENT", 176, 190]]], ["Furthermore, airflow generated in negative and positive pressure rooms (on the order of 12\u201320 air exchanges per hour) may be inhibited by these barrier devices, and it is possible that airborne contaminants may continue to disperse over the course of many minutes or even hours.DISCUSSIONPatient positioning may have a significant impact on HCW exposure.", [["airflow", "PROBLEM", 13, 20], ["these barrier devices", "TREATMENT", 138, 159], ["airborne contaminants", "PROBLEM", 185, 206], ["negative", "OBSERVATION", 34, 42], ["positive", "OBSERVATION_MODIFIER", 47, 55], ["pressure", "OBSERVATION_MODIFIER", 56, 64], ["significant", "OBSERVATION_MODIFIER", 319, 330]]], ["Optimal intubating conditions include placing the patient\u2019s head, neck, and shoulders in sniffing position.", [["head", "ANATOMY", 60, 64], ["neck", "ANATOMY", 66, 70], ["shoulders", "ANATOMY", 76, 85], ["patient", "ORGANISM", 50, 57], ["head", "ORGANISM_SUBDIVISION", 60, 64], ["neck", "ORGANISM_SUBDIVISION", 66, 70], ["shoulders", "ORGANISM_SUBDIVISION", 76, 85], ["patient", "SPECIES", 50, 57], ["Optimal intubating conditions", "TREATMENT", 0, 29], ["the patient\u2019s head, neck, and shoulders in sniffing position", "TEST", 46, 106], ["head", "ANATOMY", 60, 64], ["neck", "ANATOMY", 66, 70], ["shoulders", "ANATOMY", 76, 85]]], ["However, slight reverse Trendelenburg positioning may redirect aerosol flow away from a HCW standing at the head of the bed.", [["head", "ANATOMY", 108, 112], ["head", "ORGANISM_SUBDIVISION", 108, 112], ["slight reverse Trendelenburg positioning", "TREATMENT", 9, 49], ["slight", "OBSERVATION_MODIFIER", 9, 15], ["reverse Trendelenburg", "OBSERVATION", 16, 37], ["bed", "ANATOMY", 120, 123]]], ["Although reverse Trendelenburg is not ideal for direct laryngoscopy, video laryngoscopy is currently recommended for COVID-19 patients, and thus this minor change should have minimal impact on intubation time.29,30 Given our observation that the intubation box directs more aerosol toward the foot of the bed, it may be prudent for assistants to also stand at the head of the bed to minimize exposure.", [["foot", "ANATOMY", 293, 297], ["head", "ANATOMY", 364, 368], ["patients", "ORGANISM", 126, 134], ["foot", "ORGANISM_SUBDIVISION", 293, 297], ["head", "ORGANISM_SUBDIVISION", 364, 368], ["intubation box", "DNA", 246, 260], ["patients", "SPECIES", 126, 134], ["direct laryngoscopy", "TEST", 48, 67], ["video laryngoscopy", "TEST", 69, 87], ["COVID", "TEST", 117, 122], ["the intubation box", "TREATMENT", 242, 260], ["minimal", "OBSERVATION_MODIFIER", 175, 182], ["foot", "ANATOMY", 293, 297], ["bed", "ANATOMY", 305, 308]]], ["Finally, our observations suggest that an intubator wearing a forehead-mounted face shield without either neck protection or a powered air-purifying respirator (PAPR) may inadvertently trap aerosol near their face and increase their risk of exposure.", [["intubator", "ANATOMY", 42, 51], ["forehead", "ANATOMY", 62, 70], ["neck", "ANATOMY", 106, 110], ["neck", "ORGANISM_SUBDIVISION", 106, 110], ["an intubator", "TREATMENT", 39, 51], ["a forehead-mounted face shield", "TREATMENT", 60, 90], ["neck protection", "TREATMENT", 106, 121], ["a powered air-purifying respirator (PAPR", "TREATMENT", 125, 165]]], ["This potential shortfall was also noticed by our clinical intubating team and warrants further investigation.DISCUSSIONDue to the urgent need for information during the COVID-19 pandemic, we rapidly developed a cough model that has several limitations.", [["further investigation", "TEST", 87, 108], ["a cough model", "PROBLEM", 209, 222], ["cough", "OBSERVATION", 211, 216]]], ["While our cough simulator does not achieve the maximal flow rates of a human cough, it exceeds the average flow rates and is sufficient to propel droplets and aerosols 2.4\u20132.6 m vertically and horizontally, which approximates a human cough.31\u201333 The simulated cough may even overestimate the strength of a cough in a COVID-19 patient with respiratory decompensation.", [["respiratory", "ANATOMY", 339, 350], ["cough", "DISEASE", 10, 15], ["cough", "DISEASE", 77, 82], ["cough", "DISEASE", 234, 239], ["cough", "DISEASE", 260, 265], ["cough", "DISEASE", 306, 311], ["respiratory decompensation", "DISEASE", 339, 365], ["human", "ORGANISM", 71, 76], ["human", "ORGANISM", 228, 233], ["patient", "ORGANISM", 326, 333], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 228, 233], ["patient", "SPECIES", 326, 333], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 228, 233], ["a human cough", "PROBLEM", 69, 82], ["aerosols", "TREATMENT", 159, 167], ["a human cough", "PROBLEM", 226, 239], ["The simulated cough", "PROBLEM", 246, 265], ["a cough", "PROBLEM", 304, 311], ["respiratory decompensation", "PROBLEM", 339, 365], ["cough", "OBSERVATION", 234, 239], ["cough", "OBSERVATION", 260, 265], ["cough", "OBSERVATION", 306, 311], ["respiratory decompensation", "OBSERVATION", 339, 365]]], ["Although more complex cough simulator designs might afford an increase in fidelity, they come at significant cost and time, while requiring further expertise, which limits the ability of others to replicate our studyand test their own protective equipment.DISCUSSIONIn conclusion, both intubation boxes and sheets may reduce the intubator\u2019s exposure to droplets during simulated coughs, but both may merely redirect aerosolized particles, potentially toward HCWs.", [["cough", "DISEASE", 22, 27], ["coughs", "DISEASE", 379, 385], ["more complex cough simulator designs", "PROBLEM", 9, 45], ["an increase in fidelity", "PROBLEM", 59, 82], ["our studyand test", "TEST", 207, 224], ["both intubation boxes", "TREATMENT", 281, 302], ["simulated coughs", "PROBLEM", 369, 385], ["increase", "OBSERVATION_MODIFIER", 62, 70]]], ["Patients should be positioned to facilitate intubation, but it is possible that incorporating slight reverse Trendelenburg may direct aerosols away from the intubator.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["intubation", "TREATMENT", 44, 54], ["slight reverse Trendelenburg", "TREATMENT", 94, 122], ["the intubator", "TREATMENT", 153, 166]]], ["Although barrier devices like the intubation box and sheet were developed to protect HCWs, our observations suggest that these barriers might be ineffective at containing certain infectious particles, and may even increase operator exposure, particularly with aerosolized particles.", [["barrier devices", "TREATMENT", 9, 24], ["the intubation box", "TREATMENT", 30, 48], ["certain infectious particles", "PROBLEM", 171, 199], ["barrier devices", "OBSERVATION", 9, 24]]], ["Further study is necessary to better quantify and investigate the effectiveness of these barrier devices and make way for further innovation.DISCLOSURESName: Eric A. Fried, MD.DISCLOSURESContribution: This author helped with study conception, cough model design, data collection, and manuscript preparation, and discussed the results and contributed to the final manuscript.DISCLOSURESName: George Zhou, MD.DISCLOSURESContribution: This author helped with study conception, cough model design, data collection, data visualization and analysis, and manuscript preparation, and discussed the results and contributed to the final manuscript.DISCLOSURESName: Ronak Shah, MD.DISCLOSURESContribution: This author helped design the study and collect the data, and discussed the results and contributed to the final manuscript.DISCLOSURESName: Da Wi Shin, BE.DISCLOSURESContribution: This author helped analyze the data, discussed the results and contributed to the final manuscript.DISCLOSURESName: Anjan Shah, MD.DISCLOSURESContribution: This author helped collect the data, discussed the results and contributed to the final manuscript.DISCLOSURESName: Daniel Katz, MD.DISCLOSURESContribution: This author helped design the study and prepare the manuscript, and discussed the results and contributed to the final manuscript.DISCLOSURESName: Garrett W. Burnett, MD.DISCLOSURESContribution: This author helped with study design, cough model design, data collection, and manuscript preparation, and discussed the results and contributed to the final manuscript.DISCLOSURESThis manuscript was handled by: Narasimhan Jagannathan, MD, MBA.", [["Further study", "TEST", 0, 13], ["these barrier devices", "TREATMENT", 83, 104], ["further innovation", "TREATMENT", 122, 140], ["study conception", "TREATMENT", 225, 241], ["cough model design, data collection", "PROBLEM", 243, 278], ["study conception", "TREATMENT", 456, 472], ["cough", "PROBLEM", 474, 479], ["data collection", "TEST", 494, 509], ["data visualization", "TEST", 511, 529], ["analysis", "TEST", 534, 542], ["the study", "TEST", 721, 730], ["the study", "TEST", 1215, 1224], ["data collection", "TEST", 1442, 1457], ["Shin", "ANATOMY", 842, 846]]]], "ec8f78b6845c7b762589200f3bcea5c285929486": [["The Canadian Institutes of Health Research specifically stress the \"synthesis, dissemination, exchange and ethically sound application\" as key components of the knowledge translation process [5] .", [["dissemination, exchange", "TREATMENT", 79, 102], ["ethically sound application", "TREATMENT", 107, 134]]], ["One popular knowledge translation model, Knowledge-to-Action, outlines both cycles of knowledge creation and knowledge application [5, 6] cation cycle involves adapting knowledge to the local context of users, as well as identifying barriers to using and accessing this knowledge [5] .", [["5, 6] cation", "CHEMICAL", 132, 144]]], ["End users include a variety of individuals, including health care professionals, policy makers, patients, and families [5] .", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104]]], ["As more members of the public use the internet as a means of accessing health information [7] , the synthesis and dissemination of research knowledge to lay audiences is becoming a key responsibility of researchers, not merely an occasional by-product.IntroductionThere are several barriers facing laypersons trying to access research information online.", [["the synthesis", "TREATMENT", 96, 109]]], ["Although these stylistic choices are appropriate and even encouraged in academia, it can be alienating for lay audiences [9, 10] .IntroductionLay summaries have been demonstrated to make findings accessible and understandable to these non-specialist audiences [9] [10] [11] [12] .", [["[9] [10] [11] [12]", "SIMPLE_CHEMICAL", 260, 278]]], ["This style of writing focuses on clear, engaging, and concise writing with the removal of technical jargon [13] .", [["the removal", "TREATMENT", 75, 86]]], ["This difficulty is caused by many factors, including the vast difference in style between scientific and lay writing, the overabundance of scientific jargon, the heterogeneous nature of the lay audience, and fear of over-generalizing research findings [15] .IntroductionOne platform that has made extensive use of lay summaries is HDBuzz, an online knowledge translation website that focuses on Huntington's disease research [16] .", [["Huntington's disease", "DISEASE", 395, 415], ["heterogeneous", "OBSERVATION_MODIFIER", 162, 175]]], ["Huntington's disease is a fatal neurodegenerative disorder caused by an abnormal expansion of CAG triplet repeats in the huntingtin gene [17] .", [["Huntington's disease", "DISEASE", 0, 20], ["neurodegenerative disorder", "DISEASE", 32, 58], ["huntingtin", "GENE_OR_GENE_PRODUCT", 121, 131], ["CAG triplet repeats", "DNA", 94, 113], ["huntingtin gene", "DNA", 121, 136], ["Huntington's disease", "PROBLEM", 0, 20], ["a fatal neurodegenerative disorder", "PROBLEM", 24, 58], ["an abnormal expansion", "PROBLEM", 69, 90], ["CAG triplet repeats", "TREATMENT", 94, 113], ["fatal", "OBSERVATION_MODIFIER", 26, 31], ["neurodegenerative", "OBSERVATION_MODIFIER", 32, 49], ["abnormal", "OBSERVATION_MODIFIER", 72, 80], ["expansion", "OBSERVATION_MODIFIER", 81, 90]]], ["HDBuzz was launched in January 2011 by Drs. Ed Wild and Jeffrey Carroll, motivated by discussions with Huntington's disease patients [16] .", [["HDBuzz", "CHEMICAL", 0, 6], ["Huntington's disease", "DISEASE", 103, 123], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132]]], ["This platform provides short lay summaries written by clinicians or scientists, explaining how a particular research article fits into the broader Huntington's disease literature [16] .IntroductionInspired by HDBuzz and discussions with ataxia patients and family members at the 2018 National Ataxia Foundation's Ataxia Investigators Meeting, we wanted to launch a knowledge translation website focusing on another form of fatal neurodegenerative disease: Spinocerebellar ataxia (SCA).", [["Huntington's disease", "DISEASE", 147, 167], ["ataxia", "DISEASE", 237, 243], ["Ataxia", "DISEASE", 293, 299], ["Ataxia", "DISEASE", 313, 319], ["neurodegenerative disease", "DISEASE", 429, 454], ["Spinocerebellar ataxia", "DISEASE", 456, 478], ["SCA", "DISEASE", 480, 483], ["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 244, 252], ["fatal neurodegenerative disease", "PROBLEM", 423, 454], ["Spinocerebellar ataxia (SCA)", "PROBLEM", 456, 484], ["Spinocerebellar ataxia", "OBSERVATION", 456, 478], ["SCA", "ANATOMY", 480, 483]]], ["Lack of communication between ataxia researchers and patients has previously been identified as a barrier to patient engagement [18] .", [["ataxia", "DISEASE", 30, 36], ["patients", "ORGANISM", 53, 61], ["patient", "ORGANISM", 109, 116], ["patients", "SPECIES", 53, 61], ["patient", "SPECIES", 109, 116], ["ataxia", "PROBLEM", 30, 36]]], ["SCAs are a group of autosomal dominant disorders that primarily cause ataxia, the loss of motor control and balance [19] .", [["SCAs", "DISEASE", 0, 4], ["autosomal dominant disorders", "DISEASE", 20, 48], ["ataxia", "DISEASE", 70, 76], ["loss of motor control", "DISEASE", 82, 103], ["SCAs", "CANCER", 0, 4], ["autosomal dominant disorders", "PROBLEM", 20, 48], ["ataxia", "PROBLEM", 70, 76], ["the loss of motor control and balance", "PROBLEM", 78, 115], ["dominant", "OBSERVATION_MODIFIER", 30, 38], ["disorders", "OBSERVATION", 39, 48]]], ["Six subtypes of SCA are CAG triplet repeat expansion diseases like Huntington's disease, and there is some similarity in symptoms between these conditions [20] .IntroductionIn September 2018 we launched SCAsource, an online knowledge translation platform where peer-reviewed research papers on ataxia are translated into lay summaries.", [["SCA", "DISEASE", 16, 19], ["Huntington's disease", "DISEASE", 67, 87], ["ataxia", "DISEASE", 294, 300], ["SCA", "PROBLEM", 16, 19], ["CAG triplet repeat expansion diseases", "PROBLEM", 24, 61], ["Huntington's disease", "PROBLEM", 67, 87], ["some similarity in symptoms", "PROBLEM", 102, 129], ["ataxia", "PROBLEM", 294, 300], ["SCA", "ANATOMY", 16, 19], ["expansion", "OBSERVATION_MODIFIER", 43, 52], ["diseases", "OBSERVATION", 53, 61], ["Huntington", "OBSERVATION_MODIFIER", 67, 77]]], ["The main objective of SCAsource is to make ataxia research more accessible and understandable to patients and families.", [["ataxia", "DISEASE", 43, 49], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["ataxia", "PROBLEM", 43, 49], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Secondary objectives include providing opportunities for junior ataxia researchers to develop and hone their knowledge translation skills, improving the quality of patient communication across the ataxia community.IntroductionSCAsource began as a low-budget pilot project, with initial start-up costs (\ufffd$500 USD) being covered by members of the SCAsource team.", [["ataxia", "DISEASE", 64, 70], ["ataxia", "DISEASE", 197, 203], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["junior ataxia", "PROBLEM", 57, 70], ["the ataxia community", "PROBLEM", 193, 213], ["IntroductionSCAsource", "TREATMENT", 214, 235], ["a low-budget pilot project", "TREATMENT", 245, 271]]], ["The website was set up through Word-Press, an online content management system which allowed for the creation of a professional website by persons with limited web design experience.", [["persons", "ORGANISM", 139, 146], ["persons", "SPECIES", 139, 146], ["an online content management system", "TREATMENT", 43, 78]]], ["We chose to create an independent website, as opposed to going through an already existing ataxia organization, to limit perceived bias towards a particular geographic location and reach as wide of an audience as possible.IntroductionArticle style and quality assurance guidelines were developed by volunteers who had previous knowledge translation training with other organizations.", [["ataxia", "DISEASE", 91, 97], ["volunteers", "ORGANISM", 299, 309], ["an already existing ataxia organization", "PROBLEM", 71, 110], ["translation training", "TREATMENT", 337, 357], ["ataxia", "OBSERVATION", 91, 97]]], ["Initial advertisement of articles was done through social media with support from the National Ataxia Foundation.IntroductionVolunteer contributors are recruited through word-of-mouth, primarily at international conferences which focus on ataxia research.", [["Ataxia", "DISEASE", 95, 101], ["ataxia", "DISEASE", 239, 245], ["mouth", "ORGANISM_SUBDIVISION", 178, 183], ["ataxia research", "PROBLEM", 239, 254], ["mouth", "ANATOMY", 178, 183]]], ["We have also had contributors contact SCAsource directly or be referred by current volunteers.", [["volunteers", "ORGANISM", 83, 93]]], ["Most volunteers come from a basic science background.", [["volunteers", "ORGANISM", 5, 15]]], ["However, more clinical researchers have signed up to write for SCAsource as it has expanded into covering clinical trial results.", [["SCAsource", "TREATMENT", 63, 72]]], ["New volunteers are giving a training guide on how to write effective lay summaries, providing constructive editing feedback, and document guidelines for our two specific article types.", [["volunteers", "ORGANISM", 4, 14], ["a training guide", "TREATMENT", 26, 42]]], ["These new writers are then paired with more experienced editors during their first few volunteer experiences, to allow for mentorship on knowledge translation to occur through the writing and editing process.IntroductionCurrently, SCAsource has two regularly updated article types (Summaries and \"Snapshots\") and two \"static\" reference resources (a glossary and introduction to Ataxia article).", [["Ataxia", "DISEASE", 378, 384]]], ["All SCAsource content is published under a Creative Commons license, making it freely available to distribute.IntroductionSCAsource contributors follow a month-long article writing and editing process.", [["SCAsource content", "OBSERVATION", 4, 21]]], ["This includes a suitability for general audience score of 80% using De-Jargonizer, an automated jargon identification program [21] .IntroductionIn September 2019, we launched an online survey to determine if SCAsource was meeting its mandate objectives of improving readers' knowledge of ataxia research and volunteers' knowledge translation skill sets.", [["ataxia", "DISEASE", 288, 294], ["general audience score", "TEST", 32, 54], ["ataxia", "PROBLEM", 288, 294]]], ["The objective of this study was to determine the impact of SCAsource on its readers and volunteers, establish strengths of the platform, and identify areas of improvement.", [["volunteers", "ORGANISM", 88, 98], ["this study", "TEST", 17, 27], ["SCAsource", "TREATMENT", 59, 68], ["improvement", "OBSERVATION", 159, 170]]], ["Through this study, we hope to provide a framework for which other disease groups can launch and evaluate their own low-initial-cost knowledge translation websites.Ethics approvalThis study was evaluated by the Hamilton Integrated Research Ethics Board (Project Numbers 7425 & 7426) and determined to be exempted from ethics review due to it being considered secondary use of anonymous quality assurance data.Study design, participants and recruitmentTwo parallel online surveys were launched from September 27, 2019 to December 2, 2019; one for SCAsource volunteer contributors and one for SCAsource readers.", [["participants", "SPECIES", 423, 435], ["this study", "TEST", 8, 18], ["This study", "TEST", 179, 189], ["SCAsource volunteer contributors", "PROBLEM", 546, 578], ["SCAsource readers", "TREATMENT", 591, 608]]], ["Both surveys were administered through the LimeSurvey platform, taking approximately 20-30 minutes to complete.", [["the LimeSurvey platform", "TREATMENT", 39, 62]]], ["The surveys comprised of Likert-scale and multiple-choice type quantitative questions, along with open-ended qualitative questions.Study design, participants and recruitmentNo financial incentive was given for either survey.", [["participants", "SPECIES", 145, 157]]], ["To increase the response rate, a followup email was sent two weeks after initial contact.Study design, participants and recruitmentThirty-three SCAsource volunteers met the selection criteria for the contributor survey.", [["volunteers", "ORGANISM", 154, 164], ["participants", "SPECIES", 103, 115], ["a followup email", "TEST", 31, 47]]], ["This included (i) having written or edited at least one article for SCAsource between September 2018-September 2019, and (ii) not being an investigator on this study.", [["this study", "TEST", 155, 165]]], ["They were given a letter of information about the study and a link to the online survey.Study design, participants and recruitmentOur inclusion criteria for the reader survey were individuals who (i) had read at least one SCAsource article between September 2018-September 2019, (ii) were 16 years of age or older, (iii) did not act as a contributor to SCAsource, and (iv) were not an investigator on this study.", [["participants", "SPECIES", 102, 114], ["the study", "TEST", 46, 55], ["this study", "TEST", 401, 411]]], ["Estimating the population size eligible for the reader survey was more challenging, as visitor information to the website is measured in IP address statistics.", [["population", "OBSERVATION_MODIFIER", 15, 25], ["size", "OBSERVATION_MODIFIER", 26, 30]]], ["More than one individual could use the same IP address, or one person could use multiple IP addresses.", [["person", "SPECIES", 63, 69], ["multiple IP addresses", "TREATMENT", 80, 101]]], ["To recruit readers, an email was sent to the SCAsource subscription list (57 eligible participants) including the study letter of information and link to the survey.", [["participants", "SPECIES", 86, 98], ["the study", "TEST", 110, 119]]], ["Two pinned posts advertising the survey were published on the SCAsource website and Twitter account to engage readers who visit the website but are not subscribed for updates.AnalysisOnce data was collected, survey response data was formatted and transferred to the qualitative data analysis software MAXQDA (VERBI GmbH, Berlin, Germany).", [["AnalysisOnce data", "TEST", 175, 192], ["survey response data", "TEST", 208, 228], ["pinned", "OBSERVATION_MODIFIER", 4, 10], ["posts", "OBSERVATION_MODIFIER", 11, 16]]], ["Quantitative data was entered into GraphPad Prism 8 for analysis and formatting.AnalysisTo analyze qualitative data, we took a social constructivist approach to grounded theory as described by Charmaz for open coding [22] .", [["Quantitative data", "TEST", 0, 17], ["analysis", "TEST", 56, 64]]], ["Two researchers independently completed thematic analysis following a line-by-line open coding approach in MAXQDA [22] .", [["thematic analysis", "TEST", 40, 57], ["a line", "TREATMENT", 68, 74]]], ["For dependability and confirmability, we have included a detailed description of the coding process used with multiple independent coders, which included investigator triangulation to remove potential vias from the analysis.", [["the analysis", "TEST", 211, 223]]], ["Website views display seasonal fluctuations, receiving fewer views during winter holidays, with an overall increasing trend between years ( Fig 1A) .", [["Website views", "TEST", 0, 13], ["seasonal fluctuations", "PROBLEM", 22, 43], ["seasonal fluctuations", "OBSERVATION", 22, 43], ["increasing", "OBSERVATION_MODIFIER", 107, 117]]], ["Over half of SCAsource website views originate from the United States, followed by Canada (10%), the United Kingdom (5.8%), China (2.8%), and India (2.2%) ( Fig 1B) .Respondent sample characteristicsWe had an overall response rate of 58% (19/33) for volunteers, which is higher than most e-mail survey response rates [25] .", [["volunteers", "ORGANISM", 250, 260]]], ["Of the volunteers who responded to the survey, 74% (14/19) completed all sections, while 32% (6/19) skipped the qualitative feedback portion.", [["sections", "ANATOMY", 73, 81], ["volunteers", "ORGANISM", 7, 17], ["the survey", "TEST", 35, 45], ["all sections", "TEST", 69, 81]]], ["Most volunteers report they read SCAsource content, with 68% (13/19) visiting the website once a month.Respondent sample characteristicsWe had 36 respondents to the reader survey, with 75% (27/36) completing all sections of the survey.", [["volunteers", "ORGANISM", 5, 15]]], ["Although we initially hoped for a greater response rate, this level of participation is not surprising as one symptom people in our target demographic may experience is difficulty with fine motor tasks.", [["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124], ["difficulty with fine motor tasks", "PROBLEM", 169, 201]]], ["This barrier inherent to the use of an online survey protocol may explain the reduced rates of response.", [["an online survey protocol", "TREATMENT", 36, 61], ["the reduced rates of response", "PROBLEM", 74, 103]]], ["This approach was not feasible for this study because of the worldwide distribution of SCAsource readers and limited research funding.", [["this study", "TEST", 35, 45], ["SCAsource readers", "PROBLEM", 87, 104]]], ["Readers reported frequently searching for ataxia information, with 82% (29/36) searching online once a month or more.", [["ataxia", "DISEASE", 42, 48], ["ataxia", "PROBLEM", 42, 48]]], ["The sources that readers reported using most frequently were the National Ataxia Foundation (64%, n = 23), an American ataxia charity located in Minnesota, and search engine results (61%, n = 61).", [["Ataxia", "DISEASE", 74, 80], ["ataxia", "DISEASE", 119, 125], ["an American ataxia charity", "PROBLEM", 107, 133]]], ["The SCAsource website was the third most used source of ataxia information at 56% (n = 20).", [["ataxia", "DISEASE", 56, 62], ["ataxia information", "PROBLEM", 56, 74]]], ["When asked where they find out about SCAsource content, the top sources cited by readers were the SCAsource website (39%, n = 14), SCAsource subscription list (39%, n = 14), the National Ataxia Foundation's social media (36%, n = 13), and search engine results (28%, n = 10).Impact of contributing to SCAsource on volunteersFeedback from volunteers on the impact of SCAsource on their skill development was generally positive, as depicted in Fig 2.", [["Ataxia", "DISEASE", 187, 193], ["volunteers", "ORGANISM", 314, 324], ["volunteers", "ORGANISM", 338, 348], ["the National Ataxia", "PROBLEM", 174, 193], ["SCAsource on volunteers", "PROBLEM", 301, 324], ["SCAsource", "TREATMENT", 366, 375], ["positive", "OBSERVATION", 417, 425]]], ["Over half the volunteers (58%, n = 11) agreed thatPLOS ONEcontributing to SCAsource improved their writing or editing skills, with 90% (n = 32) saying it improved their confidence when communicating to lay audiences (Fig 2) .", [["volunteers", "ORGANISM", 14, 24]]], ["Volunteers also reported the amount of time they dedicate to knowledge translation activities increased (74% agree or strongly agree, n = 14), although the majority rated it had no impact on their time management skills (63% neutral, n = 12) (Fig 2) .", [["Volunteers", "ORGANISM", 0, 10], ["skills", "TEST", 213, 219]]], ["Sixty-two percent (12/19) agreed that volunteering for SCAsource was beneficial to their development as a scientist, with 53% (10/19) stating the experience enhanced their understanding of ataxia literature (Fig 2) .", [["ataxia", "DISEASE", 189, 195], ["ataxia literature", "PROBLEM", 189, 206]]], ["Most respondents (89%, n = 17) agreed they saw volunteering for SCAsource as a way to give back to the ataxia patient community (Fig 2) .", [["ataxia", "DISEASE", 103, 109], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["SCAsource", "TREATMENT", 64, 73]]], ["Based on these quantitative measures, SCAsource volunteers reported a gain in knowledge translation skills, including writing, editing, and lay audience communication, in addition to increased time spent on knowledge translation activities.PLOS ONESimilar themes of skill development and confidence in knowledge translation also emerged from the analysis of qualitative responses.", [["volunteers", "ORGANISM", 48, 58]]], ["As it has been previously shown that researchers struggle with choosing appropriate lay terminology [14] , hence, our volunteers reporting this level of conscious awareness of word choice is promising.PLOS ONEMultiple volunteers also identified improved confidence in knowledge translation as the main impact SCAsource has had on them, mirroring the quantitative Likert-style data (Fig 2) .", [["volunteers", "ORGANISM", 118, 128]]], ["This is likely tied to the high proportion of volunteers for whom SCAsource was one of theirPLOS ONEfirst opportunities to engage in knowledge translation.", [["volunteers", "ORGANISM", 46, 56]]], ["The other key strength of SCAsource from the perspective of volunteers was the potential utility to patients and families.", [["volunteers", "ORGANISM", 60, 70], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108]]], ["Volunteers specifically liked the breadth of topics covered and the emphasis of current research being quickly communicated (Table 3) .PLOS ONEWhen asked about potential areas of improvement, contributors identified training for new volunteers and public awareness of SCAsource.", [["SCAsource", "PROBLEM", 268, 277]]], ["Currently, when new volunteers are onboarded, they are given three documents outlining the SCAsource guidelines on summary writing, Snapshot writing, and editing.", [["volunteers", "ORGANISM", 20, 30]]], ["Volunteers suggested this training could be more engaging, such as a video or web module (Table 3) .", [["this training", "TREATMENT", 21, 34]]], ["Volunteers also pinpointed visibility and general awareness as an area of improvement (Table 3) .", [["visibility", "OBSERVATION_MODIFIER", 27, 37]]], ["This is consistent with informal feedback received when new contributors contact the SCAsource executive.", [["consistent with", "UNCERTAINTY", 8, 23]]], ["Increased social media use was suggested as a potential solution.PLOS ONEVolunteers also expressed that the general concept of SCAsource was a good idea and gave encouragement for the initiative to continue (Table 3 ).", [["a potential solution", "TREATMENT", 44, 64], ["social media", "OBSERVATION", 10, 22]]], ["Some volunteers also expressed beingPLOS ONE\"grateful for the opportunity to contribute\" (Volunteer 7, PDF) to SCAsource.", [["volunteers", "ORGANISM", 5, 15]]], ["This reflects the overall positive impression that contributors have of SCAsource, both with regards to personal skills development, increased confidence, and being able to make an impact on the SCA community.Impact of SCAsource content on readersReaders reported an overall positive effect of reading SCAsource content (Fig 3) .", [["SCA", "DISEASE", 195, 198], ["SCAsource", "PROBLEM", 72, 81], ["increased confidence", "PROBLEM", 133, 153], ["SCAsource content", "TREATMENT", 219, 236], ["SCAsource content", "OBSERVATION", 219, 236], ["overall", "OBSERVATION_MODIFIER", 267, 274], ["positive effect", "OBSERVATION", 275, 290]]], ["Over 88% (n = 32) agreed that reading SCAsource increased their understanding of ataxia research, while 83% (n = 30) reported they have learned more about ataxia (Fig 3) .", [["ataxia", "DISEASE", 81, 87], ["ataxia", "DISEASE", 155, 161], ["ataxia", "PROBLEM", 81, 87], ["ataxia", "PROBLEM", 155, 161]]], ["When asked if SCAsource helped them feel more connected to ongoing ataxia research, 86% (n = 31) of respondents agreed (Fig 3) .", [["ataxia", "DISEASE", 67, 73], ["ongoing ataxia research", "PROBLEM", 59, 82]]], ["A majority (94%, n = 34) reported trusting SCAsource as an unbiased source of information (Fig 3) .", [["A majority", "TEST", 0, 10]]], ["Responses were more varied when polled about how SCAsource influenced their interest in participating in current ataxia research or clinical trials.", [["ataxia", "DISEASE", 113, 119], ["current ataxia research", "TREATMENT", 105, 128]]], ["Sixty-one percent (22/36) agreed that reading SCAsource had increased their interest in participating in such studies, while 39% (n = 14) were neutral on the subject (Fig 3) .", [["such studies", "TEST", 105, 117]]], ["Readers were then asked to rate how helpful they found four different types of content on SCAsource; Summaries, Snapshots, the glossary, and the \"What is Ataxia?\" information page (Fig 4) .", [["Ataxia", "DISEASE", 154, 160], ["Ataxia", "PROBLEM", 154, 160]]], ["Summary and Snapshot articles represent the majority of SCAsource content.", [["SCAsource", "SIMPLE_CHEMICAL", 56, 65]]], ["The glossary and \"What is Ataxia?\" information page are static pages on the SCAsource platform that are infrequently updated.", [["Ataxia", "DISEASE", 26, 32], ["Ataxia", "PROBLEM", 26, 32]]], ["Volunteer themes and representative quotations.Improved communication of scientific findings to lay audiences through knowledge translation techniques\"It is very important that scientists explain lab findings to the general public and (even more important) the SCA patients.", [["SCA", "DISEASE", 261, 264], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 265, 273]]], ["(Volunteer 7, PDF)Connection and confidence in communication with ataxia patients\"Writing articles for SCAsource has helped me put myself in the shoes of ataxia patients.", [["ataxia", "DISEASE", 66, 72], ["ataxia", "DISEASE", 154, 160], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 161, 169], ["ataxia", "PROBLEM", 66, 72], ["ataxia", "PROBLEM", 154, 160]]], ["I have been able to better empathize with patients by thinking about articles, how they relate to the situations of ataxia patients, and why patients should care about scientific research.", [["ataxia", "DISEASE", 116, 122], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 141, 149], ["ataxia", "PROBLEM", 116, 122]]], ["(Volunteer 5, Research Technician)Strengths of the SCAsource InitiativeProvides opportunity for researchers to practice knowledge translation \"It has also done a great job of allowing many members of the ataxia research community to get involved.\"", [["ataxia", "DISEASE", 204, 210]]], ["(Volunteer 9, Graduate Student)Comprehensive platform for laypersons to learn about current research ataxia\"I think that having the mix of articles, snapshots and the glossary is great.", [["ataxia", "DISEASE", 101, 107], ["current research ataxia", "PROBLEM", 84, 107]]], ["I think together they all provide a really comprehensive platform for the general public to learn about the current research and background of SCAs.\"", [["SCAs", "DISEASE", 143, 147], ["SCAs", "CANCER", 143, 147]]], ["(Volunteer 7, PDF) \"I think SCAsource has done a good job at covering current topics and at providing a good platform for scientists to communicate with the SCA community.\"", [["SCA", "DISEASE", 157, 160]]], ["(Volunteer 3, PDF)Areas of improvement for the SCAsource Initiative\"I also think more training or guidance should be provided on how to communicate information to patients.", [["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171]]], ["As researchers we are used to 'overselling' the translational impact of our research for grant applications and it can be difficult to change tone and communicate to patients in a way that doesn't give false hope or isn't mistaken for medical advice.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["grant applications", "TREATMENT", 89, 107]]], ["As scientists I think we need guidance on how to realistically communicate science to patients.\"", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94]]], ["The \"What is Ataxia?\" page is aimed at readers who are new to ataxia and is written as a general overview of ataxia information covered on the website.", [["Ataxia", "DISEASE", 13, 19], ["ataxia", "DISEASE", 62, 68], ["ataxia", "DISEASE", 109, 115], ["Ataxia", "PROBLEM", 13, 19], ["ataxia", "PROBLEM", 62, 68], ["ataxia", "PROBLEM", 109, 115]]], ["The \"What is ataxia?\" page had more variability in responses.", [["ataxia", "DISEASE", 13, 19], ["ataxia", "PROBLEM", 13, 19]]], ["Overall, readers viewed frequently updated content, such as Summaries and Snapshots, as more helpful to them compared to static content on SCAsource.", [["SCAsource", "TREATMENT", 139, 148]]], ["Through analysis of narrative data, we took a closer look at what exactly readers found helpful about SCAsource content.", [["SCAsource", "SIMPLE_CHEMICAL", 102, 111], ["narrative data", "TEST", 20, 34]]], ["Key themes from SCAsource readers, along with representative quotations, are outlined in Table 4 .Areas of improvement for the SCAsource InitiativeMost reader respondents appreciated the easy-to-understand content, that SCAsource is an accessible resource, and that SCAsource provides information about ongoing research ( Table 4 ).", [["improvement", "OBSERVATION_MODIFIER", 107, 118]]], ["As Reader 7 explained, \"The articles are easier to understand than most ataxia articles\".", [["ataxia", "DISEASE", 72, 78]]], ["A few also mentioned they like how SCAsource provided links to the original research, as well as additional resources, so that they could explore topics further.", [["few", "OBSERVATION_MODIFIER", 2, 5]]], ["This mirrors past findings highlighting patient interest in primary scientific literature [9] .", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47]]], ["Readers' motivation for their interest in SCAsource differed-from understanding their own condition, a child's, or a friend's.Areas of improvement for the SCAsource InitiativeA variety of improvements for SCAsource were suggested, with the theme of current and ongoing research again emerging (Table 4 ).", [["the SCAsource", "TREATMENT", 151, 164], ["SCAsource", "TREATMENT", 205, 214], ["improvement", "OBSERVATION_MODIFIER", 135, 146]]], ["Like SCAsource volunteers, readers also identified advertising and communication as an area of Respondents were asked to rate the helpfulness of four content types of SCAsource; summaries, snapshots, the glossary, and the \"What is Ataxia?\" information page.", [["Ataxia", "DISEASE", 231, 237], ["Ataxia", "PROBLEM", 231, 237]]], ["Responses were given with the indicated 5-point Likert-type scale.Areas of improvement for the SCAsource Initiativehttps://doi.org/10.1371/journal.pone.0238512.g004PLOS ONEimprovement.", [["SCAsource", "DNA", 95, 104], ["ONEimprovement", "PROBLEM", 169, 183], ["improvement", "OBSERVATION_MODIFIER", 75, 86]]], ["In addition to the common themes for suggested improvement, some suggestions stemmed from individuals' personal preferences or needs, including a request for language translation and a request for promotion on a specific social media platform.", [["language translation", "TREATMENT", 158, 178]]], ["While these will be considered in future plans for SCAsource, they will be lower priority items.PLOS ONEWe were surprised by the number of reader respondents who advised that there were no areas of improvement for SCAsource (Table 4) .", [["SCAsource", "TREATMENT", 51, 60]]], ["This supports that the SCAsource platform is currently working.", [["the SCAsource platform", "TREATMENT", 19, 41]]], ["Similar to how volunteers were grateful for participating in SCAsource, many readers also gave thanks for the creation of SCAsource.", [["volunteers", "ORGANISM", 15, 25], ["the creation of SCAsource", "TREATMENT", 106, 131]]], ["Readers expressed that it was an \"excellent resource\" (Reader 29) and asked that volunteers \"Keep up the good work\" (Reader 10).Strengths of the SCAsource InitiativeEasy to understand content \"Scientific research written in a way that is clearly understandable.\"", [["volunteers", "ORGANISM", 81, 91]]], ["(Reader 29)Strengths of the SCAsource Initiative\"I really like that difficult topics for non-scientists to understand, such as RAN translation, is explained in a more accessible way to patients.\"", [["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193]]], ["(Reader 36)Strengths of the SCAsource Initiative\"Easily written but not to short and not to simplified\" (Reader 8)Accessible resource and information\"Quicker access to information regarding SCA and being able to link to other sites and resources for additional information.", [["SCA", "PROBLEM", 190, 193]]], ["Not being a researcher myself, the information is produced in understandable language for the average person.\"", [["person", "SPECIES", 102, 108]]], ["(Reader 14)Accessible resource and information\"Very good communication channel for ataxia research\" (Reader 20)Accessible resource and information\"It is an excellent resource\" (Reader 29)Accessible resource and informationInformation on ongoing research \"Good summaries, research articles / to see some progress in the research\" (Reader 8)Accessible resource and information\"I like to hear about the research that is currently ongoing.\"", [["ataxia", "DISEASE", 83, 89], ["ataxia", "PROBLEM", 83, 89]]], ["(Reader 3)More information about research that readers can participate in\"More information about research studies that people can participate in, and how they can participate.\"", [["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125]]], ["(Reader 36)More information about research that readers can participate in\"Some more information about the studies, e.g. READISCA, etc. Like an overview to get even more people involved\" (Reader 8)DiscussionsIn this study, we assessed the self-reported impact SCAsource has on its readers and volunteers.", [["volunteers", "ORGANISM", 293, 303], ["people", "SPECIES", 170, 176], ["the studies", "TEST", 103, 114], ["this study", "TEST", 211, 221]]], ["This was done through a mixed-methods analysis of online survey data from 36 readers and 19 volunteers.", [["volunteers", "ORGANISM", 92, 102], ["online survey data", "TEST", 50, 68]]], ["Overall, both groups reported a positive evaluation of SCAsource.", [["SCAsource", "PROBLEM", 55, 64]]], ["We demonstrated that the dissemination strategy used by HDBuzz [16] can be modified successfully to serve other disease interest groups.", [["HDBuzz", "CHEMICAL", 56, 62], ["the dissemination strategy", "TREATMENT", 21, 47]]], ["Over the past 17 months, SCAsource has overall observed an increasing trend of views ( Fig 1A) .", [["increasing", "OBSERVATION_MODIFIER", 59, 69]]], ["Views display some seasonal trends, with lower views over the winter holidays, a pattern known to occur with platforms not selling commercial goods.", [["Views", "TEST", 0, 5]]], ["SCAsource also had spikes in view count in both October 2018 and 2019 (Fig 1A) .", [["spikes", "PROBLEM", 19, 25], ["view count", "TEST", 29, 39], ["spikes", "OBSERVATION_MODIFIER", 19, 25]]], ["We postulate that could be in part due to increased sharing of SCAsource content following International Ataxia Awareness Day on September 25.", [["Ataxia", "DISEASE", 105, 111], ["SCAsource content", "PROBLEM", 63, 80], ["International Ataxia", "PROBLEM", 91, 111], ["increased", "OBSERVATION_MODIFIER", 42, 51]]], ["Over 70% of SCAsource views originate from primarily English-speaking nations, with 64.7% coming from Canada and the United States (Fig 1B) .", [["SCAsource views", "TEST", 12, 27]]], ["If SCAsource is to expand its readership to reach more ataxia patients and families, it will also need to expand its volunteer base to include more researchers from international laboratories.", [["ataxia", "DISEASE", 55, 61], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["Volunteers with fluency in languages other than English will help expand SCAsource from a unilingual to a multilingual initiative, following a similar trajectory to HDBuzz [16] .DiscussionsCurrent volunteers reported a key strength of SCAsource was the opportunity to practice knowledge translation.", [["volunteers", "ORGANISM", 197, 207]]], ["This opportunity for practice and training is possibly what led to the self-reported gains in knowledge translation skills, as well as improved confidence in communicating with lay audiences.", [["practice and training", "TREATMENT", 21, 42]]], ["This suggests that SCAsource filled a gap in training for researchers, giving them a supportive environment with constructive feedback to improve their lay summary writing.", [["a gap in training", "TREATMENT", 36, 53], ["constructive feedback", "TREATMENT", 113, 134]]], ["This is further reflected by the request for more extensive knowledge translation training for volunteers.DiscussionsIn addition to an increased understanding of ataxia research, SCAsource readers reported they felt an increased connection to ongoing ataxia research through this platform.", [["ataxia", "DISEASE", 162, 168], ["ataxia", "DISEASE", 251, 257], ["volunteers", "ORGANISM", 95, 105], ["translation training", "TREATMENT", 70, 90], ["ataxia", "PROBLEM", 162, 168], ["an increased connection", "PROBLEM", 216, 239], ["ongoing ataxia", "PROBLEM", 243, 257]]], ["Access to information about ongoing ataxia research was cited as both a strength and a potential area of improvement.", [["ataxia", "DISEASE", 36, 42], ["ongoing ataxia research", "PROBLEM", 28, 51], ["improvement", "OBSERVATION", 105, 116]]], ["This indicates SCAsource is on the right track with regards to summarizing recently published research, but we could expand this area more.", [["SCAsource", "OBSERVATION", 15, 24], ["right", "ANATOMY_MODIFIER", 35, 40]]], ["In response to this feedback, SCAsource is planning to launch a new article type that will give information about ataxia research laboratories.", [["ataxia", "DISEASE", 114, 120], ["ataxia research laboratories", "TEST", 114, 142]]], ["This will include where the laboratories are located and what areas of research they are pursuing.", [["the laboratories", "TEST", 24, 40]]], ["Our aim is that this new article type will meet the need of readers wanting to learn more about ataxia researchers, the research process, and ongoing studies.DiscussionsReaders had more mixed responses with regards to whether reading SCAsource content increased their interest in participating in clinical trials (Fig 3) .", [["ataxia", "DISEASE", 96, 102], ["ataxia", "PROBLEM", 96, 102], ["ongoing studies", "TEST", 142, 157]]], ["Past research on barriers to patient participation in clinical trials have identified lack of information and understanding as a barrier [26, 27] .", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36]]], ["Conversely, investigation into neurological clinical research participation has found that receiving information from a trusted source is a key motivator for patient participation [28] .", [["patient", "ORGANISM", 158, 165], ["patient", "SPECIES", 158, 165]]], ["Its focus is on explaining results from published clinical trial data, as well as clarifying methodological procedures common across trials.", [["published clinical trial data", "TEST", 40, 69], ["methodological procedures", "TREATMENT", 93, 118]]], ["However, it can be argued that patients who are already more interested in research participation could be more likely to seek out research information.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["Further analysis with a larger respondent sample would be needed for future investigation into this topic.DiscussionsSuggested areas of improvement from both volunteers and readers point to growth opportunities for SCAsource.", [["volunteers", "ORGANISM", 158, 168], ["Further analysis", "TEST", 0, 16], ["future investigation", "TEST", 69, 89], ["SCAsource", "PROBLEM", 215, 224]]], ["This includes more frequent article updates and additional training for volunteers.", [["volunteers", "ORGANISM", 72, 82], ["additional training", "TREATMENT", 48, 67]]], ["This feedback points to a well-received knowledge translation website that has room to grow with additional financial support.DiscussionsThemes from both surveys also demonstrate that this kind of knowledge translation platform can serve both the research community and the community of those affected by ataxia (patients, families, friends).", [["ataxia", "DISEASE", 305, 311], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 313, 321], ["financial support", "TREATMENT", 108, 125], ["ataxia", "PROBLEM", 305, 311]]], ["There was no sense of imbalance, incorrect focus, or one community benefiting over the other.", [["sense of imbalance", "PROBLEM", 13, 31], ["no sense of", "UNCERTAINTY", 10, 21], ["imbalance", "OBSERVATION", 22, 31]]], ["Early career researchers were able to practice valuable knowledge translation skills, while readers gain knowledge about ongoing ataxia research.", [["ataxia", "DISEASE", 129, 135], ["ongoing ataxia research", "PROBLEM", 121, 144]]], ["This positions SCAsource as a mutually beneficial platform connecting research and lay ataxia communities.DiscussionsWe propose that knowledge translation set-ups like HDBuzz and SCAsource could be used by other disease organizations, especially those concerned with rare diseases.", [["ataxia", "DISEASE", 87, 93], ["lay ataxia communities", "PROBLEM", 83, 105], ["HDBuzz", "TREATMENT", 168, 174], ["SCAsource", "TREATMENT", 179, 188], ["rare diseases", "PROBLEM", 267, 280], ["diseases", "OBSERVATION", 272, 280]]], ["More common research areas, such as cancer, heart disease, and diabetes, tend to have more established knowledge translation initiatives [29] [30] [31] .", [["cancer", "ANATOMY", 36, 42], ["heart", "ANATOMY", 44, 49], ["cancer", "DISEASE", 36, 42], ["heart disease", "DISEASE", 44, 57], ["diabetes", "DISEASE", 63, 71], ["cancer", "CANCER", 36, 42], ["heart", "ORGAN", 44, 49], ["cancer", "PROBLEM", 36, 42], ["heart disease", "PROBLEM", 44, 57], ["diabetes", "PROBLEM", 63, 71], ["cancer", "OBSERVATION", 36, 42], ["heart", "ANATOMY", 44, 49], ["disease", "OBSERVATION", 50, 57]]], ["Conversely, rare disease organizations have identified knowledge translation as a needed area of growth [32] .", [["rare disease organizations", "PROBLEM", 12, 38]]], ["One potential barrier is cost, as rare diseases typically receive less research funding and overall investment due to impacting only a small portion of the population [33, 34] .", [["rare diseases", "PROBLEM", 34, 47], ["small", "OBSERVATION_MODIFIER", 135, 140]]], ["This would allow for organizations to begin a knowledge translation initiative and generate enough interest to attract external funding to continue and improve efforts over time.DiscussionsMultiple knowledge translation models have been documented in the literature, with overlap allowing for key themes to emerge from the discipline [35] .", [["external funding", "TREATMENT", 119, 135]]], ["Such themes include the importance of knowledge translation being ongoing interactive processes with stakeholders, and involving multiple people with varying perspectives about ongoing research [36, 37] .", [["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144]]], ["The Knowledge-to-Action model, emphasizes the recurrent nature of knowledge creation and implementation action cycles [5] .", [["implementation action cycles", "TREATMENT", 89, 117]]], ["However, these existing models do not address specific issues that are relevant to the rare disease context [35] .DiscussionsAcross knowledge translation models there is an emphasis on monitoring outcomes, including improved survival and quality of life [35] .", [["the rare disease context", "PROBLEM", 83, 107]]], ["However, the novel treatments for rare diseases, including ataxia, tend to have incremental effects over the span of years [35] .", [["ataxia", "DISEASE", 59, 65], ["rare diseases", "PROBLEM", 34, 47], ["ataxia", "PROBLEM", 59, 65]]], ["Rather than traditional outcomes measured, learning more about these findings may influence a reader's choice to participate in research, or provide hope that new discoveries are being made.Study limitationsA limitation of this study was the use of a self-reported online survey format for gathering data.", [["Study limitations", "TEST", 190, 207], ["this study", "TEST", 223, 233], ["gathering data", "TEST", 290, 304]]], ["As previously discussed, the use of this method may have been a barrier to readers having trouble with typing and other fine motor tasks.", [["this method", "TREATMENT", 36, 47], ["trouble with typing and other fine motor tasks", "PROBLEM", 90, 136]]], ["Using number of unique IP addresses visiting the SCAsource website between September 2018 and January 2020 (approximately 11,331) to estimate total readership, the respondent sample represents less than 1% of total SCAsource readership.", [["total SCAsource readership", "TREATMENT", 209, 235]]], ["Our population sample may also have been biased towards more frequent readers of SCAsource.", [["Our population sample", "TEST", 0, 21], ["SCAsource", "PROBLEM", 81, 90]]], ["Thus, the views expressed by most reader respondents may not hold true for more casual readers of the website.Study limitationsA second limitation is that our Likert-type scales focused on self-reported outcomes which were not objectively assessed through other means.", [["Study limitations", "TEST", 110, 127]]], ["Future work should include assessment of whether volunteer and reader self-reported gains align with gains measured through other objective means.ConclusionsWe found that SCAsource has mutually beneficial outcomes for both lay person readers and volunteer contributors.", [["SCAsource", "CHEMICAL", 171, 180], ["person", "SPECIES", 227, 233], ["assessment", "TEST", 27, 37]]], ["Volunteers develop knowledge translation skills and have increased confidence in communicating results to lay audiences.", [["increased confidence", "PROBLEM", 57, 77]]], ["Readers have an increased understanding of ataxia research and access to up to date information on recent publications.", [["ataxia", "DISEASE", 43, 49], ["ataxia", "PROBLEM", 43, 49], ["increased", "OBSERVATION_MODIFIER", 16, 25]]], ["Areas of improvement were identified and will be worked towards to improve the SCAsource initiative.", [["improvement", "OBSERVATION", 9, 20]]], ["We build on past work by HDbuzz [16] to demonstrate this knowledge translation framework is effective in the context of other rare diseases.", [["other rare diseases", "PROBLEM", 120, 139], ["diseases", "OBSERVATION", 131, 139]]]], "43d2016cbba1ca1e17e68352c290dd58c52349ab": [["IntroductionFebrile seizures are the most common type of childhood seizure disorder.", [["seizures", "DISEASE", 20, 28], ["seizure disorder", "DISEASE", 67, 83], ["IntroductionFebrile seizures", "PROBLEM", 0, 28], ["childhood seizure disorder", "PROBLEM", 57, 83], ["most common", "OBSERVATION_MODIFIER", 37, 48], ["seizure", "OBSERVATION", 67, 74]]], ["About 2-5 % of children between the age of 6 and 60 months experience at least one febrile seizure [1] [2] [3] [4] [5] [6] [7] .", [["seizure", "DISEASE", 91, 98], ["[1] [2] [3] [4] [5] [6]", "CHEMICAL", 99, 122], ["children", "ORGANISM", 15, 23], ["[1] [2] [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 99, 126], ["children", "SPECIES", 15, 23], ["febrile seizure", "PROBLEM", 83, 98]]], ["Febrile seizures are classified as either simple or complex [1] [2] [3] [4] [5] [6] [7] .", [["Febrile seizures", "DISEASE", 0, 16], ["[1] [2] [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 60, 87], ["Febrile seizures", "PROBLEM", 0, 16]]], ["Recommendations for the management of febrile seizures have recently been updated by the American Academy of Pediatrics (AAP) [2] .IntroductionIn most children, febrile seizures are related to common infections, e. g., acute otitis media, bronchitis, gastrointestinal or urinary tract infection -both of bacterial and viral origin.", [["gastrointestinal", "ANATOMY", 251, 267], ["urinary tract", "ANATOMY", 271, 284], ["febrile seizures", "DISEASE", 38, 54], ["febrile seizures", "DISEASE", 161, 177], ["infections", "DISEASE", 200, 210], ["acute otitis media", "DISEASE", 219, 237], ["bronchitis", "DISEASE", 239, 249], ["gastrointestinal or urinary tract infection", "DISEASE", 251, 294], ["children", "ORGANISM", 151, 159], ["gastrointestinal", "ORGANISM_SUBDIVISION", 251, 267], ["urinary tract", "ORGANISM_SUBDIVISION", 271, 284], ["children", "SPECIES", 151, 159], ["febrile seizures", "PROBLEM", 38, 54], ["febrile seizures", "PROBLEM", 161, 177], ["common infections", "PROBLEM", 193, 210], ["acute otitis media", "PROBLEM", 219, 237], ["bronchitis", "PROBLEM", 239, 249], ["gastrointestinal or urinary tract infection", "PROBLEM", 251, 294], ["bacterial and viral origin", "PROBLEM", 304, 330], ["infections", "OBSERVATION", 200, 210], ["acute", "OBSERVATION_MODIFIER", 219, 224], ["otitis", "OBSERVATION", 225, 231], ["bronchitis", "OBSERVATION", 239, 249], ["gastrointestinal", "ANATOMY", 251, 267], ["urinary tract", "ANATOMY", 271, 284], ["infection", "OBSERVATION", 285, 294], ["bacterial", "OBSERVATION_MODIFIER", 304, 313], ["viral origin", "OBSERVATION", 318, 330]]], ["Only rarely are febrile seizures a symptom of a central nervous system infection (e. g., meningitis).", [["central nervous system", "ANATOMY", 48, 70], ["febrile seizures", "DISEASE", 16, 32], ["central nervous system infection", "DISEASE", 48, 80], ["meningitis", "DISEASE", 89, 99], ["nervous system", "ANATOMICAL_SYSTEM", 56, 70], ["febrile seizures", "PROBLEM", 16, 32], ["a central nervous system infection", "PROBLEM", 46, 80], ["meningitis", "PROBLEM", 89, 99], ["febrile", "OBSERVATION", 16, 23], ["central", "ANATOMY_MODIFIER", 48, 55], ["nervous system", "ANATOMY", 56, 70], ["infection", "OBSERVATION", 71, 80], ["meningitis", "OBSERVATION", 89, 99]]], ["However, a site of infection needs to be confirmed or excluded during the initial diagnostic work-up so as to adjust further treatment [2] .", [["infection", "DISEASE", 19, 28], ["infection", "PROBLEM", 19, 28], ["further treatment", "TREATMENT", 117, 134], ["infection", "OBSERVATION", 19, 28]]], ["Some issues and controversies surrounding febrile seizures have not been fully resolved including the need for cohortation to prevent nosocomial transmission and the use of antibiotics.", [["febrile seizures", "DISEASE", 42, 58], ["Some issues", "PROBLEM", 0, 11], ["febrile seizures", "PROBLEM", 42, 58], ["cohortation", "TREATMENT", 111, 122], ["nosocomial transmission", "TREATMENT", 134, 157], ["antibiotics", "TREATMENT", 173, 184]]], ["Timely differentiation between bacterial and viral etiologies may reduce the unnecessary use of antibiotics.", [["bacterial and viral etiologies", "PROBLEM", 31, 61], ["antibiotics", "TREATMENT", 96, 107], ["bacterial", "OBSERVATION_MODIFIER", 31, 40]]], ["Recently, the use of multiplex polymerase chain reaction (PCR) analysis for the detection of a number of common viruses has been introduced into clinical practice [8] [9] [10] .", [["multiplex polymerase chain reaction", "TREATMENT", 21, 56], ["PCR) analysis", "TEST", 58, 71], ["the detection", "TEST", 76, 89], ["common viruses", "PROBLEM", 105, 119]]], ["In our hospital, respiratory multiplex PCR analysis has been routinely used in clinical practice for children with upper and lower respiratory infections since 2010.IntroductionThe main purpose of this study was to evaluate the use and role of multiplex PCR analysis in children with febrile seizures admitted to a university children's hospital.", [["respiratory", "ANATOMY", 131, 142], ["upper and lower respiratory infections", "DISEASE", 115, 153], ["febrile seizures", "DISEASE", 284, 300], ["children", "ORGANISM", 101, 109], ["upper", "ORGANISM_SUBDIVISION", 115, 120], ["children", "ORGANISM", 270, 278], ["children", "ORGANISM", 326, 334], ["children", "SPECIES", 101, 109], ["children", "SPECIES", 270, 278], ["children", "SPECIES", 326, 334], ["respiratory multiplex PCR analysis", "TEST", 17, 51], ["upper and lower respiratory infections", "PROBLEM", 115, 153], ["this study", "TEST", 197, 207], ["multiplex PCR analysis", "TEST", 244, 266], ["febrile seizures", "PROBLEM", 284, 300], ["upper", "ANATOMY_MODIFIER", 115, 120], ["lower", "ANATOMY_MODIFIER", 125, 130], ["respiratory", "ANATOMY", 131, 142], ["infections", "OBSERVATION", 143, 153], ["main", "OBSERVATION_MODIFIER", 181, 185]]], ["In particular, the rate of detecting an underlying viral illness in this cohort was assessed.", [["viral illness", "DISEASE", 51, 64], ["an underlying viral illness", "PROBLEM", 37, 64], ["viral illness", "OBSERVATION", 51, 64]]], ["Moreover, this investigation was performed to elucidate whether the detection of viral pathogens by multiplex PCR analysis translates into a significant reduction of antibiotic use.Patients and methodsThis 5-year retrospective cohort analysis (2009) (2010) (2011) (2012) (2013) was performed at the University Children's Hospital of Saarland, Homburg, Germany.", [["Patients", "ORGANISM", 181, 189], ["Patients", "SPECIES", 181, 189], ["this investigation", "TEST", 10, 28], ["viral pathogens", "PROBLEM", 81, 96], ["multiplex PCR analysis", "TEST", 100, 122], ["antibiotic use", "TREATMENT", 166, 180], ["significant", "OBSERVATION_MODIFIER", 141, 152], ["reduction", "OBSERVATION_MODIFIER", 153, 162]]], ["Institutional Review Board approval was obtained prior to the study from the Ethics Committee of the University Hospital of Saarland, Saarbr\u00fccken, Germany.", [["the study", "TEST", 58, 67]]], ["No parental informed consent was obtained since all information in this study was collected from our hospital database (SAP, Germany), which is operational in daily, routine clinical practice.Patients and methodsAll patients with the ICD 10 diagnosis of R56.0 were included, irrespective of whether the event had been the first febrile seizure in the medical history of the individual patient.", [["febrile seizure", "DISEASE", 328, 343], ["Patients", "ORGANISM", 192, 200], ["patients", "ORGANISM", 216, 224], ["patient", "ORGANISM", 385, 392], ["Patients", "SPECIES", 192, 200], ["patients", "SPECIES", 216, 224], ["patient", "SPECIES", 385, 392], ["this study", "TEST", 67, 77], ["routine clinical practice", "TREATMENT", 166, 191], ["the ICD", "TREATMENT", 230, 237], ["the first febrile seizure", "PROBLEM", 318, 343]]], ["The following demographic data were collected: age, gender, previous medical history, first or recurrent episode of febrile seizure, simple or complex febrile seizure.", [["febrile seizure", "DISEASE", 116, 131], ["febrile seizure", "DISEASE", 151, 166], ["febrile seizure", "PROBLEM", 116, 131], ["simple or complex febrile seizure", "PROBLEM", 133, 166], ["febrile seizure", "OBSERVATION", 116, 131], ["complex", "OBSERVATION_MODIFIER", 143, 150], ["febrile", "OBSERVATION_MODIFIER", 151, 158], ["seizure", "OBSERVATION", 159, 166]]], ["Also, important data with regard to infectious etiology were obtained: type of underlying infection, results from microbiology and virology testing including multiplex PCR analysis.", [["infection", "DISEASE", 90, 99], ["underlying infection", "PROBLEM", 79, 99], ["virology testing", "TEST", 131, 147], ["multiplex PCR analysis", "TEST", 158, 180], ["infection", "OBSERVATION", 90, 99]]], ["Further laboratory results (blood count, clinical chemistry, C-reactive protein [CRP] ) and information with regard to other diagnostic modalities (e. g., sonography, other imaging studies, electroencephalography, lumbar puncture etc.) were collected.Patients and methodsMicrobiology testing was tailored individually and included the following samples and techniques: pharyngeal swabs, urine analysis and cultures, microbiology of fecal specimen, skin swabs, cerebrospinal fluid, and blood cultures.Patients and methodsOur multiplex virological panel (FTD Respiratory pathogens 21, Fast Track Diagnostics, Luxembourg) included the following viruses: influenza A/H1N1, influenza B, parainfluenza type 1, 2, 3, 4, coronavirus (NL63, 229E, OC43, HKU1), human metapneumovirus (A/B), human bocavirus, rhinovirus, adenovirus, respiratory syncytial virus (RSV A/B), parechovirus, and enterovirus.", [["blood", "ANATOMY", 28, 33], ["lumbar", "ANATOMY", 214, 220], ["pharyngeal swabs", "ANATOMY", 369, 385], ["urine", "ANATOMY", 387, 392], ["fecal specimen", "ANATOMY", 432, 446], ["skin swabs", "ANATOMY", 448, 458], ["cerebrospinal fluid", "ANATOMY", 460, 479], ["blood cultures", "ANATOMY", 485, 499], ["FTD", "DISEASE", 553, 556], ["influenza A/H1N1", "DISEASE", 651, 667], ["influenza B", "DISEASE", 669, 680], ["parainfluenza type", "DISEASE", 682, 700], ["human metapneumovirus", "DISEASE", 751, 772], ["respiratory syncytial virus", "DISEASE", 821, 848], ["enterovirus", "DISEASE", 878, 889], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 61, 79], ["CRP", "GENE_OR_GENE_PRODUCT", 81, 84], ["Patients", "ORGANISM", 251, 259], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 369, 385], ["urine", "ORGANISM_SUBSTANCE", 387, 392], ["fecal specimen", "MULTI-TISSUE_STRUCTURE", 432, 446], ["skin swabs", "MULTI-TISSUE_STRUCTURE", 448, 458], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 460, 479], ["blood", "ORGANISM_SUBSTANCE", 485, 490], ["Patients", "ORGANISM", 500, 508], ["influenza A/H1N1", "ORGANISM", 651, 667], ["influenza B", "ORGANISM", 669, 680], ["parainfluenza type 1", "ORGANISM", 682, 702], ["2", "GENE_OR_GENE_PRODUCT", 704, 705], ["3", "GENE_OR_GENE_PRODUCT", 707, 708], ["4", "GENE_OR_GENE_PRODUCT", 710, 711], ["coronavirus", "ORGANISM", 713, 724], ["NL63", "GENE_OR_GENE_PRODUCT", 726, 730], ["229E", "GENE_OR_GENE_PRODUCT", 732, 736], ["OC43", "GENE_OR_GENE_PRODUCT", 738, 742], ["HKU1", "GENE_OR_GENE_PRODUCT", 744, 748], ["human metapneumovirus", "ORGANISM", 751, 772], ["A/B", "ORGANISM", 774, 777], ["human", "ORGANISM", 780, 785], ["bocavirus", "ORGANISM", 786, 795], ["rhinovirus", "ORGANISM", 797, 807], ["adenovirus,", "ORGANISM", 809, 820], ["respiratory syncytial virus", "ORGANISM", 821, 848], ["RSV A/B", "ORGANISM", 850, 857], ["parechovirus", "GENE_OR_GENE_PRODUCT", 860, 872], ["enterovirus", "ORGANISM", 878, 889], ["C-reactive protein", "PROTEIN", 61, 79], ["CRP", "PROTEIN", 81, 84], ["Patients", "SPECIES", 251, 259], ["Patients", "SPECIES", 500, 508], ["influenza A/H1N1", "SPECIES", 651, 667], ["influenza B", "SPECIES", 669, 680], ["parainfluenza type 1", "SPECIES", 682, 702], ["human", "SPECIES", 751, 756], ["metapneumovirus", "SPECIES", 757, 772], ["human", "SPECIES", 780, 785], ["rhinovirus", "SPECIES", 797, 807], ["respiratory syncytial virus", "SPECIES", 821, 848], ["RSV", "SPECIES", 850, 853], ["A/H1N1", "SPECIES", 661, 667], ["parainfluenza type 1", "SPECIES", 682, 702], ["human metapneumovirus", "SPECIES", 751, 772], ["human bocavirus", "SPECIES", 780, 795], ["respiratory syncytial virus", "SPECIES", 821, 848], ["RSV", "SPECIES", 850, 853], ["blood count", "TEST", 28, 39], ["clinical chemistry", "TEST", 41, 59], ["C", "TEST", 61, 62], ["CRP", "TEST", 81, 84], ["sonography", "TEST", 155, 165], ["other imaging studies", "TEST", 167, 188], ["electroencephalography", "TEST", 190, 212], ["lumbar puncture", "TEST", 214, 229], ["methodsMicrobiology testing", "TEST", 264, 291], ["pharyngeal swabs", "TEST", 369, 385], ["urine analysis", "TEST", 387, 401], ["cultures", "TEST", 406, 414], ["fecal specimen", "TEST", 432, 446], ["skin swabs", "TEST", 448, 458], ["cerebrospinal fluid", "TEST", 460, 479], ["blood cultures", "TEST", 485, 499], ["Our multiplex virological panel", "TEST", 520, 551], ["FTD Respiratory pathogens", "TEST", 553, 578], ["influenza", "PROBLEM", 651, 660], ["H1N1", "PROBLEM", 663, 667], ["influenza B", "TEST", 669, 680], ["parainfluenza type", "TEST", 682, 700], ["coronavirus", "TEST", 713, 724], ["NL63", "TEST", 726, 730], ["OC43", "TEST", 738, 742], ["HKU1", "TEST", 744, 748], ["human metapneumovirus", "PROBLEM", 751, 772], ["A/B", "TEST", 774, 777], ["human bocavirus", "PROBLEM", 780, 795], ["rhinovirus", "PROBLEM", 797, 807], ["adenovirus", "PROBLEM", 809, 819], ["respiratory syncytial virus", "PROBLEM", 821, 848], ["RSV A/B)", "PROBLEM", 850, 858], ["parechovirus", "PROBLEM", 860, 872], ["enterovirus", "PROBLEM", 878, 889], ["lumbar", "ANATOMY", 214, 220], ["pharyngeal", "ANATOMY", 369, 379], ["fecal", "ANATOMY", 432, 437], ["skin", "ANATOMY", 448, 452], ["cerebrospinal", "ANATOMY", 460, 473], ["respiratory syncytial", "ANATOMY", 821, 842], ["enterovirus", "OBSERVATION", 878, 889]]], ["This commercial real-time PCR assay was performed according to the manufacturer's instructions with excellent performance in a number of studies [11] [12] [13] .Statistical analysesRelevant data were retrieved from an electronic hospital database (SAP, Germany) as well as from patients' hospital charts.", [["[11] [12] [13]", "SIMPLE_CHEMICAL", 145, 159], ["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 278, 286], ["PCR assay", "TEST", 26, 35]]], ["For comparison of categorical variables the Pearson chisquare test was employed.", [["the Pearson chisquare test", "TEST", 40, 66]]], ["The Fisher exact test was used if prerequisites for the Pearson chi-square test were not met.", [["The Fisher exact test", "TEST", 0, 21], ["the Pearson chi-square test", "TEST", 52, 79]]], ["All statistical analyses were performed using SPSS, 23.0 (Chicago, Ill.).ResultsA total of 200 children with simple (129), complex (57), and 14 undetermined febrile seizures (median age: 24.0 months; IQR: 15.8-38.2 months; 104 male, 96 female) were included.ResultsWith regard to seasonality the following pattern was seen: 58 (29 %) episodes of febrile seizures occurred in spring, 42 (21 %) in summer and fall, respectively, and another 58 (29 %) during the winter months.", [["febrile seizures", "DISEASE", 157, 173], ["seizures", "DISEASE", 354, 362], ["children", "ORGANISM", 95, 103], ["children", "SPECIES", 95, 103], ["All statistical analyses", "TEST", 0, 24], ["SPSS", "TEST", 46, 50], ["14 undetermined febrile seizures", "PROBLEM", 141, 173], ["febrile seizures", "PROBLEM", 346, 362], ["febrile", "OBSERVATION_MODIFIER", 346, 353], ["seizures", "OBSERVATION", 354, 362]]], ["The most common time of occurrence during the day was in order of frequency: evening (50; 25 %), afternoon (45; 22.5 %), at night (34; 17 %), early morning (21; 10.5 %), late morning (15; 7.5 %), noon (15; 7.5 %), and no data available in 20 (10 %) children.ResultsOf all children, 27 (13.5 %) were treated with antibiotics prior to admission to our hospital and 122 (61 %) did not receive prior antibiotic treatment; in the remaining 51 children, no definite information regarding prior antibiotic treatment could be extracted from the medical case notes.ResultsClinical sites of infection were: respiratory (89; 44.5 %), gastroenteritis (22; 11 %), tonsillitis (21; 10.5 %), acute otitis media (15; 7.5 %), and urinary tract infection (2; 1 %).", [["respiratory", "ANATOMY", 597, 608], ["urinary tract", "ANATOMY", 713, 726], ["infection", "DISEASE", 581, 590], ["gastroenteritis", "DISEASE", 623, 638], ["tonsillitis", "DISEASE", 651, 662], ["acute otitis media", "DISEASE", 677, 695], ["urinary tract infection", "DISEASE", 713, 736], ["children", "ORGANISM", 249, 257], ["children", "ORGANISM", 272, 280], ["children", "ORGANISM", 438, 446], ["urinary tract", "ORGANISM_SUBDIVISION", 713, 726], ["children", "SPECIES", 249, 257], ["children", "SPECIES", 272, 280], ["children", "SPECIES", 438, 446], ["antibiotics", "TREATMENT", 312, 323], ["prior antibiotic treatment", "TREATMENT", 390, 416], ["prior antibiotic treatment", "TREATMENT", 482, 508], ["infection", "PROBLEM", 581, 590], ["respiratory", "TEST", 597, 608], ["gastroenteritis", "PROBLEM", 623, 638], ["tonsillitis", "PROBLEM", 651, 662], ["acute otitis media", "PROBLEM", 677, 695], ["urinary tract infection", "PROBLEM", 713, 736], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["infection", "OBSERVATION", 581, 590], ["respiratory", "ANATOMY", 597, 608], ["gastroenteritis", "OBSERVATION", 623, 638], ["tonsillitis", "OBSERVATION", 651, 662], ["acute", "OBSERVATION_MODIFIER", 677, 682], ["otitis", "OBSERVATION", 683, 689], ["urinary tract", "ANATOMY", 713, 726], ["infection", "OBSERVATION", 727, 736]]], ["In two children (1 %) the event was related to vaccination.", [["children", "ORGANISM", 7, 15], ["children", "SPECIES", 7, 15]]], ["In 23 (11.5 %) of all children, a combination of different foci was seen while in 26 (13 %) no definite site of infection could be established.ResultsIn 22 (11 %) of the children, a lumbar puncture was performed, but no bacterial infection of the central nervous system and no encephalitis could be confirmed.", [["foci", "ANATOMY", 59, 63], ["site", "ANATOMY", 104, 108], ["lumbar", "ANATOMY", 182, 188], ["central nervous system", "ANATOMY", 247, 269], ["infection", "DISEASE", 112, 121], ["infection of the central nervous system", "DISEASE", 230, 269], ["encephalitis", "DISEASE", 277, 289], ["children", "ORGANISM", 22, 30], ["children", "ORGANISM", 170, 178], ["central nervous system", "ANATOMICAL_SYSTEM", 247, 269], ["children", "SPECIES", 22, 30], ["children", "SPECIES", 170, 178], ["different foci", "PROBLEM", 49, 63], ["infection", "PROBLEM", 112, 121], ["a lumbar puncture", "TEST", 180, 197], ["bacterial infection of the central nervous system", "PROBLEM", 220, 269], ["encephalitis", "PROBLEM", 277, 289], ["different", "OBSERVATION_MODIFIER", 49, 58], ["foci", "OBSERVATION", 59, 63], ["infection", "OBSERVATION", 112, 121], ["lumbar", "ANATOMY", 182, 188], ["no", "UNCERTAINTY", 217, 219], ["bacterial", "OBSERVATION_MODIFIER", 220, 229], ["infection", "OBSERVATION", 230, 239], ["central", "ANATOMY_MODIFIER", 247, 254], ["nervous system", "ANATOMY", 255, 269], ["no", "UNCERTAINTY", 274, 276], ["encephalitis", "OBSERVATION", 277, 289]]], ["Overall, the mean CRP level in this cohort was 14.7 \u00b1 1.4 mg/l (median: 5.5 mg/l; range: 0.25-140 mg/l).", [["CRP", "GENE_OR_GENE_PRODUCT", 18, 21], ["CRP", "PROTEIN", 18, 21], ["the mean CRP level", "TEST", 9, 27], ["this cohort", "TEST", 31, 42]]], ["In 121 of 200 children, the CRP level was elevated (>5 mg/l).", [["children", "ORGANISM", 14, 22], ["CRP", "GENE_OR_GENE_PRODUCT", 28, 31], ["CRP", "PROTEIN", 28, 31], ["children", "SPECIES", 14, 22], ["the CRP level", "TEST", 24, 37], ["elevated", "PROBLEM", 42, 50]]], ["In 138 children (68 %), an EEG was performed with abnormal findings in 21 patients (focal or generalized slowing, increased beta wave activity, epileptic discharges), but no anti-epileptic drug treatment was initiated.", [["epileptic", "DISEASE", 144, 153], ["children", "ORGANISM", 7, 15], ["patients", "ORGANISM", 74, 82], ["children", "SPECIES", 7, 15], ["patients", "SPECIES", 74, 82], ["an EEG", "TEST", 24, 30], ["abnormal findings", "PROBLEM", 50, 67], ["focal or generalized slowing", "PROBLEM", 84, 112], ["increased beta wave activity", "PROBLEM", 114, 142], ["epileptic discharges", "PROBLEM", 144, 164], ["anti-epileptic drug treatment", "TREATMENT", 174, 203], ["focal", "OBSERVATION_MODIFIER", 84, 89], ["generalized", "OBSERVATION_MODIFIER", 93, 104], ["slowing", "OBSERVATION_MODIFIER", 105, 112], ["no", "UNCERTAINTY", 171, 173], ["anti-epileptic drug", "OBSERVATION", 174, 193]]], ["In 34 (17 %) children, further diagnostic work-up included sonography, chest X-ray, cCT (cerebral computer tomography), and cMRI (cerebral magnetic resononce imaging) (data not shown in detail).ResultsPositive results from microbiology testing (bacterial/fungal) demonstrated a significant increase between 2009 and 2010-2013 as detailed in Table 1 .", [["cerebral", "ANATOMY", 89, 97], ["cerebral", "ANATOMY", 130, 138], ["children", "ORGANISM", 13, 21], ["cerebral", "MULTI-TISSUE_STRUCTURE", 89, 97], ["children", "SPECIES", 13, 21], ["sonography", "TEST", 59, 69], ["chest X-ray", "TEST", 71, 82], ["cCT", "TEST", 84, 87], ["cerebral computer tomography", "TEST", 89, 117], ["cMRI", "TEST", 124, 128], ["cerebral magnetic resononce imaging", "TEST", 130, 165], ["microbiology testing", "TEST", 223, 243], ["bacterial/fungal", "TEST", 245, 261], ["chest", "ANATOMY", 71, 76], ["significant", "OBSERVATION_MODIFIER", 278, 289], ["increase", "OBSERVATION_MODIFIER", 290, 298]]], ["The three most common bacteria that could be cultured were coagulase-negative staphylococcus (4), Escherichia coli (2), and Haemophilus influenzae (2).", [["Haemophilus influenzae", "DISEASE", 124, 146], ["coagulase-negative staphylococcus", "GENE_OR_GENE_PRODUCT", 59, 92], ["Escherichia coli", "ORGANISM", 98, 114], ["Haemophilus influenzae", "ORGANISM", 124, 146], ["Escherichia coli", "SPECIES", 98, 114], ["Haemophilus influenzae", "SPECIES", 124, 146], ["Escherichia coli", "SPECIES", 98, 114], ["Haemophilus influenzae", "SPECIES", 124, 146], ["The three most common bacteria", "PROBLEM", 0, 30], ["coagulase", "TEST", 59, 68], ["staphylococcus", "PROBLEM", 78, 92], ["Escherichia coli", "PROBLEM", 98, 114], ["Haemophilus influenzae", "PROBLEM", 124, 146], ["negative staphylococcus", "OBSERVATION", 69, 92], ["Escherichia coli", "OBSERVATION", 98, 114], ["Haemophilus influenzae", "OBSERVATION", 124, 146]]], ["In 2010-2013, the three most common bacteria were: Staphylococcus aureus (16) , H. influenzae (15) , and E. coli (12) .", [["Staphylococcus aureus", "DISEASE", 51, 72], ["Staphylococcus aureus", "ORGANISM", 51, 72], ["H. influenzae", "ORGANISM", 80, 93], ["E. coli", "ORGANISM", 105, 112], ["Staphylococcus aureus", "SPECIES", 51, 72], ["H. influenzae", "SPECIES", 80, 93], ["E. coli", "SPECIES", 105, 112], ["Staphylococcus aureus", "SPECIES", 51, 72], ["H. influenzae", "SPECIES", 80, 93], ["E. coli", "SPECIES", 105, 112], ["Staphylococcus aureus", "PROBLEM", 51, 72], ["H. influenzae", "TEST", 80, 93], ["E. coli", "PROBLEM", 105, 112], ["Staphylococcus aureus", "OBSERVATION", 51, 72], ["E. coli", "OBSERVATION", 105, 112]]], ["The rate of positive virological studies also significantly increased between the two study periods (Table 1 ).", [["positive virological studies", "TEST", 12, 40], ["positive", "OBSERVATION_MODIFIER", 12, 20], ["virological", "OBSERVATION", 21, 32], ["significantly", "OBSERVATION_MODIFIER", 46, 59], ["increased", "OBSERVATION_MODIFIER", 60, 69]]], ["In all, 52 positive virological results were confirmed by multiplex PCR analysis.", [["multiplex PCR analysis", "TEST", 58, 80]]], ["The most commonly detected viruses (multiple entries possible) by multiplex PCR were: adenovirus (12), human bocavirus (10), enterovirus (9), rhinovirus (7), RSV (7), human coronavirus (7), parechovirus (5)DiscussionFebrile seizures in children are typically related to common infections caused by either bacterial or viral pathogens.", [["enterovirus (9), rhinovirus (7), RSV", "DISEASE", 125, 161], ["Febrile seizures", "DISEASE", 216, 232], ["infections", "DISEASE", 277, 287], ["adenovirus", "ORGANISM", 86, 96], ["human", "ORGANISM", 103, 108], ["bocavirus", "GENE_OR_GENE_PRODUCT", 109, 118], ["enterovirus", "ORGANISM", 125, 136], ["rhinovirus", "ORGANISM", 142, 152], ["RSV", "ORGANISM", 158, 161], ["human", "ORGANISM", 167, 172], ["children", "ORGANISM", 236, 244], ["human", "SPECIES", 103, 108], ["RSV", "SPECIES", 158, 161], ["human", "SPECIES", 167, 172], ["coronavirus", "SPECIES", 173, 184], ["children", "SPECIES", 236, 244], ["human", "SPECIES", 103, 108], ["RSV", "SPECIES", 158, 161], ["human coronavirus", "SPECIES", 167, 184], ["multiplex PCR", "TEST", 66, 79], ["adenovirus", "PROBLEM", 86, 96], ["human bocavirus", "TEST", 103, 118], ["enterovirus", "PROBLEM", 125, 136], ["rhinovirus", "PROBLEM", 142, 152], ["RSV", "PROBLEM", 158, 161], ["human coronavirus", "PROBLEM", 167, 184], ["parechovirus", "PROBLEM", 190, 202], ["Febrile seizures", "PROBLEM", 216, 232], ["common infections", "PROBLEM", 270, 287], ["bacterial or viral pathogens", "PROBLEM", 305, 333], ["viruses", "OBSERVATION", 27, 34], ["bacterial", "OBSERVATION_MODIFIER", 305, 314], ["viral pathogens", "OBSERVATION", 318, 333]]], ["However, the specific reason for an individual event remains hidden in the majority of cases as no extended microbiological or virological testing is routinely performed.", [["an individual event", "PROBLEM", 33, 52], ["virological testing", "TEST", 127, 146]]], ["To the best of our knowledge, our study is unique in assessing the role of viral multiplex PCR analysis as part of the routine management of young children with febrile seizures [14] .", [["febrile seizures", "DISEASE", 161, 177], ["children", "ORGANISM", 147, 155], ["children", "SPECIES", 147, 155], ["our study", "TEST", 30, 39], ["viral multiplex PCR analysis", "TEST", 75, 103], ["the routine management", "TREATMENT", 115, 137], ["febrile seizures", "PROBLEM", 161, 177]]], ["In our large study cohort of 200 children with febrile seizures, we were able to demonstrate a significant increase in the number of detected respiratory viruses, thus providing us with important insights into the etiology of the underlying infectious disease.", [["febrile seizures", "DISEASE", 47, 63], ["respiratory viruses", "DISEASE", 142, 161], ["infectious disease", "DISEASE", 241, 259], ["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["febrile seizures", "PROBLEM", 47, 63], ["respiratory viruses", "PROBLEM", 142, 161], ["the underlying infectious disease", "PROBLEM", 226, 259], ["large", "OBSERVATION_MODIFIER", 7, 12], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["increase", "OBSERVATION_MODIFIER", 107, 115], ["respiratory viruses", "OBSERVATION", 142, 161], ["infectious", "OBSERVATION", 241, 251]]], ["Of note, we also detected an increase in the number of positive bacterial findings and viral and bacterial co-infections, and in parallel an increase in the use of antibiotics.", [["viral and bacterial co-infections", "DISEASE", 87, 120], ["positive bacterial findings", "PROBLEM", 55, 82], ["viral and bacterial co-infections", "PROBLEM", 87, 120], ["antibiotics", "TREATMENT", 164, 175], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["positive bacterial findings", "OBSERVATION", 55, 82], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["bacterial", "OBSERVATION_MODIFIER", 97, 106], ["co-infections", "OBSERVATION", 107, 120], ["increase", "OBSERVATION_MODIFIER", 141, 149]]], ["This finding is somewhat surprising since there were no overt institutional changes in clinical practice with regard to microbiology testing for bacterial infections.", [["bacterial infections", "DISEASE", 145, 165], ["overt institutional changes", "PROBLEM", 56, 83], ["microbiology testing", "TEST", 120, 140], ["bacterial infections", "PROBLEM", 145, 165], ["no", "UNCERTAINTY", 53, 55], ["infections", "OBSERVATION", 155, 165]]], ["However, the noted increase in the use of diagnostics and antibiotic treatment may be caused by children with more serious infections, as more uncomplicated cases (simple febrile seizure) are treated with minimal interventions possibly in an out-patient setting [15] .", [["infections", "DISEASE", 123, 133], ["febrile seizure", "DISEASE", 171, 186], ["children", "ORGANISM", 96, 104], ["patient", "ORGANISM", 246, 253], ["children", "SPECIES", 96, 104], ["patient", "SPECIES", 246, 253], ["diagnostics", "TREATMENT", 42, 53], ["antibiotic treatment", "TREATMENT", 58, 78], ["more serious infections", "PROBLEM", 110, 133], ["simple febrile seizure", "PROBLEM", 164, 186], ["minimal interventions", "TREATMENT", 205, 226], ["increase", "OBSERVATION_MODIFIER", 19, 27]]], ["Also, it is important to note that a substantive number of patients were started on antibiotics prior to hospital admission.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["antibiotics", "TREATMENT", 84, 95]]], ["Of note, recent clinical data indicate that molecular techniques including multiplex PCR analysis have an overall higher performance regarding sensitivity and specificity when compared with standard conventional methods (immunofluorescence and viral culture) [14] .DiscussionOur findings are of clinical importance for a number of reasons: First, the results shed light on the possible etiology of viral diseases associated with febrile 248 Role of multiplex PCR analysis in children with febrile seizures K original article seizures in children.", [["viral diseases", "DISEASE", 398, 412], ["febrile", "DISEASE", 429, 436], ["febrile seizures", "DISEASE", 489, 505], ["seizures", "DISEASE", 525, 533], ["children", "ORGANISM", 475, 483], ["children", "ORGANISM", 537, 545], ["children", "SPECIES", 475, 483], ["children", "SPECIES", 537, 545], ["molecular techniques", "TEST", 44, 64], ["multiplex PCR analysis", "TEST", 75, 97], ["standard conventional methods", "TEST", 190, 219], ["immunofluorescence", "TEST", 221, 239], ["viral culture", "TEST", 244, 257], ["viral diseases", "PROBLEM", 398, 412], ["febrile", "PROBLEM", 429, 436], ["multiplex PCR analysis", "TEST", 449, 471], ["febrile seizures", "PROBLEM", 489, 505], ["original article seizures in children", "PROBLEM", 508, 545], ["viral diseases", "OBSERVATION", 398, 412], ["article seizures", "OBSERVATION", 517, 533]]], ["Timely detection of the underlying culprit by multiplex PCR analysis may have the potential to assist in the decision to isolate or cohort patients in order to prevent nosocomial transmission.", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["multiplex PCR analysis", "TEST", 46, 68], ["nosocomial transmission", "PROBLEM", 168, 191], ["nosocomial", "OBSERVATION", 168, 178]]], ["In addition, one would suspect a contribution toward avoiding unnecessary antibiotics in febrile children.", [["febrile", "DISEASE", 89, 96], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["unnecessary antibiotics", "TREATMENT", 62, 85]]], ["Unfortunately, in our study population the use of routine multiplex PCR analysis did not translate into a reduction in the use of antibiotics.", [["routine multiplex PCR analysis", "TEST", 50, 80], ["antibiotics", "TREATMENT", 130, 141], ["reduction", "OBSERVATION_MODIFIER", 106, 115]]], ["In line with our findings, so far no benefit has been found for this diagnostic technique in children without underlying risk factors.", [["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["underlying risk factors", "PROBLEM", 110, 133]]], ["Wishaupt et al. recently investigated the role of multiplex PCR testing in 298 children (intervention group) admitted to hospital with respiratory infections.", [["respiratory", "ANATOMY", 135, 146], ["respiratory infections", "DISEASE", 135, 157], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["multiplex PCR testing", "TEST", 50, 71], ["respiratory infections", "PROBLEM", 135, 157], ["respiratory", "ANATOMY", 135, 146], ["infections", "OBSERVATION", 147, 157]]], ["Their analysis revealed that RT-PCR testing displays a high yield of viral diagnoses, but rapid communication of these results to the attending physicians does not lead to decreases in hospital admissions, shorter hospital stays, or less antibiotic use [16] .", [["Their analysis", "TEST", 0, 14], ["RT-PCR testing", "TEST", 29, 43], ["viral diagnoses", "PROBLEM", 69, 84], ["viral diagnoses", "OBSERVATION", 69, 84], ["decreases", "OBSERVATION_MODIFIER", 172, 181]]], ["The time lag in our cohort was approximately 24 h.DiscussionKrause et al. concluded in a recent review [10] that the high sensitivity of PRC-based methods is an important contribution to the diagnostic assessment of children with respiratory infections, but from a clinical perspective it still remains difficult to exclude a concomitant bacterial infection particularly in immunocompromised patients.", [["respiratory", "ANATOMY", 230, 241], ["respiratory infections", "DISEASE", 230, 252], ["bacterial infection", "DISEASE", 338, 357], ["children", "ORGANISM", 216, 224], ["patients", "ORGANISM", 392, 400], ["PRC", "PROTEIN", 137, 140], ["children", "SPECIES", 216, 224], ["patients", "SPECIES", 392, 400], ["the diagnostic assessment", "TEST", 187, 212], ["respiratory infections", "PROBLEM", 230, 252], ["a concomitant bacterial infection", "PROBLEM", 324, 357], ["infections", "OBSERVATION", 242, 252], ["bacterial", "OBSERVATION_MODIFIER", 338, 347], ["infection", "OBSERVATION", 348, 357]]], ["Moreover, children may shed viral nucleic acids of specific pathogens for prolonged periods and their detection may not be directly associated with the acute illness.DiscussionHowever, our clinical scenario (clinical diagnosis of an infection and the occurrence of a febrile seizure) strongly indicates a link between the positive results from multiplex PCR tests and the clinical presentation in our patients.", [["nucleic acids", "CHEMICAL", 34, 47], ["infection", "DISEASE", 233, 242], ["febrile seizure", "DISEASE", 267, 282], ["children", "ORGANISM", 10, 18], ["patients", "ORGANISM", 401, 409], ["children", "SPECIES", 10, 18], ["patients", "SPECIES", 401, 409], ["viral nucleic acids", "TEST", 28, 47], ["specific pathogens", "PROBLEM", 51, 69], ["the acute illness", "PROBLEM", 148, 165], ["an infection", "PROBLEM", 230, 242], ["a febrile seizure", "PROBLEM", 265, 282], ["multiplex PCR tests", "TEST", 344, 363], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["illness", "OBSERVATION", 158, 165], ["infection", "OBSERVATION", 233, 242]]], ["However, the interpretation of multiplex PCR analysis may also be difficult because PCRbased diagnostic methods often detect more than one virus especially in respiratory specimens [10, 14] .", [["respiratory specimens", "ANATOMY", 159, 180], ["multiplex PCR analysis", "TEST", 31, 53], ["diagnostic methods", "TEST", 93, 111], ["one virus", "PROBLEM", 135, 144], ["respiratory specimens", "TEST", 159, 180]]], ["Thus, the pros and cons of nucleic acid amplification tests must always be taken into account with regard to the clinical impact of a positive result [14] .DiscussionAs with many other diagnostic tools, multiplex PCR analysis should be used whenever consequences for the treatment ensue -e. g., adjusting hospital hygiene/infection prevention decisions or reevaluating the need for antibiotic treatment.", [["nucleic acid", "CHEMICAL", 27, 39], ["infection", "DISEASE", 322, 331], ["nucleic acid amplification tests", "TEST", 27, 59], ["multiplex PCR analysis", "TEST", 203, 225], ["the treatment", "TREATMENT", 267, 280], ["infection prevention", "TREATMENT", 322, 342], ["antibiotic treatment", "TREATMENT", 382, 402]]], ["So far, there are no algorithms for such an approach that have been validated in clinical practice.", [["an approach", "TREATMENT", 41, 52]]], ["This underlines the necessity of implementing antibiotic stewardship initiatives in addition to the use of more sensitive diagnostic tools for detecting vital infections [17] .", [["vital infections", "DISEASE", 153, 169], ["antibiotic stewardship initiatives", "TREATMENT", 46, 80], ["vital infections", "PROBLEM", 153, 169]]], ["In terms of treatment, the use of multiplex PCR analysis has been recommended especially in the first months of life, in children with risk factors for influenza, and in immunosuppressed patients, since clinical conse-quences such as targeted treatment with antivirals are more likely to be concluded from the results in such patients [10] .DiscussionAs with any retrospective, descriptive cohort study, a number of limitations apply when interpreting our data.", [["influenza", "DISEASE", 152, 161], ["children", "ORGANISM", 121, 129], ["patients", "ORGANISM", 187, 195], ["patients", "ORGANISM", 326, 334], ["children", "SPECIES", 121, 129], ["patients", "SPECIES", 187, 195], ["patients", "SPECIES", 326, 334], ["treatment", "TREATMENT", 12, 21], ["multiplex PCR analysis", "TEST", 34, 56], ["influenza", "PROBLEM", 152, 161], ["antivirals", "TREATMENT", 258, 268], ["descriptive cohort study", "TEST", 378, 402]]], ["When comparing historical groups in a retrospective study, no definite recommendations with regard to the role and limitations of microbial testing can be made.", [["a retrospective study", "TEST", 36, 57], ["microbial testing", "TEST", 130, 147]]], ["In general, problems with historical controls include potential changes in diagnostic criteria, differences in the population with the affected disease, differences in concomitant standards of care, differences in performing assessments that measure the endpoint, and importantly missing data in historical records as well as other data quality problems.", [["potential changes in diagnostic criteria", "PROBLEM", 54, 94], ["the affected disease", "PROBLEM", 131, 151], ["performing assessments", "TEST", 214, 236]]], ["Nevertheless, our retrospective audit demonstrates the feasibility of multiplex PCR analysis in detecting specific viruses in a large cohort of young children (n = 200) with febrile seizures that were most commonly associated with respiratory infections.", [["respiratory", "ANATOMY", 231, 242], ["febrile seizures", "DISEASE", 174, 190], ["respiratory infections", "DISEASE", 231, 253], ["children", "ORGANISM", 150, 158], ["children", "SPECIES", 150, 158], ["multiplex PCR analysis", "TEST", 70, 92], ["specific viruses", "PROBLEM", 106, 122], ["febrile seizures", "PROBLEM", 174, 190], ["respiratory infections", "PROBLEM", 231, 253], ["large", "OBSERVATION_MODIFIER", 128, 133], ["infections", "OBSERVATION", 243, 253]]], ["However, the precise role and the potential and possible limitations of multiplex PCR analysis in routine clinical practice remain to be elucidated and warrant further rigorous clinical trials.", [["multiplex PCR analysis", "TEST", 72, 94]]], ["Potential benefits related to its use may include easier cohortation and reduced use of antibiotics.What is already known?\u2022 Febrile seizures are common in young children with a very good overall prognosis. \u2022 It is of paramount importance to establish the site of infection in these children and to exclude central nervous system (CNS) involvement (encephalitis/meningitis).What this study adds\u2022 Multiplex PCR analysis is helpful in identifying a number of causative viruses in children with febrile seizures. \u2022 By defining those children with an underlying viral illness, multiplex PCR analysis has the potential to facilitate cohortation of these patients and to reduce unnecessary use of antibiotics in the future. \u2022 The precise role, importance, and limitation of multiplex PCR analysis in this cohort, however, remains to be established in rigorous prospective clinical trials.What this study addsFunding source Only local departmental funding was involved with this work.What this study addsFinancial disclosure statement None to declare.What this study addsConflict of interest J. Naric, J. Rissland, A. Simon, M. Poryo, L. Gortner, and S. Meyer declare that they have no competing interests.", [["central nervous system", "ANATOMY", 306, 328], ["CNS", "ANATOMY", 330, 333], ["Febrile seizures", "DISEASE", 124, 140], ["infection", "DISEASE", 263, 272], ["central nervous system (CNS) involvement", "DISEASE", 306, 346], ["encephalitis", "DISEASE", 348, 360], ["meningitis", "DISEASE", 361, 371], ["febrile seizures", "DISEASE", 491, 507], ["viral illness", "DISEASE", 557, 570], ["children", "ORGANISM", 161, 169], ["children", "ORGANISM", 282, 290], ["central nervous system", "ANATOMICAL_SYSTEM", 306, 328], ["CNS", "ANATOMICAL_SYSTEM", 330, 333], ["children", "ORGANISM", 477, 485], ["children", "ORGANISM", 529, 537], ["patients", "ORGANISM", 648, 656], ["children", "SPECIES", 161, 169], ["children", "SPECIES", 282, 290], ["children", "SPECIES", 477, 485], ["children", "SPECIES", 529, 537], ["patients", "SPECIES", 648, 656], ["easier cohortation", "PROBLEM", 50, 68], ["antibiotics", "TREATMENT", 88, 99], ["Febrile seizures", "PROBLEM", 124, 140], ["infection", "PROBLEM", 263, 272], ["central nervous system (CNS) involvement", "PROBLEM", 306, 346], ["encephalitis", "PROBLEM", 348, 360], ["meningitis", "PROBLEM", 361, 371], ["this study", "TEST", 378, 388], ["Multiplex PCR analysis", "TEST", 395, 417], ["febrile seizures", "PROBLEM", 491, 507], ["an underlying viral illness", "PROBLEM", 543, 570], ["multiplex PCR analysis", "TEST", 572, 594], ["antibiotics", "TREATMENT", 690, 701], ["multiplex PCR analysis", "TEST", 767, 789], ["this study", "TEST", 886, 896], ["this study", "TEST", 1048, 1058], ["infection", "OBSERVATION", 263, 272], ["central", "ANATOMY_MODIFIER", 306, 313], ["nervous system", "ANATOMY", 314, 328], ["CNS", "ANATOMY", 330, 333], ["encephalitis", "OBSERVATION", 348, 360], ["meningitis", "OBSERVATION", 361, 371], ["causative", "OBSERVATION_MODIFIER", 456, 465], ["viruses", "OBSERVATION", 466, 473], ["viral illness", "OBSERVATION", 557, 570]]]], "f7f2ce44362b2944b6c80930a2d406388933513e": [["IntroductionThe fundamental theorem of algebra states that the field of complex numbers is algebraically closed: every nonconstant polynomial with complex coefficients has at least one complex root.", [["root", "ANATOMY", 193, 197], ["root", "TISSUE", 193, 197], ["complex root", "OBSERVATION", 185, 197]]], ["By extending the field of real numbers with a single root of the polynomial X 2 + 1, we obtain a field (the complex numbers) where not only has X 2 + 1 a root but also every other polynomial.IntroductionAt the beginning of the 20th century, this theorem about the reals raised the question of which other fields could similarly be extended to be algebraically closed.", [["root", "ANATOMY", 154, 158], ["polynomial X 2 + 1", "DNA", 65, 83]]], ["It guarantees that every polynomial has a splitting field; it links algebra and geometry.", [["a splitting field", "PROBLEM", 40, 57], ["geometry", "OBSERVATION_MODIFIER", 80, 88]]], ["The Langlands Philosophy, one of the central questions in modern number theory, is a vast conjectural generalisation of these theorems, and one cannot even state the fundamental conjectures in this theory without mentioning algebraic closures.", [["algebraic closures", "TREATMENT", 224, 242], ["Philosophy", "OBSERVATION", 14, 24]]], ["Wiles and Taylor proved an extremely small fragment of these conjectures in 1994 and deduced Fermat's Last Theorem [3] .IntroductionDespite its importance, the existence of algebraic closures has never been formalised in a proof assistant.", [["an extremely small fragment of these conjectures", "PROBLEM", 24, 72], ["algebraic closures", "TREATMENT", 173, 191], ["extremely", "OBSERVATION_MODIFIER", 27, 36], ["small", "OBSERVATION_MODIFIER", 37, 42], ["fragment", "OBSERVATION", 43, 51]]], ["Here we propose to settle this: P. E. de Vilhena-The author was affiliated to\u00c9cole Polytechnique during the realisation of this work.Introduction-We formally prove that every field has an algebraic closure: an equivalent way to state that every field admits an algebraically closed extension (Sect.", [["an algebraic closure", "TREATMENT", 185, 205], ["closure", "OBSERVATION", 198, 205]]], ["4). -We describe a limitation of Isabelle's type system along with a general solution, where identity is replaced by isomorphism (Sect.", [["Isabelle's type system", "TREATMENT", 33, 55], ["a general solution", "TREATMENT", 67, 85]]], ["We start with the definition of canonical surjections, which show that every element of a quotient ring is accessible in a structure-preserving way.Definition 1 (Canonical surjection).", [["canonical surjections", "TREATMENT", 32, 53], ["a quotient ring", "TREATMENT", 88, 103], ["quotient ring", "OBSERVATION", 90, 103]]], ["Let R be a ring and I an ideal of R.The canonical surjection \u03c0 [R,I] : R \u2192 R/I is a surjective homomorphism from the ring R to the quotient R/I that associates an element r of R to its equivalence class in R/I, that is,Definition 1 (Canonical surjection).", [["Let R", "GENE_OR_GENE_PRODUCT", 0, 5], ["R \u2192 R", "GENE_OR_GENE_PRODUCT", 71, 76], ["quotient R/I", "DNA", 131, 143], ["ring", "OBSERVATION", 11, 15]]], ["Let R be a ring and I an ideal of R.The most common application of the canonical surjection in this paper is when considering the quotient between the ring of polynomials with coefficients in some field K, denoted by K [X] , and the ideal generated by some polynomial P \u2208 K[X], defined asDefinition 1 (Canonical surjection).", [["Let R", "GENE_OR_GENE_PRODUCT", 0, 5], ["asDefinition 1", "PROTEIN", 286, 300], ["ring", "OBSERVATION", 11, 15]]], ["Let R be a ring and I an ideal of R.This gives rise to the canonical surjection \u03c0 [K[X],(P )] , which can sometimes be seen as a homomorphism from K to K[X]/(P ) and not from K[X] to K[X]/(P ).", [["K", "CHEMICAL", 147, 148], ["K", "CHEMICAL", 152, 153], ["K", "CHEMICAL", 175, 176], ["P", "CHEMICAL", 158, 159], ["K", "CHEMICAL", 183, 184], ["Let R", "GENE_OR_GENE_PRODUCT", 0, 5], ["K[X]", "SIMPLE_CHEMICAL", 175, 179], ["K[X]/(P", "SIMPLE_CHEMICAL", 183, 190], ["K", "TEST", 147, 148], ["K[X]/(P", "TEST", 152, 159], ["K", "TEST", 175, 176], ["K", "TEST", 183, 184], ["ring", "OBSERVATION", 11, 15]]], ["The next proposition elucidates why it is interesting to see \u03c0 [K[X],(P )] as such: if P only has trivial factors, that is, if P is an irreducible polynomial, then the restriction of \u03c0 [K[X],(P )] to K is in fact a homomorphism of fields.Definition 2 (Irreducible polynomial).", [["K", "CHEMICAL", 200, 201], ["\u03c0 [K[X],(P )] to K", "CHEMICAL", 183, 201], ["P", "PROTEIN", 87, 88], ["P", "PROTEIN", 127, 128], ["trivial factors", "PROBLEM", 98, 113], ["an irreducible polynomial", "PROBLEM", 132, 157]]], ["Let K be a field and P a nonconstant polynomial with coefficients inProposition 1.", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5], ["P", "DNA", 21, 22]]], ["If K is a field and P is a polynomial with coefficients in K, then P is irreducible iff the quotient of K[X] by the ideal (P ) is a field.Definition 2 (Irreducible polynomial).", [["K", "CHEMICAL", 3, 4], ["K", "CHEMICAL", 104, 105], ["P", "DNA", 20, 21], ["P", "DNA", 67, 68], ["irreducible", "PROBLEM", 72, 83]]], ["Let K be a field and P a nonconstant polynomial with coefficients inGiven a homomorphism \u03c6 between two rings A and B, and a polynomial Q \u2208 A[X], we can build the polynomial Q \u03c6 \u2208 B[X] by applying \u03c6 to each of the coefficients of Q:Definition 2 (Irreducible polynomial).", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5], ["P", "DNA", 21, 22]]], ["Let K be a field and P a nonconstant polynomial with coefficients inIt follows from this definition that \u03c6 maps the evaluation of Q at an element a \u2208 A to the evaluation of Q \u03c6 at \u03c6(a):Definition 2 (Irreducible polynomial).", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5], ["P", "DNA", 21, 22], ["the evaluation", "TEST", 112, 126], ["the evaluation", "TEST", 155, 169]]], ["Let K be a field and P a nonconstant polynomial with coefficients in(1)Definition 2 (Irreducible polynomial).", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Let K be a field and P a nonconstant polynomial with coefficients inNow, consider a field K and a polynomial P \u2208 K[X].", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5], ["P", "DNA", 21, 22], ["P", "DNA", 109, 110], ["a field K", "TEST", 82, 91]]], ["From our previous discussion, the coefficients of P can be seen as constant polynomials in K[X] so that P can be seen as lying in (K[X]) [X] .", [["P", "DNA", 50, 51]]], ["Therefore, the evaluation of P at elements in K[X] is meaningful.", [["P", "DNA", 29, 30], ["the evaluation", "TEST", 11, 25]]], ["For instance, what happens if we evaluate P at the monomial X \u2208 K[X]?", [["P", "DNA", 42, 43]]], ["We recover P itself: P = P (X).", [["P", "DNA", 11, 12], ["P = P (X)", "DNA", 21, 30]]], ["Together with equation (1), we obtain the following result: \u03c0(P ) = \u03c0(P (X)) = P \u03c0 (\u03c0(X)) where \u03c0 stands for the canonical surjection \u03c0 [K[X],(P )] .", [["P", "CHEMICAL", 79, 80], ["K[X],(P )]", "CHEMICAL", 137, 147], ["\u03c0", "PROTEIN", 96, 97], ["\u03c0", "TEST", 81, 82], ["the canonical surjection", "TEST", 109, 133]]], ["Since the equivalence class of P in K[X]/(P ) is the same as the zero polynomial, we have proved that \u03c0(X) is a root of P \u03c0 .", [["root", "ANATOMY", 112, 116], ["P", "DNA", 31, 32], ["\u03c0(X)", "PROTEIN", 102, 106], ["P \u03c0", "PROTEIN", 120, 123], ["P in K[X]/(P )", "TEST", 31, 45]]], ["The next proposition rephrases this result using the terminology of a field extension when P is an irreducible polynomial.Definition 3 (Field extension).Let K and L be fields and \u03c6 : K \u2192 L a homomorphism.", [["K", "CHEMICAL", 183, 184], ["Let K", "GENE_OR_GENE_PRODUCT", 153, 158], ["P", "DNA", 91, 92], ["an irreducible polynomial", "PROBLEM", 96, 121], ["K", "TEST", 183, 184], ["irreducible", "OBSERVATION_MODIFIER", 99, 110], ["polynomial", "OBSERVATION", 111, 121]]], ["Since K is a field, \u03c6 is either the trivial map k \u2192 0 or an injective map.", [["K", "CHEMICAL", 6, 7], ["\u03c6", "DNA", 20, 21], ["injective map", "DNA", 60, 73], ["an injective map", "TEST", 57, 73]]], ["When it is injective, L is called a field extension of K under \u03c6.", [["K", "CHEMICAL", 55, 56]]], ["Let K be a field and P an irreducible polynomial in K[X].", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["The quotient of K[X] by the ideal (P ) is a field extension of K under the homomorphism \u03c0 [K[X],(P )] .", [["K", "CHEMICAL", 16, 17], ["K[X],(P )]", "CHEMICAL", 91, 101]]], ["Moreover, the polynomial P \u03c0 admits \u03c0(X) as a root in the field K[X]/(P ).", [["root", "ANATOMY", 46, 50], ["P \u03c0", "DNA", 25, 28], ["\u03c0(X)", "PROTEIN", 36, 40], ["root", "ANATOMY", 46, 50]]], ["Consider the real polynomial X 2 + 1.", [["X 2 + 1", "DNA", 29, 36]]], ["It's irreducible, therefore by Proposition 2 the ring R[X]/(X 2 + 1) is actually a field extension of R under the homomorphism \u03c0.", [["irreducible", "OBSERVATION_MODIFIER", 5, 16]]], ["Furthermore, \u03c0(X) is a root of the polynomial (X 2 +1) \u03c0 .", [["\u03c0(X)", "PROTEIN", 13, 17], ["root", "ANATOMY_MODIFIER", 23, 27]]], ["This fact can be formally stated by considering the map \u03c0(a + b X) \u2192 a + bi, which establishes an isomorphism from R[X]/(X 2 + 1) to the field C of complex numbers.Definition 3 (Field extension).Related to the notion of a field extension is the notion of a subfield:Definition 4 (Subfield).Let L be a field.", [["Let L", "GENE_OR_GENE_PRODUCT", 290, 295], ["the map", "TEST", 48, 55], ["a field extension", "PROBLEM", 220, 237]]], ["A subset K \u2286 L is called a subfield of L if it verifies the axioms of a field when equipped with the same laws as L.Definition 4 (Subfield).This relation is actually bidirectional:Definition 4 (Subfield).1.", [["A subset K", "TEST", 0, 10]]], ["If L is a field extension of K under the homomorphism \u03c6, then the image \u03c6(K) is a subfield of L. 2.", [["the image", "TEST", 62, 71]]], ["If K is a subfield of L, then L is a field extension of K under the identity homomorphism k \u2192 k.Definition 4 (Subfield).It is important to notice the nuances of the definition of an irreducible polynomial in the context of subfields.", [["K", "CHEMICAL", 3, 4], ["K", "CHEMICAL", 56, 57], ["K", "TEST", 3, 4], ["an irreducible polynomial", "PROBLEM", 179, 204], ["irreducible", "OBSERVATION_MODIFIER", 182, 193], ["polynomial", "OBSERVATION", 194, 204]]], ["If K is a subfield of L, then a polynomial P in K[X] has its coefficients in both K and L. When we say that P is an irreducible polynomial we have to specify in which field: while P may have no nontrivial factor with coefficients in K, it may have one with coefficients in L. To make the distinction unambiguous, we say that P is irreducible in K expressing that it only has trivial factors in the ring K[X].Definition 4 (Subfield).The next natural notion is that of an algebraic element:Definition 4 (Subfield).Definition 5 (Algebraic).", [["K", "CHEMICAL", 3, 4], ["K", "CHEMICAL", 48, 49], ["P", "DNA", 43, 44], ["P", "DNA", 108, 109], ["P", "DNA", 325, 326], ["K", "TEST", 3, 4], ["nontrivial factor with coefficients in K", "PROBLEM", 194, 234], ["trivial factors", "PROBLEM", 375, 390]]], ["Let L be a field and K a subfield of L. Then an element l \u2208 L is algebraic over K if there exists a polynomial P with coefficients in K such that P (l) = 0, that is, l is a root of P .Definition 4 (Subfield).The subset of elements of L which are algebraic over K is a subfield of L. Moreover, since the polynomial X \u2212 k belongs to the ring K[X] if k \u2208 K, every element of the field K is algebraic over K. In addition, the field K is a subfield of the subset of algebraics of L, which gives the following inclusions:Definition 4 (Subfield).Finally, we introduce the formal definition of an algebraically closed field and the closely related notion of the algebraic closure.Definition 6 (Algebraically closed).", [["root", "ANATOMY", 173, 177], ["K", "CHEMICAL", 428, 429], ["Let L", "GENE_OR_GENE_PRODUCT", 0, 5], ["element l \u2208 L", "DNA", 48, 61], ["P", "DNA", 111, 112], ["P", "DNA", 181, 182], ["polynomial X \u2212 k", "DNA", 303, 319], ["k", "TEST", 348, 349], ["K", "TEST", 352, 353], ["the field K", "TEST", 372, 383], ["the field K", "TEST", 418, 429], ["an algebraically closed field", "TREATMENT", 586, 615], ["the algebraic closure", "TREATMENT", 650, 671], ["root", "OBSERVATION", 173, 177], ["L", "ANATOMY_MODIFIER", 234, 235], ["algebraic closure", "OBSERVATION", 654, 671]]], ["A field K is algebraically closed if every nonconstant polynomial with coefficients in K has at least one root in K.Definition 7 (Algebraic closure).", [["root", "ANATOMY", 106, 110], ["A field K", "TEST", 0, 9], ["Algebraic closure", "TREATMENT", 130, 147], ["root", "OBSERVATION_MODIFIER", 106, 110]]], ["Let K and L be two fields.", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5], ["Let K", "TEST", 0, 5], ["L", "ANATOMY_MODIFIER", 10, 11], ["two", "ANATOMY_MODIFIER", 15, 18], ["fields", "ANATOMY_MODIFIER", 19, 25]]], ["Then L is an algebraic closure of K if there exists a homomorphism \u03c6 : K \u2192 L such that 1.", [["K", "CHEMICAL", 71, 72], ["an algebraic closure", "TREATMENT", 10, 30], ["K", "TEST", 71, 72], ["closure", "OBSERVATION", 23, 30]]], ["Every polynomial P of degree n with coefficients in the subfield \u03c6(K) has n roots in L: that is, P splits in L.Every element of L is algebraic over the subfield \u03c6(K).It is usual to refer to L as the algebraic closure: they are unique up to isomorphism.", [["the algebraic closure", "TREATMENT", 195, 216], ["roots", "ANATOMY", 76, 81], ["closure", "OBSERVATION", 209, 216]]], ["An additional remark is that if P splits in L, then P only has trivial irreducible factors.", [["P", "DNA", 32, 33], ["P", "DNA", 52, 53], ["P splits in L", "PROBLEM", 32, 45], ["trivial irreducible factors", "PROBLEM", 63, 90], ["trivial", "OBSERVATION_MODIFIER", 63, 70], ["irreducible", "OBSERVATION", 71, 82]]], ["That is, for every irreducible polynomial Q \u2208 L[X], if Q divides P , then Q must have degree 1.", [["P", "DNA", 65, 66]]], ["The converse also holds.Every element of L is algebraic over the subfield \u03c6(K).Our last claim in this section formally connects these notions:Every element of L is algebraic over the subfield \u03c6(K).The following three statements are equivalent:Every element of L is algebraic over the subfield \u03c6(K).1.", [["L", "ANATOMY_MODIFIER", 41, 42], ["L", "ANATOMY_MODIFIER", 159, 160]]], ["There exists an algebraically closed field extension of K.Every element of L is algebraic over the subfield \u03c6(K).2.", [["algebraically", "OBSERVATION_MODIFIER", 16, 29], ["closed", "OBSERVATION_MODIFIER", 30, 36], ["field", "OBSERVATION_MODIFIER", 37, 42], ["extension", "OBSERVATION_MODIFIER", 43, 52], ["L", "ANATOMY_MODIFIER", 75, 76]]], ["There exists an algebraic closure of K.Every element of L is algebraic over the subfield \u03c6(K).3.", [["an algebraic closure", "TREATMENT", 13, 33], ["algebraic closure", "OBSERVATION", 16, 33]]], ["There exists a field extension L of K under a homomorphism \u03c6 such that every polynomial with coefficients in the subfield \u03c6(K) splits in L.Every element of L is algebraic over the subfield \u03c6(K).The way we establish that every field admits an algebraically closed extension in our formal development is by proving that (3) implies (2) , that (2) implies (1) and that assertion (3) holds.", [["an algebraically closed extension", "PROBLEM", 239, 272], ["field", "OBSERVATION_MODIFIER", 15, 20], ["L", "ANATOMY_MODIFIER", 156, 157]]], ["We begin by presenting a technique for changing the underlying type of an algebraic structure.", [["a technique", "TREATMENT", 23, 34], ["algebraic structure", "OBSERVATION", 74, 93]]], ["The application of this procedure is named the induction of a structure.", [["this procedure", "TREATMENT", 19, 33]]], ["Both of these two features play an important role in the formal proof of the existence of the algebraic closure, and they surely have other applications.Induced StructuresThe type of monoids is formalised in the HOL-Algebra library as a record with three fields: the carrier, which has the polymorphic type a set, the composition operator and finally the unit.Induced Structuresrecord a monoid = carrier :: a set mult :: a \u21d2 a \u21d2 a one :: aInduced StructuresThe binary or direct product of two monoids is defined as follows:Induced StructuresThis takes two monoids as arguments, G and H. It returns a monoid whose carrier is the Cartesian product of the carriers of G and H, with composition defined element-wise.", [["H", "CHEMICAL", 671, 672], ["G", "SIMPLE_CHEMICAL", 665, 666], ["HOL-Algebra library", "DNA", 212, 231], ["the algebraic closure", "TREATMENT", 90, 111], ["Induced Structures", "PROBLEM", 523, 541], ["closure", "OBSERVATION", 104, 111]]], ["Isabelle assigns DirProd the typeInduced StructuresNow, let's say we want to define the direct product of a list of monoids Gs, that is, the n-ary product of monoids where n is the length of Gs.", [["Gs", "GENE_OR_GENE_PRODUCT", 124, 126]]], ["Consider the following attempt to define this by recursion on the list:Induced StructuresSuch an attempt to define an n-ary product of monoids from a list of monoids must fail, as the result type would depend on the length of the list.Induced StructuresTo solve this problem, we introduce the concept of induced structures.", [["Induced Structures", "PROBLEM", 71, 89], ["an n-ary product of monoids", "PROBLEM", 115, 142], ["Induced Structures", "PROBLEM", 235, 253], ["induced structures", "PROBLEM", 304, 322]]], ["The idea is that, given the pair of an algebraic structure such as a monoid G of type a monoid and an injective function f of type a \u21d2 b, we can induce a monoid H of type b monoid such that f is an isomorphism between the monoids G and H. Thus, H has the same algebraic properties as G but with the type we want.Definition 8 (Induced monoid).", [["H", "CHEMICAL", 161, 162], ["monoid G", "PROTEIN", 69, 77], ["H", "PROTEIN", 245, 246]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:We obtain a monoid f (G), called the monoid induced by G and f .", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["Furthermore, f is an isomorphism between the monoids G and f (G).Definition 8 (Induced monoid).", [["f (G)", "GENE_OR_GENE_PRODUCT", 59, 64]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:Here is the formal Isabelle definition (where ' denotes the image operator):Definition 8 (Induced monoid).", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:, using the inverse of the function f .", [["G \u2192 H", "CHEMICAL", 35, 40], ["H", "CHEMICAL", 102, 103], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["We use the inv into function (from Isabelle's standard library), which denotes the inverse of f A (the function f restricted to domain A).Definition 8 (Induced monoid).", [["f A", "GENE_OR_GENE_PRODUCT", 94, 97], ["inv", "DNA", 11, 14], ["f A", "PROTEIN", 94, 97], ["domain A", "PROTEIN", 128, 136]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:Let's return to the definition of the function DirProd list.", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40], ["DirProd", "PROTEIN", 215, 222]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:Now, the definition is accepted by Isabelle, yielding the isomorphismDefinition 8 (Induced monoid).", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:Algebraically speaking, an isomorphism is enough: we do not need true equality.Definition 8 (Induced monoid).", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:More generally, given a monoid G of type a monoid and an injective function f of type a \u21d2 b, we prove that the function f is an isomorphism between the monoids G and image monoid f G.Definition 8 (Induced monoid).", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:Other algebraic structures such as groups, rings and fields can also benefit from this construction.", [["G \u2192 H", "CHEMICAL", 35, 40], ["H", "CHEMICAL", 102, 103], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40], ["this construction", "TREATMENT", 250, 267]]], ["The difference between groups and monoids in HOL-Algebra is only logical: they satisfy different axioms but both have the same type, so image monoid can be applied to groups.", [["The difference between groups and monoids in HOL", "PROBLEM", 0, 48], ["image monoid", "TREATMENT", 136, 148], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:The ability to choose the type of an algebraic structure while preserving its abstract properties can also be useful in the formalisation of certain proofs of existence.", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["Let K be a field and P a polynomial with coefficients in K. Then there exists a field extension L under a homomorphism \u03c6 : K \u2192 L such that the polynomial P \u03c6 splits in L.Definition 8 (Induced monoid).", [["K", "CHEMICAL", 123, 124], ["Let K", "GENE_OR_GENE_PRODUCT", 0, 5], ["P \u03c6", "DNA", 154, 157], ["K", "TEST", 123, 124]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:Proof.", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["By induction on the degree of P .", [["P", "DNA", 30, 31]]], ["If deg P = 0, then P already splits in K. Thus, K itself (with the identity homomorphism) is the required field extension.Definition 8 (Induced monoid).", [["K", "CHEMICAL", 48, 49], ["deg P = 0", "DNA", 3, 12], ["P", "DNA", 19, 20]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:If deg P = n+1 for some n then there exists an irreducible polynomial Q with coefficients in K such that Q divides P .", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40], ["P", "DNA", 283, 284], ["an irreducible polynomial Q with coefficients in K", "PROBLEM", 212, 262], ["irreducible", "OBSERVATION_MODIFIER", 215, 226]]], ["Since Q is irreducible, by Proposition 2 we obtain the field extension K[X]/(Q) where Q \u03c0 has \u03c0(X) as a root.", [["root", "ANATOMY", 104, 108], ["Q \u03c0", "PROTEIN", 86, 89], ["\u03c0(X)", "PROTEIN", 94, 98], ["the field extension K", "TEST", 51, 72], ["irreducible", "OBSERVATION_MODIFIER", 11, 22], ["root", "ANATOMY", 104, 108]]], ["Since R \u2192 R \u03c0 is a homomorphism, Q \u03c0 divides P \u03c0 .", [["P", "CHEMICAL", 45, 46], ["R \u2192 R", "GENE_OR_GENE_PRODUCT", 6, 11], ["R \u2192 R \u03c0", "PROTEIN", 6, 13], ["Q \u03c0", "PROTEIN", 33, 36], ["P \u03c0", "DNA", 45, 48]]], ["Consequently, \u03c0(X) is also a root of P \u03c0 and hence X \u2212 \u03c0(X) divides P \u03c0 .Definition 8 (Induced monoid).", [["P", "CHEMICAL", 37, 38], ["P", "CHEMICAL", 68, 69], ["\u03c0(X)", "PROTEIN", 14, 18], ["P \u03c0", "PROTEIN", 37, 40], ["X", "PROTEIN", 51, 52], ["X", "PROTEIN", 57, 58], ["P \u03c0", "PROTEIN", 68, 71]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:Let R denote the division of P \u03c0 by the polynomial X \u2212 \u03c0(X), that is, R is a polynomial with coefficients in K[X]/(Q) such that P \u03c0 = (X \u2212 \u03c0(X)) R. Then deg(R) = n and by induction hypothesis we obtain a field L and a homo-Definition 8 (Induced monoid).", [["G \u2192 H", "CHEMICAL", 35, 40], ["P", "CHEMICAL", 296, 297], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40], ["Let R", "GENE_OR_GENE_PRODUCT", 168, 173], ["Let R", "PROTEIN", 168, 173], ["P \u03c0", "DNA", 197, 200], ["coefficients", "TEST", 261, 273], ["K", "TEST", 277, 278], ["induction hypothesis", "TEST", 339, 359]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:There are a number of obstacles to the formalisation of this proof in Isabelle, starting with the statement itself.", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40], ["number", "OBSERVATION_MODIFIER", 180, 186]]], ["The theorem asserts the existence of a field, which in Isabelle has type a ring, where a is the type of the elements of its carrier.", [["ring", "OBSERVATION_MODIFIER", 75, 79]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:In a dependent type setting, the problem could be avoided.", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40], ["dependent type", "OBSERVATION_MODIFIER", 173, 187]]], ["This is not possible in Isabelle, but let's say that we have a type b that could satisfy the requirements of Theorem 1.", [["not possible", "UNCERTAINTY", 8, 20]]], ["Then, another problem appears: the application of the inductive hypothesis to the polynomial R fails with a type unification issue, because its coefficients belong to K[X]/(Q) while those of P belong to K. In Isabelle, these fields have different types: if K has type a ring and a poly is the type of polynomials with coefficients of type a, then the quotient field K[X]/(Q) would have the type (( a poly) set) ring.", [["K", "CHEMICAL", 257, 258], ["P", "DNA", 191, 192], ["the inductive hypothesis", "PROBLEM", 50, 74], ["type a ring", "PROBLEM", 263, 274], ["the quotient field K", "TEST", 347, 367], ["the type (( a poly) set) ring", "TREATMENT", 386, 415]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:The solution we propose goes in another direction.", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40], ["The solution", "TREATMENT", 168, 180]]], ["The idea is to prove an intermediate result where we fix a well chosen type b for the elements of both the fields K and L. Then, after we build the field K[X]/(Q) of type (( b poly) set) ring during the proof, we use our type-switching mechanism to induce a field of type b ring with the same properties of K[X]/(Q).", [["K", "CHEMICAL", 307, 308], ["type (( b poly)", "TREATMENT", 166, 181], ["our type-switching mechanism", "TREATMENT", 217, 245], ["type b ring", "TREATMENT", 267, 278]]], ["At this point, it will be possible to use the induction hypothesis and to conclude the proof.Definition 8 (Induced monoid).", [["the induction hypothesis", "TREATMENT", 42, 66]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:The tricky part is choosing the type b.", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["Now, the situation is less clear: we need to come up with a type b such that an injective function of type ( b poly) set \u21d2 b exists.Definition 8 (Induced monoid).", [["type ( b poly)", "TREATMENT", 102, 116]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:Observe that the function only needs to be injective on the carrier of the structure we are planning to use as a model for the induction of a new one.", [["G \u2192 H", "CHEMICAL", 35, 40], ["H", "CHEMICAL", 102, 103], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40]]], ["Therefore, the definition of an injective function of type ( b poly) set \u21d2 b does not constitute a violation of Cantor's theorem, since the injectivity only needs to hold in the subset of the elements of type ( b poly) set composed by those which belong to the carrier of the field K[X]/(Q).Definition 8 (Induced monoid).", [["an injective function of type ( b poly)", "TREATMENT", 29, 68], ["type ( b poly)", "TREATMENT", 204, 218]]], ["Let G be a monoid, H a set and f : G \u2192 H an injection from G to H. Now the image f (G) is a subset of H, which can be equipped with a monoid structure as defined below:The type we conceived to satisfy these conditions is the type of multivariate polynomials, or, polynomials with indexed variables.", [["G \u2192 H", "CHEMICAL", 35, 40], ["Let G", "GENE_OR_GENE_PRODUCT", 0, 5], ["G \u2192 H", "GENE_OR_GENE_PRODUCT", 35, 40], ["multivariate polynomials", "PROBLEM", 233, 257]]], ["Below we discuss how these are formalised and how they solve the problem for our development.Multivariate PolynomialsPolynomials with coefficients in a field K are usually treated as linear combinations of successive powers of a formal letter X. Multivariate polynomials follow the same idea, but, instead of dealing with the powers of a fixed formal letter X n , we manipulate the linear combination of arbitrary expressions of the form j X nj j , where j runs over a finite subset of a fixed indexing set J. The formalisation of multivariate polynomials that we are about to present relies on the notion of finite maps.", [["Multivariate PolynomialsPolynomials", "PROBLEM", 93, 128], ["a fixed indexing", "TREATMENT", 486, 502], ["multivariate polynomials", "PROBLEM", 531, 555], ["PolynomialsPolynomials", "OBSERVATION", 106, 128]]], ["A finite map from the set A to the set B is a partial function from elements of A to elements of B whose support is finite.", [["B", "GENE_OR_GENE_PRODUCT", 97, 98], ["A finite map", "TEST", 0, 12], ["partial function", "OBSERVATION", 46, 62]]], ["If Mon J denotes the set of monomials over variables indexed by J, then we haveMultivariate PolynomialsWe define multivariate polynomials similarly, as finite maps from monomials Mon J to K * , the set of nonzero elements of K. The elements in the support of the finite map are the monomials involved in the linear combination.", [["Mon J", "PROTEIN", 3, 8], ["multivariate polynomials", "TEST", 113, 137], ["finite maps", "TEST", 152, 163], ["the finite map", "TEST", 259, 273], ["linear", "OBSERVATION_MODIFIER", 308, 314]]], ["The value in K * associated to each monomial is the choice of coefficient.", [["K", "CHEMICAL", 13, 14], ["The value", "TEST", 0, 9]]], ["Accordingly, if K[J] denotes the set of polynomials over variables indexed by J and coefficients in K, thenMultivariate PolynomialsIsabelle's predefined type of multisets comprises the finite maps into Z >0 .", [["K", "CHEMICAL", 16, 17], ["K", "TEST", 100, 101], ["Polynomials", "TEST", 120, 131]]], ["So, if the indexing set J has type c set, then a monomial would have the type c multiset.Multivariate PolynomialsFor polynomials, there was no shortcut.", [["the type c multiset", "TREATMENT", 69, 88], ["polynomials", "TEST", 117, 128], ["no", "UNCERTAINTY", 140, 142]]], ["They are modelled as functions from monomials to K and we require that the image of this function is zero save for a finite set of monomials.", [["K", "TEST", 49, 50]]], ["Therefore, a multivariate polynomial has the type c multiset \u21d2 a, where, as usual, a is the type of the elements in the field K. Now, we substantiate our claim that if the type b is instantiated with the type of multivariate polynomials, then there exists an injective function of type ( b poly) set \u21d2 b.Multivariate PolynomialsFirst, remember that the set constructor was introduced because it is the type of the elements of the quotient field K[X]/(Q): equivalence classes are encoded as cosets of the form \u03c0(P ) for some P \u2208 K[X].", [["\u03c0(P )", "PROTEIN", 509, 514], ["P", "PROTEIN", 524, 525], ["K.", "SPECIES", 126, 128], ["multivariate polynomials", "PROBLEM", 212, 236], ["type ( b poly)", "TREATMENT", 281, 295]]], ["Let M be a field and Q a polynomial with coefficients in M .", [["Let M", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["We let mod [M,Q] denote the function which assigns the remainder of the euclidean division of P by Q to each equivalence class \u03c0(P ) forMultivariate PolynomialsWe use the letter M for an arbitrary field instead of the usual letter K, because we instantiate this definition with a field whose elements have type b, that is, a field included in K[J].", [["P", "DNA", 94, 95]]], ["Thus, back in Isabelle, we are able to define an injective function of type ( b poly) set \u21d2 b poly.", [["type ( b poly) set \u21d2 b poly", "TREATMENT", 71, 98]]], ["The problem becomes simpler, since now it suffices to define an injective function of type b poly \u21d2 b.Multivariate PolynomialsIn other words, given a polynomial P with coefficients in K[J], we need to define a unique way to recover an element of K[J].", [["P", "DNA", 161, 162], ["type b poly \u21d2 b.", "TREATMENT", 86, 102], ["a polynomial P with coefficients in K[J]", "TREATMENT", 148, 188]]], ["We do this by replacing the formal letter X from the polynomial P with an indexed one, X l .", [["letter X", "DNA", 35, 43], ["P", "DNA", 64, 65]]], ["However, in order to get injectivity, we constrain the coefficients of P to not use the indexed variable X l .", [["P", "DNA", 71, 72]]], ["Let M be a subset of K[J] and l \u2208 J be an index.", [["Let M", "GENE_OR_GENE_PRODUCT", 0, 5], ["index", "OBSERVATION", 42, 47]]], ["Then l is free in M if M is a subset of K[J \u00a0{l}].Intuitively, l is free in M if X l does not appear in the writing of any term in M .", [["free", "OBSERVATION_MODIFIER", 10, 14], ["free", "OBSERVATION_MODIFIER", 68, 72]]], ["The idea of replacing the formal letter X with X l is captured as follows:Definition 11 (Eval).", [["letter X", "DNA", 33, 41], ["X l", "DNA", 47, 50]]], ["Let K be a field, J be an indexing set and l an index in J. We define Eval l , an injective function from polynomials with coefficients in K[J \u00a0{l}] to elements in K[J]:Finally, we are able to define an injective function of type ( b poly) set \u21d2 b as the composition of Eval and mod .", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5], ["Eval", "TEST", 70, 74], ["polynomials", "TEST", 106, 117], ["coefficients", "TEST", 123, 135], ["type ( b poly)", "TREATMENT", 225, 239], ["Eval", "TEST", 270, 274]]], ["Let K be a field, J be an indexing set, M be a field whose elements belong to K[J] and Q an irreducible polynomial in M [X].", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["If l \u2208 J is a free index in M , then the composition Eval l \u2022mod [M,Q] is an injective map fromMoreover, let L denote the structure induced by Eval l \u2022 mod [M,Q] .", [["an injective map", "TREATMENT", 74, 90]]], ["Furthermore, M is a subfield of L and the indexed variable X l is a root of Q in L.Lemma 1.", [["root", "ANATOMY", 68, 72], ["L", "ANATOMY_MODIFIER", 32, 33], ["root", "OBSERVATION_MODIFIER", 68, 72]]], ["Let K be a field, J be an indexing set, M be a field whose elements belong to K[J] and Q an irreducible polynomial in M [X].", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["If l \u2208 J is a free index in M , then the composition Eval l \u2022mod [M,Q] is an injective map fromProof.", [["an injective map fromProof", "TREATMENT", 74, 100]]], ["Injectivity of the map Eval l \u2022 mod [M,Q] comes from the composition of injective maps.", [["the map", "TEST", 15, 22], ["injective maps", "TREATMENT", 72, 86]]], ["Now, let L denote the field induced by Eval l \u2022 mod [M,Q] .", [["let L", "GENE_OR_GENE_PRODUCT", 5, 10]]], ["For instance, there exists a root of Q in L: it is the element that realises \u03c0(X), that is, (Eval n \u2022 mod [M,Q] )(\u03c0(X)).", [["root", "OBSERVATION_MODIFIER", 29, 33]]], ["However, remember that \u03c0(X) was a root of the polynomial Q \u03c0 in M [X]/(Q).", [["\u03c0(X)", "PROTEIN", 23, 27], ["Q \u03c0", "PROTEIN", 57, 60]]], ["So, the elementLemma 1.", [["elementLemma 1", "DNA", 8, 22], ["elementLemma", "OBSERVATION", 8, 20]]], ["Let K be a field, J be an indexing set, M be a field whose elements belong to K[J] and Q an irreducible polynomial in M [X].", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["If l \u2208 J is a free index in M , then the composition Eval l \u2022mod [M,Q] is an injective map fromis actually a root of the polynomial Q Evaln\u2022mod [ Therefore, the field M is a subfield of L, the polynomial Q has its coefficients in the field L and X n is a root of Q in L.Lemma 1.", [["the composition", "TEST", 37, 52], ["an injective map", "TEST", 74, 90], ["root", "OBSERVATION_MODIFIER", 255, 259]]], ["Let K be a field, J be an indexing set, M be a field whose elements belong to K[J] and Q an irreducible polynomial in M [X].", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["If l \u2208 J is a free index in M , then the composition Eval l \u2022mod [M,Q] is an injective map fromWe can finally proceed to the proof of the intermediate result that enjoys a direct analogue in Isabelle as suggested in the previous subsection.Lemma 2.", [["the composition", "TEST", 37, 52], ["a direct analogue in Isabelle", "PROBLEM", 170, 199]]], ["Let M \u2286 K[N] be a field and let P be a polynomial with coefficients in M .", [["K", "CHEMICAL", 8, 9]]], ["Suppose that for everyj \u2208 {0, . . . , deg P \u2212 1}, the index j is free in M .Under these hypotheses, there exists a field L \u2286 K[N], such that M is a subfield of L and P splits in L.Proof.", [["L.Proof", "PROTEIN", 178, 185], ["L", "ANATOMY_MODIFIER", 160, 161]]], ["By induction on the degree of P .", [["P", "DNA", 30, 31]]], ["If deg P = 0, then P splits in M and we are done.", [["P", "DNA", 19, 20]]], ["If deg P > 0, then there exists an irreducible polynomial Q \u2208 M [X] such that Q divides P .", [["P", "DNA", 88, 89], ["an irreducible polynomial Q \u2208 M", "PROBLEM", 32, 63]]], ["We can suppose that deg Q > 1, otherwise P have only trivial irreducible factors and would split in M .Under these hypotheses, there exists a field L \u2286 K[N], such that M is a subfield of L and P splits in L.With the polynomial Q and the index n, we are in position to apply Lemma 1; let S be the field induced by the injective map Eval n \u2022 mod [M,Q] such that M is a subfield of S and X n is a root of Q in S.Under these hypotheses, there exists a field L \u2286 K[N], such that M is a subfield of L and P splits in L.Since the only free index in M that becomes nonfree in S is the index n, we are allowed to instantiate the induction hypothesis with the field S and the polynomial P/(X \u2212X n ), whose degree is equal to n.", [["P", "CHEMICAL", 499, 500], ["L.Since", "PROTEIN", 511, 518], ["trivial irreducible factors", "PROBLEM", 53, 80], ["mod [M", "PROBLEM", 340, 346], ["the induction hypothesis", "TREATMENT", 616, 640], ["the polynomial P/(X \u2212X n", "TREATMENT", 662, 686], ["trivial", "OBSERVATION_MODIFIER", 53, 60], ["irreducible", "OBSERVATION", 61, 72], ["free index", "OBSERVATION", 528, 538]]], ["We obtain a field L \u2286 K[N], such that S is a subfield of L and the polynomial P/(X \u2212 X n ) splits in L. It is easy to see that P splits in L as well.Under these hypotheses, there exists a field L \u2286 K[N], such that M is a subfield of L and P splits in L.To recover the proper statement of Theorem 1, we only need to find a way to embed K into the set K[N].", [["P", "PROTEIN", 78, 79], ["X", "PROTEIN", 81, 82], ["P", "DNA", 127, 128], ["a field L \u2286 K[N", "TEST", 10, 25], ["splits in L.", "PROBLEM", 91, 103]]], ["If we have a homomorphism \u03c6 : K \u2192 M such that M is a subset of K[N] , then the field we get from Lemma 2 together with \u03c6 will be the field extension satisfying the conditions assured by Theorem 1.", [["K", "CHEMICAL", 30, 31], ["K", "CHEMICAL", 63, 64], ["K[N]", "CHEMICAL", 63, 67]]], ["Using our representation of multivariate polynomials as finite maps, we can make this intuition precise: Definition 12.", [["finite maps", "TEST", 56, 67]]], ["Let K be a field and J an indexing set.", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["We define const # a function from K to the set K[J]:Under these hypotheses, there exists a field L \u2286 K[N], such that M is a subfield of L and P splits in L.where \u2192 denotes the singleton map and {}, the empty one.Under these hypotheses, there exists a field L \u2286 K[N], such that M is a subfield of L and P splits in L.It is an injective map, therefore we can promote the function const # to an isomorphism between K and the induced field const # (K), written K # for brevity.Corollary 1 (Same statement as Theorem 1).Proof.", [["K", "CHEMICAL", 412, 413], ["K", "CHEMICAL", 457, 458], ["P", "PROTEIN", 142, 143], ["L.where", "PROTEIN", 154, 161], ["the singleton map", "TEST", 172, 189], ["a subfield of L and P splits in L.", "PROBLEM", 282, 316], ["empty", "OBSERVATION", 202, 207], ["L", "ANATOMY_MODIFIER", 296, 297]]], ["Consider the field K # \u2286 K [N] .", [["the field K", "TEST", 9, 20]]], ["Observe that every index n \u2208 N is free in K # .", [["K", "CHEMICAL", 42, 43]]], ["Indeed, an element of K # is the image const # (a) for some a in K and no indexed variable is involved in such terms.", [["K", "CHEMICAL", 22, 23], ["K #", "GENE_OR_GENE_PRODUCT", 22, 25], ["K #", "DNA", 22, 25], ["some a in K", "PROBLEM", 55, 66]]], ["We obtain a field L \u2286 K[N] such that K # is a subfield of L and P const # splits in L. Rephrase it with \u03c6 = const # : the field L is a field extension of K under the homomorphism \u03c6 such that the polynomial P \u03c6 splits in L.Corollary 1 (Same statement as Theorem 1).The proof of Lemma 2 follows the same structure as the one from Theorem 1: obtain an irreducible factor, build the quotient field and then apply induction.", [["K", "CHEMICAL", 37, 38], ["P \u03c6", "DNA", 206, 209], ["a field L", "TEST", 10, 19], ["an irreducible factor", "PROBLEM", 346, 367], ["Lemma", "OBSERVATION", 277, 282], ["irreducible", "OBSERVATION", 349, 360]]], ["The major difference is that now we have instrumented the proof with technical arguments concerning indexes.", [["major", "OBSERVATION_MODIFIER", 4, 9], ["difference", "OBSERVATION_MODIFIER", 10, 20]]], ["After all, we've built a splitting field of a polynomial in the same set from which we started.", [["a polynomial", "TREATMENT", 44, 56]]], ["Notice that all field extensions explicitly mentioned in the proof are those under the identity homomorphism.Corollary 1 (Same statement as Theorem 1).A final remark: we do not define how multivariate polynomials compose with each other; we just show how they can be represented.", [["all", "OBSERVATION_MODIFIER", 12, 15], ["field", "OBSERVATION_MODIFIER", 16, 21]]], ["We do not define the ring operations as we do not need their algebraic properties.", [["the ring operations", "TREATMENT", 17, 36]]], ["We use only their set properties, which ease the definition of an injective function as described and allow the construction of an induced structure.", [["an injective function", "TREATMENT", 63, 84], ["an induced structure", "PROBLEM", 128, 148]]], ["Moreover, this procedure of inducing structures engenders the composition laws for free.ConceptionIn this section we outline the main ideas behind our formal proof of the existence of an algebraic closure.", [["this procedure", "TREATMENT", 10, 24], ["an algebraic closure", "TREATMENT", 184, 204], ["algebraic closure", "OBSERVATION", 187, 204]]], ["We start with a short survey of existing proofs.", [["existing proofs", "TREATMENT", 32, 47]]], ["Technical details are left for the next section.ConceptionWe mentioned in the introduction that the existence of an algebraic closure was proved by Steinitz in 1910.", [["the next section", "TREATMENT", 31, 47], ["an algebraic closure", "TREATMENT", 113, 133]]], ["Let F be a field.", [["Let F", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Consider the ring F [F [X]] of multivariate polynomials over variables indexed by polynomials in F [X] and coefficients in F .", [["multivariate polynomials", "PROBLEM", 31, 55]]], ["Then the ring F [F [X]] admits an ideal I with two key properties: (1) the quotient F [F [X]]/I is a field; (2) every nonconstant polynomial in F [X] has a root in F [F [X]]/I. This yields a field extension of F where every nonconstant polynomial with coefficients in F has at least one root.", [["root", "ANATOMY", 156, 160], ["root", "ANATOMY", 287, 291], ["root", "ORGAN", 156, 160], ["root", "ORGAN", 287, 291], ["root", "ANATOMY", 156, 160], ["root", "ANATOMY", 287, 291]]], ["Let F be a field.", [["Let F", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Consider the ring F [F [X]] of multivariate polynomials over variables indexed by polynomials in F [X] and coefficients in F .", [["multivariate polynomials", "PROBLEM", 31, 55]]], ["Then the ring F [F [X]] admits an ideal I with two key properties: (1) the quotient F [F [X]]/I is a field; (2) every nonconstant polynomial in F [X] has a root in F [F [X]where K is the field for which we intend to find an algebraically closed extension and E n+1 is the field obtained by instantiating F with the field E n .", [["root", "ANATOMY", 156, 160], ["root", "ANATOMY", 156, 160]]], ["It is a field E left invariant by the construction described above, that is, a fixed point: every nonconstant polynomial in E[X] has a root in E. Thus, E is an algebraically closed field.Proof.", [["root", "ANATOMY", 135, 139], ["root", "ORGAN", 135, 139], ["root", "ANATOMY", 135, 139]]], ["Let F be a field.", [["Let F", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Consider the ring F [F [X]] of multivariate polynomials over variables indexed by polynomials in F [X] and coefficients in F .", [["multivariate polynomials", "PROBLEM", 31, 55]]], ["Then the ring F [F [X]] admits an ideal I with two key properties: (1) the quotient F [F [X]]/I is a field; (2) every nonconstant polynomial in F [X] has a root in F [F [X]There are two main components in Artin's proof: the construction of a field and its iteration.", [["root", "ANATOMY", 156, 160], ["root", "ORGAN", 156, 160], ["polynomial in F", "PROBLEM", 130, 145], ["root", "ANATOMY", 156, 160]]], ["They consider the larger ring of multivariate polynomials K[K[X] \u00d7 N] with the product K[X] \u00d7 N as the choice of indexing set and prove that a slightly different construction engenders an algebraically closed field extension of K directly, without iteration.Proof.", [["multivariate polynomials K", "TEST", 33, 59], ["K[", "TEST", 60, 62], ["the product K", "TEST", 75, 88], ["a slightly different construction", "TREATMENT", 141, 174]]], ["Let F be a field.", [["Let F", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Consider the ring F [F [X]] of multivariate polynomials over variables indexed by polynomials in F [X] and coefficients in F .", [["multivariate polynomials", "PROBLEM", 31, 55]]], ["Then the ring F [F [X]] admits an ideal I with two key properties: (1) the quotient F [F [X]]/I is a field; (2) every nonconstant polynomial in F [X] has a root in F [F [X]Our proof goes in the opposite direction.", [["root", "ANATOMY", 156, 160], ["root", "ORGAN", 156, 160], ["polynomial in F", "PROBLEM", 130, 145], ["Our proof", "TEST", 172, 181], ["root", "ANATOMY", 156, 160], ["opposite", "ANATOMY_MODIFIER", 194, 202]]], ["Let F be a field.", [["Let F", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Consider the ring F [F [X]] of multivariate polynomials over variables indexed by polynomials in F [X] and coefficients in F .", [["multivariate polynomials", "PROBLEM", 31, 55]]], ["Then the ring F [F [X]] admits an ideal I with two key properties: (1) the quotient F [F [X]]/I is a field; (2) every nonconstant polynomial in F [X] has a root in F [F [X]The increment now is small.", [["root", "ANATOMY", 156, 160], ["root", "ORGAN", 156, 160], ["polynomial in F", "PROBLEM", 130, 145], ["root", "ANATOMY", 156, 160], ["small", "OBSERVATION_MODIFIER", 193, 198]]], ["Proposition 2 states that we add only one root at each step, while the previous construction found one root for every polynomial with coefficients in the current field.", [["root", "ANATOMY", 42, 46], ["root", "ANATOMY", 103, 107], ["root", "ORGAN", 42, 46]]], ["We compensate for this deficit through the use of Zorn's lemma, which guarantees the existence of a maximal element of a partially ordered set.", [["this deficit", "PROBLEM", 18, 30], ["Zorn's lemma", "TREATMENT", 50, 62]]], ["Let F be a field.", [["Let F", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Consider the ring F [F [X]] of multivariate polynomials over variables indexed by polynomials in F [X] and coefficients in F .", [["multivariate polynomials", "PROBLEM", 31, 55]]], ["Then the ring F [F [X]] admits an ideal I with two key properties: (1) the quotient F [F [X]]/I is a field; (2) every nonconstant polynomial in F [X] has a root in F [F [X]In our proof, we need this ability.", [["root", "ANATOMY", 156, 160], ["root", "ORGAN", 156, 160], ["root", "ANATOMY", 156, 160]]], ["With the construction from Artin's proof, we were content to iterate \"vertically\" over the degree of each polynomial at the same time.", [["Artin's proof", "TREATMENT", 27, 40]]], ["Let F be a field.", [["Let F", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Consider the ring F [F [X]] of multivariate polynomials over variables indexed by polynomials in F [X] and coefficients in F .", [["multivariate polynomials", "PROBLEM", 31, 55]]], ["Then the ring F [F [X]] admits an ideal I with two key properties: (1) the quotient F [F [X]]/I is a field; (2) every nonconstant polynomial in F [X] has a root in F [F [X]More precisely, given both a field E n in the sequence of Artin's proof and a polynomial P with coefficients in the field E n , we can find a k such that P splits in the field E n+k .", [["root", "ANATOMY", 156, 160], ["Artin", "PROTEIN", 230, 235], ["P", "DNA", 326, 327], ["Artin's proof", "TREATMENT", 230, 243], ["root", "ANATOMY", 156, 160]]], ["It suffices to take k larger than the degree of P .", [["P", "DNA", 48, 49], ["take k larger", "OBSERVATION_MODIFIER", 15, 28]]], ["With our new construction however, the distance between the field where a polynomial has its coefficients and the field in which the same polynomial splits might be larger than every natural number.", [["new", "OBSERVATION_MODIFIER", 9, 12], ["construction", "OBSERVATION", 13, 25], ["field", "ANATOMY_MODIFIER", 60, 65], ["coefficients", "OBSERVATION_MODIFIER", 93, 105], ["polynomial splits", "OBSERVATION", 138, 155], ["might be", "UNCERTAINTY", 156, 164], ["larger", "OBSERVATION_MODIFIER", 165, 171]]], ["Let F be a field.", [["Let F", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Consider the ring F [F [X]] of multivariate polynomials over variables indexed by polynomials in F [X] and coefficients in F .", [["multivariate polynomials", "PROBLEM", 31, 55]]], ["Then the ring F [F [X]] admits an ideal I with two key properties: (1) the quotient F [F [X]]/I is a field; (2) every nonconstant polynomial in F [X] has a root in F [F [X]This simplification eases the formalisation in a number of ways.", [["root", "ANATOMY", 156, 160], ["root", "ORGAN", 156, 160], ["This simplification", "PROBLEM", 172, 191], ["root", "ANATOMY", 156, 160]]], ["Moreover, the proof that I enjoys the two key properties discussed in the proof sketch relies on the intermediate result that every field admits an extension that splits a finite set of polynomials (a corollary of Theorem 1).", [["an extension", "PROBLEM", 145, 157]]], ["We would have to prove a lemma that would immediately be subsumed by our intended theorem: the existence of an algebraically closed extension.Proof.", [["an algebraically closed extension", "PROBLEM", 108, 141]]], ["Let F be a field.", [["Let F", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Consider the ring F [F [X]] of multivariate polynomials over variables indexed by polynomials in F [X] and coefficients in F .", [["multivariate polynomials", "PROBLEM", 31, 55]]], ["Then the ring F [F [X]] admits an ideal I with two key properties: (1) the quotient F [F [X]]/I is a field; (2) every nonconstant polynomial in F [X] has a root in F [F [X]The idea of coupling a simpler construction with Zorn's lemma is also seen in Jelonek [8] .", [["root", "ANATOMY", 156, 160], ["root", "ORGAN", 156, 160], ["a simpler construction", "TREATMENT", 193, 215], ["Zorn's lemma", "TREATMENT", 221, 233], ["root", "ANATOMY", 156, 160]]], ["But while he relies on set-theoretical arguments to obtain a set sufficiently large to host an algebraic closure, we exhibit this set explicitly.The ProofIn this section, we explain our proof that every field admits an algebraic closure.", [["an algebraic closure", "TREATMENT", 92, 112], ["an algebraic closure", "TREATMENT", 216, 236], ["closure", "OBSERVATION", 229, 236]]], ["Let \u2264 be a binary relation on a set S. Then (S, \u2264) is a partial order if \u2264 is transitive, reflexive and anti-symmetric.", [["Let", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["A chain of S is a subset of S for which every two of its elements are \u2264-comparable.", [["chain", "OBSERVATION_MODIFIER", 2, 7]]], ["A maximal element is some a \u2208 S such that for all x \u2208 S, if a \u2264 x then a = x, while an upper bound of S is some a \u2208 S for which a \u2265 x for all x \u2208 S. Lemma 3 (Zorn).", [["A maximal element", "PROBLEM", 0, 17], ["maximal element", "OBSERVATION", 2, 17]]], ["Suppose every chain C \u2286 S has an upper bound.", [["chain C \u2286 S", "PROTEIN", 14, 25], ["an upper bound", "PROBLEM", 30, 44], ["upper", "ANATOMY_MODIFIER", 33, 38]]], ["Then (S, \u2264) has a maximal element.The ProofLet K be a field.", [["ProofLet K", "CHEMICAL", 38, 48]]], ["We will search for an algebraic closure of K in the set K[J] of multivariate polynomials indexed by a well-chosen set J. Recall that an algebraic closure is a field extension, hence we have to search both for a field L and for a homomorphism \u03c6 : K \u2192 L. We make some decisions to reduce the search space.", [["K", "CHEMICAL", 246, 247], ["K \u2192 L.", "SPECIES", 246, 252], ["an algebraic closure", "TREATMENT", 19, 39], ["multivariate polynomials", "TREATMENT", 64, 88], ["an algebraic closure", "TREATMENT", 133, 153], ["the search space", "PROBLEM", 286, 302], ["search space", "OBSERVATION", 290, 302]]], ["We expect L to be an extension of the induced field K # .", [["K", "CHEMICAL", 52, 53]]], ["Thus, we anticipate \u03c6 to be the natural homomorphism const # : K \u2192 K # from K to the induced field K # .", [["K", "CHEMICAL", 63, 64], ["K", "CHEMICAL", 67, 68], ["K", "CHEMICAL", 76, 77], ["K", "CHEMICAL", 99, 100], ["K", "TEST", 63, 64], ["K", "TEST", 67, 68], ["K", "TEST", 76, 77]]], ["Now, given a field L embedded in K[J] such that K # is a subfield of L, we can simply put L to be the field extension of K under const # .The ProofLet's simplify further.", [["K", "CHEMICAL", 48, 49], ["a field L embedded in K[J", "TREATMENT", 11, 36], ["The ProofLet's", "TREATMENT", 138, 152]]], ["Let's search for a field L \u2286 K[J] such that K # is a subfield of L and every polynomial with coefficients in K # splits in L. Such a field is not necessarily an algebraic closure of K # , with each of its elements algebraic over K # .", [["K", "CHEMICAL", 44, 45], ["K", "CHEMICAL", 182, 183], ["K", "CHEMICAL", 229, 230], ["a field L \u2286 K[J", "TEST", 17, 32], ["K", "TEST", 44, 45], ["splits in L.", "PROBLEM", 113, 125], ["L", "ANATOMY_MODIFIER", 65, 66], ["not necessarily", "UNCERTAINTY", 142, 157], ["closure", "OBSERVATION", 171, 178]]], ["Still, exhibiting a field with these simpler characteristics is sufficient to prove the existence of an algebraic closure, as it proves assertion (3) from Proposition 3.The ProofWith these considerations in mind, let's define the concrete set of fields.The ProofDefinition 14.", [["an algebraic closure", "TREATMENT", 101, 121], ["closure", "OBSERVATION", 114, 121]]], ["For a field K, let A K denote the set of fields L \u2286 K[K [X] \u00d7 N] satisfying the following properties:The Proofand natural number n, if the pair (P, n) is a nonfree index of L, then the indexed variable X (P,n) is a root of P const # in L.The ProofThe intuition for property (2) and for the choice of indexing set, K[X] \u00d7 N, follows from the insights developed in the last section.", [["root", "ANATOMY", 215, 219], ["a field K", "TEST", 4, 13], ["A K", "TEST", 19, 22], ["fields", "TEST", 41, 47], ["L", "TEST", 48, 49], ["K", "TEST", 52, 53], ["K", "TEST", 54, 55]]], ["Recall the main idea: to build a chain of fields where at each step we add a new root to the preceding field.", [["root", "ANATOMY", 81, 85], ["root", "TISSUE", 81, 85]]], ["What property (2) intuitively does is to ensure that the role of the new root is taken by a formal letter X j , where j is some previously free index j.", [["root", "ANATOMY", 73, 77], ["root", "ORGAN", 73, 77]]], ["Additionally, it also ensures that the choice of index was judicious: if we choose to include the variable X (P,n) in the next round of the iteration, then it must be in a way such that it is a root of the polynomial P const # .", [["root", "ANATOMY", 194, 198], ["P", "DNA", 217, 218]]], ["Look both at the statement of Lemma 2 and its proof for an example of similar reasoning.The ProofNext, we equip A K with a partial ordering, aiming to use Zorn's lemma.The ProofDefinition 15 (Subfield relation).", [["Zorn's lemma", "TREATMENT", 155, 167]]], ["Let L 1 and L 2 be two fields.", [["Let L 1", "GENE_OR_GENE_PRODUCT", 0, 7], ["L 2", "GENE_OR_GENE_PRODUCT", 12, 15], ["L 2", "DNA", 12, 15], ["L 2", "ANATOMY_MODIFIER", 12, 15], ["two", "ANATOMY_MODIFIER", 19, 22], ["fields", "ANATOMY_MODIFIER", 23, 29]]], ["We write L 1 L 2 to denote that L 1 is a subfield of L 2 .Lemma 4.If K is a field, then A K has a maximal element with respect to the partial order (A K , ).Lemma 4.Proof.", [["K", "CHEMICAL", 69, 70], ["K", "CHEMICAL", 90, 91], ["K", "TEST", 69, 70], ["A K", "TEST", 88, 91], ["Lemma", "OBSERVATION", 58, 63]]], ["Consider a chain C \u2286 A K and let E = F \u2208C F .", [["F \u2208C F", "CHEMICAL", 37, 43], ["C F", "PROTEIN", 40, 43], ["a chain C", "TEST", 9, 18], ["A K", "TEST", 21, 24]]], ["For any two elements a and b in E, there exists a field L \u2208 C such that a, b \u2208 L. We define their composition in E (addition and multiplication) to be the same as in L. Since every two fields in C are comparable, if we obtain another field L \u2208 C such that the elements a and b belong to L , then the field L is either a subfield of L or an extension of L. In both cases, the composition of a and b gives the same result either in L or in L .", [["L.", "OBSERVATION_MODIFIER", 353, 355]]], ["It is also straightforward to check that E is an upper bound of C in A K .", [["A K", "GENE_OR_GENE_PRODUCT", 69, 72], ["upper bound", "OBSERVATION_MODIFIER", 49, 60]]], ["Since every chain has an upper bound, the result holds by Zorn's lemma.Lemma 4.Although the usual sequence of fields is hidden by the application of Zorn's lemma, we can think of the maximal element of A K as the limit of that sequence.", [["A K", "GENE_OR_GENE_PRODUCT", 202, 205], ["an upper bound", "PROBLEM", 22, 36], ["Zorn's lemma", "TREATMENT", 149, 161], ["A K", "TEST", 202, 205], ["upper bound", "OBSERVATION_MODIFIER", 25, 36]]], ["It must be a field that splits every polynomial in K # [X], since otherwise there would still be space left to add another root, contradicting its maximality: Theorem 2.", [["root", "ANATOMY", 123, 127], ["root", "ORGAN", 123, 127], ["root", "ANATOMY", 123, 127]]], ["Let K be a field and let M be the maximal element of A K for the subfield relation.", [["Let K", "GENE_OR_GENE_PRODUCT", 0, 5], ["A K", "GENE_OR_GENE_PRODUCT", 53, 56]]], ["For contradiction, suppose that there exists a polynomial with coefficients in K # that does not split in M .", [["a polynomial with coefficients in K #", "PROBLEM", 45, 82]]], ["Since the map const # is an isomorphism between the fields K and K # we can suppose that the polynomial which fails to split in M is of the form P const # where P is some polynomial with coefficients in K.Lemma 4.Let Q \u2208 M [X] be an irreducible polynomial with degree greater than 1 such that Q divides P const # and let n be a natural number such that the pair (P, n) is a free index in M .", [["P", "DNA", 145, 146], ["P", "DNA", 161, 162], ["P", "DNA", 303, 304], ["the map", "TEST", 6, 13], ["the polynomial", "PROBLEM", 89, 103], ["some polynomial with coefficients in K.Lemma 4", "PROBLEM", 166, 212], ["an irreducible polynomial", "PROBLEM", 230, 255], ["irreducible", "OBSERVATION", 233, 244]]], ["They both exist, otherwise the polynomial P const # would split in M .", [["P", "DNA", 42, 43]]], ["We are able to apply Lemma 1 instantiated with the polynomial Q and the index (P, n) to obtain a field L such that M is a subfield of L and the indexed variable X (P,n) is a root of Q in L.Lemma 4.Clearly L belongs to A K , and the indexed variable X (P,n) is an element of L that does not belong to M .", [["A K", "GENE_OR_GENE_PRODUCT", 218, 221], ["X (P,n)", "DNA", 249, 256], ["A K", "TEST", 218, 221], ["root", "ANATOMY", 174, 178]]], ["So L is an element of A k that is strictly greater than M for the subfield relation, contradicting the maximality of M .", [["A k", "TEST", 22, 25], ["element", "OBSERVATION", 11, 18], ["greater", "OBSERVATION_MODIFIER", 43, 50]]], ["Every field K admits an algebraic closure.Lemma 4.Proof.", [["an algebraic closure", "TREATMENT", 21, 41], ["closure", "OBSERVATION", 34, 41]]], ["The maximal element of A K is a field extension of K under the homomorphism const # satisfying statement 3 from Proposition 3.", [["K", "CHEMICAL", 25, 26], ["K", "CHEMICAL", 51, 52], ["maximal", "OBSERVATION_MODIFIER", 4, 11], ["element", "OBSERVATION_MODIFIER", 12, 19]]], ["By the same theorem, this is sufficient to prove the existence of an algebraic closure of K.Related WorkWe believe that our formalisation of the existence of an algebraic closure of any field is novel.", [["an algebraic closure of K.Related WorkWe", "TREATMENT", 66, 106], ["an algebraic closure", "TREATMENT", 158, 178], ["closure", "OBSERVATION", 171, 178]]], ["There is, however, a closely related theorem formalised by Gonthier as part of the Mathematical Components library: every countable field admits an algebraic closure [4] .", [["an algebraic closure", "TREATMENT", 145, 165]]], ["Since the proof is carried out in Coq, it is especially interesting for its computational content.", [["Coq", "SIMPLE_CHEMICAL", 34, 37]]], ["This is a problem for the p-adic numbers, which (unlike the reals) has no well-known algebraic closure construction.Related WorkAlso in Coq, Mathematical Components supports multivariate polynomials [7] over finite indexing sets of the form {1, . . . , n}.Related WorkSchwarzweller proved in Mizar that the real numbers and finite fields are not algebraically closed [11] .", [["algebraic closure construction", "TREATMENT", 85, 115]]], ["The Lean community maintains an online \"Algebraic closure roadmap\" [1] .Related WorkWork has also been done in Isabelle.", [["an online \"Algebraic closure roadmap", "TREATMENT", 29, 65]]], ["An AFP entry [12] uses lists to represent monomials and polynomials.", [["AFP", "GENE_OR_GENE_PRODUCT", 3, 6], ["AFP", "PROTEIN", 3, 6], ["An AFP entry", "TEST", 0, 12]]], ["Haftmann et al. [5] discuss different options for multivariate polynomials in Isabelle.", [["multivariate polynomials in Isabelle", "PROBLEM", 50, 86]]], ["The abstract representation resembles ours; it is based on finite maps.", [["finite maps", "TEST", 59, 70]]], ["We cannot use either of these Isabelle libraries because both rely on type classes to model the algebraic properties satisfied by polynomial coefficients.", [["these Isabelle libraries", "TREATMENT", 24, 48]]], ["While type classes are fine for sharing algebraic theorems between types [10] , they are too restrictive for abstract algebra, forcing algebraic objects to be types.ConclusionWe formalised a proof that every field has an algebraic closure, a fundamental theorem.", [["abstract algebra", "PROBLEM", 109, 125], ["an algebraic closure", "TREATMENT", 218, 238], ["closure", "OBSERVATION", 231, 238]]], ["We have given a precise description of the known proofs and demonstrated how Zorn's lemma led to a straightforward formalisation.ConclusionThe obstacles that we encountered during the realisation of this work led to the investigation of some problems related to Isabelle's type-discipline: that all the objects in a collection must have the same type.", [["a straightforward formalisation", "PROBLEM", 97, 128], ["some problems", "PROBLEM", 237, 250], ["collection", "OBSERVATION", 316, 326]]], ["As a solution, we introduced the notion of an induced structure, which yields an isomorphic algebraic structure having a specified type.ConclusionTo complete this project, we had to extend the HOL-Algebra library with general-purpose topics such as multivariate polynomials, arithmetic on arbitrary rings, arithmetic on the ring of polynomials, subfields, finite extensions and much of the content in Sect.", [["HOL-Algebra library", "DNA", 193, 212], ["an induced structure", "PROBLEM", 43, 63], ["multivariate polynomials", "PROBLEM", 249, 273], ["arithmetic on arbitrary rings", "PROBLEM", 275, 304], ["finite extensions", "PROBLEM", 356, 373], ["isomorphic", "OBSERVATION_MODIFIER", 81, 91], ["algebraic structure", "OBSERVATION", 92, 111], ["arbitrary rings", "OBSERVATION", 289, 304], ["ring", "ANATOMY_MODIFIER", 324, 328]]], ["It comprises nearly 15,000 nonempty lines of code in 21 new theories.", [["nonempty lines", "OBSERVATION", 27, 41]]], ["Our development is part of HOL-Algebra.", [["HOL", "DNA", 27, 30]]], ["It is included in the distribution of Isabelle, directory src/HOL/Algebra and can also be browsed online.", [["src", "GENE_OR_GENE_PRODUCT", 58, 61], ["src", "PROTEIN", 58, 61], ["HOL", "PROTEIN", 62, 65], ["Algebra", "PROTEIN", 66, 73]]]], "PMC7534583": [["COVID-19 und die Fr\u00fchen HilfenW\u00e4hrend der COVID-19-Pandemie in Deutschland \u2013 auf der Hochphase des Lockdowns \u2013 waren die Fr\u00fchen Hilfen, deren Angebote wesentlich auf dem pers\u00f6nlichen Kontakt zwischen Hilfe-Erbringenden und den Familien basieren, stark von den Kontaktbeschr\u00e4nkungen betroffen.", [["COVID-19 und die Fr\u00fchen HilfenW\u00e4hrend der COVID-19-Pandemie in Deutschland \u2013 auf der Hochphase des Lockdowns \u2013 waren die Fr\u00fchen Hilfen, deren Angebote wesentlich auf dem pers\u00f6nlichen Kontakt zwischen Hilfe-Erbringenden und den Familien basieren, stark von den Kontaktbeschr\u00e4nkungen betroffen", "SPECIES", 0, 291], ["COVID", "TEST", 0, 5], ["Pandemie", "TREATMENT", 51, 59], ["auf der Hochphase des", "TREATMENT", 77, 98]]], ["Diese Kontaktbeschr\u00e4nkungen, die deutschlandweit in der Zeit ab Mitte M\u00e4rz 2020 verordnet wurden, beinhalteten im \u00f6ffentlichen Raum ein Mindestabstandsgebot von 1,5 Metern sowie ein Kontaktverbot von Personen, die nicht im gleichen Haushalt leben.", [["der Zeit ab Mitte M\u00e4rz 2020 verordnet wurden, beinhalteten im \u00f6ffentlichen Raum ein Mindestabstandsgebot von 1,5 Metern sowie ein Kontaktverbot von Personen, die nicht im gleichen Haushalt leben", "SPECIES", 52, 246]]], ["Zudem beschlossen einige Bundesl\u00e4nder (Bayern, Berlin, Brandenburg, Saarland, Sachsen, Sachsen-Anhalt) in dieser Zeit strikte Ausgangsbeschr\u00e4nkungen, die das Verlassen der Wohnung nur in Ausnahmef\u00e4llen zulie\u00dfen.COVID-19 und die Fr\u00fchen Hilfen", [["Saarland", "TREATMENT", 68, 76], ["Sachsen", "TREATMENT", 78, 85]]]], "34c2b7bac4b15a4514c32ea5ebcb60344a9ef090": [["IntroductionIn December 2019, an unusual cluster of pneumonia cases were reported by the Chinese Centre for Disease Control (China CDC) in the city of Wuhan, Hubei province 1 It was quickly established by sequencing of airway epithelial cells that these patients were infected with a novel betacoronavirus 2 which was named by the International Committee on Taxonomy of Viruses as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to the close genetic relatedness to SARS-CoV 3 .IntroductionSince its first discovery, SARS-CoV-2 has spread around the globe reaching pandemic status, and by June 2020 has infected 9 million people and caused more than 460,000 deaths according to The World Health Organisation situation report (accessed 24 th June 2020).IntroductionGenomic regions suitable for targeting with molecular tests such as real-time reverse-transcription polymerase chain reaction (rRT-PCR) were published by Corman et al 4 early in the outbreak and comprised the RdRp, E and N genes.", [["airway epithelial cells", "ANATOMY", 219, 242], ["pneumonia", "DISEASE", 52, 61], ["acute respiratory syndrome coronavirus", "DISEASE", 388, 426], ["SARS", "DISEASE", 533, 537], ["deaths", "DISEASE", 674, 680], ["airway epithelial cells", "CELL", 219, 242], ["patients", "ORGANISM", 254, 262], ["SARS-CoV-2", "ORGANISM", 430, 440], ["SARS-CoV-2", "ORGANISM", 533, 543], ["people", "ORGANISM", 638, 644], ["airway epithelial cells", "CELL_TYPE", 219, 242], ["Genomic regions", "DNA", 780, 795], ["RdRp, E and N genes", "DNA", 989, 1008], ["patients", "SPECIES", 254, 262], ["people", "SPECIES", 638, 644], ["severe acute respiratory syndrome coronavirus", "SPECIES", 381, 426], ["SARS-CoV-2", "SPECIES", 430, 440], ["SARS-CoV", "SPECIES", 533, 541], ["pneumonia cases", "PROBLEM", 52, 67], ["airway epithelial cells", "PROBLEM", 219, 242], ["a novel betacoronavirus 2", "TREATMENT", 282, 307], ["Viruses", "TREATMENT", 370, 377], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 381, 426], ["SARS", "PROBLEM", 533, 537], ["molecular tests", "TEST", 824, 839], ["transcription polymerase chain reaction", "PROBLEM", 866, 905], ["rRT-PCR", "TREATMENT", 907, 914], ["pneumonia", "OBSERVATION", 52, 61], ["airway", "ANATOMY", 219, 225], ["epithelial cells", "OBSERVATION", 226, 242], ["severe", "OBSERVATION_MODIFIER", 381, 387], ["acute", "OBSERVATION_MODIFIER", 388, 393], ["respiratory syndrome", "OBSERVATION", 394, 414], ["SARS-CoV", "OBSERVATION", 482, 490], ["globe", "ANATOMY", 566, 571]]], ["Diagnostic tests developed targeting these regions have since been utilised for routine use in many reference and hospital laboratories around the world.", [["Diagnostic tests", "TEST", 0, 16]]], ["However, with the huge surge in diagnostic testing, laboratories began competing for the same test components and certain reagents such as RNA extraction kits became difficult to source.IntroductionConsequently, to ensure a robust, resilient diagnostic service with an increased capacity, Hampshire Hospitals NHS Foundation Trust (HHFT) sought to diversify the portfolio of testing strategies by exploring alternative chemistries which have separate reagent supplier pathways to those of rRT-PCR, and which also permit direct testing without the need for RNA extraction.IntroductionReverse-transcription loop-mediated isothermal amplification (RT-LAMP) satisfied these requirements by combining reverse-transcription and autocycling, isothermal, strand displacement DNA amplification to produce a highly sensitive, versatile and robust test 5-7 .", [["DNA", "CELLULAR_COMPONENT", 766, 769], ["diagnostic testing", "TEST", 32, 50], ["laboratories", "TEST", 52, 64], ["the same test components", "TEST", 85, 109], ["certain reagents", "TREATMENT", 114, 130], ["RNA extraction kits", "TREATMENT", 139, 158], ["an increased capacity", "PROBLEM", 266, 287], ["testing strategies", "TREATMENT", 374, 392], ["alternative chemistries", "TEST", 406, 429], ["rRT-PCR", "TEST", 488, 495], ["direct testing", "TEST", 519, 533], ["RNA extraction", "TREATMENT", 555, 569], ["transcription loop-mediated isothermal amplification", "TREATMENT", 590, 642], ["RT-LAMP", "TREATMENT", 644, 651], ["combining reverse-transcription", "TREATMENT", 685, 716], ["autocycling", "TREATMENT", 721, 732], ["isothermal", "TREATMENT", 734, 744], ["strand displacement DNA amplification", "TREATMENT", 746, 783], ["robust test", "TEST", 829, 840]]], ["LAMP chemistry is more resistant to inhibitors than rRT-PCR, enabling simplification and even removal of extraction procedures 8 .", [["LAMP chemistry", "TEST", 0, 14], ["inhibitors", "TREATMENT", 36, 46], ["rRT", "TREATMENT", 52, 55], ["PCR", "TEST", 56, 59], ["even removal of extraction procedures", "TREATMENT", 89, 126], ["more resistant", "OBSERVATION_MODIFIER", 18, 32]]], ["LAMP has been applied for the detection of a wide range of pathogens, including positive-sense RNA viruses and has been used extensively in the veterinary and plant industry [9] [10] [11] 4 and more recently in human diagnostics [12] [13] [14] [15] [16] .", [["[9] [10] [11] 4", "SIMPLE_CHEMICAL", 174, 189], ["human", "ORGANISM", 211, 216], ["[12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 229, 253], ["human", "SPECIES", 211, 216], ["human", "SPECIES", 211, 216], ["LAMP", "TREATMENT", 0, 4], ["the detection", "TEST", 26, 39], ["a wide range of pathogens", "PROBLEM", 43, 68], ["positive-sense RNA viruses", "PROBLEM", 80, 106], ["human diagnostics", "TEST", 211, 228]]], ["Herein we describe the validation of a novel SARS-CoV-2 RT-LAMP assay which can be performed on extracted RNA, or directly from viral transport medium (VTM) taken from combined oropharyngeal and nasopharyngeal swabs (ONSwab).Introduction.", [["oropharyngeal", "ANATOMY", 177, 190], ["nasopharyngeal swabs", "ANATOMY", 195, 215], ["oropharyngeal", "ORGANISM_SUBDIVISION", 177, 190], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 195, 215], ["a novel SARS", "TEST", 37, 49], ["CoV", "TEST", 50, 53], ["LAMP assay", "TEST", 59, 69], ["viral transport medium", "TREATMENT", 128, 150], ["combined oropharyngeal and nasopharyngeal swabs", "PROBLEM", 168, 215], ["oropharyngeal", "ANATOMY", 177, 190], ["nasopharyngeal swabs", "ANATOMY", 195, 215]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["MethodsVirus isolates and clinical specimensDiagnostic sensitivity (DSe) and specificity (DSp) were determined using ONSwabs submitted to HHFT, previously confirmed as either SARS-CoV-2 positive or negative by rRT-PCR.", [["specimens", "ANATOMY", 35, 44], ["HHFT", "CANCER", 138, 142], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 175, 185], ["MethodsVirus isolates", "TEST", 0, 21], ["clinical specimens", "TEST", 26, 44], ["SARS", "TEST", 175, 179], ["CoV", "TEST", 180, 183], ["rRT", "TEST", 210, 213], ["PCR", "TEST", 214, 217]]], ["All ONSwabs were collected in Sigma Virocult\u00ae medium (Sigma-Aldrich Inc.).Virus isolates and clinical specimensAnalytical sensitivity (ASe) of RNA-RT-LAMP was determined using a ten-fold dilution series of SARS-CoV-2 RNA purified from virus infected tissue culture fluid (BetaCoV/England/02/2020) obtained from Public Health England (Lot 07.02.2020) and a titration of a synthetic DNA fragment containing the SARS-CoV-2 RT-LAMP target in nuclease free water (NFW) (Integrated DNA Technologies).Virus isolates and clinical specimensASe of Direct RT-LAMP was determined using a two-fold dilution series (1:8 to 1:2048) of VTM taken from a SARS-CoV-2 positive ONswab sample.", [["ONSwabs", "ANATOMY", 4, 11], ["specimens", "ANATOMY", 102, 111], ["tissue culture fluid", "ANATOMY", 250, 270], ["specimens", "ANATOMY", 522, 531], ["ONswab sample", "ANATOMY", 657, 670], ["ONSwabs", "CANCER", 4, 11], ["Virus", "ORGANISM", 74, 79], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 206, 216], ["tissue", "TISSUE", 250, 256], ["DNA", "CELLULAR_COMPONENT", 381, 384], ["DNA", "CELLULAR_COMPONENT", 476, 479], ["Virus", "ORGANISM", 494, 499], ["VTM", "CANCER", 620, 623], ["SARS-CoV-2 RNA", "RNA", 206, 220], ["synthetic DNA fragment", "DNA", 371, 393], ["SARS-CoV-2 RT-LAMP target", "DNA", 409, 434], ["nuclease", "PROTEIN", 438, 446], ["SARS-CoV", "SPECIES", 206, 214], ["SARS-CoV", "SPECIES", 637, 645], ["Virus isolates", "TEST", 74, 88], ["clinical specimens", "TEST", 93, 111], ["Analytical sensitivity", "TEST", 111, 133], ["RNA", "TEST", 143, 146], ["a ten-fold dilution series", "TREATMENT", 176, 202], ["SARS", "TEST", 206, 210], ["CoV", "TEST", 211, 214], ["virus infected tissue", "PROBLEM", 235, 256], ["culture fluid", "TEST", 257, 270], ["BetaCoV", "TEST", 272, 279], ["a titration", "TREATMENT", 354, 365], ["a synthetic DNA fragment", "TREATMENT", 369, 393], ["the SARS", "TEST", 405, 413], ["CoV", "TEST", 414, 417], ["LAMP target in nuclease free water (NFW)", "TREATMENT", 423, 463], ["Virus isolates", "TEST", 494, 508], ["clinical specimens", "TEST", 513, 531], ["Direct RT-LAMP", "TEST", 538, 552], ["a two-fold dilution series", "TREATMENT", 574, 600], ["VTM", "PROBLEM", 620, 623], ["a SARS", "TEST", 635, 641], ["CoV", "TEST", 642, 645]]], ["A standard curve (Qnostics, Scotland, UK) was run on the rRT-PCR, allowing quantification of RNA in digital copies (Log 10 dC/ml).", [["rRT", "DNA", 57, 60], ["the rRT", "TEST", 53, 60], ["PCR", "TEST", 61, 64]]], ["Analytical specificity (ASp) was determined using the NATtrol\u2122 Respiratory Verification Panel (ZeptoMetrix Corporation, New York, United States) containing pathogens causing indistinguishable clinical signs to and a pool of meningitis encephalitis causative agents (n=7) (Table 1) .Virus isolates and clinical specimensRepeatability, inter-operator and inter-platform reproducibility were determined using combined ONSwabs submitted to HHFT, previously confirmed as SARS-CoV-2 positive, and a SARS-CoV-2 Medium Q Control 01 positive control (Qnostics, Scotland, UK) (diluted 1 in 10 and 1 in 100).Virus isolates and clinical specimensPreliminary evaluation of Direct RT-LAMP for detection of SARS-CoV-2 in other clinical samples was performed using fourteen saliva samples collected from hospital in-patients confirmed from paired ONSwabs as positive and negative for SARS-CoV-2.", [["specimens", "ANATOMY", 310, 319], ["specimens", "ANATOMY", 625, 634], ["samples", "ANATOMY", 721, 728], ["samples", "ANATOMY", 765, 772], ["meningitis", "DISEASE", 224, 234], ["encephalitis", "DISEASE", 235, 247], ["SARS", "DISEASE", 692, 696], ["Virus", "ORGANISM", 282, 287], ["Virus", "ORGANISM", 597, 602], ["SARS-CoV-2", "ORGANISM", 692, 702], ["samples", "CANCER", 721, 728], ["saliva samples", "ORGANISM_SUBSTANCE", 758, 772], ["patients", "ORGANISM", 800, 808], ["CoV-2", "ORGANISM", 873, 878], ["patients", "SPECIES", 800, 808], ["SARS-CoV", "SPECIES", 466, 474], ["SARS-CoV", "SPECIES", 493, 501], ["SARS-CoV", "SPECIES", 692, 700], ["SARS-CoV", "SPECIES", 868, 876], ["pathogens", "PROBLEM", 156, 165], ["indistinguishable clinical signs", "PROBLEM", 174, 206], ["meningitis encephalitis", "PROBLEM", 224, 247], ["Virus isolates", "TEST", 282, 296], ["clinical specimens", "TEST", 301, 319], ["SARS", "TEST", 466, 470], ["CoV", "TEST", 471, 474], ["a SARS", "TEST", 491, 497], ["CoV", "TEST", 498, 501], ["Virus isolates", "TEST", 597, 611], ["clinical specimens", "TEST", 616, 634], ["Preliminary evaluation", "TEST", 634, 656], ["Direct RT-LAMP", "TEST", 660, 674], ["SARS", "PROBLEM", 692, 696], ["CoV", "TEST", 697, 700], ["other clinical samples", "TEST", 706, 728], ["fourteen saliva samples", "TEST", 749, 772], ["paired ONSwabs", "TEST", 824, 838], ["SARS", "PROBLEM", 868, 872], ["CoV", "TEST", 873, 876], ["meningitis", "OBSERVATION", 224, 234]]], ["Collection of saliva involved the patient providing .", [["saliva", "ORGANISM_SUBSTANCE", 14, 20], ["patient", "ORGANISM", 34, 41], ["patient", "SPECIES", 34, 41]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Virus isolates and clinical specimensThe copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint a fresh saliva sample into a 10 ml universal container.", [["specimens", "ANATOMY", 227, 236], ["sample", "ANATOMY", 392, 398], ["CC", "CHEMICAL", 0, 2], ["Virus", "ORGANISM", 199, 204], ["saliva", "ORGANISM_SUBSTANCE", 385, 391], ["Virus isolates", "TEST", 199, 213], ["clinical specimens", "TEST", 218, 236], ["The copyright holder", "TREATMENT", 236, 256], ["medRxiv", "TREATMENT", 360, 367], ["a fresh saliva sample", "TREATMENT", 377, 398], ["med", "ANATOMY", 102, 105]]], ["Prior to analysis the saliva was diluted 1:5, 1:10 and 1:20 in NFW.RNA extractionRNA was extracted using the Maxwell\u00ae RSC Viral Total Nucleic Acid Purification Kit (Promega UK Ltd., Southampton, UK) according to manufacturer's instructions.", [["saliva", "ORGANISM_SUBSTANCE", 22, 28], ["RNA extractionRNA", "TEST", 67, 84], ["the Maxwell\u00ae RSC", "TREATMENT", 105, 121]]], ["Briefly, 200 \u00b5l of sample was added to 223 \u00b5l of prepared lysis solution (including 5 \u00b5l per reaction of Genesig\u00ae Easy RNA Internal extraction control, Primerdesign Ltd, Chandler's Ford, UK).", [["sample", "ANATOMY", 19, 25], ["prepared lysis solution", "TREATMENT", 49, 72], ["Genesig\u00ae", "TREATMENT", 105, 113], ["Internal extraction control", "TREATMENT", 123, 150]]], ["Samples were then inactivated for 10 minutes at room temperature within the safety cabinet and 10 minutes at 56 o C on a heat block before automated RNA extraction using a Maxwell\u00ae RSC 48 Instrument (Promega UK Ltd., Southampton, UK).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a heat block", "TREATMENT", 119, 131], ["automated RNA extraction", "TREATMENT", 139, 163], ["a Maxwell\u00ae RSC", "TREATMENT", 170, 184]]], ["RNA was eluted in 50 \u00b5l of NFW.", [["RNA", "RNA", 0, 3], ["RNA", "TEST", 0, 3]]], ["In the case of saliva, RNA was extracted from 200 \u00b5l of saliva diluted 1:20, as saliva volume was insufficient unless a dilution was performed.Real-time reverse-transcription PCR (rRT-PCR)rRT-PCR assays were performed in single replicates using 5 \u00b5l of RNA template with the COVID-19 genesig\u00ae Real-Time PCR assay (Primerdesign Ltd, Chandler's Ford, UK) according to the manufacturer's guidelines, on a MIC qPCR Cycler (Bio Molecular Systems, London, UK).", [["saliva", "ORGANISM_SUBSTANCE", 15, 21], ["saliva", "ORGANISM_SUBSTANCE", 56, 62], ["saliva", "ORGANISM_SUBSTANCE", 80, 86], ["saliva", "TREATMENT", 56, 62], ["saliva volume", "TEST", 80, 93], ["a dilution", "TEST", 118, 128], ["transcription PCR", "TEST", 161, 178], ["rRT", "TEST", 180, 183], ["PCR", "TEST", 184, 187], ["rRT", "TEST", 188, 191], ["PCR assays", "TEST", 192, 202], ["RNA template", "TREATMENT", 253, 265], ["the COVID", "TEST", 271, 280], ["a MIC qPCR Cycler", "TREATMENT", 400, 417]]], ["Single replicates were performed to ensure an adequate supply of reagents.", [["Single replicates", "TREATMENT", 0, 17]]], ["The Genesig\u00ae COVID-19 positive control included in the kit, a negative extraction control, and a no template control were also included on each rRT-PCR run.Reverse-transcription loop-mediated isothermal amplification (RT-LAMP)RT-LAMP reactions were performed using OptiGene Ltd.", [["Genesig\u00ae COVID-19", "DNA", 4, 21], ["rRT", "DNA", 144, 147], ["The Genesig\u00ae COVID", "TEST", 0, 18], ["a negative extraction control", "TREATMENT", 60, 89], ["template control", "TREATMENT", 100, 116], ["Reverse-transcription loop", "TREATMENT", 156, 182], ["isothermal amplification", "TREATMENT", 192, 216], ["RT-LAMP", "TREATMENT", 218, 225], ["RT-LAMP reactions", "TREATMENT", 226, 243], ["OptiGene Ltd", "TREATMENT", 265, 277]]], ["(Camberley, UK) COVID-19_RT-LAMP kits which target the ORF1ab region of the SARS-CoV-2 genome: (i) COVID-19_RNA RT-LAMP KIT-500 kit .", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 55, 61], ["KIT", "GENE_OR_GENE_PRODUCT", 120, 123], ["ORF1ab region", "DNA", 55, 68], ["SARS-CoV-2 genome", "DNA", 76, 93], ["KIT", "PROTEIN", 120, 123], ["SARS-CoV", "SPECIES", 76, 84], ["COVID", "TEST", 16, 21], ["LAMP kits", "TREATMENT", 28, 37], ["the SARS", "TEST", 72, 80], ["CoV", "TEST", 81, 84], ["COVID", "TEST", 99, 104], ["LAMP KIT", "TEST", 115, 123]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Reverse-transcription loop-mediated isothermal amplification (RT-LAMP)The copyright holder for this preprint this version posted July 1, 2020.", [["CC", "CHEMICAL", 0, 2], ["Reverse-transcription loop", "TREATMENT", 199, 225], ["isothermal amplification", "TREATMENT", 235, 259], ["The copyright holder", "TREATMENT", 269, 289], ["med", "ANATOMY", 102, 105]]], ["To confirm the specificity of the amplification reaction, an anneal curve was performed: RT-LAMP products were heated to 98\u00b0C for 1 min, then cooled to 80\u00b0C decreasing the temperature by 0.05\u00b0C/s.", [["the amplification reaction", "PROBLEM", 30, 56], ["an anneal curve", "TEST", 58, 73], ["RT-LAMP products", "TREATMENT", 89, 105], ["the temperature", "TEST", 168, 183]]], ["All RT-LAMP reactions were performed at least in duplicate, and a sample was considered positive when a Tp was observed in at least one replicate with amplification above 5000 fluorescence points and had an anneal temperature of between 81.50 o C and 84.05 o C with a derivative above 2500 F/ o C.Reverse-transcription loop-mediated isothermal amplification (RT-LAMP)For RNA RT-LAMP 5 \u03bcl of extracted RNA was added to the reaction and for Direct RT-LAMP 5 \u03bcl of VTM from the swab diluted 1:20 in NFW, or saliva diluted 1:5, 1:10 and 1:20 in NFW was added to the reaction.Repeatability, inter-operator and inter-platform reproducibilityRepeatability and inter-operator reproducibility for the RNA RT-LAMP and Direct RT-LAMP were measured by running eight replicates of samples with three different operators.", [["swab", "ANATOMY", 475, 479], ["samples", "ANATOMY", 768, 775], ["VTM", "CHEMICAL", 462, 465], ["NFW", "CHEMICAL", 541, 544], ["VTM", "SIMPLE_CHEMICAL", 462, 465], ["NFW", "SIMPLE_CHEMICAL", 496, 499], ["saliva", "ORGANISM_SUBSTANCE", 504, 510], ["NFW", "SIMPLE_CHEMICAL", 541, 544], ["VTM", "PROTEIN", 462, 465], ["LAMP reactions", "TEST", 7, 21], ["a sample", "TEST", 64, 72], ["a Tp", "TEST", 102, 106], ["an anneal temperature", "TEST", 204, 225], ["transcription loop", "TREATMENT", 305, 323], ["mediated isothermal amplification", "TREATMENT", 324, 357], ["RT-LAMP", "TREATMENT", 359, 366], ["RNA RT-LAMP", "TREATMENT", 371, 382], ["extracted RNA", "PROBLEM", 391, 404], ["the reaction", "PROBLEM", 418, 430], ["Direct RT-LAMP", "TREATMENT", 439, 453], ["VTM", "TREATMENT", 462, 465], ["the swab", "TEST", 471, 479], ["saliva", "TREATMENT", 504, 510], ["the reaction", "PROBLEM", 558, 570], ["Repeatability", "TEST", 571, 584], ["Repeatability", "TEST", 635, 648], ["inter-operator reproducibility", "TEST", 653, 683], ["the RNA RT", "TREATMENT", 688, 698], ["Direct RT-LAMP", "TREATMENT", 708, 722]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Repeatability, inter-operator and inter-platform reproducibilityThe copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint reproducibility was measured by running eight replicates of the samples across two Genie\u00ae platforms.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 263, 283], ["med", "ANATOMY", 102, 105]]], ["For RNA RT-LAMP, operators used the same RNA extraction for each sample; for Direct RT-LAMP operators used the same 1 in 20 dilution of a combined swab sample in NFW.Statistical analysisDSe, DSp, positive and negative likelihood ratios (LR) including 95% confidence intervals (CI), and the Cohen's Kappa statistic (\u03ba) 17 were determined using contingency tables in R 3.6.1 18 .", [["swab sample", "ANATOMY", 147, 158], ["RNA RT-LAMP", "TREATMENT", 4, 15], ["the same RNA extraction", "TREATMENT", 32, 55], ["each sample", "TEST", 60, 71], ["Direct RT-LAMP operators", "TREATMENT", 77, 101], ["a combined swab sample", "TEST", 136, 158], ["Statistical analysisDSe", "TEST", 166, 189], ["DSp", "TEST", 191, 194], ["CI", "TEST", 277, 279], ["the Cohen's Kappa statistic", "TEST", 286, 313], ["contingency tables", "TEST", 343, 361]]], ["Assessment of the diagnostic performance was made under three scenarios: 1) \"No C T cut off\" (low-to-high viral load), 2) \"C T cut off <33\" (moderate-to-high viral load) and 3) C T cut off <25 (high viral load and significant risk of shedding).Statistical analysisTo further explore the practical application of the RT-LAMP assay in clinical practice, we estimated a .", [["high viral load)", "PROBLEM", 153, 169], ["C T cut", "TEST", 177, 184], ["high viral load", "PROBLEM", 194, 209], ["the RT-LAMP assay", "TEST", 312, 329]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Statistical analysisThe copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint 3.", [["CC", "CHEMICAL", 0, 2], ["Statistical analysis", "TEST", 199, 219], ["The copyright holder", "TREATMENT", 219, 239], ["medRxiv preprint", "TREATMENT", 343, 359], ["med", "ANATOMY", 102, 105]]], ["ResultsAnalytical sensitivityUsing a synthetic DNA template titrated in NFW, the RNA-RT-LAMP and Direct-RT-LAMP assays were able to detect 1x10 1 copies each, in one of two duplicates (detection limit between 1x10 1 and 1x10 2 copies) ( Table 2) .", [["DNA", "CELLULAR_COMPONENT", 47, 50], ["NFW", "CANCER", 72, 75], ["synthetic DNA template", "DNA", 37, 59], ["NFW", "DNA", 72, 75], ["Analytical sensitivity", "TEST", 7, 29], ["a synthetic DNA template", "TREATMENT", 35, 59], ["the RNA", "TREATMENT", 77, 84], ["LAMP assays", "TEST", 107, 118]]], ["To compare the ASe of the RNA RT-LAMP with the rRT-PCR assay a 10-fold decimal dilution series of SARS-CoV-2 RNA extracted from a virus infected tissue culture media was used.", [["tissue", "ANATOMY", 145, 151], ["SARS", "DISEASE", 98, 102], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 98, 108], ["tissue", "TISSUE", 145, 151], ["ASe", "DNA", 15, 18], ["rRT", "DNA", 47, 50], ["SARS-CoV-2 RNA", "RNA", 98, 112], ["SARS-CoV", "SPECIES", 98, 106], ["the rRT-PCR assay", "TEST", 43, 60], ["SARS", "PROBLEM", 98, 102], ["CoV", "TEST", 103, 106], ["2 RNA", "PROBLEM", 107, 112], ["a virus infected tissue culture media", "TREATMENT", 128, 165]]], ["The RT-LAMP detected to a dilution of 10 -3 , equivalent to a rRT-PCR C T value of 36.0 (Table 1 ).", [["The RT-LAMP", "TEST", 0, 11], ["a dilution", "TEST", 24, 34], ["a rRT-PCR", "TEST", 60, 69], ["T value", "TEST", 72, 79]]], ["In the case of RNA RT-LAMP the dilution with a corresponding rRT-PCR C T <30 was detected in duplicate and C T >30 and <39 were detected in one of the duplicates (Table 3) .Analytical sensitivityTo compare the analytical sensitivity of the Direct RT-LAMP to the rRT-PCR assay a 2-fold decimal dilution series of SARS-CoV-2 positive VTM from a combined swab was used.", [["swab", "ANATOMY", 352, 356], ["VTM", "CANCER", 332, 335], ["rRT", "PROTEIN", 61, 64], ["rRT", "DNA", 262, 265], ["SARS-CoV-2 positive VTM", "DNA", 312, 335], ["SARS-CoV", "SPECIES", 312, 320], ["RNA RT-LAMP the dilution", "TREATMENT", 15, 39], ["a corresponding rRT", "TEST", 45, 64], ["PCR C T", "TEST", 65, 72], ["Analytical sensitivity", "TEST", 173, 195], ["the rRT", "TEST", 258, 265], ["PCR assay", "TEST", 266, 275], ["SARS", "TEST", 312, 316], ["CoV", "TEST", 317, 320], ["2 positive VTM", "PROBLEM", 321, 335], ["a combined swab", "TREATMENT", 341, 356]]], ["The Direct RT-LAMP detected dilutions spanning 1:8 to 1:512, equivalent to a rRT-PCR C T value of 22.65 (Table 3) .", [["a rRT", "TEST", 75, 80], ["T value", "TEST", 87, 94]]], ["The rRT-PCR detected dilutions spanning 1:8 to 1:2048 (Table 4 ).Performance of RNA RT-LAMPThe performance of the RT-LAMP on extracted RNA was determined using 196 individual clinical samples tested in duplicate and compared to the results of the rRT-PCR (tested in single) ( Figure 1 ).Performance of RNA RT-LAMPAll samples with a C T <30 were detected within 16 minutes.", [["samples", "ANATOMY", 184, 191], ["rRT", "DNA", 4, 7], ["rRT", "DNA", 247, 250], ["The rRT-PCR", "TEST", 0, 11], ["the RT", "TREATMENT", 110, 116], ["the rRT", "TEST", 243, 250], ["PCR", "TEST", 251, 254], ["RNA RT", "TEST", 302, 308], ["LAMPAll samples", "TEST", 309, 324], ["a C T", "TEST", 330, 335]]], ["The overall DSe was calculated as 97% (95% CI: 90 -99) and the overall DSp was 99% (95 -1.00) ( CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint likelihood ratio: 0.00 [0.00 -0.03]), indicating almost perfect agreement between the two assays (Table 5B) .", [["The overall DSe", "TEST", 0, 15], ["CI", "TEST", 43, 45], ["the overall DSp", "TEST", 59, 74], ["CC", "TEST", 96, 98], ["The copyright holder", "TREATMENT", 294, 314], ["likelihood ratio", "TEST", 435, 451], ["med", "ANATOMY", 198, 201]]], ["By employing a rRT-PCR cut-off of 24.", [["rRT", "DNA", 15, 18], ["a rRT", "TEST", 13, 18], ["PCR cut", "TEST", 19, 26]]], ["In the same study 27 each unit increase in C T value corresponded to a 32% decrease in the odds of recoverable live virus.", [["C T", "GENE_OR_GENE_PRODUCT", 43, 46], ["C T value", "TEST", 43, 52], ["recoverable live virus", "PROBLEM", 99, 121]]], ["Consequently, as the risk of SARS-CoV-2 transmission is still not fully understood, a range of C T cut-off values were set in our study, to understand in particular the performance of the Direct-RT-LAMP assay at different viral loads.", [["SARS", "DISEASE", 29, 33], ["SARS-CoV-2", "ORGANISM", 29, 39], ["C T", "GENE_OR_GENE_PRODUCT", 95, 98], ["SARS", "PROBLEM", 29, 33], ["C T cut", "TEST", 95, 102], ["our study", "TEST", 126, 135], ["LAMP assay", "TEST", 198, 208]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint Direct RT-LAMP was 67%, however, when setting C T cut-offs of <33 (low-medium viral load) and <25(which was not certified by peer review)(high viral load and significant risk of shedding) the Direct RT-LAMP DSe increased to 75% and 100%, respectively.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["C T cut-offs", "TEST", 385, 397], ["low-medium viral load", "PROBLEM", 406, 427], ["high viral load", "PROBLEM", 477, 492], ["the Direct RT", "TEST", 527, 540], ["LAMP DSe", "TEST", 541, 549], ["med", "ANATOMY", 102, 105]]], ["DSp was unchanged and remained at 97%.", [["DSp", "GENE_OR_GENE_PRODUCT", 0, 3], ["DSp", "TEST", 0, 3], ["unchanged", "OBSERVATION_MODIFIER", 8, 17]]], ["As no samples were detected beyond 14 minutes, we recommend that when using Direct RT-LAMP the length of the assay should be a maximum of 14 minutes to avoid detection of degraded nucleic acid which may be derived from the clinical sample or environment 22 .(which was not certified by peer review)The ability to detect patients with high viral load (C T <25) directly from diluted swabs, demonstrates significant potential for the use of Direct RT-LAMP for the rapid diagnosis of symptomatic patients and also for rapid screening of asymptomatic individuals.", [["samples", "ANATOMY", 6, 13], ["swabs", "ANATOMY", 382, 387], ["nucleic acid", "CHEMICAL", 180, 192], ["nucleic acid", "SIMPLE_CHEMICAL", 180, 192], ["patients", "ORGANISM", 320, 328], ["patients", "ORGANISM", 493, 501], ["patients", "SPECIES", 320, 328], ["patients", "SPECIES", 493, 501], ["samples", "TEST", 6, 13], ["Direct RT", "TREATMENT", 76, 85], ["the assay", "TEST", 105, 114], ["degraded nucleic acid", "PROBLEM", 171, 192], ["high viral load", "PROBLEM", 334, 349], ["diluted swabs", "TEST", 374, 387], ["Direct RT-LAMP", "TREATMENT", 439, 453], ["rapid screening", "TEST", 515, 530], ["asymptomatic individuals", "PROBLEM", 534, 558]]], ["This is largely supported by studies reporting similar viral loads in asymptomatic and symptomatic patient groups 28 .", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["similar viral loads in asymptomatic and symptomatic patient groups", "PROBLEM", 47, 113], ["viral loads", "OBSERVATION", 55, 66], ["symptomatic", "OBSERVATION_MODIFIER", 87, 98]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint Rapid testing of symptomatic SARS-CoV-2 positive patients within healthcare facilities allows their rapid isolation or cohorting, significantly reducing onward transmission and improving bed management and patient flow.", [["CC", "CHEMICAL", 0, 2], ["SARS", "DISEASE", 368, 372], ["patients", "ORGANISM", 388, 396], ["patient", "ORGANISM", 545, 552], ["patients", "SPECIES", 388, 396], ["patient", "SPECIES", 545, 552], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv", "TREATMENT", 322, 329], ["symptomatic SARS", "PROBLEM", 356, 372], ["CoV", "TEST", 373, 376], ["improving bed management", "TREATMENT", 516, 540], ["patient flow", "TEST", 545, 557], ["med", "ANATOMY", 102, 105]]], ["Additionally, screening of asymptomatic patient groups or at the community level may enable the rapid identification of those with high viral loads who may pose a high risk of onward transmission.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["screening", "TEST", 14, 23], ["high viral loads", "PROBLEM", 131, 147]]], ["This would allow for swift public health intervention with instruction to self-isolate/ quarantine and the rapid tracking and tracing of their contacts -essential in screening programmes aiming to reduce the reproductive number (R 0 ) and spread of the disease in a community.(which was not certified by peer review)Direct RT-LAMP offers speed, robustness and portability making it attractive as an option for nearpatient testing outside the conventional clinical laboratory, subject to the necessary risk-assessments to ensure safety of the operator 34 .", [["swift public health intervention", "TREATMENT", 21, 53], ["quarantine", "TREATMENT", 88, 98], ["screening programmes", "TREATMENT", 166, 186], ["the disease", "PROBLEM", 249, 260], ["nearpatient testing", "TEST", 410, 429], ["disease", "OBSERVATION", 253, 260]]], ["Within HHFT we are exploring its application in settings such as: a multi-disciplinary non-specialist laboratory; the emergency department; primary care and nursing/ care home settings.(which was not certified by peer review)In this study, clinical validation of the RT-LAMP assay took place in March, April and May 2020, largely during a period of high local COVID-19 prevalence (around 40% positivity of samples submitted) and on samples from largely symptomatic patients and hospital staff.", [["patients", "ORGANISM", 465, 473], ["patients", "SPECIES", 465, 473], ["this study", "TEST", 228, 238], ["the RT-LAMP assay", "TEST", 263, 280], ["high local COVID", "TREATMENT", 349, 365]]], ["It is possible that RT-LAMP assay performance on samples from asymptomatic subjects may vary dependent on the level of detectable RNA (as a surrogate of live viral shedding) in this different patient group.(which was not certified by peer review)Additionally, the RT-LAMP assay was validated using ONSwabs in VTM.", [["samples", "ANATOMY", 49, 56], ["patient", "ORGANISM", 192, 199], ["patient", "SPECIES", 192, 199], ["RT-LAMP assay performance", "TEST", 20, 45], ["asymptomatic subjects", "PROBLEM", 62, 83], ["detectable RNA", "PROBLEM", 119, 133], ["live viral shedding", "PROBLEM", 153, 172], ["the RT-LAMP assay", "TEST", 260, 277], ["ONSwabs in VTM", "TREATMENT", 298, 312]]], ["Assay performance on a limited number of salivary samples was also explored.", [["salivary samples", "ANATOMY", 41, 57], ["salivary samples", "CANCER", 41, 57], ["Assay performance", "TEST", 0, 17], ["salivary samples", "TEST", 41, 57]]], ["This preliminary analysis suggests that saliva may not be as suitable when compared to ONSwabs as the detection of SARS-CoV-2 both by rRT-PCR and Direct RT-LAMP was poorer using saliva samples.", [["samples", "ANATOMY", 185, 192], ["SARS", "DISEASE", 115, 119], ["saliva", "ORGANISM_SUBSTANCE", 40, 46], ["SARS-CoV-2", "ORGANISM", 115, 125], ["saliva samples", "ORGANISM_SUBSTANCE", 178, 192], ["SARS-CoV", "SPECIES", 115, 123], ["This preliminary analysis", "TEST", 0, 25], ["saliva", "PROBLEM", 40, 46], ["the detection", "TEST", 98, 111], ["SARS", "TEST", 115, 119], ["CoV", "TEST", 120, 123], ["rRT", "TEST", 134, 137], ["PCR", "TEST", 138, 141], ["Direct RT-LAMP", "TREATMENT", 146, 160], ["saliva samples", "TEST", 178, 192]]], ["More work is required to understand if this is due to degradation of the RNA within the sample (e.g. salivary enzymes), or inhibition due to the complex nature of this matrix.", [["sample", "ANATOMY", 88, 94], ["salivary", "ANATOMY", 101, 109], ["matrix", "ANATOMY", 168, 174], ["salivary enzymes", "GENE_OR_GENE_PRODUCT", 101, 117], ["matrix", "CELLULAR_COMPONENT", 168, 174], ["salivary enzymes", "PROTEIN", 101, 117], ["degradation of the RNA", "PROBLEM", 54, 76], ["salivary enzymes", "TEST", 101, 117]]], ["Assay performance was not evaluated on lower respiratory tract .", [["lower respiratory tract", "ANATOMY", 39, 62], ["lower", "ORGANISM_SUBDIVISION", 39, 44], ["respiratory tract", "ORGANISM_SUBDIVISION", 45, 62], ["Assay performance", "TEST", 0, 17], ["lower", "ANATOMY_MODIFIER", 39, 44], ["respiratory tract", "ANATOMY", 45, 62]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint samples or non-respiratory tract samples, and therefore future research may aim to determine the performance of both the RNA-and Direct-RT-LAMP assays using these various sample types.(which was not certified by peer review)In our experience, during the diagnostic response to this current pandemic caused by a novel emergent pathogen (SARS-CoV-2), diversity in diagnostic platforms and routes to deliver a result based on the ability and agility to switch between methodologies has been key to allowing delivery of a resilient and sustainable diagnostic service.", [["samples", "ANATOMY", 339, 346], ["non-respiratory tract samples", "ANATOMY", 350, 379], ["CC", "CHEMICAL", 0, 2], ["non-respiratory tract samples", "CANCER", 350, 379], ["SARS-CoV-2", "ORGANISM", 675, 685], ["SARS-CoV", "SPECIES", 675, 683], ["The copyright holder", "TREATMENT", 198, 218], ["non-respiratory tract samples", "TEST", 350, 379], ["the RNA", "TEST", 456, 463], ["LAMP assays", "TEST", 478, 489], ["a novel emergent pathogen", "PROBLEM", 648, 673], ["med", "ANATOMY", 102, 105], ["non-respiratory tract", "ANATOMY", 350, 371]]], ["Factors such as: analyser availability; staff-skill mix;(which was not certified by peer review)dynamic changes in patient groups tested or disease prevalence; and particularly in the UK; consumable and reagent supply, have highlighted the need for diagnostic services to have adaptability and capability to explore novel and alternative techniques.Ethical approvalNo ethical approval was required for this service improvement study.AcknowledgementsWe would like to thank the clinical teams and Helen Denman the Microbiology Laboratory manager at Hampshire Hospitals NHS Foundation Trust.Acknowledgements.", [["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["dynamic changes in patient groups", "PROBLEM", 96, 129], ["disease prevalence", "PROBLEM", 140, 158], ["diagnostic services", "TREATMENT", 249, 268], ["alternative techniques", "TREATMENT", 326, 348], ["improvement study", "TEST", 415, 432]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint detection and characterization of foot-and-mouth disease virus in East Africa using a field-PHE.", [["CC", "CHEMICAL", 0, 2], ["foot-and-mouth disease", "DISEASE", 787, 809], ["PHE", "CHEMICAL", 845, 848], ["foot-and-mouth disease virus", "ORGANISM", 787, 815], ["foot-and-mouth disease virus", "SPECIES", 787, 815], ["foot-and-mouth disease virus", "SPECIES", 787, 815], ["The copyright holder", "TREATMENT", 198, 218], ["The copyright holder", "TREATMENT", 405, 425], ["The copyright holder", "TREATMENT", 612, 632], ["medRxiv preprint detection", "TEST", 736, 762], ["foot", "TEST", 787, 791], ["mouth disease virus", "PROBLEM", 796, 815], ["med", "ANATOMY", 102, 105], ["med", "ANATOMY", 309, 312], ["med", "ANATOMY", 516, 519], ["foot", "ANATOMY", 787, 791], ["mouth", "ANATOMY", 796, 801]]], ["COVID-19: safe handling and processing for samples in laboratories.", [["samples", "ANATOMY", 43, 50], ["COVID-19", "CHEMICAL", 0, 8], ["samples in laboratories", "TEST", 43, 66]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv preprint", "TREATMENT", 322, 338], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv preprint", "TREATMENT", 322, 338], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint Table 5 .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Overall diagnostic sensitivity (DSe) and specificity (DSp) of the RNA RT-LAMP with all rRT-PCR C T values considered (A), and with a C T value cut-off of <33 (B) and <25 (C). .", [["rRT", "PROTEIN", 87, 90], ["the RNA RT", "TEST", 62, 72], ["all rRT", "TREATMENT", 83, 90], ["PCR C T values", "TEST", 91, 105], ["a C T value cut", "TEST", 131, 146]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["The copyright holder", "TREATMENT", 405, 425], ["med", "ANATOMY", 102, 105], ["med", "ANATOMY", 309, 312]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprintSupplementary informationLinking pre-and post-test probability of infection In clinical practice diagnosis is made using a combination of the patient pre-test probability of being infected and the test result.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 404, 413], ["patient", "ORGANISM", 480, 487], ["patient", "SPECIES", 480, 487], ["The copyright holder", "TREATMENT", 198, 218], ["infection", "PROBLEM", 404, 413], ["the test result", "TEST", 531, 546], ["med", "ANATOMY", 102, 105], ["infection", "OBSERVATION", 404, 413], ["infected", "OBSERVATION", 518, 526]]], ["The combination of these two will lead to an estimation of the post-test probability of infection.", [["infection", "DISEASE", 88, 97], ["infection", "PROBLEM", 88, 97], ["infection", "OBSERVATION", 88, 97]]], ["In our study, the pre-and post-test probability of infection were estimated using an scenario-tree model, where different risks for infection in the estimation of the pre-test probabilities are taken into consideration 19 .", [["infection", "DISEASE", 51, 60], ["infection", "DISEASE", 132, 141], ["our study", "TEST", 3, 12], ["infection", "PROBLEM", 51, 60], ["infection", "PROBLEM", 132, 141], ["infection", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 132, 141]]], ["Pre-test probability of infection In this model the pre-test probability of infection was given by: = * * Where is the prevalence of infection in the population, is the adjusted risk ratio for infection of a symptomatic or asymptomatic patient and is the risk ratio of a patient being infected who did have a risk contact compared with a patient who did not have a risk contact (Table S1 ).", [["infection", "DISEASE", 24, 33], ["infection", "DISEASE", 76, 85], ["infection", "DISEASE", 133, 142], ["infection", "DISEASE", 193, 202], ["patient", "ORGANISM", 236, 243], ["patient", "ORGANISM", 271, 278], ["patient", "ORGANISM", 338, 345], ["patient", "SPECIES", 236, 243], ["patient", "SPECIES", 271, 278], ["patient", "SPECIES", 338, 345], ["infection", "PROBLEM", 24, 33], ["infection", "PROBLEM", 76, 85], ["infection", "PROBLEM", 133, 142], ["infection", "PROBLEM", 193, 202], ["infection", "OBSERVATION", 24, 33], ["infection", "OBSERVATION", 76, 85], ["infection", "OBSERVATION", 133, 142], ["symptomatic", "OBSERVATION_MODIFIER", 208, 219]]], ["The ARR were calculated as follows: These LRT were calculated using the Direct RT-LAMP's DSe and DSp estimates for the different viral load scenarios considered (estimated from C T 's: 1) \"No C T cut off\" (high-low viral load), 2) \"C T cut off <33\" (high-moderate viral load) and 3) C T cut off <25.", [["The ARR", "TEST", 0, 7], ["These LRT", "TEST", 36, 45], ["the Direct RT", "TEST", 68, 81], ["LAMP's DSe", "TEST", 82, 92], ["DSp estimates", "TEST", 97, 110], ["the different viral load scenarios", "PROBLEM", 115, 149], ["high-moderate viral load)", "PROBLEM", 250, 275], ["C T cut", "TEST", 283, 290]]], ["Finally, the post-test odds were transformed to post-test probabilities of infection = /(1 + ) The model was implemented in Microsoft\u00ae Excel\u00ae using the add-in software Poptools 20 .", [["infection", "DISEASE", 75, 84], ["infection", "PROBLEM", 75, 84], ["infection", "OBSERVATION", 75, 84]]], ["For estimation of pre and post probabilities (mean and 95% confidence intervals), stochastic simulations of 1000 iterations were performed.", [["mean", "TEST", 46, 50], ["stochastic simulations of 1000 iterations", "TREATMENT", 82, 123]]], ["It should be noted that these values are crude approximations which were made only as an example of and to help understand the use of Direct RT-LAMP in practice.", [["Direct RT-LAMP in practice", "TREATMENT", 134, 160]]], ["We encourage the readers who would like to use this model to quantify pre-and post-test probabilities of infection to better estimate the parameter values according to the epidemiological situation of the country/region where the test would be applied.", [["infection", "DISEASE", 105, 114], ["this model", "TREATMENT", 47, 57], ["infection", "PROBLEM", 105, 114], ["the test", "TEST", 226, 234], ["infection", "OBSERVATION", 105, 114]]], ["Alternatively, once the pre-test probabilities are estimated, post-test probabilities can be approximated using a Fagan nomogram 35 .Supplementary information.", [["post-test probabilities", "PROBLEM", 62, 85], ["a Fagan nomogram", "TEST", 112, 128]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Supplementary informationThe copyright holder for this preprint this version posted July 1, 2020. distribution (a,b,c) where a = the minimum, b = the most likely and c = the maximum values.Supplementary information.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 224, 244], ["med", "ANATOMY", 102, 105], ["most likely", "UNCERTAINTY", 349, 360]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Supplementary informationThe copyright holder for this preprint this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.20142935 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 224, 244], ["medRxiv", "TREATMENT", 348, 355], ["med", "ANATOMY", 102, 105]]]], "568bf7a3a02d3919e13beb5fa106e0bfaa63772e": [["INTRODUCTIONOn December 31, 2019, a cluster of atypical pneumonia was reported in the Chinese city of Wuhan, mediated by a novel coronavirus (CoV) called SARS-CoV-2 (1, 2) .", [["pneumonia", "DISEASE", 56, 65], ["coronavirus", "ORGANISM", 129, 140], ["CoV", "ORGANISM", 142, 145], ["SARS-CoV-2", "ORGANISM", 154, 164], ["coronavirus", "SPECIES", 129, 140], ["CoV", "SPECIES", 142, 145], ["SARS-CoV-2", "SPECIES", 154, 164], ["atypical pneumonia", "PROBLEM", 47, 65], ["a novel coronavirus", "PROBLEM", 121, 140], ["atypical", "OBSERVATION_MODIFIER", 47, 55], ["pneumonia", "OBSERVATION", 56, 65]]], ["The outbreak of this \"coronavirus disease 2019\" (COVID-19) has been declared a global pandemic by the World Health Organization (WHO), with more than 7 million cases in early June 2020 (3, 4) with a case-fatality rate of about 1%, as well as significant economic and social consequences.", [["coronavirus disease", "DISEASE", 22, 41], ["COVID-19", "CHEMICAL", 49, 57], ["this \"coronavirus disease", "PROBLEM", 16, 41], ["COVID", "TEST", 49, 54], ["fatality rate", "TEST", 204, 217], ["coronavirus disease", "OBSERVATION", 22, 41]]], ["To date, no approved antiviral agents or efficient vaccines are available against the SARS-COV-2.", [["SARS", "DISEASE", 86, 90], ["SARS-COV-2", "ORGANISM", 86, 96], ["antiviral agents", "TREATMENT", 21, 37], ["efficient vaccines", "TREATMENT", 41, 59], ["the SARS", "TEST", 82, 90]]], ["For these reasons, necessary public health measures have been deployed, including worldwide quarantining of the populations and the use of barrier gestures to stop the progression of the SARS-COV-2.INTRODUCTIONCoVs are a class of positive-sense single-stranded RNA viruses found in a wide range of host species, including birds and mammals.", [["birds", "ORGANISM", 322, 327], ["SARS-COV-2.INTRODUCTIONCoVs", "DNA", 187, 214], ["public health measures", "TREATMENT", 29, 51], ["barrier gestures", "TREATMENT", 139, 155], ["stranded RNA viruses", "PROBLEM", 252, 272], ["wide range", "OBSERVATION_MODIFIER", 284, 294], ["host species", "OBSERVATION", 298, 310]]], ["Many of beta-CoV cause intestinal and respiratory infections in animals and humans.", [["intestinal", "ANATOMY", 23, 33], ["respiratory", "ANATOMY", 38, 49], ["intestinal and respiratory infections", "DISEASE", 23, 60], ["beta-CoV", "GENE_OR_GENE_PRODUCT", 8, 16], ["intestinal", "ORGAN", 23, 33], ["humans", "ORGANISM", 76, 82], ["humans", "SPECIES", 76, 82], ["beta-CoV", "SPECIES", 8, 16], ["humans", "SPECIES", 76, 82], ["intestinal and respiratory infections in animals", "PROBLEM", 23, 71], ["beta-CoV", "OBSERVATION_MODIFIER", 8, 16], ["intestinal", "ANATOMY", 23, 33], ["respiratory", "ANATOMY", 38, 49], ["infections", "OBSERVATION", 50, 60]]], ["The zoonotic source of COVID-19 is not confirmed; however, sequencing of the SARS-CoV-2 reveals up to 80% identity with SARS-CoV and even more with several bat CoVs (5) .", [["SARS", "DISEASE", 77, 81], ["SARS", "DISEASE", 120, 124], ["SARS-CoV-2", "ORGANISM", 77, 87], ["SARS-CoV", "ORGANISM", 120, 128], ["COVID-19", "DNA", 23, 31], ["SARS-CoV-2", "DNA", 77, 87], ["SARS-CoV", "SPECIES", 120, 128], ["COVID", "TEST", 23, 28], ["the SARS", "TEST", 73, 81], ["CoV", "TEST", 82, 85], ["SARS", "TEST", 120, 124]]], ["This similarity suggests that bats could be the key reservoir, from which the virus was possibly directly transmitted to humans or through another unknown intermediate host.INTRODUCTIONA phylogenetic analysis of 160 genomes of patients with COVID-19 revealed three major variants, named A, B, and C; the Atype being the ancestral type, firstly detected in China.", [["bats", "ORGANISM", 30, 34], ["humans", "ORGANISM", 121, 127], ["patients", "ORGANISM", 227, 235], ["B", "GENE_OR_GENE_PRODUCT", 290, 291], ["C", "GENE_OR_GENE_PRODUCT", 297, 298], ["Atype", "GENE_OR_GENE_PRODUCT", 304, 309], ["160 genomes", "DNA", 212, 223], ["COVID-19", "DNA", 241, 249], ["humans", "SPECIES", 121, 127], ["patients", "SPECIES", 227, 235], ["humans", "SPECIES", 121, 127], ["the virus", "PROBLEM", 74, 83], ["phylogenetic analysis", "TEST", 187, 208], ["COVID", "TEST", 241, 246], ["ancestral type", "OBSERVATION", 320, 334]]], ["The A and C types are found in significant proportions in Europe and America, whereas the B type is the most common in East Asia (6) .INTRODUCTIONIn 2002-2003, a first \"atypical pneumonia, \" called severe acute respiratory syndrome (SARS) was reported in Guangdong Province in China.", [["pneumonia", "DISEASE", 178, 187], ["acute respiratory syndrome", "DISEASE", 205, 231], ["SARS", "DISEASE", 233, 237], ["a first \"atypical pneumonia", "PROBLEM", 160, 187], ["severe acute respiratory syndrome", "PROBLEM", 198, 231], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["proportions", "OBSERVATION_MODIFIER", 43, 54], ["pneumonia", "OBSERVATION", 178, 187], ["severe", "OBSERVATION_MODIFIER", 198, 204], ["acute", "OBSERVATION_MODIFIER", 205, 210], ["respiratory syndrome", "OBSERVATION", 211, 231]]], ["The disease then spread to 37 countries to cause more than 8,000 cases, with a case-fatality rate of \u223c10% (7) .", [["The disease", "PROBLEM", 0, 11], ["fatality rate", "TEST", 84, 97], ["disease", "OBSERVATION", 4, 11]]], ["At that time, SARS had already posed a worldwide public health threat, with a major impact on the economy.", [["SARS", "DISEASE", 14, 18], ["SARS", "PROBLEM", 14, 18]]], ["More recently, the Middle East respiratory syndrome (MERS) spread to 27 countries, causing around 2,500 cases.", [["Middle East respiratory syndrome", "DISEASE", 19, 51], ["the Middle East respiratory syndrome", "PROBLEM", 15, 51], ["Middle", "ANATOMY_MODIFIER", 19, 25], ["respiratory syndrome", "OBSERVATION", 31, 51]]], ["Among the CoVs, MERS has the highest case fatality rate (about 30%), but it is rarely transmitted between humans, only via camel (8) .", [["CoVs", "GENE_OR_GENE_PRODUCT", 10, 14], ["humans", "ORGANISM", 106, 112], ["humans", "SPECIES", 106, 112], ["humans", "SPECIES", 106, 112], ["CoVs", "OBSERVATION", 10, 14]]], ["Thus, for the third time in a few decades, a new CoV has crossed species to infect human populations.", [["CoV", "ORGANISM", 49, 52], ["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["a new CoV", "PROBLEM", 43, 52], ["crossed species", "PROBLEM", 57, 72]]], ["However, compared with the other two CoVs, SARS-CoV-2 is much more contagious.", [["SARS", "DISEASE", 43, 47], ["CoVs", "GENE_OR_GENE_PRODUCT", 37, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["SARS-CoV", "SPECIES", 43, 51], ["SARS", "TEST", 43, 47], ["contagious", "OBSERVATION_MODIFIER", 67, 77]]], ["Until now, more than 7 million cases have been diagnosed globally, with over 400,000 fatalities worldwide through early June 2020, with a basic reproductive number estimated to be from 2.2 to 3.3 and a mortality rate of around 2.3% (3, 9) .INTRODUCTIONLike the other CoVs, SARS-CoV-2 possesses a typical envelope structure with spike proteins at the surface; this characteristic certainly plays a major role in interspecies transmission.", [["surface", "ANATOMY", 350, 357], ["SARS", "DISEASE", 273, 277], ["CoVs", "GENE_OR_GENE_PRODUCT", 267, 271], ["SARS-CoV-2", "ORGANISM", 273, 283], ["surface", "CELLULAR_COMPONENT", 350, 357], ["CoVs", "DNA", 267, 271], ["spike proteins", "PROTEIN", 328, 342], ["SARS-CoV", "SPECIES", 273, 281], ["a mortality rate", "TEST", 200, 216], ["the other CoVs", "PROBLEM", 257, 271], ["SARS", "PROBLEM", 273, 277], ["a typical envelope structure", "PROBLEM", 294, 322], ["spike proteins at the surface", "PROBLEM", 328, 357], ["envelope structure", "OBSERVATION", 304, 322], ["spike", "OBSERVATION_MODIFIER", 328, 333]]], ["Based on similarities in spike structure characteristics between SARS-CoV-2 and SARS-CoV, several research groups have demonstrated that SARS-CoV-2 also utilizes the human angiotensin-converting enzyme 2 (ACE2) receptor as a cellular entry receptor (10, 11) .", [["cellular", "ANATOMY", 225, 233], ["angiotensin", "CHEMICAL", 172, 183], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV", "ORGANISM", 80, 88], ["SARS-CoV-2", "ORGANISM", 137, 147], ["human", "ORGANISM", 166, 171], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 172, 203], ["ACE2", "GENE_OR_GENE_PRODUCT", 205, 209], ["cellular", "CELL", 225, 233], ["human angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 166, 219], ["cellular entry receptor", "PROTEIN", 225, 248], ["human", "SPECIES", 166, 171], ["SARS-CoV", "SPECIES", 65, 73], ["SARS-CoV", "SPECIES", 80, 88], ["human", "SPECIES", 166, 171], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73], ["SARS", "PROBLEM", 80, 84], ["SARS", "TEST", 137, 141], ["CoV", "TEST", 142, 145], ["the human angiotensin", "TREATMENT", 162, 183]]], ["ACE2 is mainly expressed in vascular endothelial cells and the renal tubular epithelium.", [["vascular endothelial cells", "ANATOMY", 28, 54], ["renal tubular epithelium", "ANATOMY", 63, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["vascular endothelial cells", "CELL", 28, 54], ["renal tubular epithelium", "TISSUE", 63, 87], ["ACE2", "PROTEIN", 0, 4], ["vascular endothelial cells", "CELL_TYPE", 28, 54], ["ACE2", "TEST", 0, 4], ["vascular endothelial cells", "OBSERVATION", 28, 54], ["renal", "ANATOMY", 63, 68], ["tubular", "ANATOMY_MODIFIER", 69, 76], ["epithelium", "ANATOMY_MODIFIER", 77, 87]]], ["PCR analysis revealed that ACE2 is also expressed in the lungs and gastrointestinal tract, which are tissues shown to harbor viruses (12) .", [["lungs", "ANATOMY", 57, 62], ["gastrointestinal tract", "ANATOMY", 67, 89], ["tissues", "ANATOMY", 101, 108], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["lungs", "ORGAN", 57, 62], ["gastrointestinal tract", "ORGAN", 67, 89], ["tissues", "TISSUE", 101, 108], ["ACE2", "PROTEIN", 27, 31], ["PCR analysis", "TEST", 0, 12], ["ACE2", "TEST", 27, 31], ["lungs", "ANATOMY", 57, 62], ["gastrointestinal tract", "ANATOMY", 67, 89]]], ["It was also suggested that CD147 (basigin or the EMMPRIN protein) could be another cell-surface receptor for SARS-CoV-2 (13).", [["cell", "ANATOMY", 83, 87], ["surface", "ANATOMY", 88, 95], ["CD147", "GENE_OR_GENE_PRODUCT", 27, 32], ["basigin", "GENE_OR_GENE_PRODUCT", 34, 41], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 49, 56], ["cell", "CELL", 83, 87], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["CD147", "PROTEIN", 27, 32], ["basigin", "PROTEIN", 34, 41], ["EMMPRIN protein", "PROTEIN", 49, 64], ["cell-surface receptor", "PROTEIN", 83, 104], ["the EMMPRIN protein)", "TREATMENT", 45, 65], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117]]], ["By co-immunoprecipitation, ELISA, and immuno-electron microscopy, they show that anti-CD147 antibody (Meplazumab) could competitively inhibit the binding of spike protein (SP) with CD147 and thus prevent infection of target cells.", [["cells", "ANATOMY", 224, 229], ["Meplazumab", "CHEMICAL", 102, 112], ["infection", "DISEASE", 204, 213], ["Meplazumab", "CHEMICAL", 102, 112], ["anti-CD147 antibody", "GENE_OR_GENE_PRODUCT", 81, 100], ["Meplazumab", "SIMPLE_CHEMICAL", 102, 112], ["spike protein", "GENE_OR_GENE_PRODUCT", 157, 170], ["CD147", "GENE_OR_GENE_PRODUCT", 181, 186], ["cells", "CELL", 224, 229], ["anti-CD147 antibody", "PROTEIN", 81, 100], ["spike protein", "PROTEIN", 157, 170], ["SP", "PROTEIN", 172, 174], ["CD147", "PROTEIN", 181, 186], ["target cells", "CELL_TYPE", 217, 229], ["ELISA", "TEST", 27, 32], ["immuno-electron microscopy", "TEST", 38, 64], ["anti-CD147 antibody", "TEST", 81, 100], ["spike protein", "PROBLEM", 157, 170], ["CD147", "TEST", 181, 186], ["infection of target cells", "PROBLEM", 204, 229], ["infection", "OBSERVATION", 204, 213], ["target cells", "OBSERVATION", 217, 229]]], ["A phase II clinical trial entitled \"Clinical study of anti-CD147 humanized Meplazumab for injection to treat with 2019-nCoV pneumonia\" (ClinicalTrials.gov identifier: NCT04275245) is currently underway in China aiming to prevent SARS-CoV-2 SP binding and subsequent infection (14) .", [["Meplazumab", "CHEMICAL", 75, 85], ["pneumonia", "DISEASE", 124, 133], ["SARS", "DISEASE", 229, 233], ["infection", "DISEASE", 266, 275], ["anti-CD147", "SIMPLE_CHEMICAL", 54, 64], ["Meplazumab", "SIMPLE_CHEMICAL", 75, 85], ["SP", "PROTEIN", 240, 242], ["Clinical study", "TEST", 36, 50], ["anti-CD147 humanized Meplazumab", "TREATMENT", 54, 85], ["pneumonia", "PROBLEM", 124, 133], ["SARS", "PROBLEM", 229, 233], ["CoV", "PROBLEM", 234, 237], ["SP binding", "PROBLEM", 240, 250], ["subsequent infection", "PROBLEM", 255, 275], ["pneumonia", "OBSERVATION", 124, 133], ["infection", "OBSERVATION", 266, 275]]], ["CD209L (L-SGN) has been identified as another possible alternative receptor for SARS-CoV-2, as previously described for the SARS-CoV virus (15) .INTRODUCTIONThis review highlights some of the most recent advances in our understanding of the role of innate and adaptive cellular immunity in COVID-19 infection and discusses potential links to pathogenesis.IMMUNOPATHOLOGY OF COVID-19What of the Acute Infection?IMMUNOPATHOLOGY OF COVID-19The first symptoms associated with COVID-19 are mainly those of respiratory disease, although neurologic and digestive symptoms can also be observed.", [["cellular", "ANATOMY", 269, 277], ["respiratory", "ANATOMY", 501, 512], ["neurologic", "ANATOMY", 531, 541], ["digestive", "ANATOMY", 546, 555], ["SARS-CoV virus", "DISEASE", 124, 138], ["infection", "DISEASE", 299, 308], ["Infection", "DISEASE", 400, 409], ["respiratory disease", "DISEASE", 501, 520], ["neurologic and digestive symptoms", "DISEASE", 531, 564], ["COVID-19", "CHEMICAL", 429, 437], ["COVID-19", "CHEMICAL", 472, 480], ["CD209L", "GENE_OR_GENE_PRODUCT", 0, 6], ["L-SGN", "GENE_OR_GENE_PRODUCT", 8, 13], ["SARS-CoV-2", "ORGANISM", 80, 90], ["SARS-CoV virus", "ORGANISM", 124, 138], ["cellular", "CELL", 269, 277], ["COVID-19", "ORGANISM", 290, 298], ["digestive", "ORGAN", 546, 555], ["CD209L", "PROTEIN", 0, 6], ["L-SGN", "PROTEIN", 8, 13], ["CoV virus", "SPECIES", 129, 138], ["SARS-CoV", "SPECIES", 80, 88], ["SARS-CoV virus", "SPECIES", 124, 138], ["COVID-19", "SPECIES", 290, 298], ["SARS", "PROBLEM", 80, 84], ["CoV", "TEST", 85, 88], ["the SARS-CoV virus", "PROBLEM", 120, 138], ["COVID-19 infection", "PROBLEM", 290, 308], ["COVID", "TEST", 374, 379], ["the Acute Infection", "PROBLEM", 390, 409], ["COVID", "TEST", 429, 434], ["The first symptoms", "PROBLEM", 437, 455], ["COVID", "TEST", 472, 477], ["respiratory disease", "PROBLEM", 501, 520], ["neurologic and digestive symptoms", "PROBLEM", 531, 564], ["Acute", "OBSERVATION_MODIFIER", 394, 399], ["Infection", "OBSERVATION", 400, 409], ["respiratory disease", "OBSERVATION", 501, 520]]], ["The primary mode of infection is human-to-human transmission through close contact, via the spraying of droplets from infected individuals, primarily through the nasal and larynx mucosa, followed by entrance into the lungs through the respiratory tract.", [["nasal", "ANATOMY", 162, 167], ["larynx mucosa", "ANATOMY", 172, 185], ["lungs", "ANATOMY", 217, 222], ["respiratory tract", "ANATOMY", 235, 252], ["infection", "DISEASE", 20, 29], ["human", "ORGANISM", 33, 38], ["human", "ORGANISM", 42, 47], ["nasal", "ORGAN", 162, 167], ["larynx mucosa", "MULTI-TISSUE_STRUCTURE", 172, 185], ["lungs", "ORGAN", 217, 222], ["respiratory tract", "ORGANISM_SUBDIVISION", 235, 252], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 42, 47], ["infection", "PROBLEM", 20, 29], ["infected individuals", "PROBLEM", 118, 138], ["infection", "OBSERVATION", 20, 29], ["infected", "OBSERVATION", 118, 126], ["nasal", "ANATOMY", 162, 167], ["larynx mucosa", "ANATOMY", 172, 185], ["lungs", "ANATOMY", 217, 222], ["respiratory tract", "ANATOMY", 235, 252]]], ["Next, in more severe cases, damage/oedema due to extracellular fluid may let the virus enter the peripheral blood from the lungs, causing viremia.", [["extracellular fluid", "ANATOMY", 49, 68], ["peripheral blood", "ANATOMY", 97, 113], ["lungs", "ANATOMY", 123, 128], ["oedema", "DISEASE", 35, 41], ["viremia", "DISEASE", 138, 145], ["oedema", "PATHOLOGICAL_FORMATION", 35, 41], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 62], ["fluid", "ORGANISM_SUBSTANCE", 63, 68], ["peripheral blood", "ORGANISM_SUBSTANCE", 97, 113], ["lungs", "ORGAN", 123, 128], ["damage/oedema", "PROBLEM", 28, 41], ["extracellular fluid", "PROBLEM", 49, 68], ["the virus", "PROBLEM", 77, 86], ["viremia", "PROBLEM", 138, 145], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["oedema", "OBSERVATION", 35, 41], ["fluid", "OBSERVATION", 63, 68], ["peripheral", "ANATOMY_MODIFIER", 97, 107], ["blood", "ANATOMY", 108, 113], ["lungs", "ANATOMY", 123, 128], ["viremia", "OBSERVATION", 138, 145]]], ["COVID-19 has a probable asymptomatic incubation period between 2 and 14 days during which the virus can be transmitted (16) , but importantly, the duration of SARS-CoV-2 RNA detection has not been well-characterized.", [["COVID-19", "CHEMICAL", 0, 8], ["SARS", "DISEASE", 159, 163], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 159, 169], ["COVID", "TEST", 0, 5], ["the virus", "PROBLEM", 90, 99], ["SARS", "TEST", 159, 163], ["CoV-2 RNA detection", "TEST", 164, 183], ["probable", "UNCERTAINTY", 15, 23], ["asymptomatic", "OBSERVATION_MODIFIER", 24, 36], ["incubation", "OBSERVATION", 37, 47], ["virus", "OBSERVATION", 94, 99]]], ["Zhou et al. (12) found that viral titers in nasopharyngeal aspirates diminish 10-15 days after the onset of symptoms, but remains high when the clinical disease worsens.", [["nasopharyngeal aspirates", "ANATOMY", 44, 68], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 44, 68], ["viral titers in nasopharyngeal aspirates", "PROBLEM", 28, 68], ["symptoms", "PROBLEM", 108, 116], ["the clinical disease worsens", "PROBLEM", 140, 168], ["viral titers", "OBSERVATION", 28, 40], ["nasopharyngeal", "ANATOMY", 44, 58], ["aspirates", "OBSERVATION", 59, 68]]], ["It is, however, noteworthy that the presence of viral RNA in specimens does not always correlate with viral transmissibility; a major limitation remains the inability to differentiate between infective and non-infective (dead or antibody-neutralized) viruses.", [["specimens", "ANATOMY", 61, 70], ["viral RNA", "RNA", 48, 57], ["viral RNA in specimens", "PROBLEM", 48, 70], ["viral transmissibility", "PROBLEM", 102, 124], ["infective", "PROBLEM", 192, 201], ["non-infective (dead or antibody-neutralized) viruses", "PROBLEM", 206, 258], ["viral RNA", "OBSERVATION", 48, 57], ["infective", "OBSERVATION", 192, 201]]], ["For SARS and MERS, it had previously been shown that viral RNA persisted in the respiratory tract for at least 3 weeks after disease onset in a majority of patients (17) .What of the Severe Forms?More than 80% of COVID-19 cases were asymptomatic or presented with mild symptoms, while the remaining cases were severe or critical (2, 18) .", [["respiratory tract", "ANATOMY", 80, 97], ["SARS", "DISEASE", 4, 8], ["respiratory tract", "ORGANISM_SUBDIVISION", 80, 97], ["patients", "ORGANISM", 156, 164], ["COVID", "CANCER", 213, 218], ["viral RNA", "RNA", 53, 62], ["patients", "SPECIES", 156, 164], ["SARS", "PROBLEM", 4, 8], ["viral RNA", "PROBLEM", 53, 62], ["disease onset", "PROBLEM", 125, 138], ["COVID", "TEST", 213, 218], ["asymptomatic", "PROBLEM", 233, 245], ["mild symptoms", "PROBLEM", 264, 277], ["viral RNA", "OBSERVATION", 53, 62], ["respiratory tract", "ANATOMY", 80, 97], ["Severe", "OBSERVATION_MODIFIER", 183, 189], ["mild", "OBSERVATION_MODIFIER", 264, 268], ["symptoms", "OBSERVATION", 269, 277], ["severe", "OBSERVATION_MODIFIER", 310, 316], ["critical", "OBSERVATION_MODIFIER", 320, 328]]], ["It seems that the case-fatality rate of COVID-19 (about 1%) is lower than those of SARS (10%) and MERS (30%).", [["SARS", "DISEASE", 83, 87], ["COVID", "TEST", 40, 45], ["SARS", "PROBLEM", 83, 87]]], ["Like other pathogenic CoVs, COVID-19 is associated with a typical influenza-like syndrome with fever, cough, fatigue and/or myalgia.", [["influenza-like syndrome", "DISEASE", 66, 89], ["fever", "DISEASE", 95, 100], ["cough", "DISEASE", 102, 107], ["fatigue", "DISEASE", 109, 116], ["myalgia", "DISEASE", 124, 131], ["CoVs", "CANCER", 22, 26], ["COVID-19", "GENE_OR_GENE_PRODUCT", 28, 36], ["COVID-19", "DNA", 28, 36], ["other pathogenic CoVs", "PROBLEM", 5, 26], ["COVID", "TEST", 28, 33], ["a typical influenza-like syndrome", "PROBLEM", 56, 89], ["fever", "PROBLEM", 95, 100], ["cough", "PROBLEM", 102, 107], ["fatigue", "PROBLEM", 109, 116], ["myalgia", "PROBLEM", 124, 131], ["pathogenic CoVs", "OBSERVATION", 11, 26], ["typical", "OBSERVATION_MODIFIER", 58, 65], ["influenza", "OBSERVATION", 66, 75], ["myalgia", "OBSERVATION", 124, 131]]], ["Although diarrhea was reported in a foursome of patients with SARS and MERS, intestinal symptoms were rarely observed in patients with COVID-19 (2, 18, 19) .What of the Severe Forms?An early report in China found that 14% of COVID-19 patients were hospitalized, including 5% with ICU intervention (20) .", [["intestinal", "ANATOMY", 77, 87], ["diarrhea", "DISEASE", 9, 17], ["SARS", "DISEASE", 62, 66], ["MERS", "DISEASE", 71, 75], ["patients", "ORGANISM", 48, 56], ["intestinal", "ORGAN", 77, 87], ["patients", "ORGANISM", 121, 129], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 234, 242], ["diarrhea", "PROBLEM", 9, 17], ["SARS", "PROBLEM", 62, 66], ["MERS", "PROBLEM", 71, 75], ["intestinal symptoms", "PROBLEM", 77, 96], ["COVID", "TEST", 135, 140], ["COVID", "TEST", 225, 230], ["ICU intervention", "TREATMENT", 280, 296], ["diarrhea", "OBSERVATION", 9, 17], ["intestinal", "ANATOMY", 77, 87], ["Severe", "OBSERVATION_MODIFIER", 169, 175]]], ["Similar proportions were observed later in Europe and the US (4).", [["the US", "TEST", 54, 60]]], ["Among those who are seriously ill, acute hypoxemic respiratory failure due to acute respiratory distress syndrome (ARDS) is mainly observed (20, 21) .", [["respiratory", "ANATOMY", 51, 62], ["respiratory", "ANATOMY", 84, 95], ["hypoxemic respiratory failure", "DISEASE", 41, 70], ["acute respiratory distress syndrome", "DISEASE", 78, 113], ["ARDS", "DISEASE", 115, 119], ["seriously ill", "PROBLEM", 20, 33], ["acute hypoxemic respiratory failure", "PROBLEM", 35, 70], ["acute respiratory distress syndrome", "PROBLEM", 78, 113], ["ARDS", "PROBLEM", 115, 119], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["hypoxemic", "OBSERVATION_MODIFIER", 41, 50], ["respiratory failure", "OBSERVATION", 51, 70], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["respiratory distress syndrome", "OBSERVATION", 84, 113], ["ARDS", "OBSERVATION", 115, 119]]], ["At this stage, the need for mechanical ventilation is high, ranging from 40 to 100% (22) ; however, encephalitis and antiphospholipid syndrome are rare (23) .", [["encephalitis", "DISEASE", 100, 112], ["antiphospholipid syndrome", "DISEASE", 117, 142], ["mechanical ventilation", "TREATMENT", 28, 50], ["encephalitis", "PROBLEM", 100, 112], ["antiphospholipid syndrome", "PROBLEM", 117, 142], ["mechanical ventilation", "OBSERVATION", 28, 50], ["high", "OBSERVATION_MODIFIER", 54, 58], ["encephalitis", "OBSERVATION", 100, 112], ["antiphospholipid syndrome", "OBSERVATION", 117, 142]]], ["Common complications of COVID-19 include acute kidney injury, elevated liver enzymes, and cardiac injury (23) .", [["kidney", "ANATOMY", 47, 53], ["liver", "ANATOMY", 71, 76], ["cardiac", "ANATOMY", 90, 97], ["COVID-19", "CHEMICAL", 24, 32], ["acute kidney injury", "DISEASE", 41, 60], ["elevated liver enzymes", "DISEASE", 62, 84], ["cardiac injury", "DISEASE", 90, 104], ["COVID-19", "CHEMICAL", 24, 32], ["kidney", "ORGAN", 47, 53], ["liver", "ORGAN", 71, 76], ["cardiac", "ORGAN", 90, 97], ["liver enzymes", "PROTEIN", 71, 84], ["COVID", "TEST", 24, 29], ["acute kidney injury", "PROBLEM", 41, 60], ["elevated liver enzymes", "PROBLEM", 62, 84], ["cardiac injury", "PROBLEM", 90, 104], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["kidney", "ANATOMY", 47, 53], ["injury", "OBSERVATION", 54, 60], ["elevated", "OBSERVATION", 62, 70], ["liver", "ANATOMY", 71, 76], ["cardiac", "ANATOMY", 90, 97], ["injury", "OBSERVATION", 98, 104]]], ["The limited COVID-19 post mortem data show prominent alveolar edema, fibrin deposition, immune cell infiltration, and severe multi-organ damage, including renal, cardiac, and liver dysfunction (12, 24) .What of the Severe Forms?It was also reported that about 90% of COVID-19 hospitalized patients had at least one risk factor (www.cdc.gov/coronavirus/ 2019-ncov/index.html).", [["alveolar", "ANATOMY", 53, 61], ["fibrin", "ANATOMY", 69, 75], ["immune cell", "ANATOMY", 88, 99], ["multi-organ", "ANATOMY", 125, 136], ["renal", "ANATOMY", 155, 160], ["cardiac", "ANATOMY", 162, 169], ["liver", "ANATOMY", 175, 180], ["alveolar edema", "DISEASE", 53, 67], ["multi-organ damage", "DISEASE", 125, 143], ["renal, cardiac, and liver dysfunction", "DISEASE", 155, 192], ["alveolar edema", "PATHOLOGICAL_FORMATION", 53, 67], ["fibrin", "GENE_OR_GENE_PRODUCT", 69, 75], ["immune cell", "CELL", 88, 99], ["multi-organ", "ORGAN", 125, 136], ["renal", "ORGAN", 155, 160], ["cardiac", "ORGAN", 162, 169], ["liver", "ORGAN", 175, 180], ["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 289, 297], ["The limited COVID", "TEST", 0, 17], ["post mortem data", "TEST", 21, 37], ["prominent alveolar edema", "PROBLEM", 43, 67], ["fibrin deposition", "PROBLEM", 69, 86], ["immune cell infiltration", "PROBLEM", 88, 112], ["severe multi-organ damage", "PROBLEM", 118, 143], ["renal, cardiac, and liver dysfunction", "PROBLEM", 155, 192], ["COVID", "TEST", 267, 272], ["prominent", "OBSERVATION_MODIFIER", 43, 52], ["alveolar", "ANATOMY_MODIFIER", 53, 61], ["edema", "OBSERVATION", 62, 67], ["fibrin deposition", "OBSERVATION", 69, 86], ["immune cell infiltration", "OBSERVATION", 88, 112], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["multi-organ damage", "OBSERVATION", 125, 143], ["renal", "ANATOMY", 155, 160], ["cardiac", "ANATOMY", 162, 169], ["liver", "ANATOMY", 175, 180], ["dysfunction", "OBSERVATION", 181, 192], ["Severe", "OBSERVATION_MODIFIER", 215, 221]]], ["Older age, in particular, as well as a higher sequential organ failure assessment (SOFA) score on admission, are associated with a higher probability of in-hospital death, whereas elevated levels of blood IL-6, high-sensitivity cardiac troponin I, and lymphopenia are more commonly seen in severe COVID-19 illness (12) .", [["organ", "ANATOMY", 57, 62], ["blood", "ANATOMY", 199, 204], ["death", "DISEASE", 165, 170], ["lymphopenia", "DISEASE", 252, 263], ["illness", "DISEASE", 306, 313], ["organ", "ORGAN", 57, 62], ["blood", "ORGANISM_SUBSTANCE", 199, 204], ["IL-6", "GENE_OR_GENE_PRODUCT", 205, 209], ["cardiac troponin I", "GENE_OR_GENE_PRODUCT", 228, 246], ["blood IL-6", "PROTEIN", 199, 209], ["cardiac troponin I", "PROTEIN", 228, 246], ["a higher sequential organ failure assessment", "PROBLEM", 37, 81], ["in-hospital death", "PROBLEM", 153, 170], ["elevated levels", "PROBLEM", 180, 195], ["blood IL", "TEST", 199, 207], ["high-sensitivity cardiac troponin I", "PROBLEM", 211, 246], ["lymphopenia", "PROBLEM", 252, 263], ["severe COVID", "PROBLEM", 290, 302], ["organ", "ANATOMY", 57, 62], ["failure", "OBSERVATION", 63, 70], ["cardiac troponin", "ANATOMY", 228, 244], ["lymphopenia", "OBSERVATION", 252, 263], ["severe", "OBSERVATION_MODIFIER", 290, 296]]], ["It is still unknown why the cytokine storm may account for the severity of infection in elderly and immunocompromised (i.e., diabetics) but not in the young population who are mostly asymptomatic but have a fully functional immune system.", [["infection", "DISEASE", 75, 84], ["immune system", "ANATOMICAL_SYSTEM", 224, 237], ["cytokine", "PROTEIN", 28, 36], ["infection", "PROBLEM", 75, 84], ["immunocompromised", "PROBLEM", 100, 117], ["infection", "OBSERVATION", 75, 84]]], ["However, the variability of clinical cases observed during exposure and infection with SARS-CoV-2 likely suggests that human genetic factors can also influence the response to this virus.", [["infection", "DISEASE", 72, 81], ["SARS", "DISEASE", 87, 91], ["SARS-CoV-2", "ORGANISM", 87, 97], ["human", "ORGANISM", 119, 124], ["human genetic factors", "PROTEIN", 119, 140], ["human", "SPECIES", 119, 124], ["SARS-CoV", "SPECIES", 87, 95], ["human", "SPECIES", 119, 124], ["infection", "PROBLEM", 72, 81], ["SARS", "PROBLEM", 87, 91], ["human genetic factors", "PROBLEM", 119, 140], ["this virus", "PROBLEM", 176, 186], ["infection", "OBSERVATION", 72, 81]]], ["However, to date, very few studies have been conducted to determine its real impact.What of the Severe Forms?Based on patients analyzed, SARS-CoV-2 infects all age groups equally, except perhaps children and adolescents.", [["SARS", "DISEASE", 137, 141], ["patients", "ORGANISM", 118, 126], ["SARS-CoV-2", "ORGANISM", 137, 147], ["children", "ORGANISM", 195, 203], ["patients", "SPECIES", 118, 126], ["children", "SPECIES", 195, 203], ["adolescents", "SPECIES", 208, 219], ["SARS-CoV", "SPECIES", 137, 145], ["very few studies", "TEST", 18, 34], ["SARS", "PROBLEM", 137, 141], ["Severe", "OBSERVATION_MODIFIER", 96, 102]]], ["One unanswered question is why some patients develop severe disease, while others do not.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["severe disease", "PROBLEM", 53, 67], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["disease", "OBSERVATION", 60, 67]]], ["Among the different parameters that can influence the severity of this infection, we will focus on the role of the cellular immune response.RECENT PROGRESS IN IMMUNE CONTROL OF COVID-19 PATHOGENESISUsually, type I interferons (IFN-\u03b1/\u03b2) provide the first line of defense by generating cell-intrinsic antimicrobial states to limit virus replication.", [["cellular", "ANATOMY", 115, 123], ["cell", "ANATOMY", 284, 288], ["infection", "DISEASE", 71, 80], ["cellular", "CELL", 115, 123], ["type I interferons", "GENE_OR_GENE_PRODUCT", 207, 225], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 227, 232], ["\u03b2", "GENE_OR_GENE_PRODUCT", 233, 234], ["cell", "CELL", 284, 288], ["type I interferons", "PROTEIN", 207, 225], ["IFN", "PROTEIN", 227, 230], ["\u03b1", "PROTEIN", 231, 232], ["\u03b2", "PROTEIN", 233, 234], ["this infection", "PROBLEM", 66, 80], ["COVID", "TEST", 177, 182], ["type I interferons", "PROBLEM", 207, 225], ["infection", "OBSERVATION", 71, 80], ["cellular immune response", "OBSERVATION", 115, 139]]], ["It seems, however, that pathogenic CoVs are particularly adapted to dampen responses mediated by IFN-\u03b1/\u03b2 (25, 26) .", [["CoVs", "GENE_OR_GENE_PRODUCT", 35, 39], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 97, 102], ["\u03b2", "GENE_OR_GENE_PRODUCT", 103, 104], ["IFN", "PROTEIN", 97, 100], ["\u03b1", "PROTEIN", 101, 102], ["pathogenic CoVs", "PROBLEM", 24, 39], ["IFN", "TEST", 97, 100]]], ["Several hypotheses were proposed to explain this early modulation of the immune response.", [["immune response", "OBSERVATION", 73, 88]]], ["It was shown that the Orf6 protein of SARS-CoV disrupts the karyopherin transport (27) and consequently inhibits the import of transcriptional factors, such as STAT1, into the nucleus, resulting in an inhibition of IFN response.", [["nucleus", "ANATOMY", 176, 183], ["SARS", "DISEASE", 38, 42], ["Orf6", "GENE_OR_GENE_PRODUCT", 22, 26], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 38, 46], ["karyopherin", "GENE_OR_GENE_PRODUCT", 60, 71], ["STAT1", "GENE_OR_GENE_PRODUCT", 160, 165], ["nucleus", "CELLULAR_COMPONENT", 176, 183], ["IFN", "GENE_OR_GENE_PRODUCT", 215, 218], ["Orf6 protein", "PROTEIN", 22, 34], ["karyopherin", "PROTEIN", 60, 71], ["transcriptional factors", "PROTEIN", 127, 150], ["STAT1", "PROTEIN", 160, 165], ["IFN", "PROTEIN", 215, 218], ["SARS-CoV", "SPECIES", 38, 46], ["the Orf6 protein", "TEST", 18, 34], ["SARS", "PROBLEM", 38, 42], ["the karyopherin transport", "TEST", 56, 81], ["transcriptional factors", "PROBLEM", 127, 150], ["an inhibition of IFN response", "PROBLEM", 198, 227], ["nucleus", "ANATOMY", 176, 183]]], ["Similarly, the Orf3b protein of SARS-CoV inhibits phosphorylation of interferon regulatory factor 3 (IRF3) (28), a protein involved in the activation of IFN-\u03b1/\u03b2.", [["SARS", "DISEASE", 32, 36], ["Orf3b", "GENE_OR_GENE_PRODUCT", 15, 20], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 69, 99], ["IRF3) (28)", "GENE_OR_GENE_PRODUCT", 101, 111], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 153, 158], ["\u03b2.", "GENE_OR_GENE_PRODUCT", 159, 161], ["Orf3b protein", "PROTEIN", 15, 28], ["interferon regulatory factor 3", "PROTEIN", 69, 99], ["IRF3", "PROTEIN", 101, 105], ["IFN", "PROTEIN", 153, 156], ["SARS-CoV", "SPECIES", 32, 40], ["the Orf3b protein", "TEST", 11, 28], ["SARS", "TEST", 32, 36], ["phosphorylation of interferon regulatory factor", "TREATMENT", 50, 97], ["a protein", "TEST", 113, 122]]], ["In China, the guidelines for the treatment of COVID-19 recommended administering IFN-\u03b1 in combination with ribavirin (29), although no improvement was recorded.", [["COVID-19", "CHEMICAL", 46, 54], ["IFN-\u03b1", "CHEMICAL", 81, 86], ["ribavirin", "CHEMICAL", 107, 116], ["COVID-19", "CHEMICAL", 46, 54], ["ribavirin", "CHEMICAL", 107, 116], ["IFN-\u03b1", "SIMPLE_CHEMICAL", 81, 86], ["ribavirin", "SIMPLE_CHEMICAL", 107, 116], ["IFN", "PROTEIN", 81, 84], ["COVID", "TEST", 46, 51], ["IFN", "TREATMENT", 81, 84], ["ribavirin", "TREATMENT", 107, 116]]], ["Interestingly, IFN-\u03b1 effectively inhibited SARS-CoV replication but 50-90 times lower than IFN-\u03b2 (30) (31) (32) , suggesting that IFN\u03b2 could be a better antiviral component in patients' treatment.", [["IFN-\u03b1", "CHEMICAL", 15, 20], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 15, 20], ["SARS-CoV", "ORGANISM", 43, 51], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 130, 134], ["patients", "ORGANISM", 176, 184], ["IFN", "PROTEIN", 15, 18], ["IFN", "PROTEIN", 91, 94], ["IFN\u03b2", "PROTEIN", 130, 134], ["patients", "SPECIES", 176, 184], ["SARS-CoV", "SPECIES", 43, 51], ["IFN", "TEST", 15, 18], ["SARS", "PROBLEM", 43, 47], ["CoV replication", "TEST", 48, 63], ["IFN", "TEST", 91, 94], ["IFN", "PROBLEM", 130, 133], ["patients' treatment", "TREATMENT", 176, 195]]], ["Thus, in the European DisCoVeRy trial, a combination of subcutaneous IFN-\u03b2 with lopinavir/ritonavir is compared to hydroxychloroquine and remdesivir.RECENT PROGRESS IN IMMUNE CONTROL OF COVID-19 PATHOGENESISThe loss of the \"front line\" antiviral defense mechanism mediated by IFN-\u03b1/\u03b2 deficiency could be implicated in the induction of the cytokine storm leading to macrophage activation syndrome (MAS)-like pathology (33, 34) .", [["subcutaneous", "ANATOMY", 56, 68], ["front line", "ANATOMY", 224, 234], ["macrophage", "ANATOMY", 365, 375], ["IFN-\u03b2", "CHEMICAL", 69, 74], ["lopinavir/ritonavir", "CHEMICAL", 80, 99], ["hydroxychloroquine", "CHEMICAL", 115, 133], ["remdesivir", "CHEMICAL", 138, 148], ["MAS", "DISEASE", 397, 400], ["lopinavir", "CHEMICAL", 80, 89], ["ritonavir", "CHEMICAL", 90, 99], ["hydroxychloroquine", "CHEMICAL", 115, 133], ["remdesivir", "CHEMICAL", 138, 148], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 69, 74], ["lopinavir", "SIMPLE_CHEMICAL", 80, 89], ["ritonavir", "SIMPLE_CHEMICAL", 90, 99], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 115, 133], ["remdesivir", "SIMPLE_CHEMICAL", 138, 148], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 276, 281], ["\u03b2", "GENE_OR_GENE_PRODUCT", 282, 283], ["macrophage", "CELL", 365, 375], ["IFN", "PROTEIN", 69, 72], ["IFN", "PROTEIN", 276, 279], ["\u03b2", "PROTEIN", 282, 283], ["cytokine", "PROTEIN", 339, 347], ["subcutaneous IFN", "TREATMENT", 56, 72], ["lopinavir", "TREATMENT", 80, 89], ["ritonavir", "TREATMENT", 90, 99], ["hydroxychloroquine", "TREATMENT", 115, 133], ["remdesivir", "TREATMENT", 138, 148], ["COVID", "TEST", 186, 191], ["the \"front line", "TREATMENT", 219, 234], ["antiviral defense mechanism", "TREATMENT", 236, 263], ["deficiency", "PROBLEM", 284, 294], ["the cytokine storm", "TREATMENT", 335, 353], ["macrophage activation syndrome", "PROBLEM", 365, 395], ["MAS)", "PROBLEM", 397, 401]]], ["This cytokine storm is considered as the root cause of pathogenic inflammation in COVID-19.", [["root", "ANATOMY", 41, 45], ["inflammation", "DISEASE", 66, 78], ["cytokine", "PROTEIN", 5, 13], ["pathogenic inflammation", "PROBLEM", 55, 78], ["COVID", "TEST", 82, 87], ["pathogenic", "OBSERVATION_MODIFIER", 55, 65], ["inflammation", "OBSERVATION", 66, 78]]], ["However, its initial trigger is not yet known, but it likely involves the immune system's detection of a large quantity of viral antigens released by dying cells.", [["cells", "ANATOMY", 156, 161], ["cells", "CELL", 156, 161], ["viral antigens", "PROTEIN", 123, 137], ["dying cells", "CELL_TYPE", 150, 161], ["viral antigens", "PROBLEM", 123, 137], ["large", "OBSERVATION_MODIFIER", 105, 110], ["quantity", "OBSERVATION_MODIFIER", 111, 119], ["viral antigens", "OBSERVATION", 123, 137]]], ["One in two fatal cases of COVID-19 experience a cytokine storm, 82% of whom are over the age of 60 (35) .", [["cytokine", "PROTEIN", 48, 56], ["COVID", "TEST", 26, 31]]], ["Interestingly, NLRP3, a major protein component of the inflammasome, could play a role.", [["NLRP3", "GENE_OR_GENE_PRODUCT", 15, 20], ["NLRP3", "PROTEIN", 15, 20], ["NLRP3", "TREATMENT", 15, 20], ["inflammasome", "OBSERVATION", 55, 67]]], ["During aging, there is a steady increase in the abundance and activity of NLRP3 in immune cells in the lung, which contribute to pulmonary fibrosis (36) .", [["immune cells", "ANATOMY", 83, 95], ["lung", "ANATOMY", 103, 107], ["pulmonary", "ANATOMY", 129, 138], ["pulmonary fibrosis", "DISEASE", 129, 147], ["NLRP3", "GENE_OR_GENE_PRODUCT", 74, 79], ["immune cells", "CELL", 83, 95], ["lung", "ORGAN", 103, 107], ["pulmonary", "ORGAN", 129, 138], ["NLRP3", "PROTEIN", 74, 79], ["immune cells", "CELL_TYPE", 83, 95], ["a steady increase", "PROBLEM", 23, 40], ["NLRP3 in immune cells", "TREATMENT", 74, 95], ["pulmonary fibrosis", "PROBLEM", 129, 147], ["steady", "OBSERVATION_MODIFIER", 25, 31], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["abundance", "OBSERVATION_MODIFIER", 48, 57], ["activity", "OBSERVATION_MODIFIER", 62, 70], ["immune cells", "OBSERVATION", 83, 95], ["lung", "ANATOMY", 103, 107], ["pulmonary", "ANATOMY", 129, 138], ["fibrosis", "OBSERVATION", 139, 147]]], ["After age and hematological cancers, obesity is the next major risk factor for COVID-19 fatality, similar to type 2 diabetes.", [["hematological cancers", "ANATOMY", 14, 35], ["hematological cancers", "DISEASE", 14, 35], ["obesity", "DISEASE", 37, 44], ["fatality", "DISEASE", 88, 96], ["type 2 diabetes", "DISEASE", 109, 124], ["hematological cancers", "CANCER", 14, 35], ["hematological cancers", "PROBLEM", 14, 35], ["obesity", "PROBLEM", 37, 44], ["COVID", "TEST", 79, 84], ["type 2 diabetes", "PROBLEM", 109, 124], ["hematological", "ANATOMY", 14, 27], ["cancers", "OBSERVATION", 28, 35], ["obesity", "OBSERVATION", 37, 44], ["diabetes", "OBSERVATION", 116, 124]]], ["Obesity is well-known to increase the activity of NLRP3 and stimulate inflammation during viral infection (37) .RECENT PROGRESS IN IMMUNE CONTROL OF COVID-19 PATHOGENESISThe cytokine storm is mainly associated with a high production of pro-inflammatory cytokines (i.e. IL-1\u03b2, IL-6, TNF\u03b1) (Figure 1) .", [["Obesity", "DISEASE", 0, 7], ["inflammation", "DISEASE", 70, 82], ["viral infection", "DISEASE", 90, 105], ["NLRP3", "GENE_OR_GENE_PRODUCT", 50, 55], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 269, 274], ["IL-6", "GENE_OR_GENE_PRODUCT", 276, 280], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 282, 286], ["NLRP3", "PROTEIN", 50, 55], ["cytokine", "PROTEIN", 174, 182], ["pro-inflammatory cytokines", "PROTEIN", 236, 262], ["IL", "PROTEIN", 269, 271], ["IL-6", "PROTEIN", 276, 280], ["TNF\u03b1", "PROTEIN", 282, 286], ["Obesity", "PROBLEM", 0, 7], ["the activity of NLRP3", "TREATMENT", 34, 55], ["stimulate inflammation", "PROBLEM", 60, 82], ["viral infection", "PROBLEM", 90, 105], ["COVID", "TEST", 149, 154], ["cytokine storm", "PROBLEM", 174, 188], ["a high production of pro-inflammatory cytokines", "PROBLEM", 215, 262], ["IL", "TEST", 269, 271], ["IL", "TEST", 276, 278], ["cytokine storm", "OBSERVATION", 174, 188]]], ["For example, IL-6 production is about 3-fold higher in patients with complicated COVID-19 compared to asymptomatic patients (38) .", [["IL-6", "GENE_OR_GENE_PRODUCT", 13, 17], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 115, 123], ["IL-6", "PROTEIN", 13, 17], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 115, 123], ["IL", "TEST", 13, 15], ["complicated COVID", "TEST", 69, 86]]], ["Preliminary data with tocilizumab, a humanized anti-IL-6 monoclonal antibody, in patients with COVID-19 pneumonia reveal clinical improvement in a small number of patients (39) .", [["tocilizumab", "CHEMICAL", 22, 33], ["pneumonia", "DISEASE", 104, 113], ["tocilizumab", "SIMPLE_CHEMICAL", 22, 33], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 47, 56], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 163, 171], ["humanized anti-IL-6 monoclonal antibody", "PROTEIN", 37, 76], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 163, 171], ["Preliminary data", "TEST", 0, 16], ["tocilizumab", "TREATMENT", 22, 33], ["a humanized anti-IL", "TEST", 35, 54], ["monoclonal antibody", "TEST", 57, 76], ["COVID", "TEST", 95, 100], ["pneumonia", "PROBLEM", 104, 113], ["pneumonia", "OBSERVATION", 104, 113], ["improvement", "OBSERVATION_MODIFIER", 130, 141], ["small", "OBSERVATION_MODIFIER", 147, 152], ["number", "OBSERVATION_MODIFIER", 153, 159]]], ["Similarly, interferon gamma-induced protein 10 (IP-10) is correlated with patient viral load, whereas monocyte-chemotactic protein 3 (MCP3) is associated with loss of lung function (PaO 2 /FaO 2 ratio), lung injury (Murray Score) and fatal outcome (40) .", [["lung", "ANATOMY", 167, 171], ["lung", "ANATOMY", 203, 207], ["lung injury", "DISEASE", 203, 214], ["interferon gamma-induced protein 10", "GENE_OR_GENE_PRODUCT", 11, 46], ["IP-10", "GENE_OR_GENE_PRODUCT", 48, 53], ["patient", "ORGANISM", 74, 81], ["monocyte-chemotactic protein 3", "GENE_OR_GENE_PRODUCT", 102, 132], ["MCP3", "GENE_OR_GENE_PRODUCT", 134, 138], ["lung", "ORGAN", 167, 171], ["PaO 2", "GENE_OR_GENE_PRODUCT", 182, 187], ["FaO 2", "GENE_OR_GENE_PRODUCT", 189, 194], ["lung", "ORGAN", 203, 207], ["interferon gamma-induced protein 10", "PROTEIN", 11, 46], ["monocyte-chemotactic protein 3", "PROTEIN", 102, 132], ["MCP3", "PROTEIN", 134, 138], ["patient", "SPECIES", 74, 81], ["interferon gamma-induced protein", "TEST", 11, 43], ["IP", "TEST", 48, 50], ["patient viral load", "TEST", 74, 92], ["monocyte", "TEST", 102, 110], ["chemotactic protein", "TEST", 111, 130], ["MCP3", "TEST", 134, 138], ["loss of lung function", "PROBLEM", 159, 180], ["PaO", "TEST", 182, 185], ["FaO", "TEST", 189, 192], ["lung injury", "PROBLEM", 203, 214], ["viral load", "OBSERVATION", 82, 92], ["associated with", "UNCERTAINTY", 143, 158], ["loss", "OBSERVATION", 159, 163], ["lung", "ANATOMY", 167, 171], ["lung", "ANATOMY", 203, 207], ["injury", "OBSERVATION", 208, 214]]], ["Systemic inflammation was also observed in fatal cases of H1N1, with high IL-6 and IP-10 concentrations in the lungs, associated with massive infiltration of immune cells in the lung (41) , also reported in severe or fatal forms of avian H5N1 and H7N9 pulmonary infection (42, 43) .What of the Cell-Innate Immunity?The epithelium of the lungs is the largest surface in the human body (>200 m 2 ) in direct contact with the external environment.What of the Cell-Innate Immunity?The lungs inhale daily about 10,000 l of air that contains various pathogenic particles, like the SARS-CoV-2 in fine droplets.", [["lungs", "ANATOMY", 111, 116], ["immune cells", "ANATOMY", 158, 170], ["lung", "ANATOMY", 178, 182], ["pulmonary", "ANATOMY", 252, 261], ["Cell", "ANATOMY", 294, 298], ["epithelium", "ANATOMY", 319, 329], ["lungs", "ANATOMY", 337, 342], ["surface", "ANATOMY", 358, 365], ["body", "ANATOMY", 379, 383], ["Cell", "ANATOMY", 456, 460], ["lungs", "ANATOMY", 481, 486], ["inflammation", "DISEASE", 9, 21], ["H1N1", "DISEASE", 58, 62], ["avian H5N1 and H7N9 pulmonary infection", "DISEASE", 232, 271], ["IL-6", "GENE_OR_GENE_PRODUCT", 74, 78], ["IP-10", "GENE_OR_GENE_PRODUCT", 83, 88], ["lungs", "ORGAN", 111, 116], ["immune cells", "CELL", 158, 170], ["lung", "ORGAN", 178, 182], ["avian H5N1", "ORGANISM", 232, 242], ["H7N9", "ORGANISM", 247, 251], ["pulmonary", "ORGAN", 252, 261], ["Cell", "CELL", 294, 298], ["epithelium", "TISSUE", 319, 329], ["lungs", "ORGAN", 337, 342], ["surface", "CELLULAR_COMPONENT", 358, 365], ["human", "ORGANISM", 373, 378], ["body", "ORGANISM_SUBDIVISION", 379, 383], ["Cell", "CELL", 456, 460], ["lungs", "ORGAN", 481, 486], ["immune cells", "CELL_TYPE", 158, 170], ["avian H5N1", "SPECIES", 232, 242], ["human", "SPECIES", 373, 378], ["H7N9", "SPECIES", 247, 251], ["human", "SPECIES", 373, 378], ["Systemic inflammation", "PROBLEM", 0, 21], ["H1N1", "PROBLEM", 58, 62], ["high IL", "TREATMENT", 69, 76], ["IP", "TEST", 83, 85], ["massive infiltration of immune cells in the lung", "PROBLEM", 134, 182], ["avian H5N1", "PROBLEM", 232, 242], ["H7N9 pulmonary infection", "PROBLEM", 247, 271], ["various pathogenic particles", "PROBLEM", 536, 564], ["the SARS", "TEST", 571, 579], ["CoV", "TEST", 580, 583], ["inflammation", "OBSERVATION", 9, 21], ["H1N1", "OBSERVATION", 58, 62], ["high", "OBSERVATION_MODIFIER", 69, 73], ["10 concentrations", "OBSERVATION_MODIFIER", 86, 103], ["lungs", "ANATOMY", 111, 116], ["associated with", "UNCERTAINTY", 118, 133], ["massive", "OBSERVATION_MODIFIER", 134, 141], ["infiltration", "OBSERVATION", 142, 154], ["immune cells", "OBSERVATION", 158, 170], ["lung", "ANATOMY", 178, 182], ["severe", "OBSERVATION_MODIFIER", 207, 213], ["fatal", "OBSERVATION_MODIFIER", 217, 222], ["avian H5N1", "OBSERVATION", 232, 242], ["H7N9", "OBSERVATION_MODIFIER", 247, 251], ["pulmonary", "ANATOMY", 252, 261], ["infection", "OBSERVATION", 262, 271], ["epithelium", "ANATOMY_MODIFIER", 319, 329], ["lungs", "ANATOMY", 337, 342], ["largest", "OBSERVATION_MODIFIER", 350, 357], ["surface", "OBSERVATION_MODIFIER", 358, 365], ["human", "ANATOMY", 373, 378], ["body", "ANATOMY_MODIFIER", 379, 383], ["lungs", "ANATOMY", 481, 486], ["air", "OBSERVATION", 518, 521], ["various", "OBSERVATION_MODIFIER", 536, 543], ["pathogenic particles", "OBSERVATION", 544, 564]]], ["Thus, this constant exposure to pathogens requires a very efficient immune system to sense the challenge and protect the host.", [["immune system", "ANATOMY", 68, 81], ["pathogens", "PROBLEM", 32, 41], ["a very efficient immune system", "TREATMENT", 51, 81]]], ["To this end, the airways are endowed with physical barriers such as a layer of mucus, which is present over its entire surface to defend this tissue against pathogens, but also a vast network of cellular and humoral host defense mechanisms.What of the Cell-Innate Immunity?This network is mainly composed of epithelial cells of the respiratory tract, dendritic cells (DC) and alveolar macrophages.", [["airways", "ANATOMY", 17, 24], ["mucus", "ANATOMY", 79, 84], ["surface", "ANATOMY", 119, 126], ["tissue", "ANATOMY", 142, 148], ["cellular", "ANATOMY", 195, 203], ["Cell", "ANATOMY", 252, 256], ["epithelial cells", "ANATOMY", 308, 324], ["respiratory tract", "ANATOMY", 332, 349], ["dendritic cells", "ANATOMY", 351, 366], ["DC", "ANATOMY", 368, 370], ["alveolar macrophages", "ANATOMY", 376, 396], ["airways", "MULTI-TISSUE_STRUCTURE", 17, 24], ["mucus", "ORGANISM_SUBSTANCE", 79, 84], ["surface", "CELLULAR_COMPONENT", 119, 126], ["tissue", "TISSUE", 142, 148], ["cellular", "CELL", 195, 203], ["Cell", "CELL", 252, 256], ["epithelial cells", "CELL", 308, 324], ["respiratory tract", "ANATOMICAL_SYSTEM", 332, 349], ["dendritic cells", "CELL", 351, 366], ["DC", "CELL", 368, 370], ["alveolar macrophages", "CELL", 376, 396], ["epithelial cells", "CELL_TYPE", 308, 324], ["dendritic cells", "CELL_TYPE", 351, 366], ["DC", "CELL_TYPE", 368, 370], ["alveolar macrophages", "CELL_TYPE", 376, 396], ["physical barriers", "TREATMENT", 42, 59], ["pathogens", "PROBLEM", 157, 166], ["epithelial cells of the respiratory tract", "PROBLEM", 308, 349], ["dendritic cells (DC) and alveolar macrophages", "PROBLEM", 351, 396], ["airways", "ANATOMY", 17, 24], ["layer", "OBSERVATION_MODIFIER", 70, 75], ["mucus", "OBSERVATION", 79, 84], ["pathogens", "OBSERVATION", 157, 166], ["vast", "OBSERVATION_MODIFIER", 179, 183], ["cellular", "OBSERVATION_MODIFIER", 195, 203], ["humoral host defense", "OBSERVATION", 208, 228], ["epithelial cells", "OBSERVATION", 308, 324], ["respiratory tract", "ANATOMY", 332, 349], ["dendritic cells", "OBSERVATION", 351, 366], ["alveolar macrophages", "OBSERVATION", 376, 396]]], ["These cells trigger pro-inflammatory downstream immune responses in the presence of viral particles.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["These cells", "PROBLEM", 0, 11], ["viral particles", "PROBLEM", 84, 99], ["pro-inflammatory", "OBSERVATION_MODIFIER", 20, 36], ["viral particles", "OBSERVATION", 84, 99]]], ["Liao et al. (44) found that the depletion of tissue-resident alveolar macrophages and the accumulation of inflammatory macrophages in bronchoalveolar lavage cells were associated with disease severity.", [["tissue", "ANATOMY", 45, 51], ["alveolar macrophages", "ANATOMY", 61, 81], ["macrophages", "ANATOMY", 119, 130], ["bronchoalveolar lavage cells", "ANATOMY", 134, 162], ["tissue", "TISSUE", 45, 51], ["alveolar macrophages", "CELL", 61, 81], ["macrophages", "CELL", 119, 130], ["bronchoalveolar lavage cells", "CELL", 134, 162], ["tissue-resident alveolar macrophages", "CELL_TYPE", 45, 81], ["inflammatory macrophages", "CELL_TYPE", 106, 130], ["bronchoalveolar lavage cells", "CELL_TYPE", 134, 162], ["alveolar macrophages", "PROBLEM", 61, 81], ["inflammatory macrophages", "PROBLEM", 106, 130], ["bronchoalveolar lavage cells", "PROBLEM", 134, 162], ["disease severity", "PROBLEM", 184, 200], ["depletion", "OBSERVATION", 32, 41], ["tissue", "ANATOMY", 45, 51], ["alveolar macrophages", "OBSERVATION", 61, 81], ["accumulation", "OBSERVATION_MODIFIER", 90, 102], ["inflammatory macrophages", "OBSERVATION", 106, 130], ["bronchoalveolar lavage cells", "OBSERVATION", 134, 162]]], ["However, it would be necessary to finely test the infectivity of the monocyte/macrophage lineage with SARS-CoV-2 to determine better its impact on inflammatory responses.", [["monocyte", "ANATOMY", 69, 77], ["macrophage lineage", "ANATOMY", 78, 96], ["monocyte", "CELL", 69, 77], ["macrophage lineage", "CELL", 78, 96], ["SARS-CoV-2", "ORGANISM", 102, 112], ["monocyte/macrophage lineage", "CELL_TYPE", 69, 96], ["CoV", "TEST", 107, 110], ["monocyte", "ANATOMY", 69, 77], ["inflammatory", "OBSERVATION", 147, 159]]], ["In this acute inflammatory reaction, neutrophils are also attracted and localized mainly in the bronchoalveolar space (45) .", [["neutrophils", "ANATOMY", 37, 48], ["bronchoalveolar space", "ANATOMY", 96, 117], ["neutrophils", "CELL", 37, 48], ["bronchoalveolar space", "MULTI-TISSUE_STRUCTURE", 96, 117], ["neutrophils", "CELL_TYPE", 37, 48], ["this acute inflammatory reaction", "PROBLEM", 3, 35], ["neutrophils", "PROBLEM", 37, 48], ["acute", "OBSERVATION_MODIFIER", 8, 13], ["inflammatory", "OBSERVATION_MODIFIER", 14, 26], ["neutrophils", "OBSERVATION", 37, 48], ["bronchoalveolar space", "ANATOMY", 96, 117]]], ["Consistently, elevated neutrophil levels were reported in COVID-19 + patients (46, 47) .", [["neutrophil", "ANATOMY", 23, 33], ["neutrophil", "CELL", 23, 33], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["elevated neutrophil levels", "PROBLEM", 14, 40], ["COVID", "TEST", 58, 63], ["elevated", "OBSERVATION_MODIFIER", 14, 22], ["neutrophil levels", "OBSERVATION", 23, 40]]], ["Importantly, the lung constitutes the most important reservoir of neutrophils in the systemic circulation (\u223c40% of total body neutrophils).", [["lung", "ANATOMY", 17, 21], ["neutrophils", "ANATOMY", 66, 77], ["body neutrophils", "ANATOMY", 121, 137], ["lung", "ORGAN", 17, 21], ["neutrophils", "CELL", 66, 77], ["body neutrophils", "CELL", 121, 137], ["neutrophils", "CELL_TYPE", 66, 77], ["neutrophils", "CELL_TYPE", 126, 137], ["the systemic circulation", "TEST", 81, 105], ["total body neutrophils", "TEST", 115, 137], ["lung", "ANATOMY", 17, 21], ["neutrophils", "OBSERVATION", 66, 77], ["systemic circulation", "ANATOMY", 85, 105]]], ["It is plausible that elevated neutrophil level is associated with increased reactive oxygen species (ROS) and neutrophil extracellular traps (NETs), both considered as the most potent antimicrobial mechanisms used by neutrophils.", [["neutrophil", "ANATOMY", 30, 40], ["neutrophil extracellular", "ANATOMY", 110, 134], ["neutrophils", "ANATOMY", 217, 228], ["oxygen", "CHEMICAL", 85, 91], ["ROS", "CHEMICAL", 101, 104], ["oxygen", "CHEMICAL", 85, 91], ["neutrophil", "CELL", 30, 40], ["reactive oxygen species", "SIMPLE_CHEMICAL", 76, 99], ["ROS", "SIMPLE_CHEMICAL", 101, 104], ["neutrophil extracellular traps", "GENE_OR_GENE_PRODUCT", 110, 140], ["neutrophils", "CELL", 217, 228], ["neutrophils", "CELL_TYPE", 217, 228], ["elevated neutrophil level", "PROBLEM", 21, 46], ["increased reactive oxygen species", "PROBLEM", 66, 99], ["neutrophil extracellular traps", "TEST", 110, 140], ["neutrophils", "TEST", 217, 228], ["elevated", "OBSERVATION_MODIFIER", 21, 29], ["neutrophil", "OBSERVATION", 30, 40], ["associated with", "UNCERTAINTY", 50, 65], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["reactive", "OBSERVATION_MODIFIER", 76, 84], ["oxygen species", "OBSERVATION", 85, 99]]], ["Inappropriate levels of these neutrophil-derived products could contribute to the development of the \"cytokine storm\" initiated by the lung-infiltrating macrophages, and then to the partial destruction of lung tissues (Figure 1) (2, 48) .What of the Cell-Innate Immunity?Mucosal-associated invariant T (MAIT) cells represent a population of innate T cells.", [["neutrophil", "ANATOMY", 30, 40], ["lung-infiltrating macrophages", "ANATOMY", 135, 164], ["lung tissues", "ANATOMY", 205, 217], ["Cell", "ANATOMY", 250, 254], ["Mucosal", "ANATOMY", 271, 278], ["invariant T (MAIT) cells", "ANATOMY", 290, 314], ["T cells", "ANATOMY", 348, 355], ["neutrophil", "CELL", 30, 40], ["lung-infiltrating macrophages", "CELL", 135, 164], ["lung tissues", "TISSUE", 205, 217], ["Cell", "CELL", 250, 254], ["Mucosal-associated invariant T", "GENE_OR_GENE_PRODUCT", 271, 301], ["innate T cells", "CELL", 341, 355], ["neutrophil", "CELL_TYPE", 30, 40], ["cytokine", "PROTEIN", 102, 110], ["lung-infiltrating macrophages", "CELL_TYPE", 135, 164], ["Mucosal-associated invariant T (MAIT) cells", "CELL_TYPE", 271, 314], ["innate T cells", "CELL_TYPE", 341, 355], ["these neutrophil-derived products", "TREATMENT", 24, 57], ["the \"cytokine storm", "PROBLEM", 97, 116], ["infiltrating macrophages", "PROBLEM", 140, 164], ["the partial destruction of lung tissues", "PROBLEM", 178, 217], ["Mucosal-associated invariant T (MAIT) cells", "PROBLEM", 271, 314], ["lung", "ANATOMY", 135, 139], ["infiltrating macrophages", "OBSERVATION", 140, 164], ["partial", "OBSERVATION_MODIFIER", 182, 189], ["destruction", "OBSERVATION", 190, 201], ["lung tissues", "ANATOMY", 205, 217], ["population", "OBSERVATION_MODIFIER", 327, 337], ["innate T cells", "OBSERVATION", 341, 355]]], ["They recognize metabolites that are presented by the major histocompatibility complex (MHC) class I-related protein MR1.", [["MR1", "GENE_OR_GENE_PRODUCT", 116, 119], ["major histocompatibility complex (MHC) class I-related protein", "PROTEIN", 53, 115], ["MR1", "PROTEIN", 116, 119], ["protein MR1", "PROBLEM", 108, 119]]], ["Potential effectors of MAIT cell antimicrobial activity include the secretion of TNF-\u03b1, IFN-\u03b3, IL-17A, and IL-22 as well as granzyme B and perforin (49, 50) .", [["MAIT cell", "ANATOMY", 23, 32], ["MAIT cell", "CELL", 23, 32], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 81, 86], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 88, 93], ["IL-17A", "GENE_OR_GENE_PRODUCT", 95, 101], ["IL-22", "GENE_OR_GENE_PRODUCT", 107, 112], ["granzyme B", "GENE_OR_GENE_PRODUCT", 124, 134], ["perforin", "GENE_OR_GENE_PRODUCT", 139, 147], ["TNF", "PROTEIN", 81, 84], ["IFN", "PROTEIN", 88, 91], ["IL", "PROTEIN", 95, 97], ["IL-22", "PROTEIN", 107, 112], ["granzyme B", "PROTEIN", 124, 134], ["perforin", "PROTEIN", 139, 147], ["MAIT cell antimicrobial activity", "TREATMENT", 23, 55], ["TNF", "TEST", 81, 84], ["IFN", "TREATMENT", 88, 91], ["IL", "TEST", 95, 97], ["IL", "TEST", 107, 109], ["MAIT cell antimicrobial activity", "OBSERVATION", 23, 55]]], ["Changes in MAIT cell frequencies have been reported in several viral infections; for example, higher cell numbers were found in survivors infected by H7N9 influenza, compared to samples from fatalities (51) .", [["MAIT cell", "ANATOMY", 11, 20], ["cell", "ANATOMY", 101, 105], ["samples", "ANATOMY", 178, 185], ["viral infections", "DISEASE", 63, 79], ["influenza", "DISEASE", 155, 164], ["fatalities", "DISEASE", 191, 201], ["MAIT cell", "CELL", 11, 20], ["cell", "CELL", 101, 105], ["H7N9 influenza", "ORGANISM", 150, 164], ["MAIT", "PROTEIN", 11, 15], ["H7N9", "SPECIES", 150, 154], ["Changes in MAIT cell frequencies", "PROBLEM", 0, 32], ["several viral infections", "PROBLEM", 55, 79], ["higher cell numbers", "PROBLEM", 94, 113], ["H7N9 influenza", "PROBLEM", 150, 164], ["MAIT cell frequencies", "OBSERVATION", 11, 32], ["several", "OBSERVATION_MODIFIER", 55, 62], ["viral", "OBSERVATION_MODIFIER", 63, 68], ["infections", "OBSERVATION", 69, 79]]], ["Consistently, in vitro coculture of primary peripheral blood mononuclear cells and H7N9-infected A549 airway epithelial cells was associated with increased intracellular IFN-\u03b3 and granzyme B levels in MAIT cells (51) .", [["peripheral blood mononuclear cells", "ANATOMY", 44, 78], ["A549 airway epithelial cells", "ANATOMY", 97, 125], ["intracellular", "ANATOMY", 156, 169], ["MAIT cells", "ANATOMY", 201, 211], ["peripheral blood mononuclear cells", "CELL", 44, 78], ["H7N9", "CELL", 83, 87], ["A549 airway epithelial cells", "CELL", 97, 125], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 156, 169], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 170, 175], ["granzyme B", "GENE_OR_GENE_PRODUCT", 180, 190], ["MAIT cells", "CELL", 201, 211], ["primary peripheral blood mononuclear cells", "CELL_TYPE", 36, 78], ["H7N9-infected A549 airway epithelial cells", "CELL_LINE", 83, 125], ["IFN", "PROTEIN", 170, 173], ["granzyme B", "PROTEIN", 180, 190], ["MAIT cells", "CELL_LINE", 201, 211], ["primary peripheral blood mononuclear cells", "PROBLEM", 36, 78], ["H7N9", "PROBLEM", 83, 87], ["infected A549 airway epithelial cells", "PROBLEM", 88, 125], ["increased intracellular IFN", "PROBLEM", 146, 173], ["granzyme B levels", "TEST", 180, 197], ["MAIT cells", "TEST", 201, 211], ["peripheral", "ANATOMY_MODIFIER", 44, 54], ["blood", "ANATOMY", 55, 60], ["mononuclear cells", "OBSERVATION", 61, 78], ["infected", "OBSERVATION_MODIFIER", 88, 96], ["A549 airway epithelial cells", "OBSERVATION", 97, 125], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["intracellular IFN", "OBSERVATION", 156, 173], ["MAIT cells", "OBSERVATION", 201, 211]]], ["Very recent preliminary data also suggested a very significant decrease of MAIT cells in COVID-19 + patients; expression of the CD69 activation marker on blood MAIT cells at inclusion was predictive of COVID-19 severity (52) .What of the Cell-Innate Immunity?Natural killer (NK) cells are another key element of innate immunity (53) .", [["MAIT cells", "ANATOMY", 75, 85], ["blood MAIT cells", "ANATOMY", 154, 170], ["Cell", "ANATOMY", 238, 242], ["Natural killer (NK) cells", "ANATOMY", 259, 284], ["MAIT cells", "CELL", 75, 85], ["COVID-19", "CELL", 89, 97], ["patients", "ORGANISM", 100, 108], ["CD69", "GENE_OR_GENE_PRODUCT", 128, 132], ["blood MAIT cells", "CELL", 154, 170], ["Cell", "CELL", 238, 242], ["Natural killer (NK) cells", "CELL", 259, 284], ["MAIT cells", "CELL_LINE", 75, 85], ["CD69", "PROTEIN", 128, 132], ["blood MAIT cells", "CELL_TYPE", 154, 170], ["Natural killer (NK) cells", "CELL_TYPE", 259, 284], ["patients", "SPECIES", 100, 108], ["a very significant decrease of MAIT cells", "PROBLEM", 44, 85], ["COVID", "TEST", 89, 94], ["the CD69 activation marker", "TEST", 124, 150], ["blood MAIT cells", "TEST", 154, 170], ["COVID", "TEST", 202, 207], ["Natural killer (NK) cells", "TREATMENT", 259, 284], ["very", "OBSERVATION_MODIFIER", 46, 50], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["decrease", "OBSERVATION_MODIFIER", 63, 71], ["MAIT cells", "OBSERVATION", 75, 85]]], ["It was rapidly determined that in COVID-19 patients, the total number of NK cells is markedly decreased (54) , as previously reported for the SARS (55) .", [["NK cells", "ANATOMY", 73, 81], ["SARS", "DISEASE", 142, 146], ["patients", "ORGANISM", 43, 51], ["NK cells", "CELL", 73, 81], ["NK cells", "CELL_TYPE", 73, 81], ["patients", "SPECIES", 43, 51], ["COVID", "TEST", 34, 39], ["NK cells", "TEST", 73, 81], ["the SARS", "TEST", 138, 146], ["NK cells", "OBSERVATION", 73, 81], ["markedly", "OBSERVATION_MODIFIER", 85, 93], ["decreased", "OBSERVATION_MODIFIER", 94, 103]]], ["NK cells express a variety of receptors that transduce either activating or inhibitory signals.", [["NK cells", "ANATOMY", 0, 8], ["NK cells", "CELL", 0, 8], ["NK cells", "CELL_TYPE", 0, 8]]], ["Integration of these signals regulates the effector functions of NK cells, including cytotoxic activity and cytokine secretion (53, 56) .", [["NK cells", "ANATOMY", 65, 73], ["NK cells", "CELL", 65, 73], ["NK cells", "CELL_TYPE", 65, 73], ["cytokine", "PROTEIN", 108, 116], ["NK cells", "PROBLEM", 65, 73], ["cytotoxic activity", "TEST", 85, 103], ["cytokine secretion", "TEST", 108, 126], ["NK cells", "OBSERVATION", 65, 73], ["cytotoxic activity", "OBSERVATION", 85, 103]]], ["In patients infected with SARS-CoV-2, NKG2A expression was significantly increased on NK cells (54) .", [["NK cells", "ANATOMY", 86, 94], ["SARS", "DISEASE", 26, 30], ["patients", "ORGANISM", 3, 11], ["SARS-CoV-2", "ORGANISM", 26, 36], ["NKG2A", "GENE_OR_GENE_PRODUCT", 38, 43], ["NK cells", "CELL", 86, 94], ["NKG2A", "PROTEIN", 38, 43], ["NK cells", "CELL_TYPE", 86, 94], ["patients", "SPECIES", 3, 11], ["SARS-CoV", "SPECIES", 26, 34], ["SARS-CoV", "TEST", 26, 34], ["NKG2A expression", "TEST", 38, 54], ["NK cells", "TEST", 86, 94], ["infected", "OBSERVATION", 12, 20], ["increased", "OBSERVATION_MODIFIER", 73, 82]]], ["The CD94/NK group 2 member A (NKG2A) heterodimeric receptor is one of the most prominent NK inhibitory receptors.", [["NK", "ANATOMY", 89, 91], ["CD94", "GENE_OR_GENE_PRODUCT", 4, 8], ["NK group 2 member A", "GENE_OR_GENE_PRODUCT", 9, 28], ["NKG2A", "GENE_OR_GENE_PRODUCT", 30, 35], ["NK", "CELL", 89, 91], ["CD94", "PROTEIN", 4, 8], ["NK group 2 member A (NKG2A) heterodimeric receptor", "PROTEIN", 9, 59], ["NK inhibitory receptors", "PROTEIN", 89, 112], ["A (NKG2A) heterodimeric receptor", "TREATMENT", 27, 59], ["most prominent", "OBSERVATION_MODIFIER", 74, 88], ["NK", "OBSERVATION", 89, 91]]], ["It binds to a non-classical minimally polymorphic HLA class I molecule (HLA-E), which presents peptides derived from leader peptide sequences of other HLA class I molecules (57) .", [["HLA class I molecule", "GENE_OR_GENE_PRODUCT", 50, 70], ["HLA-E", "GENE_OR_GENE_PRODUCT", 72, 77], ["non-classical minimally polymorphic HLA class I molecule", "PROTEIN", 14, 70], ["HLA", "PROTEIN", 72, 75], ["HLA class I molecules", "PROTEIN", 151, 172]]], ["Upon ligation by peptide-loaded HLA-E, NKG2A transduces inhibitory signaling through 2 inhibitory immune-receptor tyrosine-based inhibition motifs, thus suppressing NK cytokine secretion and cytotoxicity (58) .", [["NK", "ANATOMY", 165, 167], ["tyrosine", "CHEMICAL", 114, 122], ["tyrosine", "CHEMICAL", 114, 122], ["HLA-E", "GENE_OR_GENE_PRODUCT", 32, 37], ["NKG2A", "GENE_OR_GENE_PRODUCT", 39, 44], ["tyrosine", "AMINO_ACID", 114, 122], ["NK", "CELL", 165, 167], ["NKG2A", "PROTEIN", 39, 44], ["cytokine", "PROTEIN", 168, 176], ["ligation", "TREATMENT", 5, 13], ["peptide-loaded HLA-E", "TREATMENT", 17, 37], ["NKG2A transduces inhibitory", "TREATMENT", 39, 66], ["receptor tyrosine-based inhibition motifs", "TREATMENT", 105, 146], ["NK cytokine secretion", "TEST", 165, 186], ["cytotoxicity", "TEST", 191, 203], ["ligation", "OBSERVATION", 5, 13]]], ["A clinical trial is ongoing in the presence of anti-NKG2A (Monalizumab) in Patients with advanced or metastatic cancer infected by SARS-CoV-2 (ClinicalTrials.gov Identifier: NCT04333914).", [["metastatic cancer", "ANATOMY", 101, 118], ["anti-NKG2A", "CHEMICAL", 47, 57], ["Monalizumab", "CHEMICAL", 59, 70], ["cancer infected", "DISEASE", 112, 127], ["SARS", "DISEASE", 131, 135], ["anti-NKG2A", "CHEMICAL", 47, 57], ["Monalizumab", "CHEMICAL", 59, 70], ["anti-NKG2A", "GENE_OR_GENE_PRODUCT", 47, 57], ["Monalizumab", "SIMPLE_CHEMICAL", 59, 70], ["Patients", "ORGANISM", 75, 83], ["metastatic cancer", "CANCER", 101, 118], ["Patients", "SPECIES", 75, 83], ["SARS-CoV", "SPECIES", 131, 139], ["anti-NKG2A (Monalizumab)", "TREATMENT", 47, 71], ["advanced or metastatic cancer", "PROBLEM", 89, 118], ["metastatic", "OBSERVATION_MODIFIER", 101, 111], ["cancer", "OBSERVATION", 112, 118]]], ["However, more extensive phenotypic studies of NK cells will be necessary to determine the role of other cell markers and to measure their impact in disease evolution better.", [["NK cells", "ANATOMY", 46, 54], ["cell", "ANATOMY", 104, 108], ["NK cells", "CELL", 46, 54], ["cell", "CELL", 104, 108], ["NK cells", "CELL_TYPE", 46, 54], ["NK cells", "PROBLEM", 46, 54], ["other cell markers", "TEST", 98, 116], ["disease", "OBSERVATION", 148, 155]]], ["Consistent with increased NKG2A levels on NK cells from COVID-19 patients, low polyfunctional capacities were reported (54) .", [["NK cells", "ANATOMY", 42, 50], ["NKG2A", "GENE_OR_GENE_PRODUCT", 26, 31], ["NK cells", "CELL", 42, 50], ["COVID-19", "CELL", 56, 64], ["patients", "ORGANISM", 65, 73], ["NKG2A", "PROTEIN", 26, 31], ["NK cells", "CELL_TYPE", 42, 50], ["patients", "SPECIES", 65, 73], ["increased NKG2A levels", "PROBLEM", 16, 38], ["NK cells", "TEST", 42, 50], ["COVID", "TEST", 56, 61], ["low polyfunctional capacities", "PROBLEM", 75, 104], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["NKG2A levels", "OBSERVATION", 26, 38], ["low", "OBSERVATION_MODIFIER", 75, 78], ["polyfunctional capacities", "OBSERVATION", 79, 104]]], ["Hence, SARS-CoV-2 may break down antiviral immunity mediated by NK cells at an early stage of infection, with putative consequences for the development of an efficient adaptive immunity.", [["NK cells", "ANATOMY", 64, 72], ["infection", "DISEASE", 94, 103], ["SARS-CoV-2", "ORGANISM", 7, 17], ["NK cells", "CELL", 64, 72], ["NK cells", "CELL_TYPE", 64, 72], ["SARS-CoV", "SPECIES", 7, 15], ["SARS", "PROBLEM", 7, 11], ["CoV", "TEST", 12, 15], ["antiviral immunity", "TREATMENT", 33, 51], ["NK cells", "PROBLEM", 64, 72], ["infection", "PROBLEM", 94, 103], ["early stage", "OBSERVATION_MODIFIER", 79, 90], ["infection", "OBSERVATION", 94, 103]]], ["To increase NK-cell capability, a phase I clinical trial is ongoing to evaluate the safety and efficiency of allogenic NK-cell transfer in combination with standard therapy for 30 pneumonia patients infected with SARS-CoV-2 (ClinicalTrials.gov identifier: NCT04280224).What of the Cell-Innate Immunity?In other infectious situations, such as dengue virus infection, activation of NK cells by antibodies (Abs) can enhance controlled antibody-dependent enhancement (ADE) process (Figure 1) , which occurs when Abs specific to a viral determinant facilitate secondary infection.", [["NK-cell", "ANATOMY", 12, 19], ["NK-cell", "ANATOMY", 119, 126], ["Cell", "ANATOMY", 281, 285], ["NK cells", "ANATOMY", 380, 388], ["pneumonia", "DISEASE", 180, 189], ["SARS", "DISEASE", 213, 217], ["dengue virus infection", "DISEASE", 342, 364], ["infection", "DISEASE", 565, 574], ["NK-cell", "CELL", 12, 19], ["allogenic NK-cell", "CELL", 109, 126], ["patients", "ORGANISM", 190, 198], ["Cell", "CELL", 281, 285], ["dengue virus", "ORGANISM", 342, 354], ["NK cells", "CELL", 380, 388], ["NK cells", "CELL_TYPE", 380, 388], ["antibodies", "PROTEIN", 392, 402], ["Abs", "PROTEIN", 404, 407], ["Abs", "PROTEIN", 508, 511], ["patients", "SPECIES", 190, 198], ["dengue virus", "SPECIES", 342, 354], ["SARS-CoV", "SPECIES", 213, 221], ["dengue virus", "SPECIES", 342, 354], ["NK-cell capability", "TREATMENT", 12, 30], ["allogenic NK-cell transfer", "TREATMENT", 109, 135], ["standard therapy", "TREATMENT", 156, 172], ["30 pneumonia", "PROBLEM", 177, 189], ["SARS", "PROBLEM", 213, 217], ["other infectious situations", "PROBLEM", 305, 332], ["dengue virus infection", "PROBLEM", 342, 364], ["NK cells", "PROBLEM", 380, 388], ["antibodies (Abs", "TEST", 392, 407], ["controlled antibody-dependent enhancement", "PROBLEM", 421, 462], ["secondary infection", "PROBLEM", 555, 574], ["cell capability", "OBSERVATION", 15, 30], ["pneumonia", "OBSERVATION", 180, 189], ["infectious", "OBSERVATION", 311, 321], ["NK cells", "OBSERVATION", 380, 388], ["dependent enhancement", "OBSERVATION_MODIFIER", 441, 462], ["secondary", "OBSERVATION_MODIFIER", 555, 564], ["infection", "OBSERVATION", 565, 574]]], ["Interestingly, it was shown previously that sera from SARS-CoV infected patients enhance viral entry into Fc receptor-expressing cells (59, 60) .", [["sera", "ANATOMY", 44, 48], ["cells", "ANATOMY", 129, 134], ["SARS-CoV infected", "DISEASE", 54, 71], ["sera", "ORGANISM_SUBSTANCE", 44, 48], ["SARS-CoV", "ORGANISM", 54, 62], ["patients", "ORGANISM", 72, 80], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 106, 117], ["cells", "CELL", 129, 134], ["Fc receptor", "PROTEIN", 106, 117], ["expressing cells", "CELL_TYPE", 118, 134], ["patients", "SPECIES", 72, 80], ["SARS-CoV", "SPECIES", 54, 62], ["SARS", "PROBLEM", 54, 58]]], ["This mechanism should be extensively studied in a COVID-19 context to guide the development of future vaccine and antibody-based drug therapy.What of the Cell-Innate Immunity?Together, the preliminary data on COVID-19 patients suggest that SARS-CoV-2 could use different strategies to evade and/or antagonize different arms of the innate immune system.What of the Cell-Adaptive Immunity?Severe lymphopenia was observed until death in non-survivor patients with COVID-19 (12) .", [["Cell", "ANATOMY", 154, 158], ["Cell", "ANATOMY", 364, 368], ["SARS", "DISEASE", 240, 244], ["lymphopenia", "DISEASE", 394, 405], ["death", "DISEASE", 425, 430], ["COVID-19", "CHEMICAL", 461, 469], ["COVID-19", "CHEMICAL", 461, 469], ["Cell", "CELL", 154, 158], ["COVID-19", "ORGANISM", 209, 217], ["patients", "ORGANISM", 218, 226], ["SARS-CoV-2", "ORGANISM", 240, 250], ["immune system", "ANATOMICAL_SYSTEM", 338, 351], ["Cell", "CELL", 364, 368], ["patients", "ORGANISM", 447, 455], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 447, 455], ["future vaccine", "TREATMENT", 95, 109], ["antibody-based drug therapy", "TREATMENT", 114, 141], ["COVID", "TEST", 209, 214], ["SARS", "PROBLEM", 240, 244], ["different strategies", "TREATMENT", 261, 281], ["Severe lymphopenia", "PROBLEM", 387, 405], ["COVID", "TEST", 461, 466], ["lymphopenia", "OBSERVATION", 394, 405]]], ["Consistently, the acute phase of SARS in human patients was associated with marked leukopenia in up to 80% of hospitalized patients, associated with a dramatic loss of CD4 and CD8 T cells (61, 62) .", [["CD4", "ANATOMY", 168, 171], ["CD8 T cells", "ANATOMY", 176, 187], ["SARS", "DISEASE", 33, 37], ["leukopenia", "DISEASE", 83, 93], ["human", "ORGANISM", 41, 46], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 123, 131], ["CD4", "GENE_OR_GENE_PRODUCT", 168, 171], ["CD8", "GENE_OR_GENE_PRODUCT", 176, 179], ["CD4", "PROTEIN", 168, 171], ["CD8 T cells", "CELL_TYPE", 176, 187], ["human", "SPECIES", 41, 46], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 123, 131], ["human", "SPECIES", 41, 46], ["SARS", "PROBLEM", 33, 37], ["marked leukopenia", "PROBLEM", 76, 93], ["a dramatic loss of CD4 and CD8 T cells", "PROBLEM", 149, 187], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["phase", "OBSERVATION_MODIFIER", 24, 29], ["SARS", "OBSERVATION", 33, 37], ["marked", "OBSERVATION_MODIFIER", 76, 82], ["leukopenia", "OBSERVATION", 83, 93], ["dramatic", "OBSERVATION_MODIFIER", 151, 159]]], ["In SARS-CoV-infected patients, it was shown that infection of T lymphocytes directly contributes to lymphopenia and atrophy of the spleen and lymphoid tissue (63) .", [["T lymphocytes", "ANATOMY", 62, 75], ["spleen", "ANATOMY", 131, 137], ["lymphoid tissue", "ANATOMY", 142, 157], ["SARS-CoV-infected", "DISEASE", 3, 20], ["infection", "DISEASE", 49, 58], ["lymphopenia", "DISEASE", 100, 111], ["atrophy", "DISEASE", 116, 123], ["SARS-CoV", "ORGANISM", 3, 11], ["patients", "ORGANISM", 21, 29], ["T lymphocytes", "CELL", 62, 75], ["spleen", "ORGAN", 131, 137], ["lymphoid tissue", "TISSUE", 142, 157], ["T lymphocytes", "CELL_TYPE", 62, 75], ["patients", "SPECIES", 21, 29], ["SARS-CoV", "SPECIES", 3, 11], ["SARS", "PROBLEM", 3, 7], ["infection of T lymphocytes", "PROBLEM", 49, 75], ["lymphopenia", "PROBLEM", 100, 111], ["atrophy of the spleen and lymphoid tissue", "PROBLEM", 116, 157], ["infected", "OBSERVATION", 12, 20], ["infection", "OBSERVATION", 49, 58], ["lymphopenia", "OBSERVATION", 100, 111], ["atrophy", "OBSERVATION", 116, 123], ["spleen", "ANATOMY", 131, 137], ["lymphoid tissue", "OBSERVATION", 142, 157]]], ["Lymphopenia is also observed in MERS patients, albeit to a lesser degree than in SARS patients (64) .", [["Lymphopenia", "DISEASE", 0, 11], ["SARS", "DISEASE", 81, 85], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 86, 94], ["Lymphopenia", "PROBLEM", 0, 11], ["lesser degree", "OBSERVATION_MODIFIER", 59, 72]]], ["Understanding the mechanism of lymphopenia could open the way to the development of a new strategy for the treatment of COVID-19.", [["lymphopenia", "DISEASE", 31, 42], ["COVID-19", "CHEMICAL", 120, 128], ["lymphopenia", "PROBLEM", 31, 42], ["COVID", "TEST", 120, 125], ["lymphopenia", "OBSERVATION", 31, 42]]], ["Several potential mechanisms could be considered: (i) The virus might directly infect lymphocytes, resulting in lymphocyte death, as recently reported by Wang et al. (65) for the SARS-CoV-1. (ii) The virus can damage different target organs, such as bone marrow and thymus, which can no longer function normally. (iii) Inflammatory cytokines are massively produced, perhaps leading to lymphocyte apoptosis. (iv) Lymphocytes are trapped in infected tissues (Figure 1) .", [["lymphocytes", "ANATOMY", 86, 97], ["lymphocyte", "ANATOMY", 112, 122], ["organs", "ANATOMY", 234, 240], ["bone marrow", "ANATOMY", 250, 261], ["thymus", "ANATOMY", 266, 272], ["lymphocyte", "ANATOMY", 385, 395], ["Lymphocytes", "ANATOMY", 412, 423], ["tissues", "ANATOMY", 448, 455], ["death", "DISEASE", 123, 128], ["SARS", "DISEASE", 179, 183], ["lymphocytes", "CELL", 86, 97], ["lymphocyte", "CELL", 112, 122], ["SARS-CoV-1", "ORGANISM", 179, 189], ["organs", "ORGAN", 234, 240], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 250, 261], ["thymus", "ORGAN", 266, 272], ["lymphocyte", "CELL", 385, 395], ["Lymphocytes", "CELL", 412, 423], ["tissues", "TISSUE", 448, 455], ["lymphocytes", "CELL_TYPE", 86, 97], ["Inflammatory cytokines", "PROTEIN", 319, 341], ["Lymphocytes", "CELL_TYPE", 412, 423], ["SARS-CoV-1", "SPECIES", 179, 189], ["The virus", "PROBLEM", 54, 63], ["lymphocyte death", "PROBLEM", 112, 128], ["the SARS", "TEST", 175, 183], ["CoV", "TEST", 184, 187], ["The virus", "PROBLEM", 196, 205], ["Inflammatory cytokines", "PROBLEM", 319, 341], ["lymphocyte apoptosis", "PROBLEM", 385, 405], ["Lymphocytes", "PROBLEM", 412, 423], ["infected tissues", "PROBLEM", 439, 455], ["infect lymphocytes", "OBSERVATION", 79, 97], ["lymphocyte death", "OBSERVATION", 112, 128], ["bone marrow", "ANATOMY", 250, 261], ["thymus", "ANATOMY", 266, 272], ["Inflammatory", "OBSERVATION_MODIFIER", 319, 331], ["cytokines", "OBSERVATION", 332, 341], ["perhaps leading to", "UNCERTAINTY", 366, 384], ["lymphocyte apoptosis", "OBSERVATION", 385, 405], ["Lymphocytes", "ANATOMY", 412, 423], ["infected tissues", "OBSERVATION", 439, 455]]], ["Importantly, the loss of lymphocytes was transient; CD8 + T lymphocytes and memory CD4 + T cells of SARS patients returned to normal within 2-3 and 12 months after infection, whereas other CD4 + T cell subsets were still lower than in healthy controls (66) .What of the Cell-Adaptive Immunity?The first study on patients with COVID-19 revealed that low levels of IFN-\u03b3 and TNF-\u03b1 in CD4 + T cells are associated with severity.", [["lymphocytes", "ANATOMY", 25, 36], ["CD8 + T lymphocytes", "ANATOMY", 52, 71], ["memory CD4 + T cells", "ANATOMY", 76, 96], ["CD4 + T cell", "ANATOMY", 189, 201], ["Cell", "ANATOMY", 270, 274], ["CD4 + T cells", "ANATOMY", 382, 395], ["SARS", "DISEASE", 100, 104], ["infection", "DISEASE", 164, 173], ["lymphocytes", "CELL", 25, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 52, 55], ["patients", "ORGANISM", 105, 113], ["CD4", "GENE_OR_GENE_PRODUCT", 189, 192], ["Cell", "CELL", 270, 274], ["patients", "ORGANISM", 312, 320], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 363, 368], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 373, 378], ["CD4", "GENE_OR_GENE_PRODUCT", 382, 385], ["lymphocytes", "CELL_TYPE", 25, 36], ["CD8", "PROTEIN", 52, 55], ["T lymphocytes", "CELL_TYPE", 58, 71], ["memory CD4 + T cells", "CELL_TYPE", 76, 96], ["CD4", "PROTEIN", 189, 192], ["T cell subsets", "CELL_TYPE", 195, 209], ["IFN", "PROTEIN", 363, 366], ["TNF-\u03b1", "PROTEIN", 373, 378], ["CD4 + T cells", "CELL_TYPE", 382, 395], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 312, 320], ["the loss of lymphocytes", "PROBLEM", 13, 36], ["transient", "PROBLEM", 41, 50], ["CD8", "TEST", 52, 55], ["lymphocytes", "TEST", 60, 71], ["memory CD4", "TEST", 76, 86], ["SARS", "PROBLEM", 100, 104], ["infection", "PROBLEM", 164, 173], ["other CD4", "TEST", 183, 192], ["T cell subsets", "TEST", 195, 209], ["The first study", "TEST", 293, 308], ["COVID", "TEST", 326, 331], ["low levels", "PROBLEM", 349, 359], ["IFN", "TEST", 363, 366], ["TNF", "TEST", 373, 376], ["CD4", "TEST", 382, 385], ["T cells", "PROBLEM", 388, 395], ["severity", "PROBLEM", 416, 424], ["loss", "OBSERVATION_MODIFIER", 17, 21], ["lymphocytes", "ANATOMY", 25, 36], ["infection", "OBSERVATION", 164, 173], ["cell subsets", "OBSERVATION", 197, 209], ["low levels", "OBSERVATION_MODIFIER", 349, 359]]], ["Consistently, in CD8 + T cells, the frequency of the exhausted (PD-1 + CTLA-4 + TIGIT + ) subset was significantly higher in the severe group (67) .", [["CD8 + T cells", "ANATOMY", 17, 30], ["PD-1 + CTLA-4 + TIGIT +", "ANATOMY", 64, 87], ["CD8", "GENE_OR_GENE_PRODUCT", 17, 20], ["PD-1", "GENE_OR_GENE_PRODUCT", 64, 68], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 71, 77], ["CD8 + T cells", "CELL_TYPE", 17, 30], ["TIGIT", "PROTEIN", 80, 85], ["PD", "TEST", 64, 66], ["CTLA", "TEST", 71, 75], ["TIGIT", "TEST", 80, 85], ["higher", "OBSERVATION_MODIFIER", 115, 121], ["severe", "OBSERVATION_MODIFIER", 129, 135]]], ["Consequently, the no (low) functionality of CD8 + T cells in severe patients could impact an efficient control of infection (67), as previously described in SARS-CoV infection (68) .", [["CD8 + T cells", "ANATOMY", 44, 57], ["infection", "DISEASE", 114, 123], ["SARS-CoV infection", "DISEASE", 157, 175], ["CD8", "GENE_OR_GENE_PRODUCT", 44, 47], ["patients", "ORGANISM", 68, 76], ["SARS-CoV", "ORGANISM", 157, 165], ["CD8 + T cells", "CELL_TYPE", 44, 57], ["patients", "SPECIES", 68, 76], ["SARS-CoV", "SPECIES", 157, 165], ["T cells", "PROBLEM", 50, 57], ["infection", "PROBLEM", 114, 123], ["SARS", "PROBLEM", 157, 161], ["CoV infection", "PROBLEM", 162, 175], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["infection", "OBSERVATION", 114, 123], ["CoV", "OBSERVATION_MODIFIER", 162, 165], ["infection", "OBSERVATION", 166, 175]]], ["Furthermore, COVID-19 was associated with a significant decrease of T cell activation, determined by CD25, CD28, and CD69 expression on CD4 + and CD8 + T cell subsets (68) .", [["T cell", "ANATOMY", 68, 74], ["CD4 + and CD8 + T cell", "ANATOMY", 136, 158], ["COVID-19", "GENE_OR_GENE_PRODUCT", 13, 21], ["T cell", "CELL", 68, 74], ["CD25", "GENE_OR_GENE_PRODUCT", 101, 105], ["CD28", "GENE_OR_GENE_PRODUCT", 107, 111], ["CD69", "GENE_OR_GENE_PRODUCT", 117, 121], ["CD4", "GENE_OR_GENE_PRODUCT", 136, 139], ["CD8", "GENE_OR_GENE_PRODUCT", 146, 149], ["COVID-19", "DNA", 13, 21], ["CD25", "PROTEIN", 101, 105], ["CD28", "PROTEIN", 107, 111], ["CD69", "PROTEIN", 117, 121], ["CD4", "PROTEIN", 136, 139], ["CD8", "PROTEIN", 146, 149], ["COVID", "TEST", 13, 18], ["a significant decrease of T cell activation", "PROBLEM", 42, 85], ["CD25", "TEST", 101, 105], ["CD28", "TEST", 107, 111], ["CD69 expression", "TEST", 117, 132], ["CD4", "TEST", 136, 139], ["CD8", "TEST", 146, 149], ["T cell subsets", "TEST", 152, 166], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["decrease", "OBSERVATION_MODIFIER", 56, 64], ["T cell activation", "OBSERVATION", 68, 85]]], ["Despite a wave of information on the specific T cell responses to many other pathogens, less is known about respiratory CoV infections.", [["T cell", "ANATOMY", 46, 52], ["respiratory CoV infections", "DISEASE", 108, 134], ["T cell", "CELL", 46, 52], ["respiratory CoV", "ORGANISM", 108, 123], ["respiratory CoV", "SPECIES", 108, 123], ["many other pathogens", "PROBLEM", 66, 86], ["respiratory CoV infections", "PROBLEM", 108, 134], ["CoV infections", "OBSERVATION", 120, 134]]], ["CD8 + T cells are typically required for the control of influenza virus and other respiratory viruses (68) .", [["CD8 + T cells", "ANATOMY", 0, 13], ["influenza virus", "DISEASE", 56, 71], ["respiratory viruses", "DISEASE", 82, 101], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["influenza virus", "ORGANISM", 56, 71], ["CD8", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 6, 13], ["influenza virus", "SPECIES", 56, 71], ["influenza virus", "SPECIES", 56, 71], ["CD8", "TEST", 0, 3], ["T cells", "PROBLEM", 6, 13], ["influenza virus", "PROBLEM", 56, 71], ["other respiratory viruses", "PROBLEM", 76, 101], ["T cells", "OBSERVATION", 6, 13], ["influenza", "OBSERVATION", 56, 65], ["respiratory viruses", "OBSERVATION", 82, 101]]], ["Furthermore, T resident memory cells (TRM) are critical in preventing re-infection from influenza virus (69) .", [["T resident memory cells", "ANATOMY", 13, 36], ["TRM", "ANATOMY", 38, 41], ["influenza", "DISEASE", 88, 97], ["T resident memory cells", "CELL", 13, 36], ["TRM", "CELL", 38, 41], ["influenza virus", "ORGANISM", 88, 103], ["T resident memory cells", "CELL_TYPE", 13, 36], ["TRM", "CELL_TYPE", 38, 41], ["influenza virus", "SPECIES", 88, 103], ["re-infection", "PROBLEM", 70, 82], ["influenza virus", "PROBLEM", 88, 103], ["re-infection", "OBSERVATION", 70, 82]]], ["Their role in SARS-Co-V2 infection should be, however, more finely determined.", [["SARS", "DISEASE", 14, 18], ["infection", "DISEASE", 25, 34], ["Co-V2", "GENE_OR_GENE_PRODUCT", 19, 24], ["SARS", "PROBLEM", 14, 18], ["Co-V2 infection", "PROBLEM", 19, 34], ["SARS", "OBSERVATION", 14, 18], ["infection", "OBSERVATION", 25, 34]]], ["In senescent mice infected by SARS-CoV, CD8 + CTLs alone are not sufficient to clear the virus in the absence of both CD4 + T cells and specific Abs (70) .What of the Cell-Adaptive Immunity?On the other hand, depletion of CD4 + T cells in SARSinfected patients reduced production of neutralizing Abs and Th1 cytokines and induced lower recruitment of inflammatory monocytes in the lung.", [["CD8 + CTLs", "ANATOMY", 40, 50], ["CD4 + T cells", "ANATOMY", 118, 131], ["Cell", "ANATOMY", 167, 171], ["CD4 + T cells", "ANATOMY", 222, 235], ["inflammatory monocytes", "ANATOMY", 351, 373], ["lung", "ANATOMY", 381, 385], ["mice", "ORGANISM", 13, 17], ["SARS-CoV", "ORGANISM", 30, 38], ["CD8", "GENE_OR_GENE_PRODUCT", 40, 43], ["CD4", "GENE_OR_GENE_PRODUCT", 118, 121], ["Cell", "CELL", 167, 171], ["CD4", "GENE_OR_GENE_PRODUCT", 222, 225], ["patients", "ORGANISM", 252, 260], ["monocytes", "CELL", 364, 373], ["lung", "ORGAN", 381, 385], ["CD8", "PROTEIN", 40, 43], ["CTLs", "CELL_TYPE", 46, 50], ["CD4", "PROTEIN", 118, 121], ["T cells", "CELL_TYPE", 124, 131], ["Abs", "PROTEIN", 145, 148], ["CD4", "PROTEIN", 222, 225], ["T cells", "CELL_TYPE", 228, 235], ["neutralizing Abs", "PROTEIN", 283, 299], ["Th1 cytokines", "PROTEIN", 304, 317], ["inflammatory monocytes", "CELL_TYPE", 351, 373], ["mice", "SPECIES", 13, 17], ["patients", "SPECIES", 252, 260], ["mice", "SPECIES", 13, 17], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "PROBLEM", 30, 34], ["CTLs", "PROBLEM", 46, 50], ["the virus", "PROBLEM", 85, 94], ["specific Abs", "TEST", 136, 148], ["CD4 + T cells", "PROBLEM", 222, 235], ["neutralizing Abs", "TEST", 283, 299], ["Th1 cytokines", "TREATMENT", 304, 317], ["inflammatory monocytes in the lung", "PROBLEM", 351, 385], ["infected", "OBSERVATION_MODIFIER", 18, 26], ["virus", "OBSERVATION", 89, 94], ["neutralizing Abs", "OBSERVATION", 283, 299], ["lower", "OBSERVATION_MODIFIER", 330, 335], ["recruitment", "OBSERVATION_MODIFIER", 336, 347], ["inflammatory monocytes", "OBSERVATION", 351, 373], ["lung", "ANATOMY", 381, 385]]], ["This mechanism can be bypassed by a passive transfer of neutralizing Abs against SARS-CoV, suggesting that the CD4-mediated control of infection most likely operates through Ab-and/or cytokine-dependent mechanisms.", [["SARS", "DISEASE", 81, 85], ["infection", "DISEASE", 135, 144], ["SARS-CoV", "ORGANISM", 81, 89], ["CD4", "GENE_OR_GENE_PRODUCT", 111, 114], ["Ab", "GENE_OR_GENE_PRODUCT", 174, 176], ["neutralizing Abs", "PROTEIN", 56, 72], ["CD4", "PROTEIN", 111, 114], ["cytokine", "PROTEIN", 184, 192], ["SARS-CoV", "SPECIES", 81, 89], ["neutralizing Abs", "TREATMENT", 56, 72], ["SARS", "PROBLEM", 81, 85], ["CoV", "PROBLEM", 86, 89], ["the CD4", "TEST", 107, 114], ["infection", "PROBLEM", 135, 144], ["Ab", "TEST", 174, 176], ["infection", "OBSERVATION", 135, 144]]], ["In fatal human fulminant cases of H1N1 influenza pneumonia that required mechanical ventilation, a strong effector T-cell response in the lungs was also observed in conjunction with high production of IFN-\u03b3 and IP-10, suggesting a massive and effective translocation of specific T cells to the lungs (41) .What of the Cell-Adaptive Immunity?Genetic differences in HLA haplotypes are also key parameters, known to contribute to individual sensitivity against pathogens as previously described for tuberculosis, leprosy, HIV, hepatitis B, and influenza (71) .", [["T-cell", "ANATOMY", 115, 121], ["lungs", "ANATOMY", 138, 143], ["T cells", "ANATOMY", 279, 286], ["lungs", "ANATOMY", 294, 299], ["Cell", "ANATOMY", 318, 322], ["influenza pneumonia", "DISEASE", 39, 58], ["tuberculosis", "DISEASE", 496, 508], ["leprosy", "DISEASE", 510, 517], ["HIV, hepatitis B", "DISEASE", 519, 535], ["influenza", "DISEASE", 541, 550], ["human", "ORGANISM", 9, 14], ["T-cell", "CELL", 115, 121], ["lungs", "ORGAN", 138, 143], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 201, 206], ["IP-10", "GENE_OR_GENE_PRODUCT", 211, 216], ["T cells", "CELL", 279, 286], ["lungs", "ORGAN", 294, 299], ["Cell", "CELL", 318, 322], ["HLA", "GENE_OR_GENE_PRODUCT", 364, 367], ["hepatitis B", "ORGANISM", 524, 535], ["IFN", "PROTEIN", 201, 204], ["T cells", "CELL_TYPE", 279, 286], ["human", "SPECIES", 9, 14], ["H1N1 influenza pneumonia", "SPECIES", 34, 58], ["HIV", "SPECIES", 519, 522], ["human", "SPECIES", 9, 14], ["HIV", "SPECIES", 519, 522], ["hepatitis B", "SPECIES", 524, 535], ["H1N1 influenza pneumonia", "PROBLEM", 34, 58], ["mechanical ventilation", "TREATMENT", 73, 95], ["IP", "TEST", 211, 213], ["a massive and effective translocation of specific T cells", "PROBLEM", 229, 286], ["Genetic differences in HLA haplotypes", "PROBLEM", 341, 378], ["individual sensitivity", "PROBLEM", 427, 449], ["pathogens", "PROBLEM", 458, 467], ["tuberculosis", "PROBLEM", 496, 508], ["leprosy", "PROBLEM", 510, 517], ["HIV", "PROBLEM", 519, 522], ["hepatitis B", "PROBLEM", 524, 535], ["influenza", "PROBLEM", 541, 550], ["fatal", "OBSERVATION_MODIFIER", 3, 8], ["fulminant", "OBSERVATION_MODIFIER", 15, 24], ["H1N1", "OBSERVATION", 34, 38], ["pneumonia", "OBSERVATION", 49, 58], ["mechanical ventilation", "OBSERVATION", 73, 95], ["lungs", "ANATOMY", 138, 143], ["massive", "OBSERVATION_MODIFIER", 231, 238], ["effective", "OBSERVATION_MODIFIER", 243, 252], ["lungs", "ANATOMY", 294, 299], ["tuberculosis", "OBSERVATION", 496, 508]]], ["For example, HLA-A * 11, HLA-B * 35, and HLA-DRB1 * 10 confer susceptibility to H1N1 infection (72) .", [["H1N1 infection", "DISEASE", 80, 94], ["HLA-A", "GENE_OR_GENE_PRODUCT", 13, 18], ["HLA-B * 35", "GENE_OR_GENE_PRODUCT", 25, 35], ["HLA-DRB1 * 10", "GENE_OR_GENE_PRODUCT", 41, 54], ["HLA-DRB1 * 10", "DNA", 41, 54], ["HLA", "TEST", 13, 16], ["HLA", "TEST", 25, 28], ["HLA", "TEST", 41, 44], ["H1N1 infection", "PROBLEM", 80, 94], ["infection", "OBSERVATION", 85, 94]]], ["For SARS-CoV-2, a preliminary in silico analysis of viral peptide-MHC class-1 binding affinity suggests that individuals expressing HLA-B * 46:01 may be particularly vulnerable to COVID-19, as previously shown for the SARS.", [["SARS", "DISEASE", 218, 222], ["class-1", "GENE_OR_GENE_PRODUCT", 70, 77], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8], ["CoV", "TEST", 9, 12], ["silico analysis", "TEST", 33, 48], ["viral peptide", "TEST", 52, 65], ["COVID", "TEST", 180, 185], ["the SARS", "PROBLEM", 214, 222]]], ["At the same time, HLA-B * 15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides shared among common human CoVs (73, 74) .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 89, 99], ["human", "ORGANISM", 129, 134], ["CoVs", "CANCER", 135, 139], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["the greatest capacity", "PROBLEM", 39, 60], ["CoV", "TEST", 94, 97], ["common human CoVs", "TEST", 122, 139], ["SARS", "OBSERVATION", 89, 93]]], ["This observation suggests that the HLA distribution could affect the cellular immune response to SARS-CoV-2, and might explain the differences in COVID-19 susceptibility around the world.", [["cellular", "ANATOMY", 69, 77], ["SARS", "DISEASE", 97, 101], ["HLA", "GENE_OR_GENE_PRODUCT", 35, 38], ["cellular", "CELL", 69, 77], ["SARS-CoV-2", "ORGANISM", 97, 107], ["SARS-CoV", "SPECIES", 97, 105], ["This observation", "TEST", 0, 16], ["the HLA distribution", "PROBLEM", 31, 51], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105], ["COVID", "TEST", 146, 151], ["cellular immune", "OBSERVATION", 69, 84]]], ["However, it seems crucial for the development of vaccine strategies to understand whether specific HLA haplotypes are associated with the development of anti-SARS-CoV-2 immunity.", [["HLA", "GENE_OR_GENE_PRODUCT", 99, 102], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 153, 168], ["vaccine strategies", "TREATMENT", 49, 67], ["specific HLA haplotypes", "PROBLEM", 90, 113], ["anti-SARS", "TEST", 153, 162]]], ["Interestingly, among the first 120 available SARS-CoV-2 sequences (as of February 21, 2020), several B cell and T cell epitopes specific to SARS-CoV-2 were identified for the spike and nucleocapsid proteins, that potentially induce protection against COVID-19 (75).CONCLUDING COMMENTSCurrent observations indicate that SARS-CoV-2 is particularly adapted to evade immune responses at the early stage of infection.", [["B cell", "ANATOMY", 101, 107], ["T cell", "ANATOMY", 112, 118], ["SARS", "DISEASE", 45, 49], ["COVID-19", "CHEMICAL", 251, 259], ["SARS", "DISEASE", 319, 323], ["infection", "DISEASE", 402, 411], ["B cell", "CELL", 101, 107], ["T cell", "CELL", 112, 118], ["SARS-CoV-2", "ORGANISM", 140, 150], ["SARS-CoV-2", "ORGANISM", 319, 329], ["SARS-CoV-2 sequences", "DNA", 45, 65], ["B cell and T cell epitopes", "PROTEIN", 101, 127], ["spike and nucleocapsid proteins", "PROTEIN", 175, 206], ["SARS-CoV", "SPECIES", 140, 148], ["SARS-CoV", "SPECIES", 319, 327], ["SARS-CoV-2 sequences", "TEST", 45, 65], ["several B cell and T cell epitopes", "PROBLEM", 93, 127], ["SARS", "TEST", 140, 144], ["CoV", "TEST", 145, 148], ["the spike and nucleocapsid proteins", "PROBLEM", 171, 206], ["COVID", "TEST", 251, 256], ["SARS", "PROBLEM", 319, 323], ["immune responses", "PROBLEM", 363, 379], ["infection", "PROBLEM", 402, 411], ["cell epitopes", "OBSERVATION", 114, 127], ["early stage", "OBSERVATION_MODIFIER", 387, 398], ["infection", "OBSERVATION", 402, 411]]], ["Most mechanisms are linked to inappropriate type 1 IFN responses, massive inflammatory cytokine production, and possibly to a defect in NK-cell functions.", [["NK-cell", "ANATOMY", 136, 143], ["type 1 IFN", "GENE_OR_GENE_PRODUCT", 44, 54], ["NK-cell", "CELL", 136, 143], ["IFN", "PROTEIN", 51, 54], ["cytokine", "PROTEIN", 87, 95], ["inappropriate type 1 IFN responses", "PROBLEM", 30, 64], ["massive inflammatory cytokine production", "PROBLEM", 66, 106], ["a defect in NK", "PROBLEM", 124, 138], ["massive", "OBSERVATION_MODIFIER", 66, 73], ["inflammatory cytokine production", "OBSERVATION", 74, 106], ["defect", "OBSERVATION", 126, 132], ["NK", "OBSERVATION", 136, 138], ["cell functions", "OBSERVATION", 139, 153]]], ["Preliminary data also suggest adaptive immune evasion, as indicated by the exhaustion of T lymphocytes.", [["T lymphocytes", "ANATOMY", 89, 102], ["T lymphocytes", "CELL", 89, 102], ["T lymphocytes", "CELL_TYPE", 89, 102], ["Preliminary data", "TEST", 0, 16], ["adaptive immune evasion", "PROBLEM", 30, 53], ["immune evasion", "OBSERVATION", 39, 53]]], ["However, current evidence strongly indicated that the Th1-type response is key to the successful control of human pathogenic CoVs, in the association with the presence of specific neutralizing Abs.", [["human", "ORGANISM", 108, 113], ["CoVs", "GENE_OR_GENE_PRODUCT", 125, 129], ["neutralizing Abs", "PROTEIN", 180, 196], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["human pathogenic CoVs", "PROBLEM", 108, 129], ["specific neutralizing Abs", "PROBLEM", 171, 196], ["pathogenic CoVs", "OBSERVATION", 114, 129], ["neutralizing Abs", "OBSERVATION", 180, 196]]], ["Although there are clear relationships between the severity of the disease and immune responses, the role of protective immunity currently remains questionable.CONCLUDING COMMENTSAlarmingly, some patients remain viral positive, while others even relapse, after discharge from hospital, as recently stated by WHO (3), suggesting that complete control of the virus by the immune response could be difficult to induce at least in some patients.", [["patients", "ORGANISM", 196, 204], ["patients", "ORGANISM", 432, 440], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 432, 440], ["the disease", "PROBLEM", 63, 74], ["protective immunity", "TREATMENT", 109, 128], ["viral positive", "PROBLEM", 212, 226], ["the virus", "PROBLEM", 353, 362], ["clear", "OBSERVATION", 19, 24], ["disease", "OBSERVATION", 67, 74], ["viral", "OBSERVATION", 212, 217]]], ["This could also have an impact on the development of the second wave of the epidemic, which is currently strongly envisaged.", [["the epidemic", "PROBLEM", 72, 84], ["impact", "OBSERVATION_MODIFIER", 24, 30], ["second", "OBSERVATION_MODIFIER", 57, 63], ["wave", "OBSERVATION_MODIFIER", 64, 68], ["epidemic", "OBSERVATION_MODIFIER", 76, 84]]], ["The vaccine remains the best way to counter this epidemic.", [["The vaccine", "TREATMENT", 0, 11]]], ["However, to define the surrogate parameters of vaccine efficacy, it should be important to better monitor T/B cell responses of recovered patients and to better understand the aging impact on the immune responses in COVID-19 patients, including the relative protection of younger individuals, excepted for some unexplained cases of Kawasakilike syndrome.", [["T/B cell", "ANATOMY", 106, 114], ["Kawasakilike syndrome", "DISEASE", 332, 353], ["T/B cell", "CELL", 106, 114], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 225, 233], ["vaccine efficacy", "TREATMENT", 47, 63], ["Kawasakilike syndrome", "PROBLEM", 332, 353], ["Kawasakilike syndrome", "OBSERVATION", 332, 353]]], ["If overlapping epitopes among different human CoVs can be identified, this could help in the design of crossreactive vaccines that protect against several pathogenic CoVs in the future.DATA AVAILABILITY STATEMENTAll datasets presented in this study are included in the article.AUTHOR CONTRIBUTIONSAll authors were involved in reading bibliography and writing the article.", [["human", "ORGANISM", 40, 45], ["CoVs", "GENE_OR_GENE_PRODUCT", 46, 50], ["CoVs", "CANCER", 166, 170], ["human CoVs", "PROTEIN", 40, 50], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["overlapping epitopes among different human CoVs", "PROBLEM", 3, 50], ["crossreactive vaccines", "TREATMENT", 103, 125], ["several pathogenic CoVs", "PROBLEM", 147, 170], ["this study", "TEST", 238, 248]]], ["All co-authors reviewed the article.FUNDINGThis study was supported in part by the Agence Nationale de la Recherche (ANR, iCovid program), and Sorbonne Universit\u00e9.", [["FUNDINGThis study", "TEST", 36, 53], ["ANR, iCovid program", "TREATMENT", 117, 136], ["Sorbonne Universit\u00e9", "TREATMENT", 143, 162]]]], "PMC7319908": [["Pre-treatment screening ::: IntroductionProper pre-treatment screening should substantially reduce the risk of contact with symptomatic patient displaying the commonest signs and symptoms of COVID-19 infection such as high temperature, new and persistent cough, loss or change to sense of smell or taste3.", [["COVID", "DISEASE", 191, 196], ["infection", "DISEASE", 200, 209], ["cough", "DISEASE", 255, 260], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["Pre-treatment screening", "TEST", 0, 23], ["Proper pre-treatment screening", "TEST", 40, 70], ["the commonest signs", "PROBLEM", 155, 174], ["symptoms", "PROBLEM", 179, 187], ["COVID-19 infection", "PROBLEM", 191, 209], ["high temperature", "PROBLEM", 218, 234], ["new and persistent cough", "PROBLEM", 236, 260], ["loss or change to sense of smell or taste3", "PROBLEM", 262, 304], ["infection", "OBSERVATION", 200, 209], ["high temperature", "OBSERVATION_MODIFIER", 218, 234], ["persistent", "OBSERVATION_MODIFIER", 244, 254], ["cough", "OBSERVATION", 255, 260]]], ["Until such time that antibody testing becomes routinely available, all patients attending for laser treatments should be presumed COVID-19 positive.Pre-treatment screening ::: IntroductionExcluded from this document are precursory checks and screening of potential patients for signs of COVID-19, general and COVID-19-specific hygiene in clinic reception etc. which are covered in detail elsewhere (https://www.jccp.org.uk/NewsEvent/covid-19-preparing-for-return-to-work)2.Risk assessment: lasers, aerosols and COVID ::: GuidanceAerosols are particles of respirable size generated by both human and environmental sources and that can remain viable and airborne for extended periods in indoor air4.Risk assessment: lasers, aerosols and COVID ::: GuidanceThe SARS-CoV-2 virus which is the causative agent of COVID-19 pandemic is thought to spread mainly from person-to-person through respiratory droplets produced when an infected person breathes, coughs, sneezes or talks.", [["coughs", "DISEASE", 946, 952], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 265, 273], ["GuidanceAerosols", "SIMPLE_CHEMICAL", 521, 537], ["human", "ORGANISM", 589, 594], ["SARS-CoV-2 virus", "ORGANISM", 757, 773], ["COVID-19", "ORGANISM", 806, 814], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 265, 273], ["human", "SPECIES", 589, 594], ["CoV-2 virus", "SPECIES", 762, 773], ["person", "SPECIES", 857, 863], ["person", "SPECIES", 867, 873], ["person", "SPECIES", 929, 935], ["human", "SPECIES", 589, 594], ["SARS-CoV-2 virus", "SPECIES", 757, 773], ["antibody testing", "TEST", 21, 37], ["laser treatments", "TREATMENT", 94, 110], ["COVID", "TEST", 130, 135], ["Pre-treatment screening", "TEST", 148, 171], ["precursory checks", "TEST", 220, 237], ["COVID", "TEST", 287, 292], ["COVID", "TEST", 309, 314], ["GuidanceAerosols", "TREATMENT", 521, 537], ["The SARS", "TEST", 753, 761], ["COVID", "TREATMENT", 806, 811], ["respiratory droplets", "PROBLEM", 882, 902], ["coughs", "PROBLEM", 946, 952], ["respirable", "OBSERVATION_MODIFIER", 555, 565], ["size", "OBSERVATION_MODIFIER", 566, 570], ["both human", "OBSERVATION", 584, 594], ["infected", "OBSERVATION", 920, 928]]], ["Infection with SARS-CoV-2 occurs primarily by inhalation of aerosolised virus or secondarily by contact with droplets and contaminated fomites such as garments, instruments and furniture.Risk assessment: lasers, aerosols and COVID ::: GuidanceSARS-CoV-2 virus has a size of 0.06\u20130.14 \u03bcm with mean size of 0.1 \u03bcm5.", [["fomites", "ANATOMY", 135, 142], ["SARS", "DISEASE", 15, 19], ["SARS-CoV-2", "ORGANISM", 15, 25], ["GuidanceSARS-CoV-2 virus", "ORGANISM", 235, 259], ["SARS-CoV", "SPECIES", 15, 23], ["GuidanceSARS-CoV-2 virus", "SPECIES", 235, 259], ["Infection", "PROBLEM", 0, 9], ["SARS", "PROBLEM", 15, 19], ["CoV", "PROBLEM", 20, 23], ["aerosolised virus", "PROBLEM", 60, 77], ["contaminated fomites", "PROBLEM", 122, 142], ["GuidanceSARS", "TEST", 235, 247], ["CoV", "TEST", 248, 251], ["a size", "TEST", 264, 270], ["mean size", "TEST", 292, 301], ["size", "OBSERVATION_MODIFIER", 266, 270], ["size", "OBSERVATION_MODIFIER", 297, 301]]], ["During a sneeze or a cough or while talking, \u201cdroplet sprays\u201d of virus laden respiratory tract fluid, typically greater than 5 \u03bcm in diameter, impact directly on a susceptible individual.", [["respiratory tract fluid", "ANATOMY", 77, 100], ["cough", "DISEASE", 21, 26], ["respiratory tract", "ORGANISM_SUBDIVISION", 77, 94], ["a cough", "PROBLEM", 19, 26], ["\u201cdroplet sprays", "TREATMENT", 45, 60], ["virus laden respiratory tract fluid", "PROBLEM", 65, 100], ["cough", "OBSERVATION", 21, 26], ["respiratory tract fluid", "OBSERVATION", 77, 100]]], ["Alternatively, a susceptible person can inhale microscopic aerosol particles (droplet nuclei) consisting of the residual solid components of evaporated respiratory droplets, which are tiny enough (< 5 \u03bcm) to remain airborne for hours, particularly in enclosed spaces with poor or no ventilation4.Risk assessment: lasers, aerosols and COVID ::: GuidanceLasers and intense pulsed light (IPL) treatment of tissues generates plumes and aerosols which include both combustion and non-combustion-generated products including tissue(s), gases, particulate materials, steam and carbonised material (smoke).", [["nuclei", "ANATOMY", 86, 92], ["respiratory droplets", "ANATOMY", 152, 172], ["tissues", "ANATOMY", 403, 410], ["tissue", "ANATOMY", 519, 525], ["tissues", "TISSUE", 403, 410], ["tissue", "TISSUE", 519, 525], ["person", "SPECIES", 29, 35], ["microscopic aerosol particles", "TREATMENT", 47, 76], ["the residual solid components", "PROBLEM", 108, 137], ["evaporated respiratory droplets", "PROBLEM", 141, 172], ["ventilation4", "TREATMENT", 283, 295], ["GuidanceLasers", "TREATMENT", 344, 358], ["intense pulsed light (IPL) treatment of tissues", "TREATMENT", 363, 410], ["plumes and aerosols", "PROBLEM", 421, 440], ["residual", "OBSERVATION_MODIFIER", 112, 120], ["solid components", "OBSERVATION", 121, 137], ["respiratory droplets", "OBSERVATION", 152, 172], ["tiny", "OBSERVATION_MODIFIER", 184, 188], ["intense", "OBSERVATION_MODIFIER", 363, 370], ["pulsed light", "OBSERVATION_MODIFIER", 371, 383], ["tissues", "ANATOMY", 403, 410]]], ["All ablative and non-ablative laser procedures can generate potentially hazardous plumes.Risk assessment: lasers, aerosols and COVID ::: GuidanceIn a recent study, gas chromatography-mass spectrometry of plume during laser hair removal showed presence of 377 chemical compounds comprising suspected carcinogens and environmental toxins6.", [["hair", "ANATOMY", 223, 227], ["hair", "MULTI-TISSUE_STRUCTURE", 223, 227], ["All ablative", "TREATMENT", 0, 12], ["non-ablative laser procedures", "TREATMENT", 17, 46], ["a recent study", "TEST", 148, 162], ["gas chromatography", "TEST", 164, 182], ["mass spectrometry of plume", "PROBLEM", 183, 209], ["laser hair removal", "TREATMENT", 217, 235], ["chemical compounds", "PROBLEM", 259, 277], ["plume", "OBSERVATION_MODIFIER", 204, 209], ["carcinogens", "OBSERVATION", 299, 310]]], ["Ablative laser-generated plume has been shown to contain intact human papillomavirus DNA, viable bacteriophages and viable human immunodeficiency virus7.", [["human immunodeficiency virus7", "DISEASE", 123, 152], ["human", "ORGANISM", 64, 69], ["papillomavirus", "ORGANISM", 70, 84], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["human immunodeficiency virus7", "ORGANISM", 123, 152], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 123, 128], ["human papillomavirus", "SPECIES", 64, 84], ["human immunodeficiency virus7", "SPECIES", 123, 152], ["Ablative laser", "TREATMENT", 0, 14], ["intact human papillomavirus DNA", "PROBLEM", 57, 88], ["viable bacteriophages", "PROBLEM", 90, 111], ["viable human immunodeficiency virus7", "PROBLEM", 116, 152], ["human immunodeficiency", "OBSERVATION", 123, 145]]], ["Similarly, micron-sized tattoo ink particles potentially contaminated with aerosolised blood products have been detected following laser tattoo removal8.Risk assessment: lasers, aerosols and COVID ::: GuidanceResults of polymerase chain reaction (PCR) and viral RNA testing for SARS-CoV-2 from blood samples of most patients with COVID-19 infection have been negative and viraemia is very uncommon9.", [["blood", "ANATOMY", 87, 92], ["blood samples", "ANATOMY", 294, 307], ["COVID-19 infection", "DISEASE", 330, 348], ["viraemia", "DISEASE", 372, 380], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["SARS-CoV-2", "ORGANISM", 278, 288], ["blood samples", "ORGANISM_SUBSTANCE", 294, 307], ["patients", "ORGANISM", 316, 324], ["COVID-19", "ORGANISM", 330, 338], ["patients", "SPECIES", 316, 324], ["SARS-CoV", "SPECIES", 278, 286], ["COVID-19", "SPECIES", 330, 338], ["micron-sized tattoo ink particles", "PROBLEM", 11, 44], ["aerosolised blood products", "TREATMENT", 75, 101], ["laser tattoo removal8", "TREATMENT", 131, 152], ["polymerase chain reaction", "PROBLEM", 220, 245], ["PCR", "TEST", 247, 250], ["viral RNA testing", "TEST", 256, 273], ["SARS", "PROBLEM", 278, 282], ["CoV", "TEST", 283, 286], ["blood samples", "TEST", 294, 307], ["COVID", "TEST", 330, 335], ["19 infection", "PROBLEM", 336, 348], ["viraemia", "PROBLEM", 372, 380], ["micron", "OBSERVATION_MODIFIER", 11, 17], ["sized", "OBSERVATION_MODIFIER", 18, 23], ["tattoo", "OBSERVATION", 24, 30], ["particles", "OBSERVATION_MODIFIER", 35, 44], ["contaminated", "OBSERVATION_MODIFIER", 57, 69]]], ["This is an important finding which should reassure practitioners that the risk of viable SARS-CoV-2 in aerosol generated from laser treatments of asymptomatic COVID-19 patients should be very low.", [["SARS", "DISEASE", 89, 93], ["SARS-CoV-2", "ORGANISM", 89, 99], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["viable SARS", "PROBLEM", 82, 93], ["CoV", "TEST", 94, 97], ["laser treatments", "TREATMENT", 126, 142], ["asymptomatic COVID", "TREATMENT", 146, 164]]], ["As of date, no studies looking at SARS-CoV-2 viral RNA on intact skin or hair follicles or the effect of laser treatments on viral particles have been published.", [["skin", "ANATOMY", 65, 69], ["hair follicles", "ANATOMY", 73, 87], ["SARS-CoV-2", "ORGANISM", 34, 44], ["skin", "ORGAN", 65, 69], ["hair follicles", "MULTI-TISSUE_STRUCTURE", 73, 87], ["SARS-CoV-2 viral RNA", "RNA", 34, 54], ["studies", "TEST", 15, 22], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["viral RNA", "PROBLEM", 45, 54], ["hair follicles", "PROBLEM", 73, 87], ["laser treatments", "TREATMENT", 105, 121], ["viral particles", "TREATMENT", 125, 140], ["skin", "ANATOMY", 65, 69], ["hair follicles", "OBSERVATION", 73, 87], ["viral particles", "OBSERVATION", 125, 140]]], ["For this reason, all laser treatments should be considered potentially COVID-19 aerosol-generating procedures (AGP) and all necessary precautions should be followed.Risk assessment: lasers, aerosols and COVID ::: GuidanceBased on the above, and until such time that evidence to the contrary is available, one could assume that the main route of COVID-19 infection in laser/IPL procedures remains patient-generated respiratory aerosol but still considers laser-generated plume/aerosol as potentially infective.General hygiene and enhanced infection control procedures ::: Risk management ::: GuidanceIn any setting, hand hygiene remains the most important defence against spread of COVID-19.", [["hand", "ANATOMY", 615, 619], ["COVID-19", "CHEMICAL", 345, 353], ["infection", "DISEASE", 354, 363], ["infection", "DISEASE", 538, 547], ["COVID-19", "CHEMICAL", 681, 689], ["COVID-19", "CHEMICAL", 681, 689], ["patient", "ORGANISM", 396, 403], ["hand", "ORGANISM_SUBDIVISION", 615, 619], ["patient", "SPECIES", 396, 403], ["all laser treatments", "TREATMENT", 17, 37], ["COVID", "TREATMENT", 71, 76], ["procedures (AGP)", "TREATMENT", 99, 115], ["all necessary precautions", "TREATMENT", 120, 145], ["COVID", "TEST", 345, 350], ["infection", "PROBLEM", 354, 363], ["laser/IPL procedures", "TREATMENT", 367, 387], ["generated respiratory aerosol", "TREATMENT", 404, 433], ["laser-generated plume/aerosol", "TREATMENT", 454, 483], ["infective", "PROBLEM", 499, 508], ["enhanced infection control procedures", "TREATMENT", 529, 566], ["hand hygiene", "TREATMENT", 615, 627], ["COVID", "TEST", 681, 686], ["infection", "OBSERVATION", 354, 363], ["respiratory aerosol", "OBSERVATION", 414, 433], ["infective", "OBSERVATION", 499, 508], ["infection", "OBSERVATION", 538, 547]]], ["Practitioners should also focus on surface decontamination procedures.", [["surface", "ANATOMY", 35, 42], ["surface decontamination procedures", "TREATMENT", 35, 69]]], ["These form the basis of reduction of virus transmission.", [["virus transmission", "PROBLEM", 37, 55], ["reduction", "OBSERVATION_MODIFIER", 24, 33], ["virus", "OBSERVATION", 37, 42]]], ["Guidance regarding this is freely available2, 3.PPE\u2014personal protection equipment comprises face masks, gloves, gowns/aprons, face shields and caps ::: Risk management ::: GuidanceBarrier precautions such as masks and respirators are regarded as the last line of defence against viral transmission secondary to hand washing and other hygiene measures.", [["hand", "ANATOMY", 311, 315], ["PPE", "TREATMENT", 48, 51], ["personal protection equipment", "TREATMENT", 52, 81], ["face masks", "TREATMENT", 92, 102], ["gloves", "TREATMENT", 104, 110], ["GuidanceBarrier precautions", "TREATMENT", 172, 199], ["respirators", "TREATMENT", 218, 229], ["viral transmission", "TREATMENT", 279, 297], ["hand washing", "TREATMENT", 311, 323], ["other hygiene measures", "TREATMENT", 328, 350]]], ["In the case of laser/IPL treatments, proper eye protection is imperative and should not be ignored.", [["eye", "ANATOMY", 44, 47], ["eye", "ORGAN", 44, 47], ["laser/IPL treatments", "TREATMENT", 15, 35], ["proper eye protection", "TREATMENT", 37, 58], ["eye", "ANATOMY", 44, 47]]], ["Resources detailing correct methods of donning and doffing of PPE are freely available10.Face masks and respirators ::: GuidanceFace masks protect against aerosol spread from inside out.", [["PPE", "TREATMENT", 62, 65], ["GuidanceFace masks", "TREATMENT", 120, 138]]], ["They offer minimal protection to the wearer from inhalation of droplets.", [["inhalation of droplets", "TREATMENT", 49, 71]]], ["Face masks can simply be classified as surgical and non-surgical.", [["Face masks", "TREATMENT", 0, 10], ["surgical", "OBSERVATION", 39, 47]]], ["Surgical masks worn by the practitioner protect the patient and the environment (air, surfaces, equipment, surgical site).", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["Surgical masks", "TREATMENT", 0, 14], ["surgical site", "TREATMENT", 107, 120]]], ["If worn by patients, they prevent contamination of the patients\u2019 surroundings and environment.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 55, 63]]], ["Standard surgical masks offer no protection to the practitioner undertaking laser procedures.", [["Standard surgical masks", "TREATMENT", 0, 23], ["laser procedures", "TREATMENT", 76, 92]]], ["If available, surgical masks or three ply cotton masks should be offered to patients undergoing non-facial laser procedures.Face masks and respirators ::: GuidanceFiltering facepiece respirators (FFP), which are sometimes called disposable respirators protect from aerosol inhalation.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["surgical masks", "TREATMENT", 14, 28], ["three ply cotton masks", "TREATMENT", 32, 54], ["non-facial laser procedures", "TREATMENT", 96, 123], ["FFP", "TREATMENT", 196, 199], ["aerosol inhalation", "TREATMENT", 265, 283]]], ["FFP are tested in the direction of inspiration (from outside to inside).", [["FFP", "SIMPLE_CHEMICAL", 0, 3], ["FFP", "PROTEIN", 0, 3], ["FFP", "TREATMENT", 0, 3]]], ["The tests take into account the efficiency of the filter and leakage to the face.", [["The tests", "TEST", 0, 9], ["the filter", "TREATMENT", 46, 56], ["leakage to the face", "PROBLEM", 61, 80], ["filter", "OBSERVATION", 50, 56], ["leakage", "OBSERVATION", 61, 68], ["face", "ANATOMY", 76, 80]]], ["FFP are subject to various regulatory standards around the world.", [["FFP", "SIMPLE_CHEMICAL", 0, 3], ["FFP", "TREATMENT", 0, 3]]], ["FFP2 and FFP3 conform to EU standard EN149:2001.", [["FFP2", "GENE_OR_GENE_PRODUCT", 0, 4], ["FFP3", "GENE_OR_GENE_PRODUCT", 9, 13], ["FFP2", "PROTEIN", 0, 4], ["FFP3", "DNA", 9, 13], ["FFP2", "TEST", 0, 4]]], ["The FFP3 standard is often considered broadly equivalent to the US N99 standard and Chinese KN99 standard.", [["The FFP3 standard", "TREATMENT", 0, 17], ["the US", "TEST", 60, 66]]], ["The FFP2 standard is often considered broadly equivalent to the US N95 standard and Chinese KN95 standard.Face masks and respirators ::: GuidanceRespirators are often more comfortable for the wearer when fitted with a valve exhalation feature, but this feature has the effect of elevating wearer safety over that of patients and others in the vicinity, and therefore is generally discouraged (Table 1)11.Face masks and respirators ::: GuidanceThe World Health Organisation recommends that health care workers should wear a particulate respirator at least as protective as a N95/ FFP2, or equivalent, when performing aerosol-generating procedures on patients suspected or confirmed of being infected with COVID-1912.Face masks and respirators ::: GuidanceThe BMLA also recommends that until proven otherwise, all patients should be considered suspected of being infected with COVID-19.", [["valve", "ANATOMY", 218, 223], ["COVID-1912", "CHEMICAL", 704, 714], ["COVID-19", "CHEMICAL", 875, 883], ["patients", "ORGANISM", 316, 324], ["patients", "ORGANISM", 649, 657], ["patients", "ORGANISM", 812, 820], ["patients", "SPECIES", 316, 324], ["patients", "SPECIES", 649, 657], ["patients", "SPECIES", 812, 820], ["The FFP2 standard", "TEST", 0, 17], ["a valve exhalation feature", "TEST", 216, 242], ["a particulate respirator", "TREATMENT", 521, 545], ["a N95/ FFP2", "TREATMENT", 572, 583], ["COVID", "TEST", 875, 880], ["infected", "OBSERVATION", 690, 698], ["infected", "OBSERVATION", 861, 869]]], ["All practitioners should wear N95 respirators as a minimum when undertaking any laser or IPL procedures.", [["N95 respirators", "TREATMENT", 30, 45], ["any laser", "TREATMENT", 76, 85], ["IPL procedures", "TREATMENT", 89, 103]]], ["This should in addition be complemented by a reusable cleanable face shield.", [["a reusable cleanable face shield", "TREATMENT", 43, 75]]], ["For all above-clavicle procedures, where risk of exposure to patient-generated respiratory aerosol is higher, where available, FFP3 respirators should be used instead (Chart 1).Face masks and respirators ::: GuidancePractitioners should be fit-tested for all respirators and should receive PPE training comprising proper hand hygiene practices, correct fit, donning and doffing to avoid cross-contamination(https://www.hse.gov.uk/respiratory-protective-equipment/fit-testing-basics.htm).Face masks and respirators ::: GuidanceConcerns about availability and costs of respirators should be taken into account.", [["hand", "ANATOMY", 321, 325], ["patient", "ORGANISM", 61, 68], ["hand", "ORGANISM_SUBDIVISION", 321, 325], ["patient", "SPECIES", 61, 68], ["clavicle procedures", "TREATMENT", 14, 33], ["respiratory aerosol", "TREATMENT", 79, 98], ["FFP3 respirators", "TREATMENT", 127, 143], ["GuidancePractitioners", "TREATMENT", 208, 229], ["all respirators", "TREATMENT", 255, 270], ["PPE training", "TREATMENT", 290, 302], ["respirators", "TREATMENT", 567, 578], ["clavicle", "ANATOMY", 14, 22]]], ["Unlike surgical masks which are single use (3\u20138 h maximum), FFP can be reusable or disposable.", [["FFP", "SIMPLE_CHEMICAL", 60, 63], ["surgical masks", "TREATMENT", 7, 21], ["FFP", "TREATMENT", 60, 63], ["surgical masks", "OBSERVATION", 7, 21]]], ["While the BMLA does not recommend extended use or reuse of disposable FFPs, when availability is an issue and, if unavoidable, it may be possible to extend the life of single use FFPs.", [["disposable FFPs", "TREATMENT", 59, 74], ["FFPs", "TREATMENT", 179, 183]]], ["The use of reusable, cleanable face shields may enhance the life of single-use FFPs.", [["reusable, cleanable face shields", "TREATMENT", 11, 43], ["FFPs", "TREATMENT", 79, 83]]], ["Thorough decontamination and safe storage of FFP are incumbent upon the user and are beyond the scope of this guidance.", [["Thorough decontamination", "TREATMENT", 0, 24], ["safe storage of FFP", "TREATMENT", 29, 48]]], ["Practices ranging from UV radiation (260\u2013285 nm), 70 \u00b0C dry heat, 70% ethanol and vaporised hydrogen peroxide (VHP) can reduce SARS-CoV-2 on N95 respirator with VHP treatment exhibiting the best combination of rapid inactivation of SARS-CoV-2 and preservation of N95 respirator integrity13, 14.Ventilation ::: GuidanceAs the SARS-CoV-2 spreads mainly through aerosol during AGP in enclosed spaces and as particle aerosol (< 10 \u03bcm) remains airborne for long durations in the laser treatment room and adjacent rooms, adequate ventilation is important to ensure appropriate air handling, containment and evacuation of contaminated air15.Ventilation ::: GuidanceStandard in-room air cleaners alone are not effective at protecting staff and preventing the spread of COVID-19.", [["ethanol", "CHEMICAL", 70, 77], ["hydrogen peroxide", "CHEMICAL", 92, 109], ["VHP", "CHEMICAL", 111, 114], ["VHP", "CHEMICAL", 161, 164], ["SARS", "DISEASE", 232, 236], ["SARS", "DISEASE", 325, 329], ["ethanol", "CHEMICAL", 70, 77], ["hydrogen peroxide", "CHEMICAL", 92, 109], ["VHP", "CHEMICAL", 111, 114], ["VHP", "CHEMICAL", 161, 164], ["COVID-19", "CHEMICAL", 761, 769], ["ethanol", "SIMPLE_CHEMICAL", 70, 77], ["vaporised hydrogen peroxide", "SIMPLE_CHEMICAL", 82, 109], ["VHP", "SIMPLE_CHEMICAL", 111, 114], ["N95", "ORGANISM", 141, 144], ["VHP", "SIMPLE_CHEMICAL", 161, 164], ["AGP", "GENE_OR_GENE_PRODUCT", 374, 377], ["air15", "GENE_OR_GENE_PRODUCT", 628, 633], ["AGP", "PROTEIN", 374, 377], ["SARS-CoV", "SPECIES", 232, 240], ["UV radiation", "TREATMENT", 23, 35], ["vaporised hydrogen peroxide", "TREATMENT", 82, 109], ["SARS", "PROBLEM", 127, 131], ["CoV", "TEST", 132, 135], ["N95 respirator", "TREATMENT", 141, 155], ["VHP treatment", "TREATMENT", 161, 174], ["rapid inactivation of SARS", "PROBLEM", 210, 236], ["CoV", "TEST", 237, 240], ["Ventilation", "TREATMENT", 294, 305], ["the SARS", "TEST", 321, 329], ["CoV", "TEST", 330, 333], ["the laser treatment", "TREATMENT", 470, 489], ["adequate ventilation", "TREATMENT", 515, 535], ["evacuation", "TREATMENT", 601, 611], ["contaminated air15", "PROBLEM", 615, 633], ["GuidanceStandard", "TREATMENT", 650, 666], ["COVID", "TEST", 761, 766], ["adequate ventilation", "OBSERVATION", 515, 535]]], ["A HEPA (high-efficiency particulate air) filter uses mechanical filtration to remove airborne particles greater than or equal to 0.3 \u03bcm in diameter at a minimum 99.97% efficiency and such filters are used in vacuum cleaners and in office buildings air management systems.", [["A HEPA (high-efficiency particulate air) filter", "TREATMENT", 0, 47], ["mechanical filtration", "TREATMENT", 53, 74], ["airborne particles", "TEST", 85, 103], ["such filters", "TREATMENT", 183, 195], ["vacuum cleaners", "TREATMENT", 208, 223], ["HEPA", "ANATOMY", 2, 6], ["mechanical filtration", "OBSERVATION", 53, 74], ["vacuum cleaners", "OBSERVATION", 208, 223]]], ["Used alone, they are not adequate for medical practices.Ventilation ::: GuidanceULPA (ultra-low particulate air) filters offer up to 99.9995% efficiency on particles down to 0.12 \u03bcm.", [["Ventilation", "TREATMENT", 56, 67], ["GuidanceULPA (ultra-low particulate air) filters", "TREATMENT", 72, 120]]], ["ULPA filters in air filtration systems and ductless fume hoods may help drawing in the airborne drops to capture and remove most of them from the airflow.Ventilation ::: GuidanceWhere possible, air conditioning units should be serviced and set at exhaust to extract air from the room to outside the building rather than in air circulation modes.", [["ULPA filters", "TREATMENT", 0, 12], ["air filtration systems", "TREATMENT", 16, 38], ["ductless fume hoods", "TREATMENT", 43, 62], ["the airborne drops", "TREATMENT", 83, 101], ["air conditioning units", "TREATMENT", 194, 216], ["air filtration", "OBSERVATION", 16, 30], ["airflow", "OBSERVATION", 146, 153], ["air conditioning", "OBSERVATION", 194, 210], ["air", "OBSERVATION", 323, 326]]], ["If required, air filters should be replaced in line with device manufacturers\u2019 recommendations.", [["air filters", "TREATMENT", 13, 24], ["air filters", "OBSERVATION", 13, 24]]], ["Negative-pressure rooms help control the spread of airborne-transmitted infections in health care facilities such as hospitals, but will not be readily available in high street clinics.", [["airborne-transmitted infections", "DISEASE", 51, 82], ["pressure rooms", "TREATMENT", 9, 23], ["pressure", "OBSERVATION_MODIFIER", 9, 17], ["spread", "OBSERVATION_MODIFIER", 41, 47], ["infections", "OBSERVATION", 72, 82]]], ["If available, laser treatments should ideally be undertaken in negative pressure rooms11.Smoke evacuation systems ::: GuidanceSmoke evacuation systems are useful to reduce aerosol and plume generated during laser procedures but should be considered as an adjunct to hand hygiene, PPE and adequate ventilation.", [["hand", "ANATOMY", 266, 270], ["hand", "ORGANISM_SUBDIVISION", 266, 270], ["laser treatments", "TREATMENT", 14, 30], ["evacuation systems", "TREATMENT", 132, 150], ["aerosol and plume", "TREATMENT", 172, 189], ["laser procedures", "TREATMENT", 207, 223], ["PPE", "TREATMENT", 280, 283], ["adequate ventilation", "TREATMENT", 288, 308]]], ["Laser smoke evacuation systems should have sub-micron filtration capability.", [["Laser smoke evacuation systems", "TREATMENT", 0, 30], ["sub-micron filtration capability", "TREATMENT", 43, 75]]], ["Several smoke evacuation systems exist in the market but all offer certain common features such as ULPA filters and minimum flow rate of 25 cfm (cubic feet per minute) with variable flow rate to accommodate various levels of smoke.Smoke evacuation systems ::: GuidanceSome devices offer multistage filtration to ensure adequate removal of all contaminants.", [["Several smoke evacuation systems", "TREATMENT", 0, 32], ["ULPA filters", "TREATMENT", 99, 111], ["minimum flow rate", "TEST", 116, 133], ["variable flow rate", "TEST", 173, 191], ["GuidanceSome devices", "TREATMENT", 260, 280], ["multistage filtration", "TREATMENT", 287, 308], ["adequate removal", "TREATMENT", 319, 335], ["all contaminants", "PROBLEM", 339, 355], ["smoke", "OBSERVATION", 8, 13]]], ["Charcoal filter comprises activated charcoal which absorbs gas and vapour.", [["charcoal", "CHEMICAL", 36, 44], ["charcoal", "SIMPLE_CHEMICAL", 36, 44], ["Charcoal filter", "TREATMENT", 0, 15], ["activated charcoal", "TREATMENT", 26, 44], ["filter", "OBSERVATION", 9, 15]]], ["It helps in elimination of strong-smelling gases such as those released from laser hair removal.", [["hair", "ANATOMY", 83, 87], ["hair", "MULTI-TISSUE_STRUCTURE", 83, 87], ["strong-smelling gases", "PROBLEM", 27, 48], ["laser hair removal", "TREATMENT", 77, 95], ["strong", "OBSERVATION_MODIFIER", 27, 33]]], ["The optimised primary HEPA filter collects over 99.9% of all vaporised tissue and secondary ULPA filter removes solid and biological particles down to 0.01 \u03bcm16, 17.Smoke evacuation systems ::: GuidanceIt is important that smoke capture device (e.g. smoke evacuation pencil capture port, tubing) is positioned as close to the surgical site as possible to effectively collect all traces of surgical smoke.", [["tissue", "ANATOMY", 71, 77], ["tissue", "TISSUE", 71, 77], ["The optimised primary HEPA filter", "TREATMENT", 0, 33], ["all vaporised tissue", "PROBLEM", 57, 77], ["secondary ULPA filter", "TREATMENT", 82, 103], ["GuidanceIt", "TREATMENT", 194, 204], ["capture device", "TREATMENT", 229, 243], ["evacuation pencil capture port", "TREATMENT", 256, 286], ["primary", "OBSERVATION_MODIFIER", 14, 21], ["HEPA filter", "OBSERVATION", 22, 33], ["ULPA filter", "OBSERVATION", 92, 103], ["surgical", "OBSERVATION", 326, 334], ["surgical smoke", "OBSERVATION", 389, 403]]], ["It has been shown that when the smoke extraction tip is moved only 2 cm from the treatment area, up to 50% of the particulate matter escaped into the local environment18, 19.", [["the smoke extraction tip", "TREATMENT", 28, 52], ["smoke", "OBSERVATION", 32, 37], ["tip", "OBSERVATION_MODIFIER", 49, 52], ["treatment", "OBSERVATION_MODIFIER", 81, 90], ["area", "OBSERVATION_MODIFIER", 91, 95], ["local environment18", "OBSERVATION", 150, 169]]], ["Used smoke evacuator filters, tubing and wands must be handled using standard precautions and disposed of as biohazardous waste20.Smoke evacuation systems ::: GuidanceSmoke evacuation systems should be serviced as per manufacturer\u2019s recommendations to ensure that they function at maximum efficiency.Laser equipment and treatments ::: GuidancePrior to resuming clinical services, practitioners much endeavour to switch on the lasers to check for any faults that may be addressed in good time.", [["smoke evacuator filters", "TREATMENT", 5, 28], ["tubing and wands", "TREATMENT", 30, 46], ["standard precautions", "TREATMENT", 69, 89], ["evacuation systems", "TREATMENT", 173, 191], ["Laser equipment", "TREATMENT", 300, 315], ["the lasers", "TREATMENT", 422, 432], ["any faults", "PROBLEM", 446, 456]]], ["Additionally, as the lockdown has lasted for well over 10 weeks, it would be prudent for practitioners to spend some time for reorientation with laser protocols.Laser equipment and treatments ::: GuidanceAs SARS-CoV-2 can persist on inanimate surfaces such as metal, glass or plastic for up to 9 days, cleaning of laser equipment, display unit, hand pieces, guiding tips, patient goggles and practitioners\u2019 laser eyewear should be meticulously decontaminated after every treatment and as per manufacturer\u2019s recommendation21.", [["hand", "ANATOMY", 345, 349], ["patient", "ORGANISM", 372, 379], ["patient", "SPECIES", 372, 379], ["laser protocols", "TREATMENT", 145, 160], ["Laser equipment", "TREATMENT", 161, 176], ["laser equipment", "TREATMENT", 314, 329], ["hand pieces", "TREATMENT", 345, 356], ["guiding tips", "TREATMENT", 358, 370], ["practitioners\u2019 laser eyewear", "TREATMENT", 392, 420], ["hand pieces", "ANATOMY", 345, 356]]], ["SARS-CoV-2 is efficiently inactivated by surface disinfection procedures with 62\u201371% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite within 1 min.", [["surface", "ANATOMY", 41, 48], ["SARS", "DISEASE", 0, 4], ["ethanol", "CHEMICAL", 85, 92], ["hydrogen peroxide", "CHEMICAL", 99, 116], ["sodium hypochlorite", "CHEMICAL", 125, 144], ["ethanol", "CHEMICAL", 85, 92], ["hydrogen peroxide", "CHEMICAL", 99, 116], ["sodium hypochlorite", "CHEMICAL", 125, 144], ["ethanol", "SIMPLE_CHEMICAL", 85, 92], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 99, 116], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 125, 144], ["ethanol", "TREATMENT", 85, 92], ["0.5% hydrogen peroxide", "TREATMENT", 94, 116], ["sodium hypochlorite", "TREATMENT", 125, 144]]], ["Practitioners must refer to manufacturer-issued COSHH advice to ensure safety of use of these products on laser equipment21.Laser equipment and treatments ::: GuidanceAlthough COVID-19 is not known to transmit through skin, pre-treatment skin cleansing should be meticulous as per local guidelines to reduce aerosolisation of the virus, if present on treatment site.Laser equipment and treatments ::: GuidanceAdditional measures can be employed to reduce the aerosol generation during laser treatments.", [["skin", "ANATOMY", 218, 222], ["skin", "ANATOMY", 238, 242], ["skin", "ORGAN", 218, 222], ["skin", "ORGAN", 238, 242], ["COVID-19", "DNA", 176, 184], ["these products", "TREATMENT", 88, 102], ["laser equipment", "TREATMENT", 106, 121], ["Laser equipment", "TREATMENT", 124, 139], ["COVID", "TEST", 176, 181], ["pre-treatment skin cleansing", "TREATMENT", 224, 252], ["aerosolisation of the virus", "PROBLEM", 308, 335], ["treatment site", "TREATMENT", 351, 365], ["Laser equipment", "TREATMENT", 366, 381], ["GuidanceAdditional measures", "TREATMENT", 401, 428], ["the aerosol generation", "TREATMENT", 455, 477], ["laser treatments", "TREATMENT", 485, 501], ["skin", "ANATOMY", 218, 222], ["skin", "ANATOMY", 238, 242], ["virus", "OBSERVATION", 330, 335], ["aerosol generation", "OBSERVATION", 459, 477]]], ["To avoid the excessive dispersal of aerosol and plume during laser treatment, wherever possible, positive cold air flow used during laser treatments for the purpose of skin cooling should be substituted by alternative methods such as gels and disposable ice packs, which should in turn be appropriately disposed of as clinical waste and sapphire tips thoroughly cleansed post-procedure.", [["skin", "ANATOMY", 168, 172], ["skin", "ORGAN", 168, 172], ["the excessive dispersal of aerosol", "TREATMENT", 9, 43], ["laser treatment", "TREATMENT", 61, 76], ["positive cold air flow", "PROBLEM", 97, 119], ["laser treatments", "TREATMENT", 132, 148], ["skin cooling", "TREATMENT", 168, 180], ["alternative methods", "TREATMENT", 206, 225], ["gels", "TREATMENT", 234, 238], ["disposable ice packs", "TREATMENT", 243, 263], ["clinical waste and sapphire tips", "TREATMENT", 318, 350], ["air flow", "OBSERVATION", 111, 119], ["skin", "ANATOMY", 168, 172]]], ["It has been demonstrated that cold sapphire skin cooling with gel suppresses plume during laser hair removal22.Laser equipment and treatments ::: GuidanceSimilarly, use of hydrogel packs or cling film can reduce tissue splatter and aerosolisation during laser tattoo removal23.", [["skin", "ANATOMY", 44, 48], ["hair", "ANATOMY", 96, 100], ["tissue", "ANATOMY", 212, 218], ["skin", "ORGAN", 44, 48], ["hair", "MULTI-TISSUE_STRUCTURE", 96, 100], ["tissue", "TISSUE", 212, 218], ["cold sapphire skin cooling", "TREATMENT", 30, 56], ["gel suppresses plume", "TREATMENT", 62, 82], ["laser hair removal", "TREATMENT", 90, 108], ["Laser equipment", "TREATMENT", 111, 126], ["hydrogel packs", "TREATMENT", 172, 186], ["cling film", "TREATMENT", 190, 200], ["tissue splatter", "PROBLEM", 212, 227], ["laser tattoo removal23", "TREATMENT", 254, 276], ["cold", "OBSERVATION_MODIFIER", 30, 34], ["sapphire", "OBSERVATION_MODIFIER", 35, 43], ["skin", "ANATOMY", 44, 48]]]], "7433a628e7fe85066cddc5c25a416fea3ffa87e5": [["IntroductionLassa virus (LASV) belongs to the family Arenaviridae, which are enveloped, single-stranded RNA viruses distributed worldwide.", [["IntroductionLassa virus", "ORGANISM", 0, 23], ["LASV", "ORGANISM", 25, 29], ["Arenaviridae", "GENE_OR_GENE_PRODUCT", 53, 65], ["IntroductionLassa virus", "SPECIES", 0, 23], ["LASV", "SPECIES", 25, 29], ["IntroductionLassa virus", "PROBLEM", 0, 23], ["Arenaviridae", "TREATMENT", 53, 65]]], ["Based on their antigenic relationships and geographic distribution, arenaviruses are divided into two major groups.", [["arenaviruses", "ORGANISM", 68, 80], ["arenaviruses", "PROBLEM", 68, 80], ["geographic", "OBSERVATION_MODIFIER", 43, 53], ["distribution", "OBSERVATION_MODIFIER", 54, 66], ["arenaviruses", "OBSERVATION", 68, 80]]], ["The Old World group includes the prototype of this family, lymphocytic choriomeningitis virus (LCMV), and LASV, which is endemic in West African countries and causes every year thousands of human infections with hemorrhagic fever as a severe clinical manifestation [1] .", [["lymphocytic choriomeningitis virus (LCMV), and LASV", "DISEASE", 59, 110], ["infections", "DISEASE", 196, 206], ["hemorrhagic fever", "DISEASE", 212, 229], ["lymphocytic choriomeningitis virus", "ORGANISM", 59, 93], ["LCMV", "ORGANISM", 95, 99], ["LASV", "ORGANISM", 106, 110], ["human", "ORGANISM", 190, 195], ["lymphocytic choriomeningitis virus", "SPECIES", 59, 93], ["human", "SPECIES", 190, 195], ["lymphocytic choriomeningitis virus", "SPECIES", 59, 93], ["LCMV", "SPECIES", 95, 99], ["LASV", "SPECIES", 106, 110], ["human", "SPECIES", 190, 195], ["lymphocytic choriomeningitis virus", "PROBLEM", 59, 93], ["LASV", "PROBLEM", 106, 110], ["human infections", "PROBLEM", 190, 206], ["hemorrhagic fever", "PROBLEM", 212, 229], ["a severe clinical manifestation", "PROBLEM", 233, 264], ["lymphocytic choriomeningitis", "OBSERVATION", 59, 87], ["endemic", "OBSERVATION_MODIFIER", 121, 128], ["hemorrhagic", "OBSERVATION_MODIFIER", 212, 223]]], ["The New World group includes among others Machupo, Junin, Guanarito and Sabia viruses which can cause viral hemorrhagic fever (VHF).", [["viral hemorrhagic fever", "DISEASE", 102, 125], ["VHF", "DISEASE", 127, 130], ["Sabia viruses", "ORGANISM", 72, 85], ["viral hemorrhagic fever", "SPECIES", 102, 125], ["Sabia viruses", "SPECIES", 72, 85], ["Junin", "PROBLEM", 51, 56], ["Sabia viruses", "PROBLEM", 72, 85], ["viral hemorrhagic fever", "PROBLEM", 102, 125], ["VHF", "PROBLEM", 127, 130], ["New", "OBSERVATION_MODIFIER", 4, 7], ["hemorrhagic", "OBSERVATION_MODIFIER", 108, 119]]], ["With the exception of the New World virus Tacaribe, which was isolated from Artibeus bats, arenaviruses are rodent-borne viruses [2] .IntroductionOver the past few years great efforts have been made to find potential therapeutic and vaccination approaches in the arenavirus field (reviewed in [3, 4, 5] ).", [["Tacaribe", "CHEMICAL", 42, 50], ["arenavirus", "DISEASE", 263, 273], ["New World virus Tacaribe", "ORGANISM", 26, 50], ["Artibeus bats", "ORGANISM", 76, 89], ["arenaviruses", "ORGANISM", 91, 103], ["rodent", "SPECIES", 108, 114], ["New World virus", "SPECIES", 26, 41], ["Artibeus bats", "SPECIES", 76, 89], ["the New World virus Tacaribe", "PROBLEM", 22, 50], ["Artibeus bats", "PROBLEM", 76, 89], ["arenaviruses", "PROBLEM", 91, 103], ["therapeutic and vaccination approaches", "TREATMENT", 217, 255], ["New", "OBSERVATION_MODIFIER", 26, 29], ["virus Tacaribe", "OBSERVATION", 36, 50], ["Artibeus bats", "OBSERVATION", 76, 89]]], ["Until now there is no specific and effective treatment available to combat hemorrhagic fevers caused by arenaviruses.", [["hemorrhagic fevers", "DISEASE", 75, 93], ["arenaviruses", "DISEASE", 104, 116], ["arenaviruses", "ORGANISM", 104, 116], ["effective treatment", "TREATMENT", 35, 54], ["hemorrhagic fevers", "PROBLEM", 75, 93], ["arenaviruses", "PROBLEM", 104, 116], ["no", "UNCERTAINTY", 19, 21], ["arenaviruses", "OBSERVATION", 104, 116]]], ["Administration of convalescent plasma has been reported to reduce the mortality rates of patients with Argentine hemorrhagic fever, however, 10% of immune-plasma recipients developed a late neurological syndrome of unknown origin [6] .", [["plasma", "ANATOMY", 31, 37], ["immune-plasma", "ANATOMY", 148, 161], ["neurological", "ANATOMY", 190, 202], ["Argentine hemorrhagic fever", "DISEASE", 103, 130], ["neurological syndrome", "DISEASE", 190, 211], ["convalescent", "ORGANISM", 18, 30], ["plasma", "ORGANISM_SUBSTANCE", 31, 37], ["patients", "ORGANISM", 89, 97], ["plasma", "ORGANISM_SUBSTANCE", 155, 161], ["patients", "SPECIES", 89, 97], ["convalescent plasma", "TREATMENT", 18, 37], ["Argentine hemorrhagic fever", "PROBLEM", 103, 130], ["immune-plasma recipients", "TREATMENT", 148, 172], ["a late neurological syndrome", "PROBLEM", 183, 211], ["hemorrhagic", "OBSERVATION_MODIFIER", 113, 124], ["fever", "OBSERVATION", 125, 130], ["late", "OBSERVATION_MODIFIER", 185, 189], ["neurological syndrome", "OBSERVATION", 190, 211]]], ["The only existing drug used to treat Lassa fever and certain South American hemorrhagic fevers is the broad-spectrum antiviral agent ribavirin, a ribonucleoside analogue, which has shown to be partially effective if given early in the course of illness [7, 8, 9, 10] .", [["Lassa fever", "DISEASE", 37, 48], ["hemorrhagic fevers", "DISEASE", 76, 94], ["ribavirin", "CHEMICAL", 133, 142], ["ribonucleoside", "CHEMICAL", 146, 160], ["illness", "DISEASE", 245, 252], ["ribavirin", "CHEMICAL", 133, 142], ["ribonucleoside", "CHEMICAL", 146, 160], ["Lassa", "ORGANISM", 37, 42], ["ribavirin", "SIMPLE_CHEMICAL", 133, 142], ["ribonucleoside", "SIMPLE_CHEMICAL", 146, 160], ["Lassa fever", "PROBLEM", 37, 48], ["hemorrhagic fevers", "PROBLEM", 76, 94], ["the broad-spectrum antiviral agent ribavirin", "TREATMENT", 98, 142], ["a ribonucleoside analogue", "TREATMENT", 144, 169], ["illness", "PROBLEM", 245, 252]]], ["Even though the drug is relatively inexpensive for patients in highdeveloped countries, it is still unaffordable for many of those living in West Africa and South America.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["Moreover, several adverse effects have been associated with ribavirin therapy in patient studies and animal models [11, 12, 13, 14, 15] .", [["ribavirin", "CHEMICAL", 60, 69], ["ribavirin", "CHEMICAL", 60, 69], ["ribavirin", "SIMPLE_CHEMICAL", 60, 69], ["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["ribavirin therapy", "TREATMENT", 60, 77], ["patient studies", "TEST", 81, 96], ["animal models", "TEST", 101, 114], ["associated with", "UNCERTAINTY", 44, 59], ["ribavirin therapy", "OBSERVATION", 60, 77]]], ["The lack of effective disease control measures as well as the discovery of new fatal arenavirus species that pose a risk of epidemic potential [16, 17] , emphasize the need for novel therapeutic interventions.IntroductionLassa virions are pleomorphic lipid-enveloped particles that contain two single-stranded RNA segments, designated L (large) and S (small), encoding four viral proteins in a unique ambisense coding strategy.", [["arenavirus", "DISEASE", 85, 95], ["arenavirus", "ORGANISM", 85, 95], ["IntroductionLassa virions", "ORGANISM", 209, 234], ["L (large)", "GENE_OR_GENE_PRODUCT", 335, 344], ["viral proteins", "PROTEIN", 374, 388], ["effective disease control measures", "TREATMENT", 12, 46], ["new fatal arenavirus species", "PROBLEM", 75, 103], ["novel therapeutic interventions", "TREATMENT", 177, 208], ["IntroductionLassa virions", "TREATMENT", 209, 234], ["a unique ambisense coding strategy", "TREATMENT", 392, 426], ["effective", "OBSERVATION_MODIFIER", 12, 21], ["disease", "OBSERVATION", 22, 29], ["new", "OBSERVATION_MODIFIER", 75, 78], ["fatal", "OBSERVATION_MODIFIER", 79, 84], ["arenavirus", "OBSERVATION", 85, 95], ["enveloped particles", "OBSERVATION", 257, 276], ["two", "OBSERVATION_MODIFIER", 290, 293], ["single", "OBSERVATION_MODIFIER", 294, 300], ["stranded", "OBSERVATION", 301, 309], ["RNA segments", "ANATOMY_MODIFIER", 310, 322], ["L", "ANATOMY_MODIFIER", 335, 336], ["large", "OBSERVATION_MODIFIER", 338, 343], ["small", "OBSERVATION_MODIFIER", 352, 357], ["viral proteins", "OBSERVATION", 374, 388]]], ["The L segment encodes the viral RNA-dependent RNA polymerase (L) and the small zinc finger matrix protein (Z) [18] ; the S segment encodes the virus nucleoprotein (NP) and the virus surface glycoprotein precursor (preGP-C) [19] . preGP-C is cleaved co-translationally into a stable signal peptide and GP-C [20] .", [["zinc", "CHEMICAL", 79, 83], ["preGP-C", "CHEMICAL", 230, 237], ["RNA-dependent RNA polymerase (L)", "GENE_OR_GENE_PRODUCT", 32, 64], ["zinc finger matrix protein (Z) [18", "GENE_OR_GENE_PRODUCT", 79, 113], ["preGP-C", "GENE_OR_GENE_PRODUCT", 214, 221], ["preGP-C", "GENE_OR_GENE_PRODUCT", 230, 237], ["L segment", "DNA", 4, 13], ["viral RNA-dependent RNA polymerase", "PROTEIN", 26, 60], ["L", "PROTEIN", 62, 63], ["small zinc finger matrix protein", "PROTEIN", 73, 105], ["Z", "PROTEIN", 107, 108], ["S segment", "PROTEIN", 121, 130], ["virus nucleoprotein", "PROTEIN", 143, 162], ["NP", "PROTEIN", 164, 166], ["virus surface glycoprotein precursor", "PROTEIN", 176, 212], ["preGP", "PROTEIN", 214, 219], ["preGP", "PROTEIN", 230, 235], ["the viral RNA", "TEST", 22, 35], ["RNA polymerase", "TEST", 46, 60], ["the small zinc finger matrix protein", "TEST", 69, 105], ["Z", "TEST", 107, 108], ["the S segment encodes the virus nucleoprotein", "PROBLEM", 117, 162], ["the virus surface glycoprotein precursor", "TEST", 172, 212], ["L", "ANATOMY_MODIFIER", 4, 5], ["segment", "ANATOMY_MODIFIER", 6, 13], ["viral RNA", "OBSERVATION", 26, 35], ["dependent", "OBSERVATION_MODIFIER", 36, 45], ["RNA polymerase", "OBSERVATION", 46, 60], ["small", "OBSERVATION_MODIFIER", 73, 78], ["zinc finger", "ANATOMY", 79, 90], ["matrix protein", "OBSERVATION", 91, 105]]], ["Post-translational maturation cleavage of GP-C by the proprotein convertase site 1 protease (S1P, [21] ), also known as subtilisin kexin isozyme-1 (SKI-1, [22] ), leads then to the generation of the distal receptor-binding subunit GP-1 and the transmembrane-spanning fusion competent subunit GP-2 [23] .", [["transmembrane", "ANATOMY", 244, 257], ["GP-C", "GENE_OR_GENE_PRODUCT", 42, 46], ["proprotein convertase site 1 protease", "GENE_OR_GENE_PRODUCT", 54, 91], ["S1P", "GENE_OR_GENE_PRODUCT", 93, 96], ["subtilisin kexin isozyme-1", "GENE_OR_GENE_PRODUCT", 120, 146], ["SKI-1", "GENE_OR_GENE_PRODUCT", 148, 153], ["GP-1", "GENE_OR_GENE_PRODUCT", 231, 235], ["GP-C", "PROTEIN", 42, 46], ["proprotein convertase site 1 protease", "PROTEIN", 54, 91], ["S1P", "PROTEIN", 93, 96], ["subtilisin kexin isozyme-1", "PROTEIN", 120, 146], ["SKI", "PROTEIN", 148, 151], ["distal receptor-binding subunit GP-1", "PROTEIN", 199, 235], ["transmembrane-spanning fusion competent subunit GP", "PROTEIN", 244, 294], ["the proprotein convertase site", "TREATMENT", 50, 80], ["the transmembrane-spanning fusion", "TREATMENT", 240, 273], ["distal", "ANATOMY_MODIFIER", 199, 205]]], ["Together with the signal peptide these subunits form the tripartite glycoprotein spike complex on the viral surface [24, 25] .IntroductionThe glycoproteins of the Old World arenaviruses LASV and LCMV were the first viral glycoproteins that were shown to be proteolytically processed by S1P [23, 26] , which normally plays important physiological regulatory roles in cholesterol metabolism, ER stress response, cartilage development and other cellular processes [21, 27, 28, 29, 30, 31] .", [["surface", "ANATOMY", 108, 115], ["cartilage", "ANATOMY", 410, 419], ["cellular", "ANATOMY", 442, 450], ["S1P", "CHEMICAL", 286, 289], ["cholesterol", "CHEMICAL", 366, 377], ["cholesterol", "CHEMICAL", 366, 377], ["Old World arenaviruses LASV", "ORGANISM", 163, 190], ["LCMV", "ORGANISM", 195, 199], ["S1P", "GENE_OR_GENE_PRODUCT", 286, 289], ["cholesterol", "SIMPLE_CHEMICAL", 366, 377], ["ER", "GENE_OR_GENE_PRODUCT", 390, 392], ["cartilage", "TISSUE", 410, 419], ["cellular", "CELL", 442, 450], ["tripartite glycoprotein spike complex", "PROTEIN", 57, 94], ["viral glycoproteins", "PROTEIN", 215, 234], ["ER", "PROTEIN", 390, 392], ["Old World arenaviruses LASV", "SPECIES", 163, 190], ["LCMV", "SPECIES", 195, 199], ["the tripartite glycoprotein spike complex", "PROBLEM", 53, 94], ["the viral surface", "TEST", 98, 115], ["The glycoproteins", "TREATMENT", 138, 155], ["the Old World arenaviruses LASV", "TREATMENT", 159, 190], ["LCMV", "PROBLEM", 195, 199], ["the first viral glycoproteins", "PROBLEM", 205, 234], ["ER stress response", "PROBLEM", 390, 408], ["cartilage development and other cellular processes", "PROBLEM", 410, 460], ["LCMV", "OBSERVATION", 195, 199]]], ["Using systematic mutational analysis of the LCMV GP cleavage site, the consensus motif R-(R/K/ H)-L-(A/L/S/T/F) was determined, which is conserved in the glycoprotein sequences of the Old World viruses LASV, Mopeia and Mobala, as well as the New World virus Pichinde, suggesting that all arenavirus glycoproteins are cleaved by S1P [26, 32] .", [["S1P", "CHEMICAL", 328, 331], ["LCMV", "ORGANISM", 44, 48], ["Old World viruses LASV", "ORGANISM", 184, 206], ["New World virus Pichinde", "ORGANISM", 242, 266], ["arenavirus", "ORGANISM", 288, 298], ["S1P", "GENE_OR_GENE_PRODUCT", 328, 331], ["LCMV GP cleavage site", "DNA", 44, 65], ["glycoprotein sequences", "DNA", 154, 176], ["arenavirus glycoproteins", "PROTEIN", 288, 312], ["Old World viruses LASV", "SPECIES", 184, 206], ["New World virus", "SPECIES", 242, 257], ["systematic mutational analysis", "TEST", 6, 36], ["the consensus motif R", "TEST", 67, 88], ["R/K/ H", "TEST", 90, 96], ["A/L/S/T/F", "TEST", 101, 110], ["Mopeia", "TREATMENT", 208, 214], ["Mobala", "TREATMENT", 219, 225], ["all arenavirus glycoproteins", "TREATMENT", 284, 312]]], ["Indeed, more recently Rojek et al. reported that glycoproteins from the New World hemorrhagic fever viruses Junin, Machupo and Guanarito are also processed by S1P, although Guanarito possesses a protease recognition motif that differs from known arenavirus GP consensus cleavage sequences, indicating a broader substrate specificity of S1P than previously anticipated [33] .IntroductionProteolytic activation of LASV GP-C by S1P is not necessary for transport of GP-C to the cell surface, where budding of arenaviruses occurs, but is essential for incorporation of the cleaved subunits into virions, and thus, for the formation of infectious viral particles.", [["cell surface", "ANATOMY", 475, 487], ["virions", "ANATOMY", 591, 598], ["hemorrhagic fever", "DISEASE", 82, 99], ["Junin", "DISEASE", 108, 113], ["S1P", "CHEMICAL", 159, 162], ["Guanarito", "CHEMICAL", 173, 182], ["S1P", "CHEMICAL", 336, 339], ["S1P", "CHEMICAL", 425, 428], ["arenaviruses", "DISEASE", 506, 518], ["S1P", "CHEMICAL", 336, 339], ["New World hemorrhagic fever viruses", "ORGANISM", 72, 107], ["S1P", "GENE_OR_GENE_PRODUCT", 159, 162], ["Guanarito", "SIMPLE_CHEMICAL", 173, 182], ["S1P", "GENE_OR_GENE_PRODUCT", 336, 339], ["LASV", "ORGANISM", 412, 416], ["GP-C", "GENE_OR_GENE_PRODUCT", 417, 421], ["S1P", "GENE_OR_GENE_PRODUCT", 425, 428], ["GP-C", "GENE_OR_GENE_PRODUCT", 463, 467], ["cell surface", "CELLULAR_COMPONENT", 475, 487], ["protease recognition motif", "PROTEIN", 195, 221], ["arenavirus GP consensus cleavage sequences", "DNA", 246, 288], ["LASV GP-C", "PROTEIN", 412, 421], ["GP-C", "PROTEIN", 463, 467], ["cleaved subunits", "PROTEIN", 569, 585], ["World hemorrhagic fever", "SPECIES", 76, 99], ["New World hemorrhagic fever viruses", "SPECIES", 72, 107], ["LASV", "SPECIES", 412, 416], ["glycoproteins", "TREATMENT", 49, 62], ["World hemorrhagic fever viruses Junin", "PROBLEM", 76, 113], ["a protease recognition motif", "PROBLEM", 193, 221], ["known arenavirus GP consensus cleavage sequences", "PROBLEM", 240, 288], ["arenaviruses", "PROBLEM", 506, 518], ["the cleaved subunits into virions", "PROBLEM", 565, 598], ["infectious viral particles", "PROBLEM", 631, 657], ["hemorrhagic", "OBSERVATION_MODIFIER", 82, 93], ["arenaviruses", "OBSERVATION", 506, 518], ["infectious", "OBSERVATION_MODIFIER", 631, 641], ["viral particles", "OBSERVATION", 642, 657]]], ["In the absence of GP-C cleavage, enveloped non-infectious LASV-like particles are released containing L, NP, Z protein and viral RNA but are devoid of viral glycoproteins [23] .", [["GP-C", "GENE_OR_GENE_PRODUCT", 18, 22], ["LASV-like particles", "ORGANISM", 58, 77], ["Z protein", "GENE_OR_GENE_PRODUCT", 109, 118], ["L, NP, Z protein and viral RNA", "RNA", 102, 132], ["viral glycoproteins", "PROTEIN", 151, 170], ["LASV", "SPECIES", 58, 62], ["GP-C cleavage", "PROBLEM", 18, 31], ["enveloped non-infectious LASV", "PROBLEM", 33, 62], ["NP, Z protein", "TEST", 105, 118], ["viral RNA", "PROBLEM", 123, 132], ["viral glycoproteins", "PROBLEM", 151, 170], ["non-infectious", "OBSERVATION", 43, 57], ["viral RNA", "OBSERVATION", 123, 132]]], ["Similar results were described for LCMV and New World hemorrhagic fever viruses [33, 34] .IntroductionIn addition to its important role in the arenaviral life cycle, S1P is critical for the infectivity of Crimean-Congo hemorrhagic fever virus (CCHFV), a member of the Bunyaviridae family, through processing of the glycoprotein Gn [35, 36] .", [["hemorrhagic fever", "DISEASE", 54, 71], ["S1P", "CHEMICAL", 166, 169], ["Crimean-Congo hemorrhagic fever", "DISEASE", 205, 236], ["CCHFV", "DISEASE", 244, 249], ["LCMV", "ORGANISM", 35, 39], ["New World hemorrhagic fever viruses", "ORGANISM", 44, 79], ["S1P", "GENE_OR_GENE_PRODUCT", 166, 169], ["Crimean-Congo hemorrhagic fever virus", "ORGANISM", 205, 242], ["CCHFV", "ORGANISM", 244, 249], ["glycoprotein Gn", "PROTEIN", 315, 330], ["World hemorrhagic fever", "SPECIES", 48, 71], ["Congo hemorrhagic fever virus", "SPECIES", 213, 242], ["LCMV", "SPECIES", 35, 39], ["New World hemorrhagic fever viruses", "SPECIES", 44, 79], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 205, 242], ["CCHFV", "SPECIES", 244, 249], ["LCMV", "PROBLEM", 35, 39], ["New World hemorrhagic fever viruses", "PROBLEM", 44, 79], ["the arenaviral life cycle", "TREATMENT", 139, 164], ["Crimean", "TEST", 205, 212], ["Congo hemorrhagic fever virus", "PROBLEM", 213, 242], ["New", "OBSERVATION_MODIFIER", 44, 47], ["hemorrhagic", "OBSERVATION_MODIFIER", 54, 65]]], ["These findings make the inhibition of S1P particularly interesting for the development of a novel antiviral therapeutic that will target pathogenic viruses known to be processed by S1P.IntroductionA successful approach to inhibit proprotein convertases involves genetically engineered antitrypsins, which are derived from a 1antitrypsin (a 1 -AT). a 1 -AT is a serine protease inhibitor (serpin) with a characteristic exposed reactive center loop (RCL), which mediates binding to the active site of its target protease.", [["S1P", "CHEMICAL", 38, 41], ["S1P", "CHEMICAL", 181, 184], ["S1P", "CHEMICAL", 38, 41], ["1 -AT", "CHEMICAL", 350, 355], ["serine", "CHEMICAL", 361, 367], ["S1P", "GENE_OR_GENE_PRODUCT", 38, 41], ["S1P", "GENE_OR_GENE_PRODUCT", 181, 184], ["antitrypsins", "GENE_OR_GENE_PRODUCT", 285, 297], ["1antitrypsin", "GENE_OR_GENE_PRODUCT", 324, 336], ["1 -AT", "GENE_OR_GENE_PRODUCT", 340, 345], ["1 -AT", "SIMPLE_CHEMICAL", 350, 355], ["serpin", "GENE_OR_GENE_PRODUCT", 388, 394], ["proprotein convertases", "PROTEIN", 230, 252], ["serpin", "PROTEIN", 388, 394], ["RCL", "PROTEIN", 448, 451], ["protease", "PROTEIN", 510, 518], ["a novel antiviral therapeutic", "TREATMENT", 90, 119], ["pathogenic viruses", "PROBLEM", 137, 155], ["IntroductionA successful approach", "TREATMENT", 185, 218], ["inhibit proprotein convertases", "TREATMENT", 222, 252], ["genetically engineered antitrypsins", "PROBLEM", 262, 297], ["a serine protease inhibitor", "TREATMENT", 359, 386], ["reactive", "OBSERVATION_MODIFIER", 426, 434], ["active", "OBSERVATION_MODIFIER", 484, 490]]], ["The exploration for the potential use of modified antitrypsins with an altered inhibitory spectrum has been guided by the discovery of a natural variant of a 1 -AT, known as Pittsburgh (a 1 -AT-PIT), found in a patient who had a severe bleeding disorder caused by mutation of the P1 reactive center residue of antitrypsin from methionine to arginine [37] .", [["bleeding disorder", "DISEASE", 236, 253], ["methionine", "CHEMICAL", 327, 337], ["arginine", "CHEMICAL", 341, 349], ["methionine", "CHEMICAL", 327, 337], ["arginine", "CHEMICAL", 341, 349], ["1 -AT", "GENE_OR_GENE_PRODUCT", 158, 163], ["patient", "ORGANISM", 211, 218], ["antitrypsin", "GENE_OR_GENE_PRODUCT", 310, 321], ["methionine", "AMINO_ACID", 327, 337], ["arginine", "AMINO_ACID", 341, 349], ["antitrypsin", "PROTEIN", 310, 321], ["patient", "SPECIES", 211, 218], ["The exploration", "TEST", 0, 15], ["modified antitrypsins", "TREATMENT", 41, 62], ["a severe bleeding disorder", "PROBLEM", 227, 253], ["mutation of the P1 reactive center residue", "PROBLEM", 264, 306], ["antitrypsin from methionine", "TREATMENT", 310, 337], ["severe", "OBSERVATION_MODIFIER", 229, 235], ["bleeding", "OBSERVATION", 236, 244], ["reactive", "OBSERVATION_MODIFIER", 283, 291]]], ["This substitution changed its specificity from elastase to thrombin and other coagulation proteases.", [["elastase", "GENE_OR_GENE_PRODUCT", 47, 55], ["thrombin", "GENE_OR_GENE_PRODUCT", 59, 67], ["elastase", "PROTEIN", 47, 55], ["thrombin", "PROTEIN", 59, 67], ["coagulation proteases", "PROTEIN", 78, 99], ["This substitution", "PROBLEM", 0, 17], ["elastase", "PROBLEM", 47, 55], ["thrombin", "TREATMENT", 59, 67], ["other coagulation proteases", "TEST", 72, 99]]], ["Due to the introduction of a second mutation from alanine to arginine at P4 of the RCL, the engineered a 1antitrypsin variant Portland (a 1 -AT-PDX) showed high affinity for furin [38] . a 1 -AT-PDX efficiently inhibited the formation of infectious HIV, measles virus, and human cytomegalovirus progeny by blocking furin-dependent processing of glycoproteins gp160, F0 and gB, respectively [38, 39, 40, 41] .", [["alanine", "CHEMICAL", 50, 57], ["arginine", "CHEMICAL", 61, 69], ["1 -AT-PDX", "CHEMICAL", 138, 147], ["1 -AT-PDX", "CHEMICAL", 189, 198], ["infectious HIV, measles virus", "DISEASE", 238, 267], ["alanine", "CHEMICAL", 50, 57], ["arginine", "CHEMICAL", 61, 69], ["1 -AT-PDX", "CHEMICAL", 189, 198], ["alanine", "AMINO_ACID", 50, 57], ["arginine", "AMINO_ACID", 61, 69], ["1antitrypsin", "GENE_OR_GENE_PRODUCT", 105, 117], ["furin", "GENE_OR_GENE_PRODUCT", 174, 179], ["1 -AT-PDX", "SIMPLE_CHEMICAL", 189, 198], ["HIV", "ORGANISM", 249, 252], ["measles virus", "ORGANISM", 254, 267], ["human", "ORGANISM", 273, 278], ["cytomegalovirus", "ORGANISM", 279, 294], ["furin", "GENE_OR_GENE_PRODUCT", 315, 320], ["gp160", "GENE_OR_GENE_PRODUCT", 359, 364], ["F0", "GENE_OR_GENE_PRODUCT", 366, 368], ["gB", "GENE_OR_GENE_PRODUCT", 373, 375], ["RCL", "PROTEIN", 83, 86], ["furin", "PROTEIN", 315, 320], ["glycoproteins gp160", "PROTEIN", 345, 364], ["F0", "PROTEIN", 366, 368], ["gB", "PROTEIN", 373, 375], ["HIV", "SPECIES", 249, 252], ["measles virus", "SPECIES", 254, 267], ["human", "SPECIES", 273, 278], ["HIV", "SPECIES", 249, 252], ["measles virus", "SPECIES", 254, 267], ["human cytomegalovirus", "SPECIES", 273, 294], ["a second mutation", "TREATMENT", 27, 44], ["high affinity", "PROBLEM", 156, 169], ["infectious HIV", "PROBLEM", 238, 252], ["measles virus", "PROBLEM", 254, 267], ["human cytomegalovirus progeny", "TREATMENT", 273, 302], ["blocking furin", "TEST", 306, 320], ["glycoproteins gp160", "TEST", 345, 364], ["gB", "TEST", 373, 375], ["RCL", "ANATOMY", 83, 86], ["infectious", "OBSERVATION_MODIFIER", 238, 248], ["gB", "ANATOMY", 373, 375]]], ["Pullikotil and coworkers used this approach for the generation of highly selective a 1 -antitrypsin variants specific for S1P by introducing various S1P recognition motifs into the RCL of a 1 -antitrypsin [42] .", [["Pullikotil", "CHEMICAL", 0, 10], ["S1P", "CHEMICAL", 122, 125], ["S1P", "CHEMICAL", 149, 152], ["S1P", "CHEMICAL", 122, 125], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 85, 99], ["S1P", "GENE_OR_GENE_PRODUCT", 122, 125], ["S1P", "GENE_OR_GENE_PRODUCT", 149, 152], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 190, 204], ["S1P recognition motifs", "PROTEIN", 149, 171], ["RCL", "PROTEIN", 181, 184], ["this approach", "TREATMENT", 30, 43]]], ["The adaptation of a 1 -antitrypsin towards S1P efficiently inhibited the processing of the S1P substrates SREBP-2 (sterol regulatory element binding protein), ATF6 (activating transcription factor 6) as well as CCHFV glycoprotein [42] .", [["S1P", "CHEMICAL", 43, 46], ["S1P", "CHEMICAL", 43, 46], ["sterol", "CHEMICAL", 115, 121], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 20, 34], ["S1P", "GENE_OR_GENE_PRODUCT", 43, 46], ["S1P", "GENE_OR_GENE_PRODUCT", 91, 94], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 106, 113], ["sterol regulatory element binding protein", "GENE_OR_GENE_PRODUCT", 115, 156], ["ATF6 (activating transcription factor 6", "GENE_OR_GENE_PRODUCT", 159, 198], ["S1P substrates", "PROTEIN", 91, 105], ["SREBP-2", "PROTEIN", 106, 113], ["sterol regulatory element binding protein", "PROTEIN", 115, 156], ["ATF6", "PROTEIN", 159, 163], ["activating transcription factor 6", "PROTEIN", 165, 198], ["CCHFV glycoprotein", "PROTEIN", 211, 229], ["the S1P substrates SREBP", "TEST", 87, 111], ["sterol regulatory element binding protein)", "TREATMENT", 115, 157], ["ATF6 (activating transcription factor", "TREATMENT", 159, 196]]], ["However, the effect of these inhibitors on CCHFV infection was not analyzed in that study.", [["CCHFV infection", "DISEASE", 43, 58], ["CCHFV", "ORGANISM", 43, 48], ["CCHFV", "SPECIES", 43, 48], ["these inhibitors", "TREATMENT", 23, 39], ["CCHFV infection", "PROBLEM", 43, 58], ["that study", "TEST", 79, 89], ["infection", "OBSERVATION", 49, 58]]], ["To block cleavage of the LASV glycoprotein, we generated here recombinant a 1 -antitrypsin variants mimicking the S1P recognition motifs RRIL, RRVL and RRYL that exhibited the greatest inhibitory potential based on immunoblot quantification.", [["LASV", "ORGANISM", 25, 29], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 76, 90], ["S1P", "GENE_OR_GENE_PRODUCT", 114, 117], ["RRVL", "SIMPLE_CHEMICAL", 143, 147], ["RRYL", "SIMPLE_CHEMICAL", 152, 156], ["LASV glycoprotein", "PROTEIN", 25, 42], ["1 -antitrypsin variants", "PROTEIN", 76, 99], ["S1P recognition motifs", "PROTEIN", 114, 136], ["RRVL", "DNA", 143, 147], ["RRYL", "DNA", 152, 156], ["LASV", "SPECIES", 25, 29], ["the LASV glycoprotein", "TREATMENT", 21, 42], ["immunoblot quantification", "TEST", 215, 240]]], ["In addition, we used an a 1 -AT construct that contains the LASV GP cleavage motif RRLL in its RCL.", [["LASV", "ORGANISM", 60, 64], ["1 -AT construct", "DNA", 26, 41], ["LASV GP cleavage motif", "PROTEIN", 60, 82], ["RRLL", "PROTEIN", 83, 87], ["RCL", "PROTEIN", 95, 98], ["LASV", "SPECIES", 60, 64], ["an a 1 -AT construct", "TREATMENT", 21, 41], ["the LASV GP cleavage", "TREATMENT", 56, 76], ["LASV", "OBSERVATION", 60, 64], ["motif RRLL", "OBSERVATION", 77, 87], ["RCL", "ANATOMY", 95, 98]]], ["Using a doxycycline regulated expression system we demonstrate that S1P-adapted a 1antitrypsin variants efficiently block proteolytic maturation of the glycoprotein precursor GP-C, whereas a furin-specific a 1 -AT had no effect on GP-C processing.", [["doxycycline", "CHEMICAL", 8, 19], ["S1P", "CHEMICAL", 68, 71], ["doxycycline", "CHEMICAL", 8, 19], ["S1P", "CHEMICAL", 68, 71], ["1 -AT", "CHEMICAL", 208, 213], ["doxycycline", "SIMPLE_CHEMICAL", 8, 19], ["S1P", "GENE_OR_GENE_PRODUCT", 68, 71], ["1antitrypsin", "GENE_OR_GENE_PRODUCT", 82, 94], ["GP-C", "GENE_OR_GENE_PRODUCT", 175, 179], ["furin", "GENE_OR_GENE_PRODUCT", 191, 196], ["1 -AT", "SIMPLE_CHEMICAL", 208, 213], ["GP-C", "SIMPLE_CHEMICAL", 231, 235], ["S1P", "PROTEIN", 68, 71], ["glycoprotein precursor GP-C", "PROTEIN", 152, 179], ["furin", "PROTEIN", 191, 196], ["a doxycycline regulated expression system", "TREATMENT", 6, 47], ["a 1antitrypsin variants", "TREATMENT", 80, 103], ["a furin", "TEST", 189, 196]]], ["Virus replication of both a replication-competent recombinant vesicular stomatitis virus expressing the LASV glycoprotein GP-C (VSVDG/LASVGP) and authentic LASV was significantly inhibited in the presence of S1P-specific a 1 -antitrypsins.", [["vesicular stomatitis", "DISEASE", 62, 82], ["S1P", "CHEMICAL", 208, 211], ["S1P", "CHEMICAL", 208, 211], ["Virus", "ORGANISM", 0, 5], ["recombinant", "ORGANISM", 50, 61], ["vesicular stomatitis virus", "ORGANISM", 62, 88], ["LASV", "ORGANISM", 104, 108], ["GP-C", "GENE_OR_GENE_PRODUCT", 122, 126], ["VSVDG", "GENE_OR_GENE_PRODUCT", 128, 133], ["LASVGP", "GENE_OR_GENE_PRODUCT", 134, 140], ["LASV", "ORGANISM", 156, 160], ["S1P", "GENE_OR_GENE_PRODUCT", 208, 211], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 223, 238], ["LASV glycoprotein GP", "PROTEIN", 104, 124], ["C", "PROTEIN", 125, 126], ["VSVDG", "PROTEIN", 128, 133], ["LASVGP", "PROTEIN", 134, 140], ["S1P", "PROTEIN", 208, 211], ["1 -antitrypsins", "PROTEIN", 223, 238], ["vesicular stomatitis virus", "SPECIES", 62, 88], ["stomatitis virus", "SPECIES", 72, 88], ["LASV", "SPECIES", 104, 108], ["LASV", "SPECIES", 156, 160], ["Virus replication", "TREATMENT", 0, 17], ["a replication", "TREATMENT", 26, 39], ["competent recombinant vesicular stomatitis virus", "PROBLEM", 40, 88], ["the LASV glycoprotein GP", "TEST", 100, 124], ["C (VSVDG/LASVGP)", "PROBLEM", 125, 141], ["authentic LASV", "PROBLEM", 146, 160], ["S1P", "TEST", 208, 211], ["recombinant", "OBSERVATION_MODIFIER", 50, 61], ["vesicular stomatitis virus", "OBSERVATION", 62, 88], ["LASV", "OBSERVATION", 156, 160]]], ["The degree of inhibition of viral replication correlated with the ability of the different a 1 -antitrypsin variants to inhibit the processing of LASV GP-C.IntroductionSince glycoprotein processing by the endoprotease S1P is not only critical for virus infectivity of LASV [23] , and other arenaviruses causing hemorrhagic fever [33] , but also for members of the Bunyaviridae family [36] , further optimization based on our findings could lead to a potent and specific S1P inhibitor with the potential treatment of certain VHFs.Molecular cloning and expressioncDNA of the open reading frame of rat a 1 -antitrypsin (Gene Bank Accession Number NM_022519) (a kind gift from Dr. G. Thomas, Vollum Institute, Oregon Health & Science University, Portland, USA) was inserted into pSG5 and used as a template to generate S1P-specific a 1 -antitrypsin variants by recombinant polymerase chain reaction (PCR) using overlapping oligonucleotides [43] .", [["VHFs", "ANATOMY", 524, 528], ["S1P", "CHEMICAL", 218, 221], ["arenaviruses", "DISEASE", 290, 302], ["hemorrhagic fever", "DISEASE", 311, 328], ["VHFs", "DISEASE", 524, 528], ["S1P", "CHEMICAL", 815, 818], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 93, 107], ["LASV", "ORGANISM", 146, 150], ["S1P", "GENE_OR_GENE_PRODUCT", 218, 221], ["LASV [23]", "ORGANISM", 268, 277], ["S1P", "GENE_OR_GENE_PRODUCT", 470, 473], ["VHFs", "CANCER", 524, 528], ["rat", "ORGANISM", 595, 598], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 601, 615], ["pSG5", "GENE_OR_GENE_PRODUCT", 775, 779], ["S1P", "GENE_OR_GENE_PRODUCT", 815, 818], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 830, 844], ["1 -antitrypsin variants", "PROTEIN", 93, 116], ["LASV GP", "PROTEIN", 146, 153], ["endoprotease S1P", "PROTEIN", 205, 221], ["open reading frame", "DNA", 573, 591], ["pSG5", "DNA", 775, 779], ["S1P", "PROTEIN", 815, 818], ["1 -antitrypsin variants", "DNA", 830, 853], ["rat", "SPECIES", 595, 598], ["LASV", "SPECIES", 146, 150], ["LASV", "SPECIES", 268, 272], ["viral replication", "PROBLEM", 28, 45], ["IntroductionSince glycoprotein processing", "TREATMENT", 156, 197], ["the endoprotease S1P", "TREATMENT", 201, 221], ["virus infectivity of LASV", "PROBLEM", 247, 272], ["hemorrhagic fever", "PROBLEM", 311, 328], ["specific S1P inhibitor", "TREATMENT", 461, 483], ["certain VHFs", "PROBLEM", 516, 528], ["Molecular cloning", "PROBLEM", 529, 546], ["S1P", "TEST", 815, 818], ["a 1 -antitrypsin variants", "TREATMENT", 828, 853], ["recombinant polymerase chain reaction", "PROBLEM", 857, 894], ["PCR", "TEST", 896, 899], ["overlapping oligonucleotides", "TREATMENT", 907, 935], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["inhibition", "OBSERVATION_MODIFIER", 14, 24], ["viral replication", "OBSERVATION", 28, 45], ["LASV", "OBSERVATION", 146, 150], ["hemorrhagic", "OBSERVATION_MODIFIER", 311, 322]]], ["The sequences of the oligonucleotides used are listed in Table S1 .", [["the oligonucleotides", "TREATMENT", 17, 37]]], ["The resulting full-length PCR products were digestedAuthor SummaryThe virus family Arenaviridae includes several hemorrhagic fever causing agents such as Lassa, Guanarito, Junin, Machupo, and Sabia virus that pose a major public health concern to the human population in West African and South American countries.", [["hemorrhagic fever", "DISEASE", 113, 130], ["Lassa, Guanarito, Junin, Machupo, and Sabia virus", "DISEASE", 154, 203], ["Lassa", "ORGANISM", 154, 159], ["Sabia virus", "ORGANISM", 192, 203], ["human", "ORGANISM", 251, 256], ["Sabia virus", "SPECIES", 192, 203], ["human", "SPECIES", 251, 256], ["Sabia virus", "SPECIES", 192, 203], ["human", "SPECIES", 251, 256], ["The resulting full-length PCR products", "TREATMENT", 0, 38], ["The virus family Arenaviridae", "TREATMENT", 66, 95], ["several hemorrhagic fever", "PROBLEM", 105, 130], ["agents", "TREATMENT", 139, 145], ["Lassa", "PROBLEM", 154, 159], ["Guanarito", "TREATMENT", 161, 170], ["Junin", "TREATMENT", 172, 177], ["Machupo", "TREATMENT", 179, 186], ["Sabia virus", "PROBLEM", 192, 203], ["virus", "OBSERVATION", 70, 75], ["hemorrhagic", "OBSERVATION_MODIFIER", 113, 124], ["fever", "OBSERVATION", 125, 130]]], ["Current treatment options to control fatal outcome of disease are limited to the ribonucleoside analogue ribavirin, although its use has some significant limitations.", [["ribonucleoside", "CHEMICAL", 81, 95], ["ribavirin", "CHEMICAL", 105, 114], ["ribonucleoside", "CHEMICAL", 81, 95], ["ribavirin", "CHEMICAL", 105, 114], ["ribonucleoside", "SIMPLE_CHEMICAL", 81, 95], ["ribavirin", "SIMPLE_CHEMICAL", 105, 114], ["Current treatment options", "TREATMENT", 0, 25], ["disease", "PROBLEM", 54, 61], ["the ribonucleoside analogue ribavirin", "TREATMENT", 77, 114], ["disease", "OBSERVATION", 54, 61], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["limitations", "OBSERVATION", 154, 165]]], ["The lack of effective treatment alternatives emphasizes the need for novel antiviral therapeutics to counteract these life-threatening infections.", [["infections", "DISEASE", 135, 145], ["effective treatment alternatives", "TREATMENT", 12, 44], ["novel antiviral therapeutics", "TREATMENT", 69, 97], ["threatening infections", "PROBLEM", 123, 145]]], ["Maturation cleavage of the viral envelope glycoprotein by the host cell proprotein convertase site 1 protease (S1P) is critical for infectious virion production of several pathogenic arenaviruses.", [["S1P", "CHEMICAL", 111, 114], ["arenaviruses", "DISEASE", 183, 195], ["host cell proprotein convertase site 1 protease", "GENE_OR_GENE_PRODUCT", 62, 109], ["S1P", "GENE_OR_GENE_PRODUCT", 111, 114], ["arenaviruses", "ORGANISM", 183, 195], ["viral envelope glycoprotein", "PROTEIN", 27, 54], ["host cell proprotein convertase site 1 protease", "PROTEIN", 62, 109], ["S1P", "PROTEIN", 111, 114], ["Maturation cleavage", "PROBLEM", 0, 19], ["the viral envelope glycoprotein", "TREATMENT", 23, 54], ["the host cell proprotein convertase", "TREATMENT", 58, 93], ["infectious virion production", "TREATMENT", 132, 160], ["several pathogenic arenaviruses", "PROBLEM", 164, 195]]], ["This finding makes this protease an attractive target for the development of novel antiarenaviral therapeutics.", [["antiarenaviral", "CANCER", 83, 97], ["novel antiarenaviral therapeutics", "TREATMENT", 77, 110]]], ["We demonstrate here that highly selective S1P-adapted a 1 -antitrypsins have the potential to efficiently inhibit glycoprotein processing, which resulted in reduced Lassa virus replication.", [["S1P", "CHEMICAL", 42, 45], ["S1P", "CHEMICAL", 42, 45], ["S1P", "GENE_OR_GENE_PRODUCT", 42, 45], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 56, 71], ["Lassa virus", "ORGANISM", 165, 176], ["glycoprotein", "PROTEIN", 114, 126], ["Lassa virus", "SPECIES", 165, 176], ["glycoprotein processing", "TREATMENT", 114, 137], ["reduced Lassa virus replication", "PROBLEM", 157, 188], ["reduced", "OBSERVATION_MODIFIER", 157, 164], ["Lassa virus", "OBSERVATION", 165, 176]]], ["Our findings suggest that S1P should be considered as an antiviral target and that further optimization of modified a 1 -antitrypsins could lead to potent and specific S1P inhibitors with the potential for treatment of certain viral hemorrhagic fevers.Author SummaryEffect of S1P Inhibition on LASV Replication www.plosntds.org with BamHI and NheI and cloned into the tetracycline (Tet)controlled inducible mammalian expression vector pTRE2hyg (Clontech).", [["S1P", "CHEMICAL", 26, 29], ["1 -antitrypsins", "CHEMICAL", 118, 133], ["viral hemorrhagic fevers", "DISEASE", 227, 251], ["S1P", "CHEMICAL", 276, 279], ["tetracycline", "CHEMICAL", 368, 380], ["Tet", "CHEMICAL", 382, 385], ["S1P", "CHEMICAL", 26, 29], ["S1P", "CHEMICAL", 276, 279], ["tetracycline", "CHEMICAL", 368, 380], ["S1P", "GENE_OR_GENE_PRODUCT", 26, 29], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 118, 133], ["S1P", "GENE_OR_GENE_PRODUCT", 168, 171], ["S1P", "GENE_OR_GENE_PRODUCT", 276, 279], ["BamHI", "GENE_OR_GENE_PRODUCT", 333, 338], ["NheI", "GENE_OR_GENE_PRODUCT", 343, 347], ["tetracycline", "SIMPLE_CHEMICAL", 368, 380], ["pTRE2hyg", "GENE_OR_GENE_PRODUCT", 435, 443], ["Clontech", "GENE_OR_GENE_PRODUCT", 445, 453], ["BamHI", "DNA", 333, 338], ["NheI", "DNA", 343, 347], ["tetracycline (Tet)controlled inducible mammalian expression vector", "DNA", 368, 434], ["pTRE2hyg", "DNA", 435, 443], ["Clontech", "DNA", 445, 453], ["an antiviral target", "TREATMENT", 54, 73], ["a 1 -antitrypsins", "TREATMENT", 116, 133], ["specific S1P inhibitors", "TREATMENT", 159, 182], ["treatment", "TREATMENT", 206, 215], ["certain viral hemorrhagic fevers", "PROBLEM", 219, 251], ["S1P Inhibition", "TREATMENT", 276, 290], ["LASV Replication", "TREATMENT", 294, 310], ["BamHI", "TREATMENT", 333, 338], ["NheI", "TREATMENT", 343, 347], ["the tetracycline (Tet)controlled inducible mammalian expression vector", "TREATMENT", 364, 434], ["viral", "OBSERVATION_MODIFIER", 227, 232], ["hemorrhagic", "OBSERVATION_MODIFIER", 233, 244], ["fevers", "OBSERVATION", 245, 251]]], ["The accuracy of all constructs was confirmed by DNA sequencing.Author SummaryTo generate stably expressing cell lines, Chinese hamster ovary (CHO)-K1 Tet-On cells (Clontech) were transfected with pTRE2hyg containing the a 1 -antitrypsin constructs using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions.", [["cell lines", "ANATOMY", 107, 117], ["hamster ovary (CHO)-K1 Tet-On cells", "ANATOMY", 127, 162], ["Lipofectamine 2000", "CHEMICAL", 254, 272], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["cell lines", "CELL", 107, 117], ["Chinese hamster ovary", "CELL", 119, 140], ["CHO)-K1 Tet-On cells", "CELL", 142, 162], ["Clontech", "CELL", 164, 172], ["pTRE2hyg", "GENE_OR_GENE_PRODUCT", 196, 204], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 222, 236], ["Invitrogen", "SIMPLE_CHEMICAL", 274, 284], ["stably expressing cell lines", "CELL_LINE", 89, 117], ["Chinese hamster ovary (CHO)-K1 Tet-On cells", "CELL_LINE", 119, 162], ["Clontech", "CELL_LINE", 164, 172], ["pTRE2hyg", "PROTEIN", 196, 204], ["1 -antitrypsin constructs", "DNA", 222, 247], ["Chinese hamster", "SPECIES", 119, 134], ["DNA sequencing", "TEST", 48, 62], ["K1 Tet-On cells (Clontech)", "TREATMENT", 147, 173], ["a 1 -antitrypsin constructs", "TREATMENT", 220, 247], ["Lipofectamine", "TREATMENT", 254, 267], ["Invitrogen", "TREATMENT", 274, 284], ["cell lines", "OBSERVATION", 107, 117], ["ovary", "ANATOMY", 135, 140]]], ["Cells were then cultured for 2 weeks under selective pressure in the presence of 500 mg/ml Hygromycin B, the selection agent for the a 1 -antitrypsin expressing plasmid, and 500 mg/ml G418, the selection agent for the rtTA (reverse Tet-controlled transactivator) cassette.", [["Cells", "ANATOMY", 0, 5], ["plasmid", "ANATOMY", 161, 168], ["Hygromycin B", "CHEMICAL", 91, 103], ["G418", "CHEMICAL", 184, 188], ["Hygromycin B", "CHEMICAL", 91, 103], ["G418", "CHEMICAL", 184, 188], ["Cells", "CELL", 0, 5], ["Hygromycin B", "SIMPLE_CHEMICAL", 91, 103], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 135, 149], ["rtTA", "GENE_OR_GENE_PRODUCT", 218, 222], ["1 -antitrypsin expressing plasmid", "DNA", 135, 168], ["rtTA (reverse Tet-controlled transactivator) cassette", "DNA", 218, 271], ["Cells", "TEST", 0, 5], ["selective pressure", "TEST", 43, 61], ["Hygromycin B", "TREATMENT", 91, 103], ["the selection agent", "TREATMENT", 105, 124], ["the a 1 -antitrypsin expressing plasmid", "TREATMENT", 129, 168], ["the selection agent", "TREATMENT", 190, 209], ["the rtTA (reverse Tet-controlled transactivator) cassette", "TREATMENT", 214, 271]]], ["The selective media were replaced every 3 days.", [["The selective media", "TREATMENT", 0, 19], ["selective", "OBSERVATION_MODIFIER", 4, 13]]], ["Well-separated antibiotic-resistant cell clones were individually isolated with cloning cylinders (Sigma).", [["cell clones", "ANATOMY", 36, 47], ["cell clones", "CELL", 36, 47], ["antibiotic-resistant cell clones", "CELL_LINE", 15, 47], ["separated antibiotic", "TREATMENT", 5, 25], ["resistant cell clones", "PROBLEM", 26, 47], ["resistant cell clones", "OBSERVATION", 26, 47]]], ["Therefore, a small volume of Trypsin-EDTA (Sigma) was added and the culture dish was incubated briefly at 37uC until cells detach.", [["cells", "ANATOMY", 117, 122], ["Trypsin-EDTA", "CHEMICAL", 29, 41], ["EDTA", "CHEMICAL", 37, 41], ["Trypsin-EDTA", "SIMPLE_CHEMICAL", 29, 41], ["Sigma", "SIMPLE_CHEMICAL", 43, 48], ["cells", "CELL", 117, 122], ["Trypsin-EDTA (Sigma)", "TREATMENT", 29, 49], ["the culture dish", "TEST", 64, 80], ["small", "OBSERVATION_MODIFIER", 13, 18], ["volume", "OBSERVATION_MODIFIER", 19, 25]]], ["Cells were then collected from inside the cylinder and transferred to individual wells of a 24-well plate for further growth in selective medium.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["When grown to confluence, cells were transferred to larger flasks.", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["confluence", "OBSERVATION_MODIFIER", 14, 24], ["larger flasks", "OBSERVATION", 52, 65]]], ["Protein expression was induced with 1 mg/ml doxycycline (Clontech) and analyzed by Western Blot and immunofluorescence.", [["doxycycline", "CHEMICAL", 44, 55], ["doxycycline", "CHEMICAL", 44, 55], ["doxycycline", "SIMPLE_CHEMICAL", 44, 55], ["Protein expression", "PROBLEM", 0, 18], ["doxycycline", "TREATMENT", 44, 55], ["immunofluorescence", "TEST", 100, 118]]], ["Stable cell lines showing similar expression levels of the various a 1 -antitrypsins were chosen for further experiments.Cell culturesVero E6 cells (green monkey kidney) were cultured in Dulbecco's modified Eagle medium (DMEM, Gibco) and CHO-K1 Tet-On cells in DMEM/F12 (Gibco), both media containing penicillin (100 U/ml), streptomycin (100 mg/ml), and L-glutamine (2 mmol/l) (all from Invitrogen) as well as 10% fetal bovine serum (PAN Biotech).", [["cell lines", "ANATOMY", 7, 17], ["Cell cultures", "ANATOMY", 121, 134], ["Vero E6 cells", "ANATOMY", 134, 147], ["kidney", "ANATOMY", 162, 168], ["CHO-K1 Tet-On cells", "ANATOMY", 238, 257], ["fetal bovine serum", "ANATOMY", 414, 432], ["penicillin", "CHEMICAL", 301, 311], ["streptomycin", "CHEMICAL", 324, 336], ["-glutamine", "CHEMICAL", 355, 365], ["penicillin", "CHEMICAL", 301, 311], ["streptomycin", "CHEMICAL", 324, 336], ["-glutamine", "CHEMICAL", 355, 365], ["cell lines", "CELL", 7, 17], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 69, 84], ["Cell cultures", "CELL", 121, 134], ["Vero E6 cells", "CELL", 134, 147], ["green monkey", "ORGANISM", 149, 161], ["kidney", "ORGAN", 162, 168], ["CHO-K1 Tet-On cells", "CELL", 238, 257], ["DMEM/F12", "CELL", 261, 269], ["Gibco", "ORGANISM_SUBSTANCE", 271, 276], ["penicillin", "SIMPLE_CHEMICAL", 301, 311], ["streptomycin", "SIMPLE_CHEMICAL", 324, 336], ["L-glutamine", "SIMPLE_CHEMICAL", 354, 365], ["bovine", "ORGANISM", 420, 426], ["serum", "ORGANISM_SUBSTANCE", 427, 432], ["Stable cell lines", "CELL_LINE", 0, 17], ["1 -antitrypsins", "PROTEIN", 69, 84], ["Vero E6 cells", "CELL_LINE", 134, 147], ["CHO-K1 Tet-On cells", "CELL_LINE", 238, 257], ["Vero", "SPECIES", 134, 138], ["monkey", "SPECIES", 155, 161], ["bovine", "SPECIES", 420, 426], ["Vero E6", "SPECIES", 134, 141], ["green monkey", "SPECIES", 149, 161], ["F12", "SPECIES", 266, 269], ["bovine", "SPECIES", 420, 426], ["similar expression levels", "PROBLEM", 26, 51], ["Cell cultures", "TEST", 121, 134], ["Vero E6 cells", "PROBLEM", 134, 147], ["Gibco", "TEST", 227, 232], ["CHO", "TEST", 238, 241], ["penicillin", "TREATMENT", 301, 311], ["streptomycin", "TREATMENT", 324, 336], ["L-glutamine", "TREATMENT", 354, 365], ["10% fetal bovine serum (PAN Biotech", "TREATMENT", 410, 445], ["cell lines", "OBSERVATION", 7, 17], ["similar", "OBSERVATION_MODIFIER", 26, 33], ["expression", "OBSERVATION_MODIFIER", 34, 44], ["levels", "OBSERVATION_MODIFIER", 45, 51], ["E6 cells", "OBSERVATION", 139, 147], ["kidney", "ANATOMY", 162, 168]]], ["S1P-deficient SRD-12B cells (a generous gift from Dr. J. L. Goldstein, Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, USA) were maintained as CHO cells but supplemented with 5 mg/ml of cholesterol (Sigma), 1 mM sodium mevalonate (Sigma), and 20 mM sodium oleate (Sigma) [44] .Viruses and infectious workThe vesicular stomatitis virus reverse genetics system (VSV, Indiana serotype) was kindly provided by Dr. J.K. Rose (Department of Pathology, Yale University School of Medicine, New Haven, USA) and was described in detail earlier [45, 46, 47] .", [["SRD-12B cells", "ANATOMY", 14, 27], ["CHO cells", "ANATOMY", 186, 195], ["vesicular", "ANATOMY", 351, 360], ["S1P", "CHEMICAL", 0, 3], ["cholesterol", "CHEMICAL", 229, 240], ["sodium mevalonate", "CHEMICAL", 255, 272], ["sodium oleate", "CHEMICAL", 292, 305], ["vesicular stomatitis", "DISEASE", 351, 371], ["cholesterol", "CHEMICAL", 229, 240], ["sodium mevalonate", "CHEMICAL", 255, 272], ["sodium oleate", "CHEMICAL", 292, 305], ["S1P", "GENE_OR_GENE_PRODUCT", 0, 3], ["CHO cells", "CELL", 186, 195], ["cholesterol", "SIMPLE_CHEMICAL", 229, 240], ["Sigma", "SIMPLE_CHEMICAL", 242, 247], ["sodium mevalonate", "SIMPLE_CHEMICAL", 255, 272], ["Sigma", "SIMPLE_CHEMICAL", 274, 279], ["sodium oleate", "SIMPLE_CHEMICAL", 292, 305], ["vesicular stomatitis virus", "ORGANISM", 351, 377], ["VSV", "ORGANISM", 403, 406], ["S1P-deficient SRD-12B cells", "CELL_LINE", 0, 27], ["CHO cells", "CELL_LINE", 186, 195], ["VSV", "SPECIES", 403, 406], ["S1P", "TEST", 0, 3], ["deficient SRD-12B cells", "PROBLEM", 4, 27], ["1 mM sodium mevalonate", "TREATMENT", 250, 272], ["Viruses", "PROBLEM", 320, 327], ["infectious workThe vesicular stomatitis virus", "PROBLEM", 332, 377], ["SRD", "OBSERVATION_MODIFIER", 14, 17], ["12B cells", "OBSERVATION", 18, 27], ["infectious", "OBSERVATION", 332, 342], ["vesicular stomatitis", "OBSERVATION", 351, 371]]], ["Recombinant VSV expressing the glycoprotein GP-C of Lassa virus (LASV, strain Josiah) designated as VSVDG/LASVGP and wild-type VSV (VSVwt) were propagated in Vero E6 cells as described previously [48] .", [["Vero E6 cells", "ANATOMY", 158, 171], ["VSV", "ORGANISM", 12, 15], ["GP-C", "GENE_OR_GENE_PRODUCT", 44, 48], ["Lassa virus", "ORGANISM", 52, 63], ["LASV", "ORGANISM", 65, 69], ["strain Josiah", "ORGANISM", 71, 84], ["VSVDG/LASVGP", "ORGANISM", 100, 112], ["wild-type VSV", "ORGANISM", 117, 130], ["VSVwt", "ORGANISM", 132, 137], ["Vero E6 cells", "CELL", 158, 171], ["glycoprotein GP-C", "PROTEIN", 31, 48], ["VSVDG", "PROTEIN", 100, 105], ["LASVGP", "PROTEIN", 106, 112], ["Vero E6 cells", "CELL_LINE", 158, 171], ["VSV", "SPECIES", 12, 15], ["Lassa virus", "SPECIES", 52, 63], ["VSV", "SPECIES", 12, 15], ["Lassa virus", "SPECIES", 52, 63], ["LASV", "SPECIES", 65, 69], ["VSVDG/LASVGP and wild-type VSV", "SPECIES", 100, 130], ["Vero E6", "SPECIES", 158, 165], ["Lassa virus", "PROBLEM", 52, 63], ["strain Josiah)", "PROBLEM", 71, 85], ["VSVDG", "TEST", 100, 105], ["LASVGP", "PROBLEM", 106, 112], ["E6 cells", "OBSERVATION", 163, 171]]], ["Influenza virus A/FPV/Rostock/34 (H7N1), designated as fowl plague virus (FPV), was propagated in embryonated hen eggs and stored at 280uC until further use.", [["eggs", "ANATOMY", 114, 118], ["fowl plague", "DISEASE", 55, 66], ["Influenza virus A", "ORGANISM", 0, 17], ["FPV/Rostock/34 (H7N1)", "ORGANISM", 18, 39], ["fowl plague virus", "ORGANISM", 55, 72], ["FPV", "ORGANISM", 74, 77], ["hen", "ORGANISM", 110, 113], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 114, 118], ["Influenza virus", "SPECIES", 0, 15], ["fowl plague virus", "SPECIES", 55, 72], ["hen", "SPECIES", 110, 113], ["Influenza virus A/FPV/Rostock/34", "SPECIES", 0, 32], ["H7N1", "SPECIES", 34, 38], ["fowl plague virus", "SPECIES", 55, 72], ["FPV", "SPECIES", 74, 77], ["hen", "SPECIES", 110, 113], ["Influenza virus", "PROBLEM", 0, 15], ["fowl plague virus", "PROBLEM", 55, 72]]], ["Virus titration of FPV was described previously [49] .", [["Virus", "ORGANISM", 0, 5], ["FPV", "ORGANISM", 19, 22], ["FPV", "SPECIES", 19, 22], ["Virus titration of FPV", "TREATMENT", 0, 22]]], ["All experiments with infectious FPV were done under biological safety level 3 conditions.", [["FPV", "ORGANISM", 32, 35], ["FPV", "SPECIES", 32, 35], ["infectious FPV", "TREATMENT", 21, 35]]], ["VSVDG/LASVGP titration was performed using a microplate format plaque assay with subsequent immunostaining as described before [50] .", [["VSVDG", "SIMPLE_CHEMICAL", 0, 5], ["LASVGP", "SIMPLE_CHEMICAL", 6, 12], ["LASVGP", "DNA", 6, 12], ["LASVGP titration", "TREATMENT", 6, 22], ["a microplate format plaque assay", "TREATMENT", 43, 75]]], ["In brief, virus dilutions were incubated on Vero E6 cells with an overlay of 3% carboxymethylcellulose (CMC) during plaque formation.", [["cells", "ANATOMY", 52, 57], ["plaque", "ANATOMY", 116, 122], ["carboxymethylcellulose", "CHEMICAL", 80, 102], ["CMC", "CHEMICAL", 104, 107], ["carboxymethylcellulose", "CHEMICAL", 80, 102], ["Vero E6 cells", "CELL", 44, 57], ["carboxymethylcellulose", "SIMPLE_CHEMICAL", 80, 102], ["CMC", "SIMPLE_CHEMICAL", 104, 107], ["plaque", "PATHOLOGICAL_FORMATION", 116, 122], ["Vero E6 cells", "CELL_LINE", 44, 57], ["Vero E6", "SPECIES", 44, 51], ["virus dilutions", "TEST", 10, 25], ["Vero E6 cells", "TREATMENT", 44, 57], ["3% carboxymethylcellulose (CMC)", "TREATMENT", 77, 108], ["plaque formation", "PROBLEM", 116, 132], ["plaque", "OBSERVATION", 116, 122]]], ["Infected cells were visualized after cell fixation with paraformaldehyde (PFA, 4%) and permeabilization with 0.3% Triton-X 100 using a specific LASV GP-C/GP-2 antibody followed by incubation with horseradish peroxidase-labeled secondary anti-rabbit antibody (DAKO).", [["cells", "ANATOMY", 9, 14], ["cell", "ANATOMY", 37, 41], ["paraformaldehyde", "CHEMICAL", 56, 72], ["Triton-X 100", "CHEMICAL", 114, 126], ["paraformaldehyde", "CHEMICAL", 56, 72], ["PFA", "CHEMICAL", 74, 77], ["cells", "CELL", 9, 14], ["cell", "CELL", 37, 41], ["paraformaldehyde", "SIMPLE_CHEMICAL", 56, 72], ["PFA", "SIMPLE_CHEMICAL", 74, 77], ["Triton-X 100", "SIMPLE_CHEMICAL", 114, 126], ["LASV", "ORGANISM", 144, 148], ["GP-C", "GENE_OR_GENE_PRODUCT", 149, 153], ["GP-2", "GENE_OR_GENE_PRODUCT", 154, 158], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 196, 218], ["DAKO", "GENE_OR_GENE_PRODUCT", 259, 263], ["LASV GP-C/GP-2 antibody", "PROTEIN", 144, 167], ["horseradish peroxidase", "PROTEIN", 196, 218], ["labeled secondary anti-rabbit antibody", "PROTEIN", 219, 257], ["DAKO", "PROTEIN", 259, 263], ["horseradish", "SPECIES", 196, 207], ["anti-rabbit", "SPECIES", 237, 248], ["LASV", "SPECIES", 144, 148], ["Infected cells", "PROBLEM", 0, 14], ["cell fixation", "TREATMENT", 37, 50], ["paraformaldehyde (PFA", "TREATMENT", 56, 77], ["permeabilization", "TREATMENT", 87, 103], ["0.3% Triton", "TREATMENT", 109, 120], ["a specific LASV GP", "TEST", 133, 151], ["GP", "TEST", 154, 156], ["horseradish peroxidase", "TEST", 196, 218], ["secondary anti-rabbit antibody", "TEST", 227, 257], ["cell fixation", "OBSERVATION", 37, 50]]], ["Finally, cells were stained with True Blue Peroxidase substrate (KPL).Viruses and infectious workFor virus spread experiments, CHO cell lines were seeded into 96-well plates in the presence or absence of doxycycline.", [["cells", "ANATOMY", 9, 14], ["CHO cell lines", "ANATOMY", 127, 141], ["doxycycline", "CHEMICAL", 204, 215], ["True Blue", "CHEMICAL", 33, 42], ["doxycycline", "CHEMICAL", 204, 215], ["cells", "CELL", 9, 14], ["Peroxidase", "GENE_OR_GENE_PRODUCT", 43, 53], ["CHO cell lines", "CELL", 127, 141], ["doxycycline", "SIMPLE_CHEMICAL", 204, 215], ["True Blue Peroxidase substrate", "PROTEIN", 33, 63], ["KPL", "PROTEIN", 65, 68], ["CHO cell lines", "CELL_LINE", 127, 141], ["True Blue Peroxidase substrate (KPL)", "TREATMENT", 33, 69], ["Viruses", "PROBLEM", 70, 77], ["infectious work", "TREATMENT", 82, 97], ["virus spread experiments", "PROBLEM", 101, 125], ["CHO cell lines", "TREATMENT", 127, 141], ["doxycycline", "TREATMENT", 204, 215], ["infectious", "OBSERVATION", 82, 92], ["cell lines", "OBSERVATION", 131, 141], ["doxycycline", "OBSERVATION", 204, 215]]], ["24 h after induction, cells were infected with VSVDG/LASVGP or FPV and were grown without solid overlay.", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27], ["LASVGP", "GENE_OR_GENE_PRODUCT", 53, 59], ["FPV", "ORGANISM", 63, 66], ["FPV", "SPECIES", 63, 66], ["VSVDG", "PROBLEM", 47, 52], ["LASVGP", "PROBLEM", 53, 59], ["FPV", "PROBLEM", 63, 66], ["without", "UNCERTAINTY", 82, 89], ["solid overlay", "OBSERVATION", 90, 103]]], ["Cells were fixed at different time points post-infection and immunostaining was performed as described above using rabbit sera against VSV (kindly provided by Dr. G. Herrler, Institut f\u00fcr Virologie, Zentrum f\u00fcr Infektionsmedizin, Stiftung Tier\u00e4 rztliche Hochschule Hannover, Germany), for the detection of VSVDG/LASVGP infected cells, and against FPV, for cells infected with FPV, respectively.Viruses and infectious workVirus titration of LASV (strain Josiah, Gene Bank Accession Number NC_004297 and NC_004296) was performed by defining the 50% tissue culture infectious dose (TCID 50 ).", [["Cells", "ANATOMY", 0, 5], ["sera", "ANATOMY", 122, 126], ["cells", "ANATOMY", 328, 333], ["cells", "ANATOMY", 356, 361], ["tissue", "ANATOMY", 547, 553], ["Cells", "CELL", 0, 5], ["rabbit", "ORGANISM", 115, 121], ["sera", "ORGANISM_SUBSTANCE", 122, 126], ["VSV", "ORGANISM", 135, 138], ["VSVDG", "GENE_OR_GENE_PRODUCT", 306, 311], ["cells", "CELL", 328, 333], ["FPV", "ORGANISM", 347, 350], ["cells", "CELL", 356, 361], ["FPV", "ORGANISM", 376, 379], ["Virus", "ORGANISM", 421, 426], ["LASV", "ORGANISM", 440, 444], ["tissue", "TISSUE", 547, 553], ["LASVGP infected cells", "CELL_TYPE", 312, 333], ["rabbit", "SPECIES", 115, 121], ["rabbit", "SPECIES", 115, 121], ["VSV", "SPECIES", 135, 138], ["kindly", "SPECIES", 140, 146], ["FPV", "SPECIES", 347, 350], ["FPV", "SPECIES", 376, 379], ["LASV", "SPECIES", 440, 444], ["Cells", "TEST", 0, 5], ["immunostaining", "TEST", 61, 75], ["Zentrum", "TREATMENT", 199, 206], ["Infektionsmedizin", "TREATMENT", 211, 228], ["the detection", "TEST", 289, 302], ["VSVDG", "PROBLEM", 306, 311], ["LASVGP infected cells", "PROBLEM", 312, 333], ["FPV", "PROBLEM", 347, 350], ["cells", "PROBLEM", 356, 361], ["Viruses", "PROBLEM", 394, 401], ["infectious workVirus titration", "TREATMENT", 406, 436], ["NC", "TEST", 502, 504], ["infected cells", "OBSERVATION", 319, 333], ["infectious", "OBSERVATION_MODIFIER", 406, 416]]], ["For this, Vero cells were grown in 96-well plates to 30 to 40% confluence.", [["Vero cells", "ANATOMY", 10, 20], ["Vero cells", "CELL", 10, 20], ["Vero cells", "CELL_LINE", 10, 20], ["Vero cells", "TEST", 10, 20]]], ["Cells were inoculated with 10-fold serial dilutions of supernatants from LASV-infected CHO cell lines grown in the presence or absence of doxycycline.", [["Cells", "ANATOMY", 0, 5], ["supernatants", "ANATOMY", 55, 67], ["CHO cell lines", "ANATOMY", 87, 101], ["doxycycline", "CHEMICAL", 138, 149], ["doxycycline", "CHEMICAL", 138, 149], ["Cells", "CELL", 0, 5], ["LASV", "ORGANISM", 73, 77], ["CHO cell lines", "CELL", 87, 101], ["doxycycline", "SIMPLE_CHEMICAL", 138, 149], ["LASV-infected CHO cell lines", "CELL_LINE", 73, 101], ["LASV", "SPECIES", 73, 77], ["Cells", "TEST", 0, 5], ["supernatants", "PROBLEM", 55, 67], ["LASV", "PROBLEM", 73, 77], ["infected CHO cell lines", "TREATMENT", 78, 101], ["doxycycline", "TREATMENT", 138, 149], ["infected", "OBSERVATION_MODIFIER", 78, 86], ["CHO cell lines", "OBSERVATION", 87, 101], ["doxycycline", "OBSERVATION", 138, 149]]], ["The assays were evaluated at 7 to 9 days postinfection.", [["The assays", "TEST", 0, 10]]], ["All experiments involving LASV-infected samples were performed under biological safety level 4 conditions at the Philipps-University Marburg.Purification of viral particles from cellular supernatantAt 24 h post-infection, cell culture supernatants from infected cells were cleared from cell debris and pelleted in an SW-60 rotor through a 20% sucrose cushion at 52000 rpm at 4uC for 2 h.", [["samples", "ANATOMY", 40, 47], ["cellular", "ANATOMY", 178, 186], ["cell", "ANATOMY", 222, 226], ["supernatants", "ANATOMY", 235, 247], ["cells", "ANATOMY", 262, 267], ["cell debris", "ANATOMY", 286, 297], ["LASV-infected", "DISEASE", 26, 39], ["infection", "DISEASE", 211, 220], ["sucrose", "CHEMICAL", 343, 350], ["sucrose", "CHEMICAL", 343, 350], ["LASV", "ORGANISM", 26, 30], ["samples", "CANCER", 40, 47], ["cellular", "CELL", 178, 186], ["cell", "CELL", 222, 226], ["cells", "CELL", 262, 267], ["cell debris", "CELL", 286, 297], ["infected cells", "CELL_TYPE", 253, 267], ["LASV", "SPECIES", 26, 30], ["LASV", "PROBLEM", 26, 30], ["infected samples", "PROBLEM", 31, 47], ["viral particles", "PROBLEM", 157, 172], ["cellular supernatantAt", "PROBLEM", 178, 200], ["post-infection", "PROBLEM", 206, 220], ["cell culture supernatants", "TEST", 222, 247], ["infected cells", "PROBLEM", 253, 267], ["cell debris", "PROBLEM", 286, 297], ["a 20% sucrose cushion", "TREATMENT", 337, 358], ["viral particles", "OBSERVATION", 157, 172], ["infection", "OBSERVATION", 211, 220], ["infected cells", "OBSERVATION", 253, 267], ["cell debris", "OBSERVATION", 286, 297]]], ["The pellet was then resuspended in PBS buffer and mixed with SDS-PAGE sample buffer.", [["SDS", "CHEMICAL", 61, 64], ["The pellet", "TREATMENT", 0, 10], ["PBS buffer", "TREATMENT", 35, 45], ["SDS", "TREATMENT", 61, 64]]], ["To control the intracellular expression level, cell lysates were collected simultaneously.", [["intracellular", "ANATOMY", 15, 28], ["cell lysates", "ANATOMY", 47, 59], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 28], ["cell lysates", "ORGANISM_SUBSTANCE", 47, 59], ["cell lysates", "TEST", 47, 59], ["intracellular expression", "OBSERVATION", 15, 39]]], ["Samples were analyzed by SDS-PAGE and Western blotting using protein-specific antibodies as indicated.Acrylamide gel electrophoresis and immunoblottingProteins were separated by SDS-PAGE using 10% polyacrylamide gels.", [["Samples", "ANATOMY", 0, 7], ["Acrylamide", "CHEMICAL", 102, 112], ["Acrylamide", "CHEMICAL", 102, 112], ["polyacrylamide", "CHEMICAL", 197, 211], ["Acrylamide", "SIMPLE_CHEMICAL", 102, 112], ["protein-specific antibodies", "PROTEIN", 61, 88], ["Samples", "TEST", 0, 7], ["protein", "TEST", 61, 68], ["specific antibodies", "TEST", 69, 88], ["Acrylamide gel electrophoresis", "TREATMENT", 102, 132], ["immunoblottingProteins", "TREATMENT", 137, 159], ["10% polyacrylamide gels", "TREATMENT", 193, 216]]], ["Immunoblotting was performed as described previously [52] .", [["Immunoblotting", "TEST", 0, 14]]], ["Antiserum against Lassa virus GP-C/GP-2 was also described previously [32] .", [["Antiserum", "ORGANISM_SUBSTANCE", 0, 9], ["Lassa virus GP-C", "ORGANISM", 18, 34], ["GP-2", "GENE_OR_GENE_PRODUCT", 35, 39], ["Lassa virus", "SPECIES", 18, 29], ["Lassa virus", "SPECIES", 18, 29], ["Antiserum", "TREATMENT", 0, 9], ["Lassa virus GP", "TEST", 18, 32]]], ["Polyclonal rabbit anti-\u00df-tubulin antibody was purchased from Abcam (UK), and monoclonal mouse anti-Flag antibody from Sigma-Aldrich.", [["rabbit", "ORGANISM", 11, 17], ["anti-\u00df-tubulin antibody", "GENE_OR_GENE_PRODUCT", 18, 41], ["Abcam", "GENE_OR_GENE_PRODUCT", 61, 66], ["UK", "GENE_OR_GENE_PRODUCT", 68, 70], ["mouse", "ORGANISM", 88, 93], ["Sigma-Aldrich", "ORGANISM", 118, 131], ["Polyclonal rabbit anti-\u00df-tubulin antibody", "PROTEIN", 0, 41], ["Abcam (UK)", "PROTEIN", 61, 71], ["monoclonal mouse anti-Flag antibody", "PROTEIN", 77, 112], ["rabbit", "SPECIES", 11, 17], ["mouse", "SPECIES", 88, 93], ["rabbit", "SPECIES", 11, 17], ["mouse", "SPECIES", 88, 93], ["Polyclonal rabbit anti-\u00df-tubulin antibody", "TEST", 0, 41]]], ["Secondary antibodies labeled with Alexa680 or IRDye800 were from Molecular Probes Invitrogen and Biomol, respectively, and were used for visualization and quantification of detected proteins using the Odyssey Infrared Imaging System (LI-COR Biosciences).Immunofluorescence analysisCHO cell lines were grown on coverslips and 24 h after doxycycline-induction, cells were washed with PBS and fixed with 4% PFA in DMEM for 30 min.", [["analysisCHO cell lines", "ANATOMY", 273, 295], ["cells", "ANATOMY", 359, 364], ["Alexa680", "CHEMICAL", 34, 42], ["doxycycline", "CHEMICAL", 336, 347], ["PFA", "CHEMICAL", 404, 407], ["Alexa680", "CHEMICAL", 34, 42], ["doxycycline", "CHEMICAL", 336, 347], ["PFA", "CHEMICAL", 404, 407], ["Alexa680", "SIMPLE_CHEMICAL", 34, 42], ["IRDye800", "SIMPLE_CHEMICAL", 46, 54], ["Biomol", "GENE_OR_GENE_PRODUCT", 97, 103], ["analysisCHO cell lines", "CELL", 273, 295], ["doxycycline", "SIMPLE_CHEMICAL", 336, 347], ["cells", "CELL", 359, 364], ["PFA", "SIMPLE_CHEMICAL", 404, 407], ["antibodies", "PROTEIN", 10, 20], ["analysisCHO cell lines", "CELL_LINE", 273, 295], ["Secondary antibodies labeled", "PROBLEM", 0, 28], ["Alexa680", "TREATMENT", 34, 42], ["IRDye800", "TREATMENT", 46, 54], ["visualization", "TEST", 137, 150], ["Immunofluorescence analysisCHO cell lines", "PROBLEM", 254, 295], ["coverslips", "TEST", 310, 320], ["doxycycline", "TREATMENT", 336, 347], ["PBS", "TREATMENT", 382, 385], ["4% PFA in DMEM", "TREATMENT", 401, 415], ["cell lines", "OBSERVATION", 285, 295]]], ["The fixative was removed, and free aldehydes were quenched with 100 mM glycine in PBS.", [["aldehydes", "CHEMICAL", 35, 44], ["glycine", "CHEMICAL", 71, 78], ["aldehydes", "CHEMICAL", 35, 44], ["glycine", "CHEMICAL", 71, 78], ["free aldehydes", "SIMPLE_CHEMICAL", 30, 44], ["glycine", "SIMPLE_CHEMICAL", 71, 78], ["The fixative", "TREATMENT", 0, 12], ["free aldehydes", "TREATMENT", 30, 44], ["100 mM glycine in PBS", "TREATMENT", 64, 85]]], ["Then, samples were washed with PBS and permeabilized for 10 min with PBS containing 0.1% Triton X-100.", [["samples", "ANATOMY", 6, 13], ["Triton X-100", "CHEMICAL", 89, 101], ["Triton X-100", "CHEMICAL", 89, 101], ["Triton X-100", "SIMPLE_CHEMICAL", 89, 101], ["PBS", "TREATMENT", 31, 34], ["PBS", "TREATMENT", 69, 72]]], ["Cells were incubated in blocking solution (2% bovine serum albumin, 0.2% Tween 20, 5% glycerol, and 0.05% sodium azide in PBS) and subsequently stained with a primary mouse-anti-flag antibody (1:400) and a secondary anti-mouse antibody coupled to rhodamine (1:200, Jackson Immunoresearch).", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 53, 58], ["glycerol", "CHEMICAL", 86, 94], ["sodium azide", "CHEMICAL", 106, 118], ["rhodamine", "CHEMICAL", 247, 256], ["Tween 20", "CHEMICAL", 73, 81], ["glycerol", "CHEMICAL", 86, 94], ["sodium azide", "CHEMICAL", 106, 118], ["rhodamine", "CHEMICAL", 247, 256], ["Cells", "CELL", 0, 5], ["bovine", "ORGANISM", 46, 52], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["albumin", "SIMPLE_CHEMICAL", 59, 66], ["glycerol", "SIMPLE_CHEMICAL", 86, 94], ["sodium azide", "SIMPLE_CHEMICAL", 106, 118], ["mouse", "ORGANISM", 167, 172], ["rhodamine", "SIMPLE_CHEMICAL", 247, 256], ["primary mouse-anti-flag antibody", "PROTEIN", 159, 191], ["1:400", "PROTEIN", 193, 198], ["secondary anti-mouse antibody", "PROTEIN", 206, 235], ["bovine", "SPECIES", 46, 52], ["mouse", "SPECIES", 167, 172], ["bovine", "SPECIES", 46, 52], ["mouse", "SPECIES", 167, 172], ["blocking solution", "TREATMENT", 24, 41], ["2% bovine serum albumin", "TREATMENT", 43, 66], ["glycerol", "TREATMENT", 86, 94], ["0.05% sodium azide in PBS", "TREATMENT", 100, 125], ["flag antibody", "TEST", 178, 191], ["a secondary anti-mouse antibody", "TEST", 204, 235], ["rhodamine", "TEST", 247, 256], ["anti-mouse antibody", "OBSERVATION", 216, 235]]], ["Cell nuclei were stained with DAPI (49,69-diamidino-2-phenylindole, Sigma).", [["Cell nuclei", "ANATOMY", 0, 11], ["DAPI", "CHEMICAL", 30, 34], ["49,69-diamidino-2-phenylindole", "CHEMICAL", 36, 66], ["DAPI", "CHEMICAL", 30, 34], ["49,69-diamidino-2-phenylindole", "CHEMICAL", 36, 66], ["Cell nuclei", "CELL", 0, 11], ["DAPI", "SIMPLE_CHEMICAL", 30, 34], ["49,69-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 36, 66], ["Sigma", "SIMPLE_CHEMICAL", 68, 73], ["Cell nuclei", "TEST", 0, 11], ["DAPI", "TEST", 30, 34], ["diamidino", "TEST", 42, 51]]], ["Microscopic analysis was performed with a Zeiss ApoTome/ Axiovert 200 M microscope using a magnification of 1:40.Growth kinetics of VSVDG/LASVGP in CHO-K1 cellsReplication-competent recombinant vesicular stomatitis virus (rVSV) expressing foreign envelope glycoproteins has been demonstrated to be a suitable model system to study the role of Effect of S1P Inhibition on LASV Replication www.plosntds.org viral glycoproteins in the context of virus replication [47, 53, 54] .", [["CHO-K1 cells", "ANATOMY", 148, 160], ["CHO-K1", "CHEMICAL", 148, 154], ["vesicular stomatitis", "DISEASE", 194, 214], ["S1P", "CHEMICAL", 353, 356], ["S1P", "CHEMICAL", 353, 356], ["VSVDG", "SIMPLE_CHEMICAL", 132, 137], ["CHO-K1 cells", "CELL", 148, 160], ["recombinant", "ORGANISM", 182, 193], ["vesicular stomatitis virus", "ORGANISM", 194, 220], ["rVSV", "ORGANISM", 222, 226], ["foreign envelope glycoproteins", "GENE_OR_GENE_PRODUCT", 239, 269], ["S1P", "GENE_OR_GENE_PRODUCT", 353, 356], ["LASV", "ORGANISM", 371, 375], ["VSVDG", "PROTEIN", 132, 137], ["LASVGP", "PROTEIN", 138, 144], ["CHO-K1 cells", "CELL_LINE", 148, 160], ["foreign envelope glycoproteins", "PROTEIN", 239, 269], ["org viral glycoproteins", "PROTEIN", 401, 424], ["vesicular stomatitis virus", "SPECIES", 194, 220], ["stomatitis virus", "SPECIES", 204, 220], ["rVSV", "SPECIES", 222, 226], ["LASV", "SPECIES", 371, 375], ["Microscopic analysis", "TEST", 0, 20], ["Growth kinetics", "TEST", 113, 128], ["VSVDG", "TEST", 132, 137], ["LASVGP", "PROBLEM", 138, 144], ["Replication", "TREATMENT", 160, 171], ["competent recombinant vesicular stomatitis virus", "PROBLEM", 172, 220], ["foreign envelope glycoproteins", "PROBLEM", 239, 269], ["S1P Inhibition", "TREATMENT", 353, 367], ["LASV Replication", "TREATMENT", 371, 387], ["org viral glycoproteins", "TREATMENT", 401, 424], ["virus replication", "TREATMENT", 443, 460], ["recombinant", "OBSERVATION_MODIFIER", 182, 193], ["vesicular stomatitis virus", "OBSERVATION", 194, 220]]], ["In the present study, we took advantage of a rVSV expressing the LASV glycoprotein GP (designated VSVDG/LASVGP) [48] .", [["LASV", "ORGANISM", 65, 69], ["GP", "GENE_OR_GENE_PRODUCT", 83, 85], ["rVSV", "PROTEIN", 45, 49], ["LASV glycoprotein GP", "PROTEIN", 65, 85], ["VSVDG", "PROTEIN", 98, 103], ["LASVGP", "PROTEIN", 104, 110], ["LASV", "SPECIES", 65, 69], ["a rVSV", "TREATMENT", 43, 49]]], ["In this system biosynthesis and processing of GP was shown to be authentic compared to LASV [48] .Growth kinetics of VSVDG/LASVGP in CHO-K1 cellsIn an initial experiment we wanted to determine whether CHO-K1 cells are susceptible to VSVDG/LASVGP infection.", [["CHO-K1 cells", "ANATOMY", 133, 145], ["CHO-K1 cells", "ANATOMY", 201, 213], ["CHO-K1", "CHEMICAL", 133, 139], ["VSVDG", "CHEMICAL", 233, 238], ["infection", "DISEASE", 246, 255], ["GP", "GENE_OR_GENE_PRODUCT", 46, 48], ["VSVDG", "SIMPLE_CHEMICAL", 117, 122], ["CHO-K1 cells", "CELL", 133, 145], ["CHO-K1 cells", "CELL", 201, 213], ["VSVDG", "GENE_OR_GENE_PRODUCT", 233, 238], ["LASVGP", "GENE_OR_GENE_PRODUCT", 239, 245], ["GP", "PROTEIN", 46, 48], ["VSVDG", "PROTEIN", 117, 122], ["LASVGP", "PROTEIN", 123, 129], ["CHO-K1 cells", "CELL_LINE", 133, 145], ["CHO-K1 cells", "CELL_LINE", 201, 213], ["LASV", "SPECIES", 87, 91], ["Growth kinetics", "TEST", 98, 113], ["VSVDG", "TEST", 117, 122], ["LASVGP", "PROBLEM", 123, 129], ["CHO-K1 cells", "PROBLEM", 201, 213], ["VSVDG", "PROBLEM", 233, 238], ["LASVGP infection", "PROBLEM", 239, 255], ["infection", "OBSERVATION", 246, 255]]], ["The reason we chose CHO-K1 cells for our studies is the availability of a site 1 protease-deficient CHO cell line (designated SRD-12B cells), in which GP maturation is abolished and only GP-deficient non-infectious LASV particles are released [23] .", [["CHO-K1 cells", "ANATOMY", 20, 32], ["CHO cell line", "ANATOMY", 100, 113], ["SRD-12B cells", "ANATOMY", 126, 139], ["CHO-K1 cells", "CELL", 20, 32], ["CHO cell line", "CELL", 100, 113], ["SRD-12B cells", "CELL", 126, 139], ["GP", "GENE_OR_GENE_PRODUCT", 151, 153], ["GP", "GENE_OR_GENE_PRODUCT", 187, 189], ["LASV", "ORGANISM", 215, 219], ["CHO-K1 cells", "CELL_LINE", 20, 32], ["site 1 protease-deficient CHO cell line", "CELL_LINE", 74, 113], ["SRD-12B cells", "CELL_LINE", 126, 139], ["GP", "PROTEIN", 187, 189], ["LASV", "SPECIES", 215, 219], ["CHO-K1 cells", "TREATMENT", 20, 32], ["our studies", "TEST", 37, 48], ["a site 1 protease-deficient CHO cell line", "TREATMENT", 72, 113], ["deficient non-infectious LASV particles", "PROBLEM", 190, 229], ["CHO cell line", "OBSERVATION", 100, 113], ["non-infectious", "OBSERVATION", 200, 214]]], ["Thus, this cell clone provides an ideal control for inhibition studies.", [["cell clone", "ANATOMY", 11, 21], ["cell clone", "CELL", 11, 21], ["cell clone", "CELL_LINE", 11, 21], ["this cell clone", "TREATMENT", 6, 21], ["inhibition studies", "TEST", 52, 70]]], ["Vero E6, CHO-K1, and SRD-12B cells were infected with either VSVDG/ LASVGP or wild-type VSV (VSVwt) as a control.", [["Vero", "ANATOMY", 0, 4], ["CHO-K1", "ANATOMY", 9, 15], ["SRD-12B cells", "ANATOMY", 21, 34], ["Vero E6", "ORGANISM", 0, 7], ["CHO-K1", "CELL", 9, 15], ["SRD-12B cells", "CELL", 21, 34], ["wild-type VSV", "ORGANISM", 78, 91], ["VSVwt", "ORGANISM", 93, 98], ["Vero E6, CHO-K1, and SRD-12B cells", "CELL_LINE", 0, 34], ["VSVDG", "PROTEIN", 61, 66], ["LASVGP", "PROTEIN", 68, 74], ["Vero E6", "SPECIES", 0, 7], ["VSV", "SPECIES", 88, 91], ["Vero E6", "TEST", 0, 7], ["CHO", "TEST", 9, 12], ["SRD", "PROBLEM", 21, 24], ["12B cells", "PROBLEM", 25, 34], ["VSVDG", "TEST", 61, 66], ["LASVGP", "PROBLEM", 68, 74], ["12B cells", "OBSERVATION", 25, 34]]], ["Aliquots of cell culture supernatants were collected at different times after infection and were analyzed by plaque assay.", [["Aliquots", "ANATOMY", 0, 8], ["cell", "ANATOMY", 12, 16], ["supernatants", "ANATOMY", 25, 37], ["plaque", "ANATOMY", 109, 115], ["cell", "CELL", 12, 16], ["cell culture supernatants", "TEST", 12, 37], ["infection", "PROBLEM", 78, 87], ["plaque assay", "TEST", 109, 121], ["plaque", "OBSERVATION", 109, 115]]], ["Growth kinetics revealed that VSVDG/LASVGP grows to similar titers in CHO-K1 cells compared to Vero E6 cells which have been used in earlier studies (Fig. 1A) [48] .", [["CHO-K1 cells", "ANATOMY", 70, 82], ["Vero E6 cells", "ANATOMY", 95, 108], ["VSVDG", "GENE_OR_GENE_PRODUCT", 30, 35], ["LASVGP", "GENE_OR_GENE_PRODUCT", 36, 42], ["CHO-K1 cells", "CELL", 70, 82], ["Vero E6 cells", "CELL", 95, 108], ["VSVDG", "PROTEIN", 30, 35], ["LASVGP", "PROTEIN", 36, 42], ["CHO-K1 cells", "CELL_LINE", 70, 82], ["Vero E6 cells", "CELL_LINE", 95, 108], ["CHO-K1", "SPECIES", 70, 76], ["Vero E6", "SPECIES", 95, 102], ["Growth kinetics", "TEST", 0, 15], ["VSVDG", "TEST", 30, 35], ["LASVGP", "TEST", 36, 42], ["K1 cells", "PROBLEM", 74, 82], ["Vero E6 cells", "TEST", 95, 108], ["E6 cells", "OBSERVATION", 100, 108]]], ["These data demonstrated that CHO-K1 cells support efficient VSVDG/LASVGP replication, and thus are useful tools for further investigations.", [["CHO-K1 cells", "ANATOMY", 29, 41], ["CHO-K1 cells", "CELL", 29, 41], ["VSVDG", "GENE_OR_GENE_PRODUCT", 60, 65], ["LASVGP", "GENE_OR_GENE_PRODUCT", 66, 72], ["CHO-K1 cells", "CELL_LINE", 29, 41], ["These data", "TEST", 0, 10], ["CHO-K1 cells", "TREATMENT", 29, 41], ["efficient VSVDG/LASVGP replication", "TREATMENT", 50, 84], ["further investigations", "TEST", 116, 138]]], ["As expected, VSVDG/ LASVGP lacks efficient replication in SRD-12B cells, whereas virus growth of VSVwt remained unaffected in these cells (Fig. 1A) .", [["SRD-12B cells", "ANATOMY", 58, 71], ["cells", "ANATOMY", 132, 137], ["VSVDG", "GENE_OR_GENE_PRODUCT", 13, 18], ["LASVGP", "GENE_OR_GENE_PRODUCT", 20, 26], ["SRD-12B cells", "CELL", 58, 71], ["VSVwt", "GENE_OR_GENE_PRODUCT", 97, 102], ["cells", "CELL", 132, 137], ["VSVDG", "PROTEIN", 13, 18], ["LASVGP", "PROTEIN", 20, 26], ["SRD-12B cells", "CELL_LINE", 58, 71], ["VSVwt", "PROTEIN", 97, 102], ["VSVDG", "TEST", 13, 18], ["12B cells", "PROBLEM", 62, 71], ["virus growth of VSVwt", "PROBLEM", 81, 102], ["12B cells", "OBSERVATION", 62, 71]]], ["The reason for the low but detectable virus titers in the supernatant of VSVDG/LASVGP-infected SRD-12B cells is currently not known but has been also observed for LASV ( [23] and present study), LCMV [34] and New Word arenaviruses [33] .", [["supernatant", "ANATOMY", 58, 69], ["SRD-12B cells", "ANATOMY", 95, 108], ["VSVDG/LASVGP", "ORGANISM", 73, 85], ["SRD-12B cells", "CELL", 95, 108], ["LCMV", "ORGANISM", 195, 199], ["VSVDG/LASVGP-infected SRD-12B cells", "CELL_LINE", 73, 108], ["LASV", "SPECIES", 163, 167], ["the low", "PROBLEM", 15, 22], ["detectable virus titers", "PROBLEM", 27, 50], ["VSVDG", "TEST", 73, 78], ["LASVGP", "TEST", 79, 85], ["infected SRD-12B cells", "PROBLEM", 86, 108], ["LASV", "PROBLEM", 163, 167], ["present study", "TEST", 179, 192], ["LCMV", "TEST", 195, 199], ["New Word arenaviruses", "PROBLEM", 209, 230], ["virus", "OBSERVATION", 38, 43], ["12B cells", "OBSERVATION", 99, 108]]], ["Glycoprotein activation by a yet unknown protease though with only very low efficiency might explain this phenomenon.Growth kinetics of VSVDG/LASVGP in CHO-K1 cellsTo mimic the conditions of short-term treatment, we decided to use the inducible doxycycline-dependent Tet-On expression system, which allows regulated expression of the protein of interest [55] .", [["CHO-K1 cells", "ANATOMY", 152, 164], ["CHO-K1", "CHEMICAL", 152, 158], ["doxycycline", "CHEMICAL", 245, 256], ["doxycycline", "CHEMICAL", 245, 256], ["Glycoprotein", "GENE_OR_GENE_PRODUCT", 0, 12], ["VSVDG", "SIMPLE_CHEMICAL", 136, 141], ["CHO-K1 cells", "CELL", 152, 164], ["doxycycline", "SIMPLE_CHEMICAL", 245, 256], ["protease", "PROTEIN", 41, 49], ["VSVDG", "PROTEIN", 136, 141], ["LASVGP", "PROTEIN", 142, 148], ["CHO-K1 cells", "CELL_LINE", 152, 164], ["Glycoprotein activation", "TREATMENT", 0, 23], ["very low efficiency", "PROBLEM", 67, 86], ["this phenomenon", "PROBLEM", 101, 116], ["Growth kinetics", "TEST", 117, 132], ["VSVDG", "TEST", 136, 141], ["LASVGP", "PROBLEM", 142, 148], ["short-term treatment", "TREATMENT", 191, 211], ["the inducible doxycycline", "TREATMENT", 231, 256], ["expression system", "TREATMENT", 274, 291]]], ["To determine whether treatment of cells with doxycycline interferes with viral replication, we cultivated VSVDG/LASVGPinfected CHO-K1 Tet-On cells in the presence or absence of doxycycline (1 mg/ml) for 24 h and 48 h, respectively.", [["cells", "ANATOMY", 34, 39], ["CHO-K1 Tet-On cells", "ANATOMY", 127, 146], ["doxycycline", "CHEMICAL", 45, 56], ["doxycycline", "CHEMICAL", 177, 188], ["doxycycline", "CHEMICAL", 45, 56], ["doxycycline", "CHEMICAL", 177, 188], ["cells", "CELL", 34, 39], ["doxycycline", "SIMPLE_CHEMICAL", 45, 56], ["LASVGPinfected CHO-K1 Tet-On cells", "CELL", 112, 146], ["doxycycline", "SIMPLE_CHEMICAL", 177, 188], ["VSVDG/LASVGPinfected CHO-K1 Tet-On cells", "CELL_LINE", 106, 146], ["cells", "PROBLEM", 34, 39], ["doxycycline", "TREATMENT", 45, 56], ["viral replication", "TREATMENT", 73, 90], ["doxycycline", "TREATMENT", 177, 188]]], ["As shown in Fig. 1B , CHO-K1 Tet-On cells treated with doxycycline produced a virus titer comparable to cells that were cultivated in the absence of doxycycline, indicating that these conditions used in our experiments have no influence on efficient virus replication.Growth kinetics of VSVDG/LASVGP in CHO-K1 cellsGeneration of S1P-adapted a 1 -antitrypsin expressing cell lines Pullikotil and colleagues recently reported that various antitrypsins mimicking S1P recognition motifs are able to block processing of the S1P substrates SREBP and ATF6, although to different degrees [42] .", [["cells", "ANATOMY", 36, 41], ["cells", "ANATOMY", 104, 109], ["CHO-K1 cells", "ANATOMY", 303, 315], ["cell lines", "ANATOMY", 369, 379], ["doxycycline", "CHEMICAL", 55, 66], ["doxycycline", "CHEMICAL", 149, 160], ["CHO-K1", "CHEMICAL", 303, 309], ["S1P", "CHEMICAL", 329, 332], ["S1P", "CHEMICAL", 460, 463], ["doxycycline", "CHEMICAL", 55, 66], ["doxycycline", "CHEMICAL", 149, 160], ["S1P", "CHEMICAL", 329, 332], ["CHO-K1", "CELL", 22, 28], ["doxycycline", "SIMPLE_CHEMICAL", 55, 66], ["cells", "CELL", 104, 109], ["doxycycline", "SIMPLE_CHEMICAL", 149, 160], ["VSVDG", "SIMPLE_CHEMICAL", 287, 292], ["CHO-K1 cells", "CELL", 303, 315], ["S1P", "GENE_OR_GENE_PRODUCT", 329, 332], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 343, 357], ["cell lines", "CELL", 369, 379], ["S1P", "GENE_OR_GENE_PRODUCT", 460, 463], ["S1P", "GENE_OR_GENE_PRODUCT", 519, 522], ["SREBP", "GENE_OR_GENE_PRODUCT", 534, 539], ["ATF6", "GENE_OR_GENE_PRODUCT", 544, 548], ["CHO-K1 Tet-On cells", "CELL_LINE", 22, 41], ["VSVDG", "PROTEIN", 287, 292], ["LASVGP", "PROTEIN", 293, 299], ["CHO-K1 cells", "CELL_LINE", 303, 315], ["S1P", "PROTEIN", 329, 332], ["1 -antitrypsin expressing cell lines", "CELL_LINE", 343, 379], ["antitrypsins", "PROTEIN", 437, 449], ["S1P recognition motifs", "PROTEIN", 460, 482], ["S1P substrates", "PROTEIN", 519, 533], ["SREBP", "PROTEIN", 534, 539], ["ATF6", "PROTEIN", 544, 548], ["CHO", "TEST", 22, 25], ["Tet-On cells", "TREATMENT", 29, 41], ["doxycycline", "TREATMENT", 55, 66], ["a virus titer", "PROBLEM", 76, 89], ["doxycycline", "TREATMENT", 149, 160], ["these conditions", "PROBLEM", 178, 194], ["efficient virus replication", "TREATMENT", 240, 267], ["Growth kinetics", "TEST", 268, 283], ["VSVDG", "TEST", 287, 292], ["LASVGP", "PROBLEM", 293, 299], ["S1P", "TEST", 329, 332], ["a 1 -antitrypsin expressing cell lines", "TREATMENT", 341, 379], ["various antitrypsins mimicking S1P recognition motifs", "TREATMENT", 429, 482], ["ATF6", "TEST", 544, 548], ["Fig", "OBSERVATION", 12, 15], ["cell lines", "OBSERVATION", 369, 379]]], ["In addition to the a 1 -AT variants shown to be most effective in that study we have chosen the LASV GP-C cleavage motif RRLL to investigate whether they also inhibit LASV GP-C cleavage.", [["GP-C", "GENE_OR_GENE_PRODUCT", 101, 105], ["GP-C", "GENE_OR_GENE_PRODUCT", 172, 176], ["1 -AT variants", "DNA", 21, 35], ["LASV GP-C cleavage motif", "PROTEIN", 96, 120], ["LASV", "SPECIES", 96, 100], ["LASV", "SPECIES", 167, 171], ["that study", "TEST", 66, 76], ["the LASV GP", "TREATMENT", 92, 103], ["C cleavage motif RRLL", "TREATMENT", 104, 125]]], ["Therefore, we generated various S1Pspecific a 1 -ATs, and as a specificity control, a furin-adapted a 1 -AT, by recombinant PCR technology using the rat a 1 -AT-PIT as a template (Fig. 2A) .", [["furin", "GENE_OR_GENE_PRODUCT", 86, 91], ["rat", "ORGANISM", 149, 152], ["furin", "PROTEIN", 86, 91], ["rat a 1 -AT-PIT", "DNA", 149, 164], ["rat", "SPECIES", 149, 152], ["a template (Fig", "TREATMENT", 168, 183]]], ["To facilitate their detection, we introduced a flag epitope at the C-termini of the constructs.", [["flag epitope", "PROTEIN", 47, 59], ["C-termini", "PROTEIN", 67, 76], ["their detection", "TEST", 14, 29], ["a flag epitope", "TREATMENT", 45, 59], ["flag epitope", "OBSERVATION", 47, 59]]], ["Stable cell lines were generated and individual clones were isolated and screened for a 1 -antitrypsin expression after doxycycline induction by immunoblotting and immunofluorescence analysis.", [["cell lines", "ANATOMY", 7, 17], ["clones", "ANATOMY", 48, 54], ["doxycycline", "CHEMICAL", 120, 131], ["doxycycline", "CHEMICAL", 120, 131], ["cell lines", "CELL", 7, 17], ["clones", "CELL", 48, 54], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 88, 102], ["doxycycline", "SIMPLE_CHEMICAL", 120, 131], ["Stable cell lines", "CELL_LINE", 0, 17], ["individual clones", "PROBLEM", 37, 54], ["a 1 -antitrypsin expression", "TREATMENT", 86, 113], ["doxycycline induction", "TREATMENT", 120, 141], ["immunofluorescence analysis", "TEST", 164, 191], ["cell lines", "OBSERVATION", 7, 17]]], ["Cell lines that showed similar expression levels of a 1 -antitrypsins were chosen for further experiments (Fig. 2B and 2C ).Effect of S1P-specific a 1 -antitrypsins on LASV GP processingTo test the inhibitory potential of S1P-specific a 1 -antitrypsins on proteolytic processing of LASV GP, stably transfected CHO-K1 Tet-On cells, and non-transfected wild-type CHO-K1 Tet-On cells as well as SRD-12B cells were infected with VSVDG/ LASVGP at an MOI of 0.2 in the presence or absence of doxycycline.", [["Cell lines", "ANATOMY", 0, 10], ["CHO-K1 Tet-On cells", "ANATOMY", 310, 329], ["CHO-K1 Tet-On cells", "ANATOMY", 361, 380], ["SRD-12B cells", "ANATOMY", 392, 405], ["S1P", "CHEMICAL", 134, 137], ["S1P", "CHEMICAL", 222, 225], ["doxycycline", "CHEMICAL", 486, 497], ["S1P", "CHEMICAL", 134, 137], ["S1P", "CHEMICAL", 222, 225], ["doxycycline", "CHEMICAL", 486, 497], ["Cell lines", "CELL", 0, 10], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 54, 69], ["S1P", "GENE_OR_GENE_PRODUCT", 134, 137], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 149, 164], ["LASV", "ORGANISM", 168, 172], ["S1P", "GENE_OR_GENE_PRODUCT", 222, 225], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 237, 252], ["LASV", "ORGANISM", 282, 286], ["GP", "ORGANISM", 287, 289], ["CHO-K1 Tet-On cells", "CELL", 310, 329], ["CHO-K1 Tet-On cells", "CELL", 361, 380], ["SRD-12B cells", "CELL", 392, 405], ["doxycycline", "SIMPLE_CHEMICAL", 486, 497], ["1 -antitrypsins", "PROTEIN", 54, 69], ["LASV GP", "PROTEIN", 282, 289], ["CHO-K1 Tet-On cells", "CELL_LINE", 310, 329], ["non-transfected wild-type CHO-K1 Tet-On cells", "CELL_LINE", 335, 380], ["SRD-12B cells", "CELL_LINE", 392, 405], ["LASV", "SPECIES", 168, 172], ["LASV", "SPECIES", 282, 286], ["Cell lines", "TEST", 0, 10], ["similar expression levels", "PROBLEM", 23, 48], ["a 1 -antitrypsins", "TREATMENT", 52, 69], ["S1P", "TEST", 134, 137], ["LASV GP processing", "TREATMENT", 168, 186], ["S1P", "TEST", 222, 225], ["LASV GP", "TEST", 282, 289], ["type CHO", "TEST", 356, 364], ["SRD", "TEST", 392, 395], ["VSVDG", "TEST", 425, 430], ["LASVGP", "PROBLEM", 432, 438], ["an MOI", "TEST", 442, 448], ["doxycycline", "TREATMENT", 486, 497], ["similar", "OBSERVATION_MODIFIER", 23, 30], ["expression", "OBSERVATION_MODIFIER", 31, 41], ["levels", "OBSERVATION_MODIFIER", 42, 48], ["doxycycline", "OBSERVATION", 486, 497]]], ["To allow only one replication cycle, cell lysates were analyzed 10 h post-infection for detection of LASV GP cleavage by Western blot analysis using a GP-specific antiserum that recognizes both the precursor GP-C and the cleaved subunit GP-2.", [["cell lysates", "ANATOMY", 37, 49], ["cell lysates", "CELL", 37, 49], ["LASV", "ORGANISM", 101, 105], ["antiserum", "ORGANISM_SUBSTANCE", 163, 172], ["GP-C", "GENE_OR_GENE_PRODUCT", 208, 212], ["GP-2", "GENE_OR_GENE_PRODUCT", 237, 241], ["LASV GP", "PROTEIN", 101, 108], ["GP", "PROTEIN", 151, 153], ["precursor GP-C", "PROTEIN", 198, 212], ["cleaved subunit GP-2", "PROTEIN", 221, 241], ["LASV", "SPECIES", 101, 105], ["one replication cycle", "TREATMENT", 14, 35], ["cell lysates", "TREATMENT", 37, 49], ["infection", "PROBLEM", 74, 83], ["LASV GP cleavage", "PROBLEM", 101, 117], ["blot analysis", "TEST", 129, 142]]], ["In CHO-K1 Tet-On cells LASV GP was efficiently cleaved, regardless of whether doxycycline was present or not.", [["CHO-K1 Tet-On cells", "ANATOMY", 3, 22], ["doxycycline", "CHEMICAL", 78, 89], ["doxycycline", "CHEMICAL", 78, 89], ["CHO-K1", "CELL", 3, 9], ["doxycycline", "SIMPLE_CHEMICAL", 78, 89], ["CHO-K1 Tet-On cells", "CELL_LINE", 3, 22], ["LASV GP", "PROTEIN", 23, 30], ["LASV", "SPECIES", 23, 27], ["cells LASV GP", "TREATMENT", 17, 30], ["doxycycline", "TREATMENT", 78, 89]]], ["In contrast, virtually no detectable cleavage of GP was observed in SRD-12B cells that are deficient in S1P (Fig. 3A, lanes 1-4) .", [["SRD-12B cells", "ANATOMY", 68, 81], ["GP", "GENE_OR_GENE_PRODUCT", 49, 51], ["SRD-12B cells", "CELL", 68, 81], ["S1P", "GENE_OR_GENE_PRODUCT", 104, 107], ["GP", "PROTEIN", 49, 51], ["SRD-12B cells", "CELL_LINE", 68, 81], ["detectable cleavage of GP", "PROBLEM", 26, 51], ["no", "UNCERTAINTY", 23, 25], ["detectable", "OBSERVATION_MODIFIER", 26, 36], ["cleavage", "OBSERVATION", 37, 45], ["12B cells", "OBSERVATION", 72, 81]]], ["Without expression of the various antitrypsins efficient cleavage was detected in these stably transfected cell lines, similar to the processing of GP in wild-type CHO-K1 Tet-On cells (Fig. 3A , lanes 1, 5, 7, 9, 11, and 13) .", [["cell lines", "ANATOMY", 107, 117], ["CHO-K1 Tet-On cells", "ANATOMY", 164, 183], ["antitrypsins", "GENE_OR_GENE_PRODUCT", 34, 46], ["cell lines", "CELL", 107, 117], ["CHO-K1 Tet-On cells", "CELL", 164, 183], ["antitrypsins", "PROTEIN", 34, 46], ["stably transfected cell lines", "CELL_LINE", 88, 117], ["GP", "PROTEIN", 148, 150], ["wild-type CHO-K1 Tet-On cells", "CELL_LINE", 154, 183], ["the various antitrypsins efficient cleavage", "PROBLEM", 22, 65], ["transfected cell lines", "OBSERVATION", 95, 117]]], ["In contrast, cells expressing the S1Padapted a 1 -antitrypsins inhibited proteolytic maturation of LASV GP (Fig. 3A, lanes 6, 8, 10, and 12) .", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 47, 62], ["LASV", "ORGANISM", 99, 103], ["S1Padapted a 1 -antitrypsins", "PROTEIN", 34, 62], ["LASV GP", "PROTEIN", 99, 106], ["Fig. 3A, lanes 6, 8, 10, and 12", "PROTEIN", 108, 139], ["LASV", "SPECIES", 99, 103], ["LASV GP", "TEST", 99, 106], ["lanes", "TEST", 117, 122], ["LASV", "OBSERVATION_MODIFIER", 99, 103]]], ["Furthermore, our results show Effect of S1P Inhibition on LASV Replication www.plosntds.org that the presence of a furin-specific a 1 -AT did not influence LASV GP-C processing, demonstrating the specificity of the generated S1P-adapted a 1 -antitrypsins (Fig. 3A, lanes 13 and 14) .", [["S1P", "CHEMICAL", 40, 43], ["S1P", "CHEMICAL", 225, 228], ["S1P", "CHEMICAL", 40, 43], ["S1P", "GENE_OR_GENE_PRODUCT", 40, 43], ["LASV", "ORGANISM", 58, 62], ["furin", "GENE_OR_GENE_PRODUCT", 115, 120], ["LASV", "ORGANISM", 156, 160], ["GP-C", "GENE_OR_GENE_PRODUCT", 161, 165], ["S1P", "GENE_OR_GENE_PRODUCT", 225, 228], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 239, 254], ["furin", "PROTEIN", 115, 120], ["LASV GP", "PROTEIN", 156, 163], ["S1P", "PROTEIN", 225, 228], ["Fig. 3A, lanes 13 and 14", "PROTEIN", 256, 280], ["LASV", "SPECIES", 58, 62], ["LASV", "SPECIES", 156, 160], ["S1P Inhibition", "TREATMENT", 40, 54], ["LASV Replication", "TREATMENT", 58, 74]]], ["Quantification of GP-2 cleavage revealed that the a 1 -AT variant RRIL exhibited the greatest inhibitory effect on GP processing (.80% inhibition) followed by a 1 -AT RRLL (.60% inhibition), which possesses the amino acid cleavage motif of the LASV GP-C.", [["amino acid", "CHEMICAL", 211, 221], ["amino acid", "CHEMICAL", 211, 221], ["GP-2", "GENE_OR_GENE_PRODUCT", 18, 22], ["amino acid", "AMINO_ACID", 211, 221], ["GP", "PROTEIN", 18, 20], ["amino acid cleavage motif", "PROTEIN", 211, 236], ["LASV GP", "PROTEIN", 244, 251], ["GP", "TEST", 18, 20], ["GP processing", "TREATMENT", 115, 128], ["the amino acid cleavage", "TREATMENT", 207, 230], ["greatest", "OBSERVATION_MODIFIER", 85, 93], ["inhibitory effect", "OBSERVATION", 94, 111]]], ["Also a 1 -AT variants RRVL and RRYL were found to be inhibitory, although to a lesser extent (inhibition less than 50%) than the variants RRIL and RRLL (Fig. 3B) .", [["1 -AT variants", "DNA", 7, 21], ["RRIL", "PROTEIN", 138, 142], ["lesser extent", "OBSERVATION_MODIFIER", 79, 92]]], ["Taken together, these data clearly demonstrate that S1P-specific a 1 -antitrypsins efficiently block the maturation cleavage of LASV GP, however, they differ in regard to their inhibitory potential.S1P-specific a 1 -antitrypsin prevents LASV GP incorporation into virionsWe have shown earlier that S1P-mediated cleavage of GP-C is absolutely required for incorporation of the glycoprotein subunits into the virion envelope and thus for production of infectious LASV [23] .", [["S1P", "CHEMICAL", 52, 55], ["S1P", "CHEMICAL", 198, 201], ["S1P", "CHEMICAL", 298, 301], ["S1P", "CHEMICAL", 52, 55], ["S1P", "CHEMICAL", 198, 201], ["S1P", "CHEMICAL", 298, 301], ["S1P", "GENE_OR_GENE_PRODUCT", 52, 55], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 67, 82], ["LASV GP", "ORGANISM", 128, 135], ["S1P", "GENE_OR_GENE_PRODUCT", 198, 201], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 213, 227], ["LASV", "ORGANISM", 237, 241], ["GP", "GENE_OR_GENE_PRODUCT", 242, 244], ["S1P", "GENE_OR_GENE_PRODUCT", 298, 301], ["GP-C", "GENE_OR_GENE_PRODUCT", 323, 327], ["LASV", "ORGANISM", 461, 465], ["LASV GP", "PROTEIN", 128, 135], ["S1P", "PROTEIN", 198, 201], ["1 -antitrypsin", "PROTEIN", 213, 227], ["LASV GP", "PROTEIN", 237, 244], ["S1P", "PROTEIN", 298, 301], ["GP-C", "PROTEIN", 323, 327], ["glycoprotein subunits", "PROTEIN", 376, 397], ["LASV", "SPECIES", 128, 132], ["LASV", "SPECIES", 237, 241], ["LASV", "SPECIES", 461, 465], ["S1P", "TEST", 52, 55], ["S1P", "TEST", 198, 201], ["LASV GP incorporation", "TREATMENT", 237, 258], ["the glycoprotein subunits", "TREATMENT", 372, 397], ["infectious LASV", "PROBLEM", 450, 465], ["virions", "OBSERVATION", 264, 271], ["infectious", "OBSERVATION", 450, 460]]], ["Therefore, we addressed the question of whether a S1P-specific a 1 -AT has the potential to prevent GP incorporation by blocking glycoprotein processing.", [["S1P", "CHEMICAL", 50, 53], ["S1P", "CHEMICAL", 50, 53], ["1 -AT", "CHEMICAL", 65, 70], ["S1P", "GENE_OR_GENE_PRODUCT", 50, 53], ["1 -AT", "GENE_OR_GENE_PRODUCT", 65, 70], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 129, 141], ["glycoprotein", "PROTEIN", 129, 141], ["GP incorporation", "TREATMENT", 100, 116], ["blocking glycoprotein processing", "TREATMENT", 120, 152]]], ["To this end, a 1 -AT RRIL cells were infected in the presence or absence of doxycycline with either VSVDG/LASVGP or VSVwt as a control.", [["1 -AT RRIL cells", "ANATOMY", 15, 31], ["doxycycline", "CHEMICAL", 76, 87], ["VSVDG", "CHEMICAL", 100, 105], ["doxycycline", "CHEMICAL", 76, 87], ["VSVDG", "CHEMICAL", 100, 105], ["RRIL cells", "CELL", 21, 31], ["doxycycline", "SIMPLE_CHEMICAL", 76, 87], ["1 -AT RRIL cells", "CELL_LINE", 15, 31], ["a 1 -AT RRIL cells", "TREATMENT", 13, 31], ["doxycycline", "TREATMENT", 76, 87], ["VSVDG", "TREATMENT", 100, 105], ["LASVGP", "TREATMENT", 106, 112], ["VSVwt", "TREATMENT", 116, 121], ["infected", "OBSERVATION", 37, 45]]], ["At 24 h postinfection, viral particles released into the cell culture supernatant were purified over a 20% sucrose cushion and analyzed by means of immunoblotting.", [["cell culture supernatant", "ANATOMY", 57, 81], ["sucrose", "CHEMICAL", 107, 114], ["sucrose", "CHEMICAL", 107, 114], ["cell", "CELL", 57, 61], ["viral particles", "PROBLEM", 23, 38], ["the cell culture", "TEST", 53, 69], ["a 20% sucrose cushion", "TREATMENT", 101, 122], ["immunoblotting", "TREATMENT", 148, 162], ["viral particles", "OBSERVATION", 23, 38]]], ["In viral particles from supernatants of noninduced a 1 -AT RRIL cells and CHO-K1 Tet-On control cells cleaved GP-2 was readily observed, whereas in the particulate material isolated from the supernatant of a 1 -AT RRIL expressing cells no glycoprotein was detected (Fig. 4A) .", [["supernatants", "ANATOMY", 24, 36], ["1 -AT RRIL cells", "ANATOMY", 53, 69], ["cells", "ANATOMY", 96, 101], ["supernatant", "ANATOMY", 191, 202], ["cells", "ANATOMY", 230, 235], ["CHO-K1", "CELL", 74, 80], ["cells", "CELL", 96, 101], ["GP-2", "GENE_OR_GENE_PRODUCT", 110, 114], ["cells", "CELL", 230, 235], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 239, 251], ["1 -AT RRIL cells", "CELL_LINE", 53, 69], ["CHO-K1 Tet-On control cells", "CELL_LINE", 74, 101], ["GP", "PROTEIN", 110, 112], ["1 -AT RRIL expressing cells", "CELL_LINE", 208, 235], ["glycoprotein", "PROTEIN", 239, 251], ["CHO", "TEST", 74, 77], ["K1 Tet", "TEST", 78, 84], ["glycoprotein", "PROBLEM", 239, 251], ["viral particles", "OBSERVATION", 3, 18]]], ["However, Western Blot analysis for VSV proteins revealed the release of these viral proteins into the supernatant of a 1 -AT RRIL expressing cells, which is consistent with our earlier findings that, in the absence of GP-C cleavage, enveloped non-infectious LASV-like particles containing the matrix protein Z and the ribonucleoprotein (RNP) complex, but devoid of viral glycoproteins, are still released [23] .", [["supernatant", "ANATOMY", 102, 113], ["cells", "ANATOMY", 141, 146], ["VSV", "ORGANISM", 35, 38], ["cells", "CELL", 141, 146], ["GP-C", "GENE_OR_GENE_PRODUCT", 218, 222], ["matrix protein Z", "GENE_OR_GENE_PRODUCT", 293, 309], ["VSV proteins", "PROTEIN", 35, 47], ["viral proteins", "PROTEIN", 78, 92], ["1 -AT RRIL expressing cells", "CELL_LINE", 119, 146], ["matrix protein Z", "PROTEIN", 293, 309], ["ribonucleoprotein (RNP) complex", "PROTEIN", 318, 349], ["viral glycoproteins", "PROTEIN", 365, 384], ["VSV", "SPECIES", 35, 38], ["Blot analysis", "TEST", 17, 30], ["VSV proteins", "TEST", 35, 47], ["these viral proteins", "TEST", 72, 92], ["GP-C cleavage", "PROBLEM", 218, 231], ["enveloped non-infectious LASV", "PROBLEM", 233, 262], ["the matrix protein Z", "TEST", 289, 309], ["the ribonucleoprotein (RNP) complex", "PROBLEM", 314, 349], ["viral glycoproteins", "PROBLEM", 365, 384], ["viral proteins", "OBSERVATION", 78, 92], ["consistent with", "UNCERTAINTY", 157, 172], ["non-infectious", "OBSERVATION", 243, 257], ["viral glycoproteins", "OBSERVATION", 365, 384]]], ["The lower amount of VSV proteins observed in the cell lysate and supernatant of a 1 -AT RRIL expressing cells reflect lower levels of viral replication, which is due to less efficient virus spread (Fig. 4A) .", [["cell lysate", "ANATOMY", 49, 60], ["supernatant", "ANATOMY", 65, 76], ["cells", "ANATOMY", 104, 109], ["VSV", "ORGANISM", 20, 23], ["cell", "CELL", 49, 53], ["cells", "CELL", 104, 109], ["VSV proteins", "PROTEIN", 20, 32], ["1 -AT RRIL expressing cells", "CELL_LINE", 82, 109], ["VSV", "SPECIES", 20, 23], ["VSV proteins", "PROBLEM", 20, 32], ["the cell lysate", "TEST", 45, 60], ["a 1 -AT RRIL expressing cells", "TREATMENT", 80, 109], ["viral replication", "PROBLEM", 134, 151], ["less efficient virus spread", "PROBLEM", 169, 196], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["amount", "OBSERVATION_MODIFIER", 10, 16], ["VSV proteins", "OBSERVATION", 20, 32], ["cell lysate", "OBSERVATION", 49, 60], ["lower levels", "OBSERVATION_MODIFIER", 118, 130], ["viral replication", "OBSERVATION", 134, 151], ["virus", "OBSERVATION", 184, 189]]], ["In contrast to its ability to efficiently block incorporation of LASV GP into virions, the presence of a 1 -AT RRIL had no effect on the release of glycoprotein G containing wild-type VSV particles.", [["LASV", "ORGANISM", 65, 69], ["GP", "GENE_OR_GENE_PRODUCT", 70, 72], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 148, 162], ["VSV", "ORGANISM", 184, 187], ["LASV GP", "PROTEIN", 65, 72], ["glycoprotein G", "PROTEIN", 148, 162], ["LASV", "SPECIES", 65, 69], ["LASV GP into virions", "TREATMENT", 65, 85], ["glycoprotein G", "TREATMENT", 148, 162], ["type VSV particles", "PROBLEM", 179, 197], ["LASV", "OBSERVATION", 65, 69], ["VSV particles", "OBSERVATION", 184, 197]]], ["The amount of VSV proteins detected in the supernatant from a 1 -AT RRIL expressing cells was similar to the amount of viral proteins observed in supernatants of non-induced cells and CHO-K1 cells, indicating efficient viral replication and cell-to-cell spread of VSVwt despite the presence of a 1 -AT RRIL (Fig. 4B) .", [["supernatant", "ANATOMY", 43, 54], ["cells", "ANATOMY", 84, 89], ["supernatants", "ANATOMY", 146, 158], ["cells", "ANATOMY", 174, 179], ["CHO-K1 cells", "ANATOMY", 184, 196], ["cell", "ANATOMY", 241, 245], ["cell", "ANATOMY", 249, 253], ["VSV", "ORGANISM", 14, 17], ["cells", "CELL", 84, 89], ["cells", "CELL", 174, 179], ["CHO-K1 cells", "CELL", 184, 196], ["cell", "CELL", 241, 245], ["cell", "CELL", 249, 253], ["VSV proteins", "PROTEIN", 14, 26], ["1 -AT RRIL expressing cells", "CELL_LINE", 62, 89], ["viral proteins", "PROTEIN", 119, 133], ["non-induced cells", "CELL_LINE", 162, 179], ["CHO-K1 cells", "CELL_LINE", 184, 196], ["VSV", "SPECIES", 14, 17], ["CHO-K1", "SPECIES", 184, 190], ["VSV proteins", "PROBLEM", 14, 26], ["viral proteins", "PROBLEM", 119, 133], ["non-induced cells", "PROBLEM", 162, 179], ["CHO-K1 cells", "PROBLEM", 184, 196], ["efficient viral replication", "PROBLEM", 209, 236], ["cell", "TEST", 241, 245], ["cell spread of VSVwt", "PROBLEM", 249, 269], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["VSV proteins", "OBSERVATION", 14, 26], ["viral proteins", "OBSERVATION", 119, 133], ["non-induced cells", "OBSERVATION", 162, 179], ["K1 cells", "OBSERVATION", 188, 196], ["efficient", "OBSERVATION_MODIFIER", 209, 218], ["viral replication", "OBSERVATION", 219, 236], ["cell spread", "OBSERVATION", 249, 260]]], ["Taken together, these data demonstrate that S1P-specific a 1 -antitrypsins have the potential to prevent LASV GP incorporation by inhibiting glycoprotein cleavage, which is an essential prerequisite for infectious progeny.S1P-specific a 1 -antitrypsin prevents LASV GP incorporation into virionsVirus spread is reduced in the presence of specific a 1antitrypsins Next, we wanted to know whether the observed inhibition of LASV GP processing correlates with the ability of the different a 1antitrypsin variants to inhibit virus spread.", [["S1P", "CHEMICAL", 44, 47], ["S1P", "CHEMICAL", 222, 225], ["S1P", "CHEMICAL", 222, 225], ["S1P", "GENE_OR_GENE_PRODUCT", 44, 47], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 59, 74], ["LASV", "ORGANISM", 105, 109], ["S1P", "GENE_OR_GENE_PRODUCT", 222, 225], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 237, 251], ["LASV", "ORGANISM", 261, 265], ["GP", "GENE_OR_GENE_PRODUCT", 266, 268], ["Virus", "ORGANISM", 295, 300], ["LASV", "ORGANISM", 422, 426], ["GP", "GENE_OR_GENE_PRODUCT", 427, 429], ["1antitrypsin", "GENE_OR_GENE_PRODUCT", 488, 500], ["1 -antitrypsins", "PROTEIN", 59, 74], ["S1P", "PROTEIN", 222, 225], ["1 -antitrypsin", "PROTEIN", 237, 251], ["LASV GP", "PROTEIN", 261, 268], ["LASV GP", "PROTEIN", 422, 429], ["LASV", "SPECIES", 105, 109], ["LASV", "SPECIES", 261, 265], ["LASV", "SPECIES", 422, 426], ["these data", "TEST", 16, 26], ["S1P", "TEST", 44, 47], ["LASV GP incorporation", "PROBLEM", 105, 126], ["inhibiting glycoprotein cleavage", "PROBLEM", 130, 162], ["S1P", "TEST", 222, 225], ["LASV GP incorporation", "TREATMENT", 261, 282], ["Virus spread", "PROBLEM", 295, 307], ["LASV GP processing", "PROBLEM", 422, 440], ["a 1antitrypsin variants", "TREATMENT", 486, 509], ["virus spread", "PROBLEM", 521, 533], ["LASV", "OBSERVATION", 105, 109], ["essential prerequisite for", "UNCERTAINTY", 176, 202], ["infectious", "OBSERVATION", 203, 213], ["virions", "OBSERVATION", 288, 295], ["reduced", "OBSERVATION_MODIFIER", 311, 318], ["LASV", "OBSERVATION", 422, 426]]], ["To investigate this, we established a 96-well plate assay in which infected cells are immunostained with True Blue substrate as described in Materials and Methods.", [["cells", "ANATOMY", 76, 81], ["cells", "CELL", 76, 81], ["infected cells", "CELL_TYPE", 67, 81], ["plate assay", "TEST", 46, 57], ["infected cells", "PROBLEM", 67, 81], ["True Blue substrate", "PROBLEM", 105, 124], ["infected cells", "OBSERVATION", 67, 81], ["Blue substrate", "OBSERVATION", 110, 124]]], ["Virus spread can be monitored by the appearance of characteristic comet-shaped foci, showing that the virus progeny is carried over the cell monolayer, while prevention of virus spread results in limited radial growth, due to infection of only neighbouring cells.", [["foci", "ANATOMY", 79, 83], ["cell monolayer", "ANATOMY", 136, 150], ["radial", "ANATOMY", 204, 210], ["cells", "ANATOMY", 257, 262], ["infection", "DISEASE", 226, 235], ["Virus", "ORGANISM", 0, 5], ["foci", "CELL", 79, 83], ["cell monolayer", "CELL", 136, 150], ["cells", "CELL", 257, 262], ["neighbouring cells", "CELL_TYPE", 244, 262], ["Virus spread", "PROBLEM", 0, 12], ["characteristic comet-shaped foci", "PROBLEM", 51, 83], ["the virus progeny", "PROBLEM", 98, 115], ["the cell monolayer", "TREATMENT", 132, 150], ["virus spread", "PROBLEM", 172, 184], ["limited radial growth", "PROBLEM", 196, 217], ["infection", "PROBLEM", 226, 235], ["characteristic", "OBSERVATION_MODIFIER", 51, 65], ["comet", "OBSERVATION", 66, 71], ["shaped", "OBSERVATION_MODIFIER", 72, 78], ["foci", "OBSERVATION", 79, 83], ["infection", "OBSERVATION", 226, 235], ["neighbouring cells", "OBSERVATION", 244, 262]]], ["This assay allows rapid screening of potential inhibitors [50] .", [["This assay", "TEST", 0, 10], ["potential inhibitors", "TREATMENT", 37, 57]]], ["Effect of S1P Inhibition on LASV Replication www.plosntds.org type cells (Fig. 5A, upper panel) .", [["org type cells", "ANATOMY", 58, 72], ["S1P", "CHEMICAL", 10, 13], ["S1P", "CHEMICAL", 10, 13], ["S1P", "GENE_OR_GENE_PRODUCT", 10, 13], ["LASV", "ORGANISM", 28, 32], ["org type cells", "CELL", 58, 72], ["Fig. 5A", "CELL", 74, 81], ["org type cells", "CELL_TYPE", 58, 72], ["LASV", "SPECIES", 28, 32], ["S1P Inhibition", "TREATMENT", 10, 24], ["LASV Replication", "TREATMENT", 28, 44], ["org type cells", "TEST", 58, 72], ["upper panel", "TEST", 83, 94]]], ["In contrast, virus spread was significantly diminished in cells expressing a 1 -AT specific for S1P (Fig. 5A, lower panel) .", [["cells", "ANATOMY", 58, 63], ["cells", "CELL", 58, 63], ["1 -AT", "GENE_OR_GENE_PRODUCT", 77, 82], ["S1P", "GENE_OR_GENE_PRODUCT", 96, 99], ["S1P", "PROTEIN", 96, 99], ["virus spread", "PROBLEM", 13, 25], ["significantly diminished in cells", "PROBLEM", 30, 63], ["lower panel", "TEST", 110, 121], ["diminished", "OBSERVATION_MODIFIER", 44, 54]]], ["These data indicate that S1P-adapted a 1antitrypsins have the potential to specifically inhibit the processing of LASV GP, which in turn is required for efficient virus spread.", [["S1P", "CHEMICAL", 25, 28], ["S1P", "CHEMICAL", 25, 28], ["S1P", "GENE_OR_GENE_PRODUCT", 25, 28], ["1antitrypsins", "GENE_OR_GENE_PRODUCT", 39, 52], ["LASV", "ORGANISM", 114, 118], ["GP", "GENE_OR_GENE_PRODUCT", 119, 121], ["LASV GP", "PROTEIN", 114, 121], ["LASV", "SPECIES", 114, 118], ["These data", "TEST", 0, 10], ["S1P", "TEST", 25, 28], ["a 1antitrypsins", "TREATMENT", 37, 52], ["LASV GP", "PROBLEM", 114, 121], ["efficient virus spread", "PROBLEM", 153, 175], ["LASV", "OBSERVATION", 114, 118]]], ["It should be noted that the infectious foci observed in a 1 -AT RRIL expressing cells were larger compared to SRD-12B cells in which virtually no virus spread of VSVDG/LASVGP was observed, resulting in only single infected cells (Fig. 5A) .", [["foci", "ANATOMY", 39, 43], ["cells", "ANATOMY", 80, 85], ["SRD-12B cells", "ANATOMY", 110, 123], ["cells", "ANATOMY", 223, 228], ["cells", "CELL", 80, 85], ["SRD-12B cells", "CELL", 110, 123], ["VSVDG", "GENE_OR_GENE_PRODUCT", 162, 167], ["LASVGP", "GENE_OR_GENE_PRODUCT", 168, 174], ["cells", "CELL", 223, 228], ["1 -AT RRIL expressing cells", "CELL_LINE", 58, 85], ["SRD-12B cells", "CELL_LINE", 110, 123], ["VSVDG", "PROTEIN", 162, 167], ["LASVGP", "PROTEIN", 168, 174], ["infected cells", "CELL_TYPE", 214, 228], ["the infectious foci", "PROBLEM", 24, 43], ["SRD", "TEST", 110, 113], ["virus spread of VSVDG/LASVGP", "PROBLEM", 146, 174], ["single infected cells", "PROBLEM", 207, 228], ["infectious", "OBSERVATION_MODIFIER", 28, 38], ["foci", "OBSERVATION", 39, 43], ["larger", "OBSERVATION_MODIFIER", 91, 97], ["no", "UNCERTAINTY", 143, 145], ["virus", "OBSERVATION", 146, 151], ["infected cells", "OBSERVATION", 214, 228]]], ["Although similar inhibition values were observed by means of immunoblot quantification (Fig. 3) , a few remaining non-detectable cleavage events may count for this limited cell-to-cell spread in a 1 -AT RRIL expressing cells.", [["cell", "ANATOMY", 172, 176], ["cell", "ANATOMY", 180, 184], ["cells", "ANATOMY", 219, 224], ["cell", "CELL", 172, 176], ["cell", "CELL", 180, 184], ["cells", "CELL", 219, 224], ["1 -AT RRIL expressing cells", "CELL_LINE", 197, 224], ["similar inhibition values", "PROBLEM", 9, 34], ["immunoblot quantification", "TEST", 61, 86], ["a few remaining non-detectable cleavage events", "PROBLEM", 98, 144], ["this limited cell", "TEST", 159, 176], ["non-detectable cleavage", "OBSERVATION", 114, 137]]], ["Cells expressing the furin-adapted a 1 -AT variant RVKR did not prevent virus spread.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["furin", "GENE_OR_GENE_PRODUCT", 21, 26], ["furin", "PROTEIN", 21, 26], ["the furin", "TEST", 17, 26], ["virus spread", "PROBLEM", 72, 84], ["not prevent", "UNCERTAINTY", 60, 71], ["virus", "OBSERVATION", 72, 77]]], ["At first glance, we rather observed an enhancement of infectivity compared to noninduced cells, which might be due to an increase in the LASV cellular receptor a-dystroglycan on the cell surface [56] .S1P-specific a 1 -antitrypsin prevents LASV GP incorporation into virionsTo further confirm the specificity of the a 1 -AT variants, we used fowl plague virus (FPV), which contains a hemagglutinin with a multibasic cleavage motif recognized by furin [57] .", [["cells", "ANATOMY", 89, 94], ["cellular", "ANATOMY", 142, 150], ["cell surface", "ANATOMY", 182, 194], ["S1P", "CHEMICAL", 201, 204], ["fowl plague", "DISEASE", 342, 353], ["S1P", "CHEMICAL", 201, 204], ["cells", "CELL", 89, 94], ["cellular", "CELL", 142, 150], ["a-dystroglycan", "GENE_OR_GENE_PRODUCT", 160, 174], ["cell surface", "CELLULAR_COMPONENT", 182, 194], ["S1P", "GENE_OR_GENE_PRODUCT", 201, 204], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 216, 230], ["LASV", "ORGANISM", 240, 244], ["GP", "GENE_OR_GENE_PRODUCT", 245, 247], ["fowl plague virus", "ORGANISM", 342, 359], ["FPV", "ORGANISM", 361, 364], ["furin", "GENE_OR_GENE_PRODUCT", 445, 450], ["noninduced cells", "CELL_TYPE", 78, 94], ["LASV cellular receptor a-dystroglycan", "PROTEIN", 137, 174], ["S1P", "PROTEIN", 201, 204], ["1 -antitrypsin", "PROTEIN", 216, 230], ["LASV GP", "PROTEIN", 240, 247], ["1 -AT variants", "DNA", 318, 332], ["hemagglutinin", "PROTEIN", 384, 397], ["multibasic cleavage motif", "PROTEIN", 405, 430], ["furin", "PROTEIN", 445, 450], ["fowl plague virus", "SPECIES", 342, 359], ["LASV", "SPECIES", 137, 141], ["LASV", "SPECIES", 240, 244], ["fowl plague virus", "SPECIES", 342, 359], ["FPV", "SPECIES", 361, 364], ["an enhancement of infectivity", "PROBLEM", 36, 65], ["noninduced cells", "PROBLEM", 78, 94], ["an increase", "PROBLEM", 118, 129], ["S1P", "TEST", 201, 204], ["LASV GP incorporation", "TREATMENT", 240, 261], ["fowl plague virus", "PROBLEM", 342, 359], ["a hemagglutinin", "TREATMENT", 382, 397], ["a multibasic cleavage motif", "TREATMENT", 403, 430], ["enhancement", "OBSERVATION_MODIFIER", 39, 50], ["infectivity", "OBSERVATION", 54, 65], ["might be due to", "UNCERTAINTY", 102, 117], ["increase", "OBSERVATION_MODIFIER", 121, 129], ["LASV", "OBSERVATION", 137, 141], ["virions", "OBSERVATION", 267, 274]]], ["Thus, the furin-adapted a 1 -AT should prevent virus spread of FPV, while virus spread in the presence of S1P-specific a 1 -antitrypsins should remain unaffected.", [["S1P", "CHEMICAL", 106, 109], ["S1P", "CHEMICAL", 106, 109], ["furin", "GENE_OR_GENE_PRODUCT", 10, 15], ["1 -AT", "GENE_OR_GENE_PRODUCT", 26, 31], ["FPV", "ORGANISM", 63, 66], ["S1P", "GENE_OR_GENE_PRODUCT", 106, 109], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 121, 136], ["furin", "PROTEIN", 10, 15], ["S1P", "PROTEIN", 106, 109], ["FPV", "SPECIES", 63, 66], ["the furin", "TEST", 6, 15], ["virus spread of FPV", "PROBLEM", 47, 66], ["virus spread", "PROBLEM", 74, 86], ["S1P", "TEST", 106, 109]]], ["Fig. 5B clearly demonstrates that the most potent S1P-specific a 1 -AT variant RRIL had no effect on FPV replication, and that virus spread was found to be similar to that observed in wild type CHO-K1 Tet-On cells.", [["CHO-K1 Tet-On cells", "ANATOMY", 194, 213], ["S1P", "CHEMICAL", 50, 53], ["S1P", "GENE_OR_GENE_PRODUCT", 50, 53], ["RRIL", "GENE_OR_GENE_PRODUCT", 79, 83], ["FPV", "ORGANISM", 101, 104], ["CHO-K1 Tet-On cells", "CELL", 194, 213], ["wild type CHO-K1 Tet-On cells", "CELL_LINE", 184, 213], ["FPV", "SPECIES", 101, 104], ["FPV replication", "TREATMENT", 101, 116], ["virus spread", "PROBLEM", 127, 139], ["no effect", "UNCERTAINTY", 88, 97]]], ["In contrast, in cells expressing the furin-adapted a 1 -AT variant RVKR virus spread of FPV was drastically reduced, whereas FPV replication occurred efficiently under doxycycline-free conditions in these cells.", [["cells", "ANATOMY", 16, 21], ["cells", "ANATOMY", 205, 210], ["doxycycline", "CHEMICAL", 168, 179], ["doxycycline", "CHEMICAL", 168, 179], ["cells", "CELL", 16, 21], ["furin", "GENE_OR_GENE_PRODUCT", 37, 42], ["RVKR", "GENE_OR_GENE_PRODUCT", 67, 71], ["FPV", "ORGANISM", 88, 91], ["doxycycline", "SIMPLE_CHEMICAL", 168, 179], ["cells", "CELL", 205, 210], ["furin", "PROTEIN", 37, 42], ["FPV", "SPECIES", 88, 91], ["FPV", "SPECIES", 125, 128], ["the furin", "TEST", 33, 42], ["FPV", "PROBLEM", 88, 91], ["FPV replication", "PROBLEM", 125, 140], ["doxycycline", "TREATMENT", 168, 179]]], ["These results demonstrate that the generated a 1 -AT variants exhibit high specificity for the corresponding proteases, which are essential for virus spread in cell culture.Effect of a 1 -antitrypsin variants on recombinant viral replicationTo further elucidate the effect of the different a 1 -AT variants on multicycle replication, viral titers were determined.", [["cell culture", "ANATOMY", 160, 172], ["cell culture", "CELL", 160, 172], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 185, 199], ["1 -AT variants", "DNA", 47, 61], ["proteases", "PROTEIN", 109, 118], ["1 -antitrypsin variants", "PROTEIN", 185, 208], ["1 -AT variants", "DNA", 292, 306], ["the corresponding proteases", "PROBLEM", 91, 118], ["virus spread", "PROBLEM", 144, 156], ["cell culture", "TEST", 160, 172], ["a 1 -antitrypsin variants", "TREATMENT", 183, 208], ["recombinant viral replication", "TREATMENT", 212, 241], ["multicycle replication", "TREATMENT", 310, 332], ["viral titers", "TEST", 334, 346], ["viral replication", "OBSERVATION", 224, 241], ["viral titers", "OBSERVATION", 334, 346]]], ["To this end, cells were infected with VSVDG/LASVGP at an MOI of 0.02 in the presence or absence of doxycycline.", [["cells", "ANATOMY", 13, 18], ["doxycycline", "CHEMICAL", 99, 110], ["doxycycline", "CHEMICAL", 99, 110], ["cells", "CELL", 13, 18], ["doxycycline", "SIMPLE_CHEMICAL", 99, 110], ["VSVDG", "TEST", 38, 43], ["LASVGP", "TREATMENT", 44, 50], ["an MOI", "TEST", 54, 60], ["doxycycline", "TREATMENT", 99, 110], ["infected", "OBSERVATION", 24, 32], ["doxycycline", "OBSERVATION", 99, 110]]], ["Cell culture supernatants were collected 24 h and 48 h post-infection and virus titers were determined by plaque assay.", [["Cell", "ANATOMY", 0, 4], ["supernatants", "ANATOMY", 13, 25], ["plaque", "ANATOMY", 106, 112], ["Cell", "CELL", 0, 4], ["Cell culture supernatants", "TEST", 0, 25], ["virus titers", "TEST", 74, 86], ["plaque assay", "TEST", 106, 118]]], ["As shown in Table 1 , non-induced S1P-specific a 1 -AT cell lines permitted unaffected growth of Effect of S1P Inhibition on LASV Replication www.plosntds.org VSVDG/LASVGP to comparable titers, whereas virus titers were reduced in cells expressing the S1P-specific a 1 -AT variant.", [["1 -AT cell lines", "ANATOMY", 49, 65], ["cells", "ANATOMY", 231, 236], ["S1P", "CHEMICAL", 34, 37], ["S1P", "CHEMICAL", 107, 110], ["S1P", "CHEMICAL", 252, 255], ["S1P", "CHEMICAL", 107, 110], ["S1P", "GENE_OR_GENE_PRODUCT", 34, 37], ["S1P", "GENE_OR_GENE_PRODUCT", 107, 110], ["LASV", "ORGANISM", 125, 129], ["cells", "CELL", 231, 236], ["S1P", "GENE_OR_GENE_PRODUCT", 252, 255], ["1 -AT cell lines", "CELL_LINE", 49, 65], ["VSVDG", "PROTEIN", 159, 164], ["LASVGP", "PROTEIN", 165, 171], ["S1P", "PROTEIN", 252, 255], ["LASV", "SPECIES", 125, 129], ["AT cell lines", "TREATMENT", 52, 65], ["S1P Inhibition", "TREATMENT", 107, 121], ["LASV Replication", "TREATMENT", 125, 141], ["plosntds.org VSVDG", "TEST", 146, 164], ["comparable titers", "TEST", 175, 192], ["virus titers", "TEST", 202, 214], ["the S1P", "TEST", 248, 255]]], ["At 24 h post-infection virus production decreased about 100 fold in cells expressing the a 1 -AT variant RRIL compared to non-induced control cultures.", [["cells", "ANATOMY", 68, 73], ["cultures", "ANATOMY", 142, 150], ["infection", "DISEASE", 13, 22], ["cells", "CELL", 68, 73], ["non-induced control cultures", "CELL_LINE", 122, 150], ["infection virus production", "PROBLEM", 13, 39], ["non-induced control cultures", "TEST", 122, 150], ["infection", "OBSERVATION", 13, 22]]], ["The presence of a 1 -AT variant RRLL reduced the virus titer in the supernatant about 10 fold, followed by a 6.2 fold reduction of virus production in a 1 -AT variant RRVL expressing cells.", [["supernatant", "ANATOMY", 68, 79], ["cells", "ANATOMY", 183, 188], ["RRLL", "GENE_OR_GENE_PRODUCT", 32, 36], ["cells", "CELL", 183, 188], ["1 -AT variant RRVL expressing cells", "CELL_LINE", 153, 188], ["a 1 -AT variant RRLL", "PROBLEM", 16, 36], ["the virus titer", "PROBLEM", 45, 60], ["a 6.2 fold reduction of virus production", "PROBLEM", 107, 147], ["reduced", "OBSERVATION_MODIFIER", 37, 44], ["virus titer", "OBSERVATION", 49, 60], ["10 fold", "OBSERVATION_MODIFIER", 86, 93], ["6.2 fold", "OBSERVATION_MODIFIER", 109, 117], ["reduction", "OBSERVATION_MODIFIER", 118, 127], ["virus production", "OBSERVATION", 131, 147], ["expressing cells", "OBSERVATION", 172, 188]]], ["The presence of the a 1 -AT variant RRYL only exhibited a very moderate inhibitory effect on viral replication (inhibition ,2 fold).", [["a very moderate inhibitory effect", "PROBLEM", 56, 89], ["viral replication", "TREATMENT", 93, 110], ["very", "OBSERVATION_MODIFIER", 58, 62], ["moderate", "OBSERVATION_MODIFIER", 63, 71], ["inhibitory effect", "OBSERVATION", 72, 89], ["viral replication", "OBSERVATION", 93, 110]]], ["Again, the presence of the furin-adapted a 1 -AT variant RVKR did not affect VSVDG/LASVGP replication compared to non-induced control cells.", [["cells", "ANATOMY", 134, 139], ["furin", "GENE_OR_GENE_PRODUCT", 27, 32], ["VSVDG", "GENE_OR_GENE_PRODUCT", 77, 82], ["LASVGP", "GENE_OR_GENE_PRODUCT", 83, 89], ["cells", "CELL", 134, 139], ["furin", "PROTEIN", 27, 32], ["VSVDG", "PROTEIN", 77, 82], ["non-induced control cells", "CELL_LINE", 114, 139], ["the furin", "TEST", 23, 32], ["VSVDG", "PROBLEM", 77, 82], ["LASVGP replication", "PROBLEM", 83, 101], ["non-induced control cells", "PROBLEM", 114, 139]]], ["Our results indicate that the various S1P-adapted a 1 -antitrypsins exhibit different inhibitory potentials, due to their different recognition motifs.", [["S1P", "CHEMICAL", 38, 41], ["S1P", "CHEMICAL", 38, 41], ["S1P", "GENE_OR_GENE_PRODUCT", 38, 41], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 52, 67], ["1 -antitrypsins", "PROTEIN", 52, 67]]], ["However, the degree of inhibition of virus replication correlated well with the inhibitory potential of the various S1P-adapted a 1 -antitrypsin variants to block LASV GP processing.", [["S1P", "CHEMICAL", 116, 119], ["S1P", "GENE_OR_GENE_PRODUCT", 116, 119], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 130, 144], ["LASV", "ORGANISM", 163, 167], ["GP", "GENE_OR_GENE_PRODUCT", 168, 170], ["S1P", "PROTEIN", 116, 119], ["1 -antitrypsin variants", "PROTEIN", 130, 153], ["LASV GP", "PROTEIN", 163, 170], ["LASV", "SPECIES", 163, 167], ["inhibition of virus replication", "PROBLEM", 23, 54], ["a 1 -antitrypsin variants", "TREATMENT", 128, 153], ["virus replication", "OBSERVATION", 37, 54]]], ["Interestingly, following the inhibition of virus progeny over a time period of 48 h only the S1P-adapted a 1 -AT variants RRIL and RRLL sustained their inhibitory capacity, whereas in cells expressing a 1 -antitrypsin variants RRVL and RRYL virus production was found to recover although the initial expression levels of a 1 -antitrypsin variants were similar (Table 1 ).", [["cells", "ANATOMY", 184, 189], ["S1P", "CHEMICAL", 93, 96], ["S1P", "GENE_OR_GENE_PRODUCT", 93, 96], ["RRLL", "GENE_OR_GENE_PRODUCT", 131, 135], ["cells", "CELL", 184, 189], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 203, 217], ["RRVL", "GENE_OR_GENE_PRODUCT", 227, 231], ["RRYL virus", "ORGANISM", 236, 246], ["1 -antitrypsin", "GENE_OR_GENE_PRODUCT", 323, 337], ["S1P", "PROTEIN", 93, 96], ["1 -AT variants", "DNA", 107, 121], ["1 -antitrypsin variants", "DNA", 323, 346], ["the S1P", "TEST", 89, 96], ["a 1 -antitrypsin variants RRVL", "PROBLEM", 201, 231], ["RRYL virus production", "PROBLEM", 236, 257]]], ["These data indicate that the inhibitory potential of the a 1 -AT variants RRVL and RRYL is not sufficient to efficiently suppress the formation of infectious particles by effectively blocking LASV GP-C cleavage, whereas the a 1 -AT variants RRIL and RRLL seem to be appropriate candidates for efficient inhibition of LASV propagation.Inhibition of S1P impairs efficient LASV replicationFinally, we wanted to investigate the impact of blocking S1Pmediated GP processing on virus progeny of authentic LASV.", [["S1P", "CHEMICAL", 348, 351], ["RRYL", "GENE_OR_GENE_PRODUCT", 83, 87], ["GP-C", "GENE_OR_GENE_PRODUCT", 197, 201], ["RRLL", "GENE_OR_GENE_PRODUCT", 250, 254], ["LASV", "ORGANISM", 317, 321], ["S1P", "GENE_OR_GENE_PRODUCT", 348, 351], ["LASV", "ORGANISM", 370, 374], ["S1Pmediated GP", "GENE_OR_GENE_PRODUCT", 443, 457], ["LASV", "ORGANISM", 499, 503], ["1 -AT variants", "DNA", 226, 240], ["S1P", "PROTEIN", 348, 351], ["S1Pmediated GP", "PROTEIN", 443, 457], ["LASV", "SPECIES", 192, 196], ["LASV", "SPECIES", 317, 321], ["LASV", "SPECIES", 370, 374], ["LASV", "SPECIES", 499, 503], ["infectious particles", "PROBLEM", 147, 167], ["C cleavage", "PROBLEM", 200, 210], ["LASV propagation", "TREATMENT", 317, 333], ["S1P impairs", "TREATMENT", 348, 359], ["LASV replication", "TREATMENT", 370, 386], ["infectious", "OBSERVATION", 147, 157], ["LASV", "OBSERVATION", 317, 321], ["LASV", "OBSERVATION", 499, 503]]], ["Therefore, we assessed the inhibitory potential of the most potent variant, a 1 -AT RRIL, on the multiplication of LASV (strain Josiah).", [["LASV", "ORGANISM", 115, 119], ["strain Josiah", "ORGANISM", 121, 134], ["LASV", "SPECIES", 115, 119], ["LASV (strain Josiah", "TREATMENT", 115, 134], ["most potent", "OBSERVATION_MODIFIER", 55, 66], ["LASV", "OBSERVATION", 115, 119]]], ["For this purpose a 1 -AT RRIL cells and, as controls, CHO-K1-Tet-On and SRD-12B cells were infected with LASV at an MOI of 0.1.", [["1 -AT RRIL cells", "ANATOMY", 19, 35], ["SRD-12B cells", "ANATOMY", 72, 85], ["1 -AT RRIL cells", "CELL", 19, 35], ["CHO-K1", "CELL", 54, 60], ["SRD-12B cells", "CELL", 72, 85], ["LASV", "ORGANISM", 105, 109], ["1 -AT RRIL cells", "CELL_LINE", 19, 35], ["CHO-K1-Tet-On and SRD-12B cells", "CELL_LINE", 54, 85], ["LASV", "SPECIES", 105, 109], ["AT RRIL cells", "TREATMENT", 22, 35], ["CHO", "TEST", 54, 57], ["K1", "TEST", 58, 60], ["Tet", "TEST", 61, 64], ["SRD", "TEST", 72, 75], ["LASV", "TREATMENT", 105, 109], ["an MOI", "TEST", 113, 119], ["12B cells", "OBSERVATION", 76, 85]]], ["To induce a 1 -AT expression, a 1 -AT RRIL cells and, as a control for off-target effects, CHO-K1 Tet-On cells were cultivated in the presence of doxycycline.", [["1 -AT RRIL cells", "ANATOMY", 32, 48], ["CHO-K1 Tet-On cells", "ANATOMY", 91, 110], ["doxycycline", "CHEMICAL", 146, 157], ["doxycycline", "CHEMICAL", 146, 157], ["1 -AT RRIL cells", "CELL", 32, 48], ["CHO-K1 Tet-On cells", "CELL", 91, 110], ["doxycycline", "SIMPLE_CHEMICAL", 146, 157], ["1 -AT RRIL cells", "CELL_LINE", 32, 48], ["CHO-K1 Tet-On cells", "CELL_LINE", 91, 110], ["a 1 -AT RRIL cells", "TREATMENT", 30, 48], ["CHO", "TEST", 91, 94], ["K1 Tet-On cells", "TREATMENT", 95, 110], ["doxycycline", "TREATMENT", 146, 157]]], ["To determine virus titers, infectious virions released into the cell culture supernatant were analyzed by defining the 50% tissue culture infectious dose (TCID 50 ) at various times post-infection, as indicated.", [["virions", "ANATOMY", 38, 45], ["cell culture supernatant", "ANATOMY", 64, 88], ["tissue", "ANATOMY", 123, 129], ["cell", "CELL", 64, 68], ["tissue", "TISSUE", 123, 129], ["virus titers", "PROBLEM", 13, 25], ["infectious virions", "PROBLEM", 27, 45], ["the cell culture supernatant", "TEST", 60, 88]]], ["In noninduced a 1 -AT RRIL cells, LASV revealed a growth kinetic similar to that observed in CHO-K1 Tet-On control cultures, while expression of a 1 -AT RRIL resulted in an average 2 log10 reduction in viral titer (Fig. 6) .", [["1 -AT RRIL cells", "ANATOMY", 16, 32], ["cultures", "ANATOMY", 115, 123], ["1 -AT RRIL cells", "CELL", 16, 32], ["LASV", "ORGANISM", 34, 38], ["CHO-K1 Tet", "CELL", 93, 103], ["1 -AT RRIL cells", "CELL_LINE", 16, 32], ["CHO-K1 Tet-On control cultures", "CELL_LINE", 93, 123], ["1 -AT RRIL", "DNA", 147, 157], ["LASV", "SPECIES", 34, 38], ["LASV", "TEST", 34, 38], ["a growth kinetic", "PROBLEM", 48, 64], ["CHO", "TEST", 93, 96], ["control cultures", "TEST", 107, 123], ["viral titer", "TEST", 202, 213], ["growth kinetic", "OBSERVATION", 50, 64], ["viral titer", "OBSERVATION", 202, 213]]], ["The difference between infectious LASV titers in the supernatant of a 1 -AT RRIL expressing cells and SRD-12B cells correlated with the limited virus spread observed in a 1 -AT RRIL expressing cells compared to single cell infections in S1P null cells (Fig. 5) .", [["supernatant", "ANATOMY", 53, 64], ["cells", "ANATOMY", 92, 97], ["SRD-12B cells", "ANATOMY", 102, 115], ["cells", "ANATOMY", 193, 198], ["cell", "ANATOMY", 218, 222], ["S1P null cells", "ANATOMY", 237, 251], ["infections", "DISEASE", 223, 233], ["LASV", "ORGANISM", 34, 38], ["cells", "CELL", 92, 97], ["SRD-12B cells", "CELL", 102, 115], ["cells", "CELL", 193, 198], ["cell", "CELL", 218, 222], ["S1P null cells", "CELL", 237, 251], ["1 -AT RRIL expressing cells", "CELL_LINE", 70, 97], ["SRD-12B cells", "CELL_LINE", 102, 115], ["1 -AT RRIL expressing cells", "CELL_LINE", 171, 198], ["S1P null cells", "CELL_LINE", 237, 251], ["LASV", "SPECIES", 34, 38], ["infectious LASV titers", "TEST", 23, 45], ["SRD", "TEST", 102, 105], ["12B cells", "PROBLEM", 106, 115], ["the limited virus spread", "PROBLEM", 132, 156], ["single cell infections in S1P null cells", "PROBLEM", 211, 251], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["infectious", "OBSERVATION_MODIFIER", 23, 33], ["LASV", "OBSERVATION_MODIFIER", 34, 38], ["titers", "OBSERVATION_MODIFIER", 39, 45], ["12B cells", "OBSERVATION", 106, 115], ["single cell", "OBSERVATION_MODIFIER", 211, 222], ["infections", "OBSERVATION", 223, 233], ["S1P null cells", "OBSERVATION", 237, 251]]], ["Taken together, this result highlights the inhibitory activity of modified a 1 -antitrypsins against LASV and demonstrates that inhibition of endogenous S1P is a potent strategy to reduce the production of infectious LASV progeny.DiscussionCurrent drug treatment of Lassa fever and certain New World hemorrhagic fevers is limited to the guanosine analogue ribavirin [7, 8, 9] .", [["1 -antitrypsins", "CHEMICAL", 77, 92], ["S1P", "CHEMICAL", 153, 156], ["Lassa fever", "DISEASE", 266, 277], ["hemorrhagic fevers", "DISEASE", 300, 318], ["guanosine", "CHEMICAL", 337, 346], ["ribavirin", "CHEMICAL", 356, 365], ["S1P", "CHEMICAL", 153, 156], ["guanosine", "CHEMICAL", 337, 346], ["ribavirin", "CHEMICAL", 356, 365], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 77, 92], ["LASV", "ORGANISM", 101, 105], ["S1P", "GENE_OR_GENE_PRODUCT", 153, 156], ["LASV", "ORGANISM", 217, 221], ["Lassa", "ORGANISM", 266, 271], ["guanosine", "SIMPLE_CHEMICAL", 337, 346], ["ribavirin", "SIMPLE_CHEMICAL", 356, 365], ["LASV", "SPECIES", 101, 105], ["LASV", "SPECIES", 217, 221], ["LASV", "PROBLEM", 101, 105], ["a potent strategy", "TREATMENT", 160, 177], ["Lassa fever", "PROBLEM", 266, 277], ["New World hemorrhagic fevers", "PROBLEM", 290, 318], ["the guanosine analogue ribavirin", "TREATMENT", 333, 365], ["endogenous S1P", "OBSERVATION", 142, 156], ["infectious", "OBSERVATION_MODIFIER", 206, 216]]], ["Although ribavirin therapy can reduce the mortality rates of severe clinical cases, its unavailability to most patients in West Africa and South America as well as its association with severe adverse effects including anaemia [11, 13] , teratogenicity and embryo lethality [12] , argues for the development of new alternative treatment options.DiscussionIn principle, every step in the viral life cycle is a potential target for antiviral inhibitors.", [["embryo", "ANATOMY", 256, 262], ["ribavirin", "CHEMICAL", 9, 18], ["anaemia", "DISEASE", 218, 225], ["ribavirin", "CHEMICAL", 9, 18], ["ribavirin", "SIMPLE_CHEMICAL", 9, 18], ["patients", "ORGANISM", 111, 119], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 256, 262], ["patients", "SPECIES", 111, 119], ["ribavirin therapy", "TREATMENT", 9, 26], ["severe clinical cases", "PROBLEM", 61, 82], ["severe adverse effects", "PROBLEM", 185, 207], ["anaemia", "PROBLEM", 218, 225], ["teratogenicity", "PROBLEM", 237, 251], ["embryo lethality", "PROBLEM", 256, 272], ["new alternative treatment options", "TREATMENT", 310, 343], ["antiviral inhibitors", "TREATMENT", 429, 449], ["ribavirin therapy", "OBSERVATION", 9, 26]]], ["While current antiviral strategies in the arenavirus field mainly target virus entry [58, 59, 60, 61] or replication and assembly [62, 63, 64, 65, 66, 67] , inhibition studies of the glycoprotein activating endoprotease and its impact on viral replication are largely unexploited.", [["endoprotease", "GENE_OR_GENE_PRODUCT", 207, 219], ["glycoprotein activating endoprotease", "PROTEIN", 183, 219], ["current antiviral strategies", "TREATMENT", 6, 34], ["inhibition studies", "TEST", 157, 175], ["the glycoprotein activating endoprotease", "TREATMENT", 179, 219], ["viral replication", "TREATMENT", 238, 255], ["antiviral strategies", "OBSERVATION", 14, 34], ["viral replication", "OBSERVATION", 238, 255]]], ["Due to its central role in the arenavirus life cycle [23, 26, 33, 34] , S1P should be considered as a cellular target for antiviral drug development.", [["cellular", "ANATOMY", 102, 110], ["S1P", "CHEMICAL", 72, 75], ["S1P", "GENE_OR_GENE_PRODUCT", 72, 75], ["cellular", "CELL", 102, 110], ["S1P", "TREATMENT", 72, 75], ["a cellular target", "TREATMENT", 100, 117], ["antiviral drug development", "TREATMENT", 122, 148], ["central", "OBSERVATION_MODIFIER", 11, 18]]], ["In the present study we analyzed the inhibitory effect of S1P-adapted a 1 -antitrypsins on proteolytic processing of LASV GP-C and its consequences for viral replication.", [["S1P", "CHEMICAL", 58, 61], ["S1P", "CHEMICAL", 58, 61], ["S1P", "GENE_OR_GENE_PRODUCT", 58, 61], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 72, 87], ["LASV", "ORGANISM", 117, 121], ["GP-C", "GENE_OR_GENE_PRODUCT", 122, 126], ["LASV GP-C", "PROTEIN", 117, 126], ["LASV", "SPECIES", 117, 121], ["S1P", "TEST", 58, 61], ["proteolytic processing", "TREATMENT", 91, 113], ["LASV GP", "TREATMENT", 117, 124], ["viral replication", "TREATMENT", 152, 169]]], ["To our knowledge, this is the first report that Effect of S1P Inhibition on LASV Replication www.plosntds.org addresses the impact of protein-based S1P inhibition on LASV GP-C cleavage and multicycle replication.", [["S1P", "CHEMICAL", 58, 61], ["S1P", "CHEMICAL", 148, 151], ["S1P", "CHEMICAL", 58, 61], ["S1P", "CHEMICAL", 148, 151], ["S1P", "GENE_OR_GENE_PRODUCT", 58, 61], ["LASV", "ORGANISM", 76, 80], ["S1P", "GENE_OR_GENE_PRODUCT", 148, 151], ["LASV", "ORGANISM", 166, 170], ["GP-C", "GENE_OR_GENE_PRODUCT", 171, 175], ["LASV", "SPECIES", 76, 80], ["LASV", "SPECIES", 166, 170], ["S1P Inhibition", "TREATMENT", 58, 72], ["LASV Replication", "TREATMENT", 76, 92], ["org", "TREATMENT", 106, 109], ["protein", "TEST", 134, 141], ["LASV GP", "TREATMENT", 166, 173], ["C cleavage", "TREATMENT", 174, 184], ["multicycle replication", "TREATMENT", 189, 211]]], ["Furin-adapted a 1 -ATs have been shown to efficiently inhibit the formation of infectious progeny of other viruses (e.g. HIV, measles virus and human cytomegalovirus) [38, 39, 40, 41, 68, 69] .", [["Furin", "CHEMICAL", 0, 5], ["HIV, measles virus and human cytomegalovirus", "DISEASE", 121, 165], ["Furin", "SIMPLE_CHEMICAL", 0, 5], ["1 -ATs", "SIMPLE_CHEMICAL", 16, 22], ["HIV", "ORGANISM", 121, 124], ["measles virus", "ORGANISM", 126, 139], ["human", "ORGANISM", 144, 149], ["cytomegalovirus", "ORGANISM", 150, 165], ["HIV", "SPECIES", 121, 124], ["measles virus", "SPECIES", 126, 139], ["human", "SPECIES", 144, 149], ["HIV", "SPECIES", 121, 124], ["measles virus", "SPECIES", 126, 139], ["human", "SPECIES", 144, 149], ["Furin", "TEST", 0, 5], ["other viruses", "PROBLEM", 101, 114], ["HIV", "PROBLEM", 121, 124], ["measles virus", "PROBLEM", 126, 139], ["human cytomegalovirus", "TEST", 144, 165], ["infectious", "OBSERVATION", 79, 89]]], ["Using a replication-competent recombinant VSV pseudotyped with the LASV glycoprotein GP [48] , we demonstrate that proteolytic maturation of the precursor GP-C is sensitive to S1Padapted a 1 -ATs.", [["VSV", "ORGANISM", 42, 45], ["GP-C", "GENE_OR_GENE_PRODUCT", 155, 159], ["LASV glycoprotein GP", "PROTEIN", 67, 87], ["precursor GP-C", "PROTEIN", 145, 159], ["VSV", "SPECIES", 42, 45], ["VSV", "SPECIES", 42, 45], ["LASV", "SPECIES", 67, 71], ["a replication", "TREATMENT", 6, 19], ["competent recombinant VSV pseudotyped", "TREATMENT", 20, 57], ["the LASV glycoprotein GP", "TREATMENT", 63, 87]]], ["Mutagenesis of the reactive centre loop (RCL) into the S1P recognition motif RRIL resulted in an abrogation of GP-C processing similar to that observed in S1P-deficient SRD-12B cells.", [["SRD-12B cells", "ANATOMY", 169, 182], ["S1P", "CHEMICAL", 55, 58], ["S1P", "CHEMICAL", 155, 158], ["S1P", "CHEMICAL", 55, 58], ["S1P", "GENE_OR_GENE_PRODUCT", 55, 58], ["GP-C", "GENE_OR_GENE_PRODUCT", 111, 115], ["S1P", "GENE_OR_GENE_PRODUCT", 155, 158], ["SRD-12B cells", "CELL", 169, 182], ["reactive centre loop", "PROTEIN", 19, 39], ["RCL", "PROTEIN", 41, 44], ["S1P recognition motif", "PROTEIN", 55, 76], ["RRIL", "PROTEIN", 77, 81], ["GP", "PROTEIN", 111, 113], ["S1P-deficient SRD-12B cells", "CELL_LINE", 155, 182], ["the reactive centre loop (RCL)", "TREATMENT", 15, 45], ["an abrogation of GP-C processing", "PROBLEM", 94, 126], ["S1P", "TEST", 155, 158], ["deficient SRD-12B cells", "PROBLEM", 159, 182], ["reactive", "OBSERVATION_MODIFIER", 19, 27], ["centre loop", "OBSERVATION", 28, 39], ["12B cells", "OBSERVATION", 173, 182]]], ["The inhibitory activity of the a 1 -AT variant RRIL on LASV GP cleavage described here is in agreement with a previous study showing its inhibitory potential on the processing of the natural S1P substrates SREBP-2 and ATF6 [42] .", [["LASV", "ORGANISM", 55, 59], ["S1P", "GENE_OR_GENE_PRODUCT", 191, 194], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 206, 213], ["ATF6", "GENE_OR_GENE_PRODUCT", 218, 222], ["LASV GP", "PROTEIN", 55, 62], ["natural S1P substrates", "PROTEIN", 183, 205], ["SREBP", "PROTEIN", 206, 211], ["ATF6", "PROTEIN", 218, 222], ["LASV", "SPECIES", 55, 59], ["LASV GP cleavage", "TREATMENT", 55, 71], ["a previous study", "TEST", 108, 124], ["SREBP", "TEST", 206, 211]]], ["Also an a 1 -AT variant that contains the LASV GP-C cleavage motif RRLL exhibited a high S1P inhibitory potential and was found to drastically reduce GP processing.", [["S1P", "CHEMICAL", 89, 92], ["S1P", "CHEMICAL", 89, 92], ["GP-C", "GENE_OR_GENE_PRODUCT", 47, 51], ["S1P", "GENE_OR_GENE_PRODUCT", 89, 92], ["LASV GP-C cleavage motif", "PROTEIN", 42, 66], ["the LASV GP", "TEST", 38, 49], ["C cleavage motif RRLL", "PROBLEM", 50, 71], ["LASV", "OBSERVATION", 42, 46]]], ["Interestingly, this variant exhibited a 100% inhibition activity on maturation cleavage of an artificial pro-PDGF (precursor of platelet-derived growth factor) mutant that is processed by S1P due to introduction of a RRLL cleavage site, but failed to inhibit cleavage of endogenously expressed SREBP-2 [42] .", [["S1P", "CHEMICAL", 188, 191], ["S1P", "CHEMICAL", 188, 191], ["pro-PDGF", "GENE_OR_GENE_PRODUCT", 105, 113], ["platelet-derived growth factor", "GENE_OR_GENE_PRODUCT", 128, 158], ["S1P", "GENE_OR_GENE_PRODUCT", 188, 191], ["RRLL", "GENE_OR_GENE_PRODUCT", 217, 221], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 294, 301], ["pro-PDGF", "PROTEIN", 105, 113], ["platelet-derived growth factor) mutant", "PROTEIN", 128, 166], ["RRLL cleavage site", "DNA", 217, 235], ["SREBP", "PROTEIN", 294, 299], ["maturation cleavage", "TREATMENT", 68, 87], ["an artificial pro-PDGF", "TREATMENT", 91, 113], ["platelet-derived growth factor", "TREATMENT", 128, 158], ["a RRLL cleavage site", "TREATMENT", 215, 235], ["SREBP", "TEST", 294, 299]]], ["These data indicate that various substrates differ in their sensitivity towards S1P inhibition.DiscussionThe outcome of severe illness increased significantly with the level of viremia in Lassa fever patients [70] .", [["S1P", "CHEMICAL", 80, 83], ["viremia", "DISEASE", 177, 184], ["Lassa fever", "DISEASE", 188, 199], ["S1P", "CHEMICAL", 80, 83], ["S1P", "GENE_OR_GENE_PRODUCT", 80, 83], ["Lassa", "ORGANISM", 188, 193], ["patients", "ORGANISM", 200, 208], ["Lassa fever", "SPECIES", 188, 199], ["patients", "SPECIES", 200, 208], ["various substrates", "PROBLEM", 25, 43], ["S1P inhibition", "TREATMENT", 80, 94], ["severe illness", "PROBLEM", 120, 134], ["viremia", "PROBLEM", 177, 184], ["Lassa fever", "PROBLEM", 188, 199], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["illness", "OBSERVATION", 127, 134]]], ["Therefore, the extent of multicycle replication of LASV and thus, the load of infectious particles in its host organism have an important impact for the progress of disease.", [["LASV", "ORGANISM", 51, 55], ["LASV", "SPECIES", 51, 55], ["multicycle replication of LASV", "TREATMENT", 25, 55], ["infectious particles", "PROBLEM", 78, 98], ["disease", "PROBLEM", 165, 172], ["multicycle replication", "OBSERVATION", 25, 47], ["LASV", "OBSERVATION", 51, 55], ["infectious", "OBSERVATION", 78, 88], ["disease", "OBSERVATION", 165, 172]]], ["Our studies revealed that a 1 -AT variants RRIL and RRLL have a potency sufficient to sustain their inhibitory capacity during multicycle replication, which resulted in a significant reduction of virus infectivity.", [["RRIL", "GENE_OR_GENE_PRODUCT", 43, 47], ["RRLL", "GENE_OR_GENE_PRODUCT", 52, 56], ["1 -AT variants", "DNA", 28, 42], ["RRLL", "PROTEIN", 52, 56], ["Our studies", "TEST", 0, 11], ["multicycle replication", "TREATMENT", 127, 149], ["a significant reduction of virus infectivity", "PROBLEM", 169, 213], ["significant", "OBSERVATION_MODIFIER", 171, 182], ["reduction", "OBSERVATION_MODIFIER", 183, 192], ["virus infectivity", "OBSERVATION", 196, 213]]], ["Inhibition of viral replication correlated with the ability of the a 1 -AT variants RRIL and RRLL to efficiently inhibit the processing of the LASV glycoprotein precursor.", [["RRIL", "GENE_OR_GENE_PRODUCT", 84, 88], ["RRLL", "GENE_OR_GENE_PRODUCT", 93, 97], ["LASV", "ORGANISM", 143, 147], ["LASV glycoprotein precursor", "PROTEIN", 143, 170], ["LASV", "SPECIES", 143, 147], ["viral replication", "TREATMENT", 14, 31], ["RRLL", "TREATMENT", 93, 97], ["the LASV glycoprotein precursor", "TREATMENT", 139, 170], ["viral replication", "OBSERVATION", 14, 31], ["LASV", "OBSERVATION", 143, 147]]], ["Although our data demonstrated that inhibition of glycoprotein cleavage by a 1 -AT RRIL reduced incorporation of the subunits GP-1 and GP-2 into virions to below detectable levels, the viral titer from a 1 -AT RRIL expressing cells was found to be greater than that obtained from S1P null cells.", [["virions", "ANATOMY", 145, 152], ["cells", "ANATOMY", 226, 231], ["S1P null cells", "ANATOMY", 280, 294], ["GP-1", "GENE_OR_GENE_PRODUCT", 126, 130], ["GP-2", "GENE_OR_GENE_PRODUCT", 135, 139], ["cells", "CELL", 226, 231], ["S1P", "GENE_OR_GENE_PRODUCT", 280, 283], ["subunits GP-1", "PROTEIN", 117, 130], ["GP", "PROTEIN", 135, 137], ["1 -AT RRIL expressing cells", "CELL_LINE", 204, 231], ["S1P null cells", "CELL_LINE", 280, 294], ["our data", "TEST", 9, 17], ["glycoprotein cleavage", "TREATMENT", 50, 71], ["the viral titer", "TEST", 181, 196], ["viral titer", "OBSERVATION", 185, 196], ["null cells", "OBSERVATION", 284, 294]]], ["Based on this observation, we consider that even the most potent a 1 -AT variant RRIL failed to entirely inhibit S1P activity.", [["S1P", "CHEMICAL", 113, 116], ["S1P", "GENE_OR_GENE_PRODUCT", 113, 116], ["S1P", "PROTEIN", 113, 116], ["this observation", "TEST", 9, 25]]], ["However, given that S1P has important biological functions in the regulation of various cellular processes, a complete inhibition of the catalytic activity of S1P is not desirable.", [["cellular", "ANATOMY", 88, 96], ["S1P", "CHEMICAL", 20, 23], ["S1P", "CHEMICAL", 159, 162], ["S1P", "CHEMICAL", 20, 23], ["S1P", "CHEMICAL", 159, 162], ["S1P", "GENE_OR_GENE_PRODUCT", 20, 23], ["cellular", "CELL", 88, 96], ["S1P", "GENE_OR_GENE_PRODUCT", 159, 162], ["various cellular processes", "PROBLEM", 80, 106], ["various cellular processes", "OBSERVATION", 80, 106]]], ["For a 1 -AT variants RRVL and RRYL, we observed similar inhibition values by immunoblot quantification analysis as described for CCHFV GP cleavage [42] .", [["CCHFV", "SPECIES", 129, 134], ["immunoblot quantification analysis", "TEST", 77, 111], ["CCHFV GP cleavage", "PROBLEM", 129, 146]]], ["Though, their inhibitory activity on LASV GP-C cleavage was not sufficient to efficiently reduce virus replication of VSVDG/LASVGP.", [["LASV", "ORGANISM", 37, 41], ["GP-C", "GENE_OR_GENE_PRODUCT", 42, 46], ["VSVDG", "PROTEIN", 118, 123], ["LASVGP", "PROTEIN", 124, 130], ["LASV", "SPECIES", 37, 41], ["LASV GP", "TREATMENT", 37, 44], ["C cleavage", "PROBLEM", 45, 55], ["VSVDG", "PROBLEM", 118, 123], ["LASVGP", "PROBLEM", 124, 130]]], ["These results should be taken into consideration for experimental setups in future studies that address the impact of S1P inhibition in arenavirus replication.DiscussionThe most potent a 1 -AT variant RRIL revealed a similar inhibitory potential on virus release of authentic LASV to that observed with the corresponding VSVDG/LASVGP pseudotype.", [["S1P", "CHEMICAL", 118, 121], ["S1P", "CHEMICAL", 118, 121], ["S1P", "GENE_OR_GENE_PRODUCT", 118, 121], ["arenavirus", "ORGANISM", 136, 146], ["LASV", "ORGANISM", 276, 280], ["VSVDG", "GENE_OR_GENE_PRODUCT", 321, 326], ["LASVGP pseudotype", "ORGANISM", 327, 344], ["VSVDG", "PROTEIN", 321, 326], ["LASV", "SPECIES", 276, 280], ["experimental setups", "TEST", 53, 72], ["future studies", "TEST", 76, 90], ["S1P inhibition", "TREATMENT", 118, 132], ["arenavirus replication", "TREATMENT", 136, 158], ["virus release", "TREATMENT", 249, 262], ["authentic LASV", "PROBLEM", 266, 280], ["the corresponding VSVDG/LASVGP pseudotype", "PROBLEM", 303, 344], ["LASV", "OBSERVATION", 276, 280], ["LASVGP pseudotype", "OBSERVATION", 327, 344]]], ["Therefore, this study also demonstrates that the replicationcompetent VSV expressing the LASV glycoprotein is an excellent surrogate model for analyzing potential antivirals that target the biological function of GP and its consequence for virus replication.", [["replicationcompetent VSV", "ORGANISM", 49, 73], ["LASV", "ORGANISM", 89, 93], ["GP", "GENE_OR_GENE_PRODUCT", 213, 215], ["LASV glycoprotein", "PROTEIN", 89, 106], ["GP", "PROTEIN", 213, 215], ["VSV", "SPECIES", 70, 73], ["LASV", "SPECIES", 89, 93], ["this study", "TEST", 11, 21], ["the replicationcompetent VSV", "PROBLEM", 45, 73], ["the LASV glycoprotein", "TREATMENT", 85, 106], ["analyzing potential antivirals", "TREATMENT", 143, 173], ["virus replication", "TREATMENT", 240, 257], ["LASV glycoprotein", "OBSERVATION", 89, 106]]], ["These studies can be performed under biosafety level 2 laboratory conditions that would otherwise require biosafety level 4 laboratory conditions [71] .", [["These studies", "TEST", 0, 13], ["biosafety level", "TEST", 106, 121]]], ["Taken together, our data indicate that S1P-adapted a 1 -antitrypsins may represent a promising lead compound for the development of a new class of anti-arenavirus inhibitors.DiscussionIn recent years improvements were made in the application of bioengineered serpins to combat bacterial and viral infections [39, 72] .", [["S1P", "CHEMICAL", 39, 42], ["bacterial and viral infections", "DISEASE", 277, 307], ["S1P", "CHEMICAL", 39, 42], ["S1P", "GENE_OR_GENE_PRODUCT", 39, 42], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 53, 68], ["anti-arenavirus", "SIMPLE_CHEMICAL", 147, 162], ["S1P", "TEST", 39, 42], ["a 1 -antitrypsins", "TREATMENT", 51, 68], ["anti-arenavirus inhibitors", "TREATMENT", 147, 173], ["bioengineered serpins", "TREATMENT", 245, 266], ["bacterial and viral infections", "PROBLEM", 277, 307]]], ["For example, the addition of exogenous a 1 -AT-PDX, a potent and selective furin inhibitor, was found to efficiently block human cytomegalovirus infection [39] .", [["1 -AT-PDX", "CHEMICAL", 41, 50], ["cytomegalovirus infection", "DISEASE", 129, 154], ["1 -AT-PDX", "CHEMICAL", 41, 50], ["1 -AT-PDX", "SIMPLE_CHEMICAL", 41, 50], ["furin", "GENE_OR_GENE_PRODUCT", 75, 80], ["human", "ORGANISM", 123, 128], ["cytomegalovirus", "ORGANISM", 129, 144], ["human", "SPECIES", 123, 128], ["human cytomegalovirus", "SPECIES", 123, 144], ["selective furin inhibitor", "TREATMENT", 65, 90], ["human cytomegalovirus infection", "PROBLEM", 123, 154], ["cytomegalovirus", "OBSERVATION_MODIFIER", 129, 144], ["infection", "OBSERVATION", 145, 154]]], ["However, in contrast to furin, which is known to recycle between the plasma membrane and the TGN via endosomal compartments, membrane-bound S1P is localized in the secretory pathway and can be sorted to endosomal compartments but not to the cell surface [73, 74, 75] .", [["plasma membrane", "ANATOMY", 69, 84], ["TGN", "ANATOMY", 93, 96], ["endosomal compartments", "ANATOMY", 101, 123], ["membrane", "ANATOMY", 125, 133], ["endosomal compartments", "ANATOMY", 203, 225], ["cell surface", "ANATOMY", 241, 253], ["S1P", "CHEMICAL", 140, 143], ["furin", "GENE_OR_GENE_PRODUCT", 24, 29], ["plasma membrane", "CELLULAR_COMPONENT", 69, 84], ["TGN", "CELLULAR_COMPONENT", 93, 96], ["endosomal compartments", "CELLULAR_COMPONENT", 101, 123], ["membrane", "CELLULAR_COMPONENT", 125, 133], ["S1P", "GENE_OR_GENE_PRODUCT", 140, 143], ["endosomal compartments", "CELLULAR_COMPONENT", 203, 225], ["cell surface", "CELLULAR_COMPONENT", 241, 253], ["furin", "PROTEIN", 24, 29], ["TGN", "PROTEIN", 93, 96], ["S1P", "PROTEIN", 140, 143], ["the plasma membrane", "TEST", 65, 84], ["bound S1P", "OBSERVATION", 134, 143]]], ["Follow-up studies with small synthetic peptides, which are derived from S1P-specific a 1 -antitrypsins described in the present work, are currently in progress and will address cellular delivery and organelle specific targeting, as well as their inhibitory potential on authentic LASV replication.", [["cellular", "ANATOMY", 177, 185], ["organelle", "ANATOMY", 199, 208], ["S1P", "CHEMICAL", 72, 75], ["S1P", "GENE_OR_GENE_PRODUCT", 72, 75], ["1 -antitrypsins", "SIMPLE_CHEMICAL", 87, 102], ["cellular", "CELL", 177, 185], ["organelle", "CELLULAR_COMPONENT", 199, 208], ["LASV", "ORGANISM", 280, 284], ["LASV", "SPECIES", 280, 284], ["Follow-up studies", "TEST", 0, 17], ["small synthetic peptides", "PROBLEM", 23, 47], ["cellular delivery", "TREATMENT", 177, 194], ["authentic LASV replication", "TREATMENT", 270, 296], ["LASV", "OBSERVATION", 280, 284]]], ["In analogy to inhibition strategies of the eukaryotic subtilase furin, we previously designed and developed a cell-permeable peptidyl chloromethylketone S1P inhibitor, which contained the LASV GP-C cleavage site, designated dec-RRLL-cmk [76, 77, 78] .", [["cell", "ANATOMY", 110, 114], ["chloromethylketone", "CHEMICAL", 134, 152], ["peptidyl chloromethylketone", "CHEMICAL", 125, 152], ["furin", "GENE_OR_GENE_PRODUCT", 64, 69], ["cell", "CELL", 110, 114], ["peptidyl chloromethylketone", "SIMPLE_CHEMICAL", 125, 152], ["S1P", "GENE_OR_GENE_PRODUCT", 153, 156], ["GP-C", "GENE_OR_GENE_PRODUCT", 193, 197], ["eukaryotic subtilase furin", "PROTEIN", 43, 69], ["LASV GP-C cleavage site", "DNA", 188, 211], ["the eukaryotic subtilase furin", "TREATMENT", 39, 69], ["a cell-permeable peptidyl chloromethylketone S1P inhibitor", "TREATMENT", 108, 166], ["C cleavage site", "PROBLEM", 196, 211]]], ["This irreversible inhibitor efficiently blocked the processing of LASV GP at nanomolar concentrations, however, because of cell type-dependent toxicity observed by us and others, its potential in vitro use requires further investigation [79, 80] .DiscussionDue to the essential roles of S1P in cholesterol metabolism and fatty acid synthesis, this enzyme has attracted great attention by the pharmaceutical industry.", [["cell", "ANATOMY", 123, 127], ["toxicity", "DISEASE", 143, 151], ["S1P", "CHEMICAL", 287, 290], ["cholesterol", "CHEMICAL", 294, 305], ["fatty acid", "CHEMICAL", 321, 331], ["S1P", "CHEMICAL", 287, 290], ["cholesterol", "CHEMICAL", 294, 305], ["fatty acid", "CHEMICAL", 321, 331], ["LASV", "ORGANISM", 66, 70], ["GP", "GENE_OR_GENE_PRODUCT", 71, 73], ["cell", "CELL", 123, 127], ["S1P", "GENE_OR_GENE_PRODUCT", 287, 290], ["cholesterol", "SIMPLE_CHEMICAL", 294, 305], ["fatty acid", "SIMPLE_CHEMICAL", 321, 331], ["LASV GP", "PROTEIN", 66, 73], ["LASV", "SPECIES", 66, 70], ["This irreversible inhibitor", "PROBLEM", 0, 27], ["LASV GP at nanomolar concentrations", "TREATMENT", 66, 101], ["cell type-dependent toxicity", "PROBLEM", 123, 151], ["further investigation", "TEST", 215, 236], ["fatty acid synthesis", "PROBLEM", 321, 341], ["this enzyme", "TEST", 343, 354], ["fatty acid", "OBSERVATION", 321, 331]]], ["Research efforts are currently directed towards the development of S1P inhibitors that may be used in the treatment of dyslipidemia and a variety of cardiometabolic risk factors associated with diabetes and obesity [81] .", [["dyslipidemia", "DISEASE", 119, 131], ["diabetes", "DISEASE", 194, 202], ["obesity", "DISEASE", 207, 214], ["S1P", "GENE_OR_GENE_PRODUCT", 67, 70], ["Research efforts", "TREATMENT", 0, 16], ["S1P inhibitors", "TREATMENT", 67, 81], ["dyslipidemia", "PROBLEM", 119, 131], ["cardiometabolic risk factors", "PROBLEM", 149, 177], ["diabetes", "PROBLEM", 194, 202], ["obesity", "PROBLEM", 207, 214], ["dyslipidemia", "OBSERVATION", 119, 131]]], ["Identification of specific S1P inhibitors in this therapeutic area may also be beneficial in treatment of hemorrhagic fevers caused by viruses known to be processed by S1P.", [["hemorrhagic fevers", "DISEASE", 106, 124], ["S1P", "CHEMICAL", 168, 171], ["S1P", "GENE_OR_GENE_PRODUCT", 27, 30], ["S1P", "GENE_OR_GENE_PRODUCT", 168, 171], ["specific S1P inhibitors", "TREATMENT", 18, 41], ["hemorrhagic fevers", "PROBLEM", 106, 124], ["viruses", "PROBLEM", 135, 142], ["S1P inhibitors", "OBSERVATION", 27, 41], ["hemorrhagic", "OBSERVATION_MODIFIER", 106, 117], ["fevers", "OBSERVATION", 118, 124], ["viruses", "OBSERVATION", 135, 142]]], ["Future studies Effect of S1P Inhibition on LASV Replication www.plosntds.org will have to elucidate the anti-viral efficacy of these and other novel S1P inhibitors that have been developed [82, 83] .DiscussionWhile most conventional antiviral drugs target proteins that are virus-encoded, cellular proteins essential for viral replication are currently considered to be alternative potential targets for antiviral therapy [84, 85, 86] .", [["cellular", "ANATOMY", 289, 297], ["S1P", "CHEMICAL", 25, 28], ["S1P", "CHEMICAL", 25, 28], ["S1P", "GENE_OR_GENE_PRODUCT", 25, 28], ["LASV", "ORGANISM", 43, 47], ["S1P", "GENE_OR_GENE_PRODUCT", 149, 152], ["cellular", "CELL", 289, 297], ["cellular proteins", "PROTEIN", 289, 306], ["LASV", "SPECIES", 43, 47], ["Future studies", "TEST", 0, 14], ["S1P Inhibition", "TREATMENT", 25, 39], ["LASV Replication", "TREATMENT", 43, 59], ["novel S1P inhibitors", "TREATMENT", 143, 163], ["conventional antiviral drugs target proteins", "TREATMENT", 220, 264], ["virus", "PROBLEM", 274, 279], ["cellular proteins", "TREATMENT", 289, 306], ["viral replication", "PROBLEM", 321, 338], ["antiviral therapy", "TREATMENT", 404, 421]]], ["With the exception of Ebola virus, whose glycoprotein cleavage by the proprotein convertase furin is not essential for virus replication in cell culture and virulence in nonhuman primates [71, 87, 88, 89] , maturation cleavage of surface glycoproteins of several virus species by endoproteases is a key determinant for host cell tropism and pathogenicity [90] .", [["cell culture", "ANATOMY", 140, 152], ["surface", "ANATOMY", 230, 237], ["cell", "ANATOMY", 324, 328], ["Ebola", "DISEASE", 22, 27], ["Ebola virus", "ORGANISM", 22, 33], ["furin", "GENE_OR_GENE_PRODUCT", 92, 97], ["cell", "CELL", 140, 144], ["nonhuman primates", "ORGANISM", 170, 187], ["endoproteases", "GENE_OR_GENE_PRODUCT", 280, 293], ["host cell", "CELL", 319, 328], ["proprotein convertase furin", "PROTEIN", 70, 97], ["surface glycoproteins", "PROTEIN", 230, 251], ["endoproteases", "PROTEIN", 280, 293], ["Ebola virus", "SPECIES", 22, 33], ["Ebola virus", "SPECIES", 22, 33], ["Ebola virus", "PROBLEM", 22, 33], ["whose glycoprotein cleavage", "TREATMENT", 35, 62], ["the proprotein convertase furin", "TREATMENT", 66, 97], ["virus replication", "TREATMENT", 119, 136], ["cell culture", "TEST", 140, 152], ["maturation cleavage of surface glycoproteins", "PROBLEM", 207, 251], ["several virus species", "PROBLEM", 255, 276], ["host cell tropism", "PROBLEM", 319, 336], ["pathogenicity", "PROBLEM", 341, 354], ["Ebola virus", "OBSERVATION", 22, 33], ["host cell tropism", "OBSERVATION", 319, 336]]], ["Thus, the emergence of viral escape mutants that confer resistance due to targeted inhibition of an endogenous protease is rather unlikely.", [["endogenous protease", "PROTEIN", 100, 119], ["viral escape mutants", "PROBLEM", 23, 43], ["an endogenous protease", "PROBLEM", 97, 119], ["endogenous protease", "OBSERVATION", 100, 119], ["rather unlikely", "UNCERTAINTY", 123, 138]]], ["In S1P-deficient SRD-12B cells, which were persistently infected with Junin virus vaccine strain Candid 1, no virus escape variants possessing a cleavage motif other than a S1P recognition motif have evolved, indicating a low potential of arenaviruses to develop de novo a different glycoprotein maturation pathway [33] .", [["SRD-12B cells", "ANATOMY", 17, 30], ["S1P", "CHEMICAL", 3, 6], ["S1P", "CHEMICAL", 173, 176], ["S1P", "GENE_OR_GENE_PRODUCT", 3, 6], ["SRD-12B cells", "CELL", 17, 30], ["Junin virus vaccine strain Candid 1", "ORGANISM", 70, 105], ["S1P", "GENE_OR_GENE_PRODUCT", 173, 176], ["arenaviruses", "ORGANISM", 239, 251], ["S1P-deficient SRD-12B cells", "CELL_LINE", 3, 30], ["S1P recognition motif", "PROTEIN", 173, 194], ["glycoprotein", "PROTEIN", 283, 295], ["Junin virus vaccine", "SPECIES", 70, 89], ["Junin virus", "SPECIES", 70, 81], ["Candid 1", "SPECIES", 97, 105], ["S1P", "TEST", 3, 6], ["deficient SRD", "PROBLEM", 7, 20], ["12B cells", "PROBLEM", 21, 30], ["persistently infected", "PROBLEM", 43, 64], ["Junin virus vaccine", "TREATMENT", 70, 89], ["virus escape variants", "PROBLEM", 110, 131], ["a cleavage motif", "TREATMENT", 143, 159], ["a S1P recognition motif", "TEST", 171, 194], ["a low potential of arenaviruses", "PROBLEM", 220, 251], ["deficient", "OBSERVATION_MODIFIER", 7, 16], ["SRD", "OBSERVATION_MODIFIER", 17, 20], ["12B cells", "OBSERVATION", 21, 30], ["infected", "OBSERVATION_MODIFIER", 56, 64], ["Junin virus", "OBSERVATION", 70, 81]]], ["This observation together with our findings that inhibition of S1P significantly affects LASV GP processing and virus infectivity should encourage the development of S1P inhibitors as a potential drug target to counteract infections caused by pathogenic arenaviruses.Supporting InformationAlternative Language Abstract S1 Translation of the abstract and author summary into French by Stephane Daffis.Supporting InformationFound at: doi:10.1371/journal.pntd.0000446.s001 (0.05 MB PDF)", [["S1P", "CHEMICAL", 63, 66], ["S1P", "CHEMICAL", 166, 169], ["infections", "DISEASE", 222, 232], ["S1P", "CHEMICAL", 63, 66], ["S1P", "GENE_OR_GENE_PRODUCT", 63, 66], ["LASV", "ORGANISM", 89, 93], ["GP", "GENE_OR_GENE_PRODUCT", 94, 96], ["S1P", "GENE_OR_GENE_PRODUCT", 166, 169], ["arenaviruses", "ORGANISM", 254, 266], ["LASV", "SPECIES", 89, 93], ["This observation", "TEST", 0, 16], ["S1P", "PROBLEM", 63, 66], ["LASV GP processing", "PROBLEM", 89, 107], ["virus infectivity", "PROBLEM", 112, 129], ["S1P inhibitors", "TREATMENT", 166, 180], ["counteract infections", "PROBLEM", 211, 232], ["pathogenic arenaviruses", "PROBLEM", 243, 266]]]]}